



BDL ONCOLOGY
(Beta Drugs Limited)



19th
ANNUAL
REPORT
2023-24

BETA DRUGS LIMITED

(CIN: L24230HP2005PLC028969)

Dedicated To Oncology....



TABLE OF CONTENT

PARTICULARS	PAGE NO.
Company Information	2
Financial Highlights	3
Chairman Message	4
Notice to Shareholders	5-21
Directors Report	22-32
Secretarial Audit Report	33-35
CSR Details	36-37
Management's Discussion and Analysis	38-40
Standalone Financial Statements of Beta Drugs Limited along with Auditor's Report	41-83
Consolidated Financial Statements along with Auditor's Report	84-126
Standalone Financial Statements of Adley Formulations Private Limited along with Auditor's Report (Wholly owned Subsidiary)	127-163
Standalone Financial Statements of Adley Lab Limited along with Auditor's Report (Wholly owned Subsidiary)	164-196
Standalone Financial Statements of Beta Research Private Limited along with Auditor's Report (Wholly owned Subsidiary)	197-213
Attendance Slip	214
Proxy Form	215
Ballot Form	216
AGM Venue Map	217



19TH ANNUAL REPORT 2023-24
COMPANY INFORMATION
CIN NO: L24230HP2005PLC028969

Board of Directors

Chairperson & Managing Director	: Mr. Rahul Batra (DIN: 02229234)
Joint Managing Director	: Mr. Varun Batra (DIN: 02148383)
Whole Time Director	: Mr. Balwant Singh(DIN: 01089968)
Whole-time Director	: Mrs. Seema Chopra(DIN: 08510586)
Whole-time Director	: Mr. Ashutosh Shukla (DIN: 09461568)
Independent Director	: Mr. Rohit Parti (DIN: 07889944)
Independent Director	: Mr. Manmohan Khanna(DIN:07888319)

Chief Financial Officer

: Mr. Nipun Arora
Email:nipun@betadrugslimited.com

Company Secretary & Compliance Officer

: Mrs. Rajni Brar
Email:cs@betadrugslimited.com

Registered Office

:Village Nandpur, Lodhimajra Road
Baddi, Distt Solan, Himachal Pradesh-174101
Website: www.betadrugslimited.com
Email: cs@betadrugslimited.com

Corporate Office

: SCO-184, Sector-5, Panchkula-134114
Ph no. 0172-2585481,483

Statutory Auditors

:M/s Kalra Rai & Associates, Chartered Accountants, Chandigarh

Secretarial Auditors

:Mr Dinesh Bhandari, Company Secretary, Chandigarh

Internal Auditor

:M/s Srivastava V.K. & Associates, Chartered Accountants, Chandigarh

Cost Auditor

: M/s Charu Jindal & Company, Cost Accountants, Dehradun

Shares Listed::

National Stock Exchange of India Limited (SME)
Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra
(E), Mumbai-400051, Maharashtra, India

Registrar & Transfer Agent

: Link Intime India Pvt Ltd.
C-101, 247 Park, L.B.S. Marg, Vikhroli(W), Mumbai-400083

ISIN No.

: INE351Y01019

Bankers

: HDFC Bank Limited, Chandigarh
ICICI Bank Limited, Panchkula

AGM Date

: 30.09.2024

Book Closure Date


:From 24.09.2024 to 30.09.2024




FINANCIAL HIGHLIGHTS

CONSOLIDATED


Net Sales (In Lacs)



EBITDA (In Lacs)



Net Profit before tax (In Lacs)



Net Profit after tax (In Lacs)





CHAIRMAN MESSAGE

Dear Shareholders,

The fiscal year 2023-24 was a challenging year as the world continued to go through significant changes. The pandemic led to severe supply chain disruptions, which in turn caused an economic slowdown, particularly in developed markets. Just as early signs of stability were beginning to surface, the escalation of military conflicts this year has further exacerbated these disruptions, continuing to strain global supply chains. After a couple of years of recessionary fears, persistently high inflation, and unprecedented monetary tightening, the global macro-outlook looks relatively better now with improving growth, disinflation, and monetary easing in sight.

However, Beta has continued to march forward. The company consolidated revenues from operations for FY24 increased by 30.2% to Rs 296 crores from Rs 227 crores compared with the same period a year ago due to growth across all its segments. Consolidated EBITDA came at Rs. 61.4 crores while EBITDA margins stood at 21%. The decrease in margin was primarily driven by two factors one was a loss of Rs 4 crore in cosmeceutical division and second was due to higher raw material prices for Platins because of global price rise in gold and platinum prices.

Net profit too grew by 19% to Rs 36.4 crores from Rs 30.7 crores compared with the same period a year ago. Beta continues to be net debt free. Cash & Cash Equivalents are in surplus by Rs. 18 crores over the borrowings which was Rs 3 crores in the last financial year. In addition, its new Cosmeceutical division has become marginally profitable.

Beta continues to be among the fastest growing scaled up companies in Indian branded oncology pharma market. The company's focus on novel delivery and formulation development innovation has helped to establish differentiation in the Indian market. The company remains on track to be among top five players in the next couple of years

Going forward, Beta's top priority would be to improve and strengthen our position in the Indian oncology market, expand our presence in Latin American and other developing markets while continuing to focus on improving our backward integration. Beta's strong R&D engine with differentiated offerings including NDDS and FTL/ FFTL pipeline which will help drive strong growth over many years to come. The Company continues to invest aggressively in R&D, talent and product dossiers which will help accelerate growth going forward.

While the company expects revenues to double in the next three years it does not foresee any major capex for the same period. We expect significant operating leverage to payout which will lead to expansion in our operating margins.

On behalf of the Board and management, I would like to thank our shareholders, customers, distributors and other stakeholders for their continued support and trust. And a special thanks to all our employees for their sheer hard work and commitment, which has helped the company to become a leader in the Oncology segment.

It is an honor to serve you all.

With Warm Regards

Sd/-

Rahul Batra & Varun Batra
Chairman & Managing Director
Joint Managing Director



NOTICE TO SHAREHOLDERS

Notice is hereby given that the 19th Annual General Meeting of the Company will be held on Monday, the 30th day of September, 2024 at 10:30 a.m. at Registered Office of the company situated at Village Nandpur, Lodhimajra Road, Baddi, Distt Solan, Himachal Pradesh-174101 to transact the following businesses:-

ORDINARY BUSINESS:-

1. Adoption of Financial Statements

(I) Audited Standalone Financial Statements of the Company for the financial year ended on March 31, 2024 and the Reports of the Board of Directors and Auditors thereon;

and

(II) Audited Consolidated Financial Statements of the Company for the financial year ended on March 31, 2024, together with the Report of the Auditors thereon

2. To appoint a Director in place of Mr. Varun Batra (DIN: 02148383), who retires by rotation and being eligible, offers himself for re-appointment.

3. To appoint a Director in place of Mrs. Seema Chopra (DIN: 08510586), who retires by rotation and being eligible, offers herself for re-appointment.

4. To appoint Statutory Auditors from the conclusion of this Annual General Meeting until the conclusion of the Twenty first Annual General Meeting and to fix their remuneration:

To consider and if thought fit to pass with or without modification the following resolution as **Ordinary Resolution**:

"RESOLVED THAT pursuant to Sections 139, 142 of the Companies Act, 2013 ("Act") and other applicable provisions, if any, of the said Act and Companies (Audit and Auditors) Rules, 2014 made thereunder and other applicable rules, if any, under the said Act (including any statutory modification(s) or re-enactment thereof for the time being in force) **M/s Khurana Sharma & Co., (FRN- 010920N)**, Chartered Accountant be and is hereby appointed as the Statutory Auditors of the Company commencing from the conclusion of this Annual General Meeting till the conclusion of Twenty First Annual General Meeting at a remuneration to be fixed by the Audit Committee and/or Board of Directors of the Company, in addition to the re-imbursment of applicable taxes and actual out of pocket and travelling expenses, etc. incurred in connection with the audit."

"RESOLVED FURTHER THAT Mr Rahul Batra, (DIN:02229234) Chairman cum Managing Director and/or **Mr Varun Batra, (DIN: 02148383)** Joint Managing Director of the Company be and are hereby severally authorized to file necessary forms/returns with Registrar of Companies and to take such actions as may be necessary in this regard."

SPECIAL BUSINESS:

5. To ratify the remuneration payable to the Cost Auditor appointed by the Board of Directors of the Company for the financial year 2024-25 pursuant to Section 148 and all other applicable provisions of Companies Act, 2013.

To consider and if thought fit, to pass the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 148(3) of the Companies Act, 2013 read with Rule 14 of Companies (Audit and Auditors) Rules, 2014 and other applicable provisions of the Companies Act, 2013, the remuneration of **Rs.1,25,000/- (Rupees One Lac twenty five thousand Only)** with reimbursement of conveyance expenses at actual and GST as applicable payable to **M/s Charu Jindal & Co, Cost Accountants**, bearing Firm Registration Number 103508, for conducting cost audit of the Company for the financial year 2024-25, as approved by the Board of Directors of the Company, be and is hereby ratified."



“RESOLVED FURTHER THAT Mr.Rahul Batra, (DIN:02229234) Chairman cum Managing Director and/or Mr Varun Batra, (DIN: 02148383) Joint Managing Director of the Company be and are hereby severally authorized to do all such acts, deeds, matters and things as it may in its absolute discretion consider necessary, proper or desirable for the purpose of giving effect to this resolution.”

6. To revise the remuneration payable to Mr. Rahul Batra (DIN No. 02229234), Managing Director of the company.

To consider and if thought fit to pass with or without modification the following resolution as Special Resolution: -

“RESOLVED THAT pursuant to the provisions of sections 196, 197 read with the schedule V and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modifications or re-enactment thereof for the time being in force), applicable clauses of Article of Association and as recommended by the Nomination and Remuneration Committee & approved by the Board of Directors, approval of the Shareholders be and is hereby accorded for the revision in the remuneration of Mr. Rahul Batra (DIN : 02229234), Chairman cum Managing Director of the company w.e.f. 1st April, 2024 for the balance term upto 26th January, 2026 on the following terms and conditions as mentioned below:-

a) Remuneration : Rs 12.50 lacs per month +Annual Diwali Bonus as per the company policy

b) Perquisites:

The Following perquisite shall not be included in the computation of the ceiling on remuneration:

- i) Contribution to provident fund, superannuation fund or annuity fund to the extent these either single or put together are not taxable under Income Tax Act, 1961.
- ii) gratuity payable at the rate not exceeding half a month’s salary for each completed year of service.
- iii) encashment of leave at the end of tenure.

“RESOLVED FURTHER THAT Mr. Rahul Batra, (DIN: 02229234) will also be entitled for the reimbursement of actual entertainment, travelling, boarding and lodging expenses incurred by him in connection with the company’s business and such other benefits and other privileges, as any from time to time be available to other senior executives of the company.”

“RESOLVED FURTHER THAT Board of the Directors are authorized to revise the remuneration (basic salary, allowances, perquisites, etc) from time to time by giving suitable increment / decrement after review of his performance each year, subject to the condition that total monthly remuneration not to exceed Rs. 50 lacs in any case.”

“RESOLVED FURTHER THAT In case of absence or inadequacy of profits in any financial year, remuneration as mentioned above shall be paid to Mr. Rahul Batra which will exceed the limits prescribed under Schedule V of Companies Act, 2013.”

7. To revise the remuneration payable to Mr. Varun Batra (DIN No. 02148383), Joint Managing Director of the company.

To consider and if thought fit to pass with or without modification the following resolution as Special Resolution:-

“RESOLVED THAT pursuant to the provisions of sections 196, 197 read with the schedule V and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modifications or re-enactment thereof for the time being in force), applicable clauses of Article of Association and as recommended by the Nomination and Remuneration Committee & approved by the Board of Directors, approval of the Shareholders be and is hereby accorded for the revision in the remuneration of Mr. Varun Batra (DIN : 02148383), Joint Managing Director of the company w.e.f. 1st April, 2024 for the balance term upto 26th January, 2026 on the following terms and conditions as mentioned below:-

a) **Remuneration: Rs 12.50 lacs per month** + Annual Diwali bonus as per the company policy

b) Perquisites: The Following perquisite shall not be included in the computation of the ceiling on remuneration:

- i) Contribution to provident fund, superannuation fund or annuity fund to the extent these either single or put together are not taxable under Income Tax Act, 1961.
- ii) Gratuity payable at the rate not exceeding half a month salary for each completed year of service.
- iii) Encashment of leave at the end of tenure.

“RESOLVED FURTHER THAT Mr. Varun Batra (DIN 02148383), will also be entitled for the reimbursement of actual entertainment,



travelling, boarding and lodging expenses incurred by him in connection with the company's business and such other benefits and other privileges, as any from time to time be available to other senior executives of the company."

"RESOLVED FURTHER THAT subject to approval of shareholders, Board of the Directors are authorized to revised the remuneration (basic salary, allowances, perquisites, etc) from time to time by giving suitable increment / decrement after review of his performance each year, subject to the condition that total monthly remuneration not to exceed Rs. 50 lacs in any case."

"RESOLVED FURTHER THAT In case of absence or inadequacy of profits in any financial year, remuneration as mentioned above shall be paid to Mr. Varun Batra which will exceed the limits prescribed under Schedule V of Companies Act, 2013."

8. Re-appointment of Mr. Balwant Singh (DIN: 01089968) as Whole-time Director of the Company w.e.f. 5th August, 2024 till 4th August, 2029.

To consider and if thought fit, to pass with or without modification(s), the following resolutions as **Special Resolutions**:

"RESOLVED THAT pursuant to recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors and pursuant to the provisions of Sections 196, 197, 198, 203 and all other applicable provisions if any, read with Schedule V of the Companies Act, 2013 ('Act') and pursuant to the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended from time to time and other applicable provisions of the Companies Act, 2013 and Rules made thereunder (including any statutory modification(s) or re-enactment thereof for the time being in force) and any subsequent amendment / modification in the Rules, Act and/or applicable laws in this regard, the approval of the Members of the Company be and is hereby accorded for the re-appointment of **Mr. Balwant Singh (DIN 01089968)**, as Whole-time Director of the Company for a period of 5 (five) years with effect from **5th August, 2024 upto period ended 4th August, 2029** on the terms and conditions including remuneration as mentioned below:-

a) REMUNERATION: Rs. 2,67,630/- p.m. + Annual Diwali bonus as per the company policy

However Board of the Directors are authorized to revised the same from time to time by giving suitable increment / decrement after review of his performance each year, subject to the condition that total remuneration not to exceed **Rs. 4,00,000 p.m.** in any case.

2) NATURE OF DUTIES & POWERS:

Mr. Balwant Singh (DIN- 01089968), Executive Director, shall look after the entire day to day operations of the Company including as occupier of the factory premises of the Company at Baddi, subject to superintendence, control and Directors of the Board of Directors and he shall exercise all such powers as may be assigned, granted and entrusted to him by the Board of Directors of the Company from time to time for the proper performance, discharge and execution of his duties and responsibilities under various applicable laws / Acts to Company.

"RESOLVED FURTHER THAT In case of absence or inadequacy of profits in any financial year, remuneration as mentioned above shall be paid to Mr. Balwant Singh which may exceed the limits prescribed under Schedule V of Companies Act, 2013."

"RESOLVED FURTHER THAT **Mr. Rahul Batra (DIN:01083215)**, Chairman cum Managing Director and/or **Mr. Varun Batra, (DIN: 02148383)** Joint Managing Director of the Company be and are hereby severally authorized to issue letter of re-appointment and also file necessary forms/returns with Registrar of Companies and to take such actions as may be necessary in this regard."

9. Re-appointment of Mrs. Seema Chopra (DIN: 08510586) as Whole-time Director of the Company w.e.f. 1st August, 2024 till 31st July, 2029.

To consider and if thought fit, to pass with or without modification(s), the following resolutions as **Special Resolutions**:

"RESOLVED THAT pursuant to recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors and pursuant to the provisions of Sections 196, 197, 198, 203 and all other applicable provisions if any, read with Schedule V of the Companies Act, 2013 ('Act') and pursuant to the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended from time to time and other applicable provisions of the Companies Act, 2013 and Rules made thereunder (including any statutory modification(s) or re-enactment thereof for the time being in force) and any subsequent



amendment / modification in the Rules, Act and/or applicable laws in this regard, the approval of the Members of the Company be and is hereby accorded for the re-appointment of **Mrs Seema Chopra (DIN: 08510586)**, as Whole-time Director of the Company for a period of 5 (five) years with effect from 1st August, 2024 upto period ended 31st July, 2029 on the terms and conditions including remuneration as mentioned below:-

a) Remuneration: Rs 1,01,957 per month w.e.f. 1.04.2024 + Diwali Bonus

b) Perquisites:

The Following perquisite shall not be included in the computation of the ceiling on remuneration:

- i) Contribution to provident fund, superannuation fund or annuity fund to the extent these either single or put together are not taxable under Income Tax Act, 1961
- ii) Gratuity payable at the rate not exceeding half a month salary for each completed year of service.
- iii) Encashment of leave at the end of tenure.

“RESOLVED FURTHER THAT Mrs. Seema Chopra will also be entitled for the reimbursement of actual entertainment, travelling, boarding and lodging expenses incurred by her in connection with the company’s business and such other benefits and other privileges, as any from time to time be available to other senior executives of the company.”

“RESOLVED FURTHER THAT Board of the Directors are authorized to revised the remuneration (basic salary, allowances, perquisites, etc) from time to time by giving suitable increment / decrement after review of her performance each year, subject to the condition that total monthly remuneration not to exceed Rs. 2,50,000 p.m. in any case.”

“RESOLVED FURTHER THAT In case of absence or inadequacy of profits in any financial year, remuneration as mentioned above shall be paid to Mrs. Seema Chopra which may exceed the limits prescribed under Schedule V of Companies Act, 2013.”

10. To revise the remuneration payable to Mr. Ashutosh Shukla (DIN No. 09461568), Whole time Director of the company.

To consider and if thought fit to pass with or without modification the following resolution as Special Resolution:-

“RESOLVED THAT pursuant to the provisions of sections 196, 197 read with the schedule V and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modifications or re-enactment thereof for the time being in force), applicable clauses of Article of Association and as recommended by the Nomination and Remuneration Committee & approved by the Board of Directors, approval of the Shareholders be and is hereby accorded for the revision in the remuneration of Mr. Ashutosh Shukla (DIN : 09461568), Whole time Director of the company w.e.f. 1st April, 2024 for the balance term upto 19th January, 2027 on the following terms and conditions as mentioned below:-

a) Remuneration: Rs 3,64,419 per month w.e.f. 01.04.2024 plus Diwali Bonus

b) Incentive shall be paid additionally not exceeding the gross salary

c) Perquisites:

The Following perquisite shall not be included in the computation of the ceiling on remuneration:

- i) Contribution to provident fund, superannuation fund or annuity fund to the extent these either single or put together are not taxable under Income Tax Act, 1961.
- ii) Gratuity payable at the rate not exceeding half a month salary for each completed year of service.
- iii) Encashment of leave at the end of tenure.

“RESOLVED FURTHER THAT Mr. Ashutosh Shukla (DIN:09461568) will also be entitled for the reimbursement of actual entertainment, travelling, boarding and lodging expenses incurred by her in connection with the company’s business and such other benefits and other privileges, as any from time to time be available to other senior executives of the company.”

“RESOLVED FURTHER THAT subject to approval of shareholders, Board of the Directors are authorized to revised the remuneration (basic salary, allowances, perquisites, etc) from time to time by giving suitable increment / decrement after review of his performance each year, subject to the condition that total monthly remuneration not to exceed Rs. 10 lacs in any case.”

“RESOLVED FURTHER THAT In case of absence or inadequacy of profits in any financial year, remuneration as mentioned above shall be paid to Mr. Ashutosh Shukla Chopra which may exceed the limits prescribed under Schedule V of Companies Act, 2013.”



11. To alter the incidental object of the Memorandum of Association of the company

To consider and if thought fit, to pass the following resolutions as Special Resolution:-

“RESOLVED THAT pursuant to the provisions of Section 13 and all other applicable provisions of the Companies Act, 2013, including any statutory modification(s) or re-enactment thereof, for the time being in force, and subject to such other requisite approvals, if any, in this regard from appropriate authorities and terms(s), condition(s), amendment(s), modification(s), as may be required or suggested by any such appropriate authorities, and agreed to by the Board of Directors of the Company (hereinafter referred to as “Board” which term shall include any Committee), the consent of the members of the Company be and is hereby accorded to alter the incidental object of the Memorandum of Association of the company by way of addition after clause no. **3 (b) (18)**, copy of which is placed before the meeting as follow:-

"To subscribe for, purchase, or otherwise acquire, undertake, or take options over shares, stocks, bonds, debentures, or other marketable securities of a like nature in or of any incorporated company or other body corporate, derivatives, units or any other instrument issued by any collective investment scheme to the investors in such schemes, units or any other such instrument issued to the investors under any mutual fund scheme, Government securities or such other instruments as may be declared by the Central Government to be securities and to hold, sell, lend, exchange, or otherwise dispose of, with or without consideration, such shares, stocks, bonds, debentures, or other securities."

“RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to do all acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution.”

Dated: 31.08.2024
Place: Panchkula

By Order of the Board of Directors
sd/-
Rahul Batra
Chairman & Managing Director
(DIN:02229234)



NOTES:

1. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON POLL INSTEAD OF HIMSELF AND PROXY NEED NOT BE A MEMBER. PROXIES, IN ORDER TO BE EFFECTIVE, MUST BE RECEIVED BY THE COMPANY NOT LESS THAT 48 HOURS BEFORE THE COMMENCEMENT OF MEETING.
2. A PERSON CAN ACT AS PROXY ON BEHALF OF MEMBERS NOT EXCEEDING FIFTY AND HOLDING IN THE AGGREGATE NOT MORE THAN TEN PERCENT OF THE TOTAL SHARE CAPITAL OF THE COMPANY CARRYING VOTING RIGHTS. A MEMBER HOLDING MORE THAN TEN PERCENT OF THE TOTAL SHARE CAPITAL OF THE COMPANY CARRYING VOTING RIGHTS MAY APPOINT A SINGLE PERSON AS PROXY AND SUCH PERSON SHALL NOT ACT AS PROXY FOR ANY OTHER PERSON OR SHAREHOLDER.
3. Pursuant to the provisions of SEBI (LODR) Regulations, 2015 and section 91 of the Companies Act, 2013, Register of Members and Shares Transfer Books of the Company will remain closed from **Tuesday, 24th September, 2024 to Monday, 30thSeptember, 2024. (both days inclusive)**.
4. Members intending to require information about accounts at the meeting are requested to write to the Company at least 10 days in advance of the Annual General Meeting.
5. Shareholders holding shares in dematerialized form should communicate the change of address, if any, to their Depository Participant and other who hold shares in physical form should communicate the change of address, to the Registrar and Share Transfer Agent of the Company at the following address:
Link Intime India Pvt Limited.
C-101, 247 Park, L.B.S. Marg, Vikhroli West, Mumbai-400083.
6. Members/Proxies should bring their attendance slip duly filed in for attending the meeting.
7. The Notice of the **19thAGM** along with the attendance slip and proxy form are being sent by electronic mode to all the members whose email addresses are registered with Company/ Depository Participant(s) unless a member has requested for a hard copy of the same. For members who have not registered their email addresses, physical copies of the aforesaid documents are being sent by the permitted mode.
8. In terms of provisions of Section 107 of the Companies Act, 2013, read with Rule 20 of the Companies (Management and Administration) Rules, 2014 since the Company is voluntary providing the facility of remote e-voting to the shareholders, there shall be no voting by show of hands at the AGM. The facility for ballot / polling paper shall be made available at the Meeting and the members attending the Meeting who have not cast their vote by remote e-voting shall be able to vote at the Meeting through ballot / polling paper. The shareholders can opt for only one mode of voting i.e. remote e-voting or physical polling at the meeting. In case of voting by both the modes, vote casted through remote e-voting will be considered final and voting through physical ballot will not be considered. The members who have cast their vote by remote e-voting may also attend the Meeting.
9. The cut-off date for remote E-Voting/ Poll Paper is Monday, 23rd September, 2024.
10. Members may also note that the notice of the Annual General Meeting and the Annual Report will also be available on the Company's website for their download. The physical copies of the aforesaid documents will also be available at the Company's Registered Office at Village Nandpur, Lodhimajra Road, Baddi, Distt Solan, H.P. 174101, for inspection during normal business hours on working days. Even after registering for e-communication, members are entitled to receive such communication in physical form, upon making a request for the same by post free of cost.
11. All the statutory registers under Companies Act, 2013 will remain open for inspection by the members during the AGM.
12. CS Dinesh Bhandari, FCS 5887 Practicing Company Secretary appointed as a scrutinizer to scrutinize the remote E-voting and voting through Ballot Form during the AGM to be carried out in a fair and transparent manner and they have communicated their willingness to be appointed and will be available for the said purpose.
13. An Explanatory Statement pursuant to Section 102 of the Act in respect of **Item nos. 4 to 11** of the Notice set out above is annexed hereto.
14. A route map giving directions to reach the venue of the 19th Annual General Meeting is enclosed for the convenience of the members.



REMOTE E-VOTING INSTRUCTIONS FOR SHAREHOLDERS:-

The remote e-voting period begins on Thursday, 26th September, 2024 at 09:00 A.M. and ends on Sunday, 29th September, 2024 at 05:00 P.M. During this period, Members holding shares as on Monday, 23rd September, 2024 i.e. cut-off date, may cast their vote electronically. The e-Voting module shall be disabled by Linkintime for voting thereafter. Members have the option to cast their vote on any of the resolutions using the remote e-Voting facility either during the period commences 26th September, 2024 to 29th September, 2024 or Voting through poll paper during the AGM. Members who have voted on some of the resolutions during the said voting period are also eligible to vote on the remaining resolutions during the AGM.

As per the SEBI circular dated December 9, 2020, individual shareholders holding securities in demat mode can register directly with the depository or will have the option of accessing various ESP portals directly from their demat accounts.

Login method for Individual shareholders holding securities in demat mode is given below:

Individual Shareholders holding securities in demat mode with NSDL:

METHOD 1 - If registered with NSDL IDeAS facility

Users who have registered for NSDL IDeAS facility:

- Visit URL: <https://eservices.nsdl.com> and click on "Beneficial Owner" icon under "Login".
- Enter user id and password. Post successful authentication, click on "Access to e-voting".
- Click on "LINKINTIME" or "evoting link displayed alongside Company's Name" and you will be redirected to Link Intime InstaVote website for casting the vote during the remote e-voting period.

OR

User not registered for IDeAS facility:

- To register, visit URL: <https://eservices.nsdl.com> and select "Register Online for IDeAS Portal" or click on <https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp> "
- Proceed with updating the required fields.
- Post registration, user will be provided with Login ID and password.
- After successful login, click on "Access to e-voting".
- Click on "LINKINTIME" or "evoting link displayed alongside Company's Name" and you will be redirected to Link Intime InstaVote website for casting the vote during the remote e-voting period.

METHOD 2 - By directly visiting the e-voting website of NSDL:

- Visit URL: <https://www.evoting.nsdl.com/>
- Click on the "Login" tab available under 'Shareholder/Member' section.
- Enter User ID (i.e., your sixteen-digit demat account number held with NSDL), Password/OTP and a Verification Code as shown on the screen.
- Post successful authentication, you will be re-directed to NSDL depository website wherein you can see "Access to e-voting".
- Click on "LINKINTIME" or "evoting link displayed alongside Company's Name" and you will be redirected to Link Intime InstaVote website for casting the vote during the remote e-voting period.

Individual Shareholders holding securities in demat mode with CDSL:

METHOD 1 - From Easi/Easiest

Users who have registered/ opted for Easi/Easiest

- Visit URL: <https://web.cdslindia.com/myeasitoken/Home/Login> or www.cdslindia.com.
- Click on New System Myeasi
- Login with user id and password
- After successful login, user will be able to see e-voting menu. The menu will have links of e-voting service providers i.e., LINKINTIME, for voting during the remote e-voting period.
- Click on "LINKINTIME" or "e-voting link displayed alongside Company's Name" and you will be redirected to Link Intime InstaVote website for casting the vote during the remote e-voting period.

OR

Users not registered for Easi/Easiest

- To register, visit URL: <https://web.cdslindia.com/myeasitoken/Registration/EasiRegistration> / <https://web.cdslindia.com/myeasitoken/Registration/EasiestRegistration>
- Proceed with updating the required fields.
- Post registration, user will be provided Login ID and password.
- After successful login, user able to see e-voting menu.
- Click on "LINKINTIME" or "e-voting link displayed alongside Company's Name" and you will be redirected to Link Intime InstaVote website for casting the vote during the remote e-voting period.

METHOD 2 - By directly visiting the e-voting website of CDSL.

- Visit URL: <https://www.cdslindia.com/>
- Go to e-voting tab.



- c) Enter Demat Account Number (BO ID) and PAN No. and click on "Submit".
- d) System will authenticate the user by sending OTP on registered Mobile and Email as recorded in Demat Account
- e) After successful authentication, click on "LINKINTIME" or "evoting link displayed alongside Company's Name" and you will be redirected to Link Intime InstaVote website for casting the vote during the remote e-voting period.

Individual Shareholders holding securities in demat mode with Depository Participant:

Individual shareholders can also login using the login credentials of your demat account through your depository participant registered with NSDL/CDSL for e-voting facility.

- a) Login to DP website
- b) After Successful login, members shall navigate through "e-voting" tab under Stocks option.
- c) Click on e-voting option, members will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-voting menu.
- d) After successful authentication, click on "LINKINTIME" or "evoting link displayed alongside Company's Name" and you will be redirected to Link Intime InstaVote website for casting the vote during the remote e-voting period.

Login method for Individual shareholders holding securities in physical form/ Non-Individual Shareholders holding securities in demat mode is given below:

Individual Shareholders of the company, holding shares in physical form / Non-Individual Shareholders holding securities in demat mode as on the cut-off date for e-voting may register for e-Voting facility of Link Intime as under:

1. Visit URL: <https://instavote.linkintime.co.in>
2. Click on "Sign Up" under 'SHARE HOLDER' tab and register with your following details: -

A. User ID:

Shareholders holding shares in physical form shall provide Event No + Folio Number registered with the Company. Shareholders holding shares in NSDL demat account shall provide 8 Character DP ID followed by 8 Digit Client ID; Shareholders holding shares in CDSL demat account shall provide 16 Digit Beneficiary ID.

B. PAN: Enter your 10-digit Permanent Account Number (PAN) (Shareholders who have not updated their PAN with the Depository Participant (DP)/ Company shall use the sequence number provided to you, if applicable.

C. DOB/DOI: Enter the Date of Birth (DOB) / Date of Incorporation (DOI) (As recorded with your DP / Company - in DD/MM/YYYY format)

D. Bank Account Number: Enter your Bank Account Number (last four digits), as recorded with your DP/Company.

**Shareholders holding shares in physical form but have not recorded 'C' and 'D', shall provide their Folio number in 'D' above*

**Shareholders holding shares in NSDL form, shall provide 'D' above*

- ▶ Set the password of your choice (The password should contain minimum 8 characters, at least one special Character (@!#\$%&*), at least one numeral, at least one alphabet and at least one capital letter).
 - ▶ Click "confirm" (Your password is now generated).
3. Click on 'Login' under 'SHARE HOLDER' tab.
 4. Enter your User ID, Password and Image Verification (CAPTCHA) Code and click on 'Submit'.

Cast your vote electronically:

1. After successful login, you will be able to see the notification for e-voting. Select 'View' icon.
2. E-voting page will appear.
3. Refer the Resolution description and cast your vote by selecting your desired option 'Favour / Against' (If you wish to view the entire Resolution details, click on the 'View Resolution' file link).
4. After selecting the desired option i.e. Favour / Against, click on 'Submit'. A confirmation box will be displayed. If you wish to confirm your vote, click on 'Yes', else to change your vote, click on 'No' and accordingly modify your vote.
- 5.

Guidelines for Institutional shareholders ("Corporate Body/ Custodian/Mutual Fund"):

STEP 1 – Registration

- a) Visit URL: <https://instavote.linkintime.co.in>
- b) Click on Sign up under "Corporate Body/ Custodian/Mutual Fund"
- c) Fill up your entity details and submit the form.



- d) A declaration form and organization ID is generated and sent to the Primary contact person email ID (which is filled at the time of sign up). The said form is to be signed by the Authorised Signatory, Director, Company Secretary of the entity & stamped and sent to insta.vote@linkintime.co.in.
- e) Thereafter, Login credentials (User ID; Organisation ID; Password) will be sent to Primary contact person's email ID.
- f) While first login, entity will be directed to change the password and login process is completed.

STEP 2 –Investor Mapping

- a) Visit URL: <https://instavote.linkintime.co.in> and login with credentials as received in Step 1 above.
- b) Click on "Investor Mapping" tab under the Menu Section
- c) Map the Investor with the following details:
 - a. 'Investor ID' -
 - i. *Members holding shares in NSDL demat account shall provide 8 Character DP ID followed by 8 Digit Client ID i.e., IN00000012345678*
 - ii. *Members holding shares in CDSL demat account shall provide 16 Digit Beneficiary ID.*
 - b. 'Investor's Name - Enter full name of the entity.
 - c. 'Investor PAN' - Enter your 10-digit PAN issued by Income Tax Department.
 - d. 'Power of Attorney' - Attach Board resolution or Power of Attorney. File Name for the Board resolution/Power of Attorney shall be – DP ID and Client ID. Further, Custodians and Mutual Funds shall also upload specimen signature card.
- d) Click on Submit button and investor will be mapped now.
- e) The same can be viewed under the "Report Section".

STEP 3 – Voting through remote e-voting.

The corporate shareholder can vote by two methods, once remote e-voting is activated:

METHOD 1 - VOTES ENTRY

- a) Visit URL: <https://instavote.linkintime.co.in> and login with credentials as received in Step 1 above.
- b) Click on 'Votes Entry' tab under the Menu section.
- c) Enter Event No. for which you want to cast vote. Event No. will be available on the home page of Instavote before the start of remote evoting.
- d) Enter '16-digit Demat Account No.' for which you want to cast vote.
- e) Refer the Resolution description and cast your vote by selecting your desired option 'Favour / Against' (If you wish to view the entire Resolution details, click on the '**View Resolution**' file link).
- f) After selecting the desired option i.e., Favour / Against, click on 'Submit'.
- g) A confirmation box will be displayed. If you wish to confirm your vote, click on 'Yes', else to change your vote, click on 'No' and accordingly modify your vote. (Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently).

OR

VOTES UPLOAD:

- a) Visit URL: <https://instavote.linkintime.co.in> and login with credentials as received in Step 1 above.
- b) You will be able to see the notification for e-voting in inbox.
- c) Select '**View**' icon for '**Company's Name / Event number**'. E-voting page will appear.
- d) Download sample vote file from 'Download Sample Vote File' option.
- e) Cast your vote by selecting your desired option 'Favour / Against' in excel and upload the same under 'Upload Vote File' option.
- f) Click on 'Submit'. 'Data uploaded successfully' message will be displayed. (Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently).

Helpdesk:

Helpdesk for Individual shareholders holding securities in physical form/ Non-Individual Shareholders holding securities in demat mode:

Shareholders facing any technical issue in login may contact Link Intime INSTAVOTE helpdesk by sending a request at enotices@linkintime.co.in or contact on: - Tel: 022 – 4918 6000.

Helpdesk for Individual Shareholders holding securities in demat mode:

Individual Shareholders holding securities in demat mode may contact the respective helpdesk for any technical issues related to login through Depository i.e., NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders	Members facing any technical issue in login can contact NSDL helpdesk by



holding securities in demat mode with NSDL	sending a request at evoting@nsdl.co.in or call at : 022 - 4886 7000 and 022 - 2499 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 22 55 33

Forgot Password:

Individual shareholders holding securities in physical form has forgotten the password:

If an Individual shareholders holding securities in physical form has forgotten the USER ID [Login ID] or Password or both then the shareholder can use the "Forgot Password" option available on the e-Voting website of Link Intime: <https://instavote.linkintime.co.in>

- o Click on 'Login' under 'SHARE HOLDER' tab and further Click 'forgot password?'
- o Enter User ID, select Mode and Enter Image Verification code (CAPTCHA). Click on "SUBMIT".

In case shareholders is having valid email address, Password will be sent to his / her registered e-mail address. Shareholders can set the password of his/her choice by providing the information about the particulars of the Security Question and Answer, PAN, DOB/DOI, Bank Account Number (last four digits) etc. as mentioned above. The password should contain a minimum of 8 characters, at least one special character (@!#\$%&), at least one numeral, at least one alphabet and at least one capital letter.*

User ID for Shareholders holding shares in Physical Form (i.e. Share Certificate): Your User ID is Event No + Folio Number registered with the Company

User ID for Shareholders holding shares in NSDL demat account is 8 Character DP ID followed by 8 Digit Client ID

User ID for Shareholders holding shares in CDSL demat account is 16 Digit Beneficiary ID.

Institutional shareholders ("Corporate Body/ Custodian/Mutual Fund") has forgotten the password:

If a Non-Individual Shareholders holding securities in demat mode has forgotten the USER ID [Login ID] or Password or both then the shareholder can use the "Forgot Password" option available on the e-Voting website of Link Intime: <https://instavote.linkintime.co.in>

- o Click on 'Login' under 'Corporate Body/ Custodian/Mutual Fund' tab and further Click 'forgot password?'
- o Enter User ID, Organization ID and Enter Image Verification code (CAPTCHA). Click on "SUBMIT".

In case shareholders is having valid email address, Password will be sent to his / her registered e-mail address. Shareholders can set the password of his/her choice by providing the information about the particulars of the Security Question and Answer, PAN, DOB/DOI, Bank Account Number (last four digits) etc. as mentioned above. The password should contain a minimum of 8 characters, at least one special character (@!#\$%&), at least one numeral, at least one alphabet and at least one capital letter.*

Individual Shareholders holding securities in demat mode with NSDL/ CDSL has forgotten the password:

Shareholders who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned depository/ depository participants website.

- It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- For shareholders/ members holding shares in physical form, the details can be used only for voting on the resolutions contained in this Notice.
- During the voting period, shareholders/ members can login any number of time till they have voted on the resolution(s) for a particular "Event".

**InstaVote Support Desk
Link Intime India Private Limited**



EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013 IN RESPECT OF SPECIAL BUSINESSES MENTIONED IN THE NOTICE OF 19TH ANNUAL GENERAL MEETING.

ITEM NO. 4

M/s Khurana Sharma & Co., Chartered Accountants (ICAI Firm Registration Number 010920N), appointed as statutory auditors of the Company, for a period of **2 years**, to hold office from conclusion of the 19th Annual General Meeting until the conclusion of the 21st Annual General Meeting of the Company. In terms of the provisions of Section 139 of the Companies Act, 2013, the Companies (Audit and Auditors) Rules, 2014, and other applicable provisions, the Company can appoint or reappoint an audit firm as statutory auditors for not more than 2 (two) terms of 5 (five) consecutive years. Based on the recommendations of the Audit Committee, the Board of Directors at their meeting held on 31st August, 2024, approved the appointment of M/s Khurana Sharma & Co., Chartered Accountant (FRN- 010920N), as the Statutory Auditors of the Company to hold office for a term of 2 (Two) years from conclusion of the 19th Annual General Meeting until the conclusion of the 21st Annual General Meeting of the Company to be held for the financial year 2025-26.

The company has received consent cum eligibility certificate from M/s Khurana Sharma & Co., Chartered Accountant regarding their proposed appointment as statutory auditor of the company for a period of 2 years prescribed under section 139 and other applicable provisions of the Companies Act, 2013 and related rules.

The Board of Directors, in consultation with the Audit Committee, may alter and vary the terms and conditions of appointment, including remuneration, in such manner and to such extent as may be mutually agreed with the Statutory Auditors. Considering the evaluation of the experience and expertise of M/s Khurana Sharma & Co and based on the recommendation of the Audit Committee, it is proposed to appoint M/s Khurana Sharma & Co, Chartered Accountant as Statutory Auditors of the Company for a term of two consecutive years till the conclusion of the 21st Annual General Meeting of the Company in terms of the aforesaid provisions.

The Board of Directors recommend the ordinary resolution as set out at item no.4 of the Notice for the approval of the Members.

None of the Directors, Key Managerial Personnel or their relatives are, financially or otherwise, concerned or interested in the said resolution.

Brief profile of M/s Khurana Sharma & Co :-

The Firm M/s Khurana Sharma and Co., (FRN- 010920N), was formed in the year 1990 by Mr. Rajiv Khurana. The Firm has a roll dedicated team of two partners (Chartered Accountants), One Qualified Associate, four audit Assistant and eight Articles to render specialized advice to various clients.

Mr. Rajiv Khurana qualified as a Chartered Accountant in 1991. He formed a reputed firm of long standing with a special experience in Statutory Audit, Internal Audit, and Practicing in Income Tax, Tax Audit and other related work.

ITEM NO.5

The Board, on the recommendation of the Audit Committee, has approved in its meeting held on **31.08.2024**, the appointment of **M/s Charu Jindal & Co, Cost Accountants** bearing Firm Registration Number **103508**, at a remuneration of **Rs.1,25,000/- (Rupees One Lac twenty five thousand only)** with reimbursement of conveyance expenses at actual and GST as applicable to conduct the Cost Audit of the Company for the financial year 2024-25. In accordance with the provisions of Section 148 (3) of the Companies Act, 2013 read with Rule 14 of Companies (Audit & Auditor Rules), 2014, the remuneration payable to the Cost Auditor is required to be ratified by the members of the Company.

None of the Directors, Key Managerial Personnel of the Company or their relatives is in any way, concerned or interested, financially or otherwise, in the resolution.

The Board of Directors recommends the Ordinary Resolution for your approval.

ITEM NO. 6 & 7

Mr. Rahul Batra (DIN No. 02229234), Managing Director & Mr. Varun Batra (DIN No. 02148383), Joint Managing Director hold office w.e.f. 27.01.2021 upto 26.01.2026. During the Financial year 2023-24 Mr. Rahul Batra & Mr. Varun Batra were paid remuneration of Rs 10 lacs p.m. in accordance with the approval received from the shareholders of the company and remuneration was revised by the Board of



Directors w.e.f. 1st April, 2024 to Rs 12.5 lakh p.m. Approval of members of the company is proposed to be taken with delegation of power to the Board of Directors of the company to revise the remuneration payable to Mr. Rahul Batra, Managing Director & Mr. Varun Batra, Joint Managing Director (basic salary, allowances, perquisites, etc) from time to time by giving suitable increment / decrement after review of their performances each year, subject to the condition that their total monthly remuneration not to exceed Rs. 50 lacs p.m. respectively in any case.

As per Section 197 read with Schedule V of Companies Act, 2013, the approval of shareholders is proposed to be obtained for a payment of managerial remuneration as mentioned above (which will exceed the higher maximum limits prescribed even in case of absence or inadequate profits in any year) for a period of 3 years from 30.08.2024 upto his present tenure i.e. 26.01.2026 by way of special resolution.

Mr. Rahul Batra, (DIN No. 02229234) aged 40 years holds Master of Science degree in Business and Management from University Strathclyde Scotland. He is presently directors in following companies:

1. Adley Formulations Private Limited
2. Adley Lab Limited
3. BT Associates Pvt Limited
4. Beta Research Private Limited

Mr. Varun Batra, (DIN No. 02148383) aged 39 years holds Degree in Business Management from Toronto Canada. He is presently directors in following companies:

1. Adley Formulations Private Limited
2. Adley Lab Limited
3. BT Associates Pvt Limited
4. Beta Research Private Limited

Presently Mr. Rahul Batra is holding 39,650 Equity Shares constituting 0.41% in the Company & member of Audit Committee, Nomination & Remuneration Committee, Stakeholder Relationship Committee, Corporate Social Responsibility Committee of the company.

Mr. Varun Batra is holding 33,230 Equity Shares constituting 0.34% in the Company & he is member of Corporate Social Responsibility Committee of the company.

Presently both are also withdrawing remuneration of Rs 12,50,000/-p.m. each from Adley Formulations Pvt Ltd. (wholly owned subsidiary of Beta Drugs Limited) and the maximum higher limit for withdrawing remuneration is Rs 1,00,00,000 p.m. and hence the total remuneration drawn from both the companies by each director is within the higher of the above limits.

In case of absence or inadequacy of profits during any financial year, remuneration to be paid to Mr. Rahul Batra, Managing Director (DIN: 02229234) and Mr. Varun Batra, Joint Managing Director (DIN: 02148383) will exceed the limit prescribed under Schedule V of Companies Act, 2013 therefore approval of shareholders is sought in advance by way of **special resolution** for making payment of remuneration in excess of the above limits.

Statement of information pursuant to Section II of Part II of Schedule V of the Companies Act, 2013 is given in **Annexure 1**.

Mr. Varun Batra and Mr. Rahul Batra himself, is concerned or interested in the passing of respective resolutions set out at item No. 6 & 7 of the notice.

None of the other Directors of the Company or their relatives or key managerial personnel are interested financially or otherwise in the passing of said resolutions.

ITEM NO. 8

Mr Balwant Singh (DIN: 01089968), aged 54 years, is Whole-time Director of the company. He holds a degree in PGDPM-HR IR from DAV College of Management, Chandigarh. He holds 20 years of experience in the field of pharmaceuticals and his scope of work includes managing over all affairs of the Company.

He is presently director in NIL companies

He is presently holding **590** Equity Shares constituting **0.01 %** in the Company.



He is neither Chairman nor member of committee in the company and in any other company.

As per the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors in their respective meetings held on 8th July, 2024, subject to approval of Members at this Annual General Meeting and considering the increased activities, responsibilities and contribution of Mr Balwant Singh in development and growth of the Company, consent of the Members was sought for the re-appointment of **Mr Balwant Singh** as a Whole-time Director of the Company for further period of 5 years **w.e.f. 5th August, 2024 to 4th August, 2029**, on the terms and conditions as set out in this item of the Notice. Mr Balwant Singh satisfies all the conditions set out in Part-I of Schedule V to the Companies Act, 2013 (including any amendments thereto) as also the conditions set out under sub-section (3) of Section 196 of the Companies Act, 2013 for being eligible for re-appointment. Disclosure under Regulation 36(3) of the Listing Regulations and Secretarial Standard-2 issued by the Institute of Company Secretaries of India are set out in the Annexure to the Explanatory Statement. Accordingly, consent of the Members is sought for passing **Special Resolution** as set out in this item of the Notice for re-appointment of Mr Balwant Singh as Whole-time Director of the Company **w.e.f. 5th August, 2024 to 4th August, 2029**. Mr Balwant Singh, Whole-time Director of the Company may be considered to be concerned or interested in the said resolution it relates to his own re-appointment.

Statement of information pursuant to Section II of Part II of Schedule V of the Companies Act, 2013 is given in **Annexure 1** & the details required under regulation 36 of SEBI(LODR) regulations is given in **Annexure 2**.

None of the other Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financially or otherwise, in the said resolution.

The Board recommends the resolution set forth in **Item no.8** for the approval of the members as **Special resolution**.

ITEM NO. 9

Mrs Seema Chopra (DIN: **08510586**), aged 49 years, is Whole-time Director of the company. **Mrs Seema Chopra** is a post graduate and working with the adley group from last 25 years as marketing executive and her scope of work includes managing purchase department of the Company.

She is presently director in NIL companies & holding Nil Equity Shares constituting in the Company.

She is neither Chairman nor member of committee in the company and in any other company.

As per the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors in their respective meetings held on 8th July, 2024, subject to approval of Members at this Annual General Meeting and considering the increased activities, responsibilities and contribution of Mrs Seema Chopra in development and growth of the Company, consent of the Members was sought for the re-appointment of Mrs Seema Chopra as a Whole-time Director of the Company for further period of 5 years **w.e.f. 1st August, 2024 to 31st July, 2029** on the terms and conditions as set out in this item of the Notice. Mrs Seema Chopra satisfies all the conditions set out in Part-I of Schedule V to the Companies Act, 2013 (including any amendments thereto) as also the conditions set out under sub-section (3) of Section 196 of the Companies Act, 2013 for being eligible for re-appointment. Disclosure under Regulation 36(3) of the Listing Regulations and Secretarial Standard-2 issued by the Institute of Company Secretaries of India are set out in the Annexure to the Explanatory Statement. Accordingly, consent of the Members is sought for passing **Special Resolution** as set out in this item of the Notice for re-appointment of Mrs Seema Chopra as Whole-time Director of the Company **w.e.f. 1st August, 2024 to 31st July, 2029**. Mrs Seema Chopra, Whole-time Director of the Company may be considered to be concerned or interested in the said resolution it relates to her own re-appointment.

Statement of information pursuant to Section II of Part II of Schedule V of the Companies Act, 2013 is given in **Annexure 1** & the details required under regulation 36 of SEBI(LODR) regulations is given in **Annexure 2**.

None of the other Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financially or otherwise, in the said resolution.

The Board recommends the resolution set forth in **Item no.9** for the approval of the members as **Special resolution**.



ITEM NO. 10

Mr. Ashutosh Shukla (DIN: 09461568), Whole-time Director of the company aged 46 years, is having 22 years of pharma experience and working with Beta Drugs Limited from last 5 years. He did his Executive MBA from Symbiosis Institute of Business Management.

He is presently directors in NIL companies.

He is presently holding Nil Equity Shares in the Company.

He is neither Chairman nor member of committee in the company and in any other company.

As per the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors in their respective meetings held on 8th July, 2024 and subject to the approval of Members at this Annual General Meeting and considering the increased activities, responsibilities and contribution of **Mr. Ashutosh Shukla** in development and growth of the Company, consent of the Members was sought to increase the remuneration of **Mr. Ashutosh Shukla** from **Rs. 3,56,084 p.m. to Rs 3,64,419 p.m. plus Diwali bonus** and Incentive shall be paid additionally not exceeding the gross salary upto his present tenure i.e. 19th January, 2027 pursuant to provisions of Section 196, 197 & 203 read with Schedule V of Companies Act, 2013 and other applicable provisions of Companies Act, 2013, if any. In case of absence or inadequacy of profits in any financial year, remuneration payable to **Mr. Ashutosh Shukla (DIN: 09461568)**, may exceed the minimum limits prescribed under Schedule V of Companies Act, 2013.

Statement of information pursuant to Section II of Part II of Schedule V of the Companies Act, 2013 is given in Annexure 1.

None of the Directors and Key Managerial Personnel of the Company and their relatives except **Mr. Ashutosh Shukla** is concerned or interested, financial or otherwise, in the resolution.

The Board recommends the resolution set forth in **Item 10** for the approval of the members as a **Special resolution**.

ITEM NO. 11

Considering the present changing scenario and as per requirement of the company and in line with the amendments in Companies Act 2013 it is proposed to alter the incidental object of the Memorandum of Association of the company with the approval of the members of the Company. The approval of the members of the company is required, by way of special resolution pursuant to section 13 of the Companies Act, 2013 and other applicable provisions if any of the Companies Act, 2013 and accordingly the Board recommended the **special resolution** for the approval of members.

Existing and new altered MOA and AOA will be available for inspection by the members of the company during the working hours upto the date of ensuing Annual General Meeting and will also be placed in the meeting for the information of the members

None of the Directors of the Company or key managerial personnel or their relatives is, in any way, concerned or interested in the resolution.

Dated: 31.08.2024

Place: Panchkula

By Order of the Board of Directors

sd/-

Rahul Batra

Chairman & Managing Director

(DIN:02229234)



Statement of information pursuant to Section II of Part II of Schedule V of the Companies Act, 2013

I. General Information

1.	Nature of Industry	The company is in the business of manufacturing of Oncology Medicines.
2.	Date or expected date of commencement of commercial production	2005
3.	In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus	N.A.
4.	Financial performance based on given indicators	The company's total revenue during the fiscal year 2023-24 was Rs 19,935.01 lakh as compared with Rs 15,891.74 lakh during the fiscal year 2022-23. Its net profit was Rs 2,193.66 lakh during the fiscal year 2023-24 as compared with net profit of Rs 1,881.61 lakh during the fiscal year 2022-23
5.	Foreign investments or collaborations, if any.	NIL

II. Information about Directors:

		Name of Directors				
Sr No.		Rahul Batra	Varun Batra	Seema Chopra	Balwant Singh	Ashutosh Shukla
1.	Background details	Rahul Batra, (DIN: 02229234) aged 39 years is the Chairman cum Managing Director of the Company. He holds Master of Science degree in Business and Management from University Strathclyde Scotland	Varun Batra, (DIN: 02148383) aged 39 years, is the Joint Managing Director of the Company. He holds Degree in Business management from Toronto Canada.	Seema Chopra, (DIN: 08510586) aged 49 years is the Whole time Director of our Company. She is post graduate.	Balwant Singh, (DIN: 01089968) aged 54 years is the Whole time Director of our Company. He holds a degree in PGDPM-HR IR from DAV College of Management, Chandigarh.	Ashutosh Shukla (DIN: 09461568) aged 46 years is the Whole time Director of our Company. He holds a degree in Executive MBA from Symbiosis Institute of Business Management.
2.	Past remuneration	Rs 10.00 lacs p.m. till 31.03.2024	Rs 10.00 lacs p.m. till 31.03.2024	Rs 98,457 p.m. till 31.03.2024	Rs 2,42,630 p.m till 31.03.2024	Rs 3,56,084 p.m. till 31.03.2024
3.	Recognition or Awards	NIL	NIL	NIL	NIL	Nil
4.	Job profile and his suitability	He holds 19 years of experience in the field of pharmaceuticals. He contributes extensively towards the growth of the company and helps the company achieve its targets and	He holds 18 years of experience in the field of pharmaceuticals He contributes extensively towards the growth of the company and helps the company achieve its targets and long term	She look after the marketing and purchase segment of the company.	He holds 20 years of experience in the field of pharmaceuticals and his scope of work includes managing over all affairs of the Company.	He is having 22 years of pharma experience and working with Beta Drugs Limited from last 5 years. He is a strategic thinker and strong team player.



		long term objectives toward the achievement of the common objectives of the organization.	objectives toward the achievement of the common objectives of the organization.			
5.	Remuneration proposed	Rs. 12.50 lac p.m. w.e.f 01.04.2024	Rs. 12.50 lac p.m. w.e.f 01.04.2024	Rs.1,01,957 p.m. w.e.f 01.04.2024	Rs 2,67,630 p.m. w.e.f 01.04.2024	Rs 3,64,419 p.m. w.e.f 01.04.2024
6.	Comparative Remuneration profile with respect to Industry, size of the Company, profile of the position and the person (in case of expatriates the relevant details would be with respect to the country of his origin)	The remuneration package is competitive and is at par with the packages offered in the industry of this size.	The remuneration package is competitive and is at par with the packages offered in the industry of this size.	The remuneration package is competitive and is at par with the packages offered in the industry of this size.	The remuneration package is competitive and is at par with the packages offered in the industry of this size.	The remuneration package is competitive and is at par with the packages offered in the industry of this size.
7.	Pecuniary Relationship directly or indirectly with the Company or relationship with the managerial Personnel, if any	Brother of Mr. Varun Batra	Brother of Mr. Rahul Batra	N.A.	N.A.	N.A.

III. Other Information

1.	Reasons of loss or inadequate profits	The Profits are considered inadequate because the remuneration exceeds the ceiling prescribed for managerial Remuneration under Section I of Part II of Schedule V to the Companies Act, 2013.
2.	Steps taken or proposed to be taken for improvement	The Company continues to earn profit and hence there are no specific steps required to take and proposed to be taken for improvement.
3.	Expected increase in productivity and profits in measurable terms	Both revenues and net profit during the current fiscal is expected to increase as compared with the same period a year ago.



DETAILS OF DIRECTORS SEEKING APPOINTMENT/ RE-APPOINTMENT AT THE ENSUING ANNUAL GENERAL MEETING UNDER REGULATION 36 OF SEBI(LODR) REGULATIONS:-

Name of Director	Mr. Varun Batra	Mrs. Seema Chopra	Mr Balwant Singh
Director Identification Number	02148383	08510586	01089968
Date of Birth	15/06/1985	03/07/1975	04/04/1970
Educational Qualification	Degree in Business Management from Toronto Canada	Post graduation in Mass Communication & Hindi	PGDPM-HR IR
Experience	18 years	25 Years	20 Years
Details of remuneration to be paid, if any	Rs 12,50,000 p.m.	Rs 1,01,957 p.m.	Rs 2,17,630 p.m.
Date of first appointment to the Board	01/08/2014	01/08/2019	01/08/2014
No. of Share held by Directors in the Company	33,230	NIL	590
Relationship with other Directors / KMPs	Brother of Mr. Rahul Batra	N.A.	N.A.
No. of Board meetings attended during the year	11	11	11
Profile	Varun Batra, (DIN: 02148383) aged 39 years, is the Joint Managing Director of the Company. He contributes extensively towards the growth of the company and helps the company achieve its targets and long term objectives toward the achievement of the common objectives of the organization.	Seema Chopra, (DIN: 08510586) aged 49 years is the Whole time Director of our Company. She is post graduate and look after the marketing and purchase segment of the company.	Balwant Singh, (DIN: 01089968) aged 54 years is the Whole time Director of our Company. He holds a degree in PGDPM-HR IR from DAV College of Management, Chandigarh. He holds 20 years of experience in the field of pharmaceuticals and his scope of work includes managing over all affairs of the Company.
Expertise in specific Functional areas	Production Department and Export sales	Marketing and Purchase segment	Managing over all affairs of the Company.
Directorship in other listed/unlisted Companies	Adley Formulations Pvt Ltd (unlisted) Adley Lab Limited (unlisted) B.T. Associates Pvt td (unlisted) Beta Research Pvt Ltd. Vintage Weaves by HB Private Limited	NIL	NIL
Chairman/ Member of Committees of the Board of other listed/unlisted Companies in which he is a Director	Member in CSR Committee of Adley Lab Limited & Adley Formulations Private Limited	NIL	NIL
listed entities from which the person has resigned in the past three years	N.A.	N.A.	N.A.
Relationship, if any, with the other members of the Board	Brother of Mr. Rahul Batra	N.A.	N.A.
Terms and Conditions of appointment and remuneration sought and remuneration last and justification	Promoted & appointed as Joint Managing Director w.e.f. 27.01.2021 upto 26.01.2026 @ remuneration of Rs 6.00 lacs p.m. Last remuneration Rs 10.00 lacs p.m.	Appointment in AGM held on 30 th September, 2019 for 5 years w.e.f. 1 st August, 2019 upto period ended 31 st July, 2024 @ remuneration of Rs 45,269/- p.m. Last remuneration Rs 98,457/- p.m.	Re-appointment for 5 years w.e.f. 5 th August, 2019 upto period ended 4 th August, 2024 @ remuneration of Rs 1,36,000 p.m. Last remuneration Rs 2,42,630 p.m.
Skills and capabilities required for the role and the manner in which the proposed person meets such requirements.	NA	NA	NA



19TH ANNUAL REPORT

BETA DRUGS LIMITED

DIRECTORS' REPORT

To
The Members of
BETA DRUGS LIMITED

Your Directors take pleasure in presenting the 19th Annual Report of the Company together with the Audited Accounts for the financial year ended on 31st March, 2024. The Management Discussion and Analysis has also been incorporated in this report.

❖ FINANCIAL SUMMARY/HIGHLIGHTS:

The brief financial results are as under:

PARTICULARS	STANDALONE (Amount in Lacs)		CONSOLIDATED (Amount in Lacs)	
	YEAR ENDED 31.03.2024	YEAR ENDED 31.03.2023	YEAR ENDED 31.03.2024	YEAR ENDED 31.03.2023
Revenue from Operations	19,762.07	15,787.46	29,571.38	22,711.36
Other Income	172.94	104.28	135.88	75.35
Total Revenue	19,935.01	15,891.74	29,707.26	22,786.71
Less: Other expenses excluding depreciation	16,514.25	12,751.31	23,853.62	17,640.06
Less: Depreciation & Preliminary expenses written off	472.46	619.48	978.22	1,041.00
Profit / (loss) before Taxation	2,948.30	2,520.95	4,875.42	4,105.65
Less : Provision for Taxation				
Current Tax	746.71	668.39	1,252.76	1,085.85
Deferred Tax	7.93	-29.05	-21.04	-52.07
Profit/ (loss) after Taxation	2,193.66	1,881.61	3,643.70	3,071.87

❖ DIVIDEND:

The Board of Directors has not recommended any dividend for the year.

❖ TRANSFER TO RESERVE:

Profit of Rs.2193.66 lakhs was transferred to surplus a/c.

❖ REVIEW OF FINANCIAL PERFORMANCE AND STATE OF COMPANY'S AFFAIRS:

During the year, your Company has emerged as one of the fastest growing company in the Oncology product segment which has contributed to significant increase in the profitability of the company.

• STANDALONE:

During the year, Revenue of the Company increased by 25.44% i.e. from Rs 15,891.74 lakhs to Rs 19,935.01 lakhs .Profit before tax increased by 16.95% i.e. from Rs. 2,520.95 lakhs to Rs.2,948.30 lakhs. Profit after tax increased by 16.58% i.e. from Rs. 1,881.61 lakhs to Rs.2193.66 lakhs.

• CONSOLIDATED:

The Consolidated Financial Statements of the Company have been prepared as per Ind AS of the Institute of Chartered Accountants of India. During the year, Company's consolidated Revenue increased by 30.37% i.e. from Rs. 22,786.71 lakhs to Rs.29,707.26 lakhs. Profit before tax increased by 18.75% i.e. from Rs. 4,105.65 lakhs to Rs.4,875.42 lakhs. Profit after tax increased by 18.62% i.e. from Rs.3,071.87 lakhs to Rs.3,643.70 lakhs.

❖ CHANGE IN THE NATURE OF BUSINESS:

During the year the Company has not changed its business.

❖ MATERIAL CHANGES:

There are no Material change occurred between the end of the financial year of the company to which the financial statements related and the date of the report, which is affecting the financial position of the company.

❖ LISTING:

The Equity Shares of the Company are listed on SME Platform of National Stock Exchange of India Limited (NSE Emerge).

The Company is regular in payment of Annual Listing Fees. The Company has paid Listing fees up to the year 2024-25.

❖ SUBSIDIARY COMPANIES/JOINT VENTURE COMPANY/ASSOCIATE COMPANY:

During the financial Year the Board of Directors of the Company at its meeting held on 7th November, 2023, inter alia, has considered and approved to write off the total investment made by the company in Beta Ubk. International Private Limited and it ceased to be subsidiary of



the company. The company continues its operations of Sales & Marketing in Uzbekistan through its own sales team from India. All the MA's (Marketing Authorizations) belong to Beta Drugs Limited, India.

Company has following Subsidiary Companies as on 31.03.2024:-

- **Adley Formulations Private Limited**, a wholly owned subsidiary of Beta Drugs Limited having Registered office at SCO-184, Sector-5, Panchkula, Haryana-134114 & Works at Kotla, Barotiwala, Distt Solan, Himachal Pradesh **with 100% Shareholding**
Business: Manufacturing & Trading of Oncology Products
- **Adley Lab Limited**, a wholly owned subsidiary of Beta Drugs Limited having Registered office & Works at D-27, Focal Point, Derabassi-140507 (SAS Nagar, Mohali) **with 100% Shareholding**
Business: Manufacturing of Oncology API
- **Beta Research Private Limited**, a wholly owned subsidiary of Beta Drugs Limited having Registered office at SCO-184, 1st Floor, Sector-5, Panchkula, Haryana-134114 with 100% Shareholding.

A statement containing the salient feature of the financial statement of Subsidiary company under the first proviso to sub-section (3) of section 129 in form AOC - 1 is appended as **Annexure – 6**

The Company is not having any other Joint Venture or Associate Company.

❖ **PERFORMANCE OF SUBSIDIARY COMPANIES:**

- **Adley Formulations Private Limited** is engaged primarily in **Manufacturing & Trading of Oncology Products**. During the period under review, **Adley Formulations Private Limited** achieved a turnover of **Rs 8,580.71 lakhs** with a profitability of **Rs 763.70 lakhs**.
- **Adley Lab Limited** is engaged in **manufacturing of Oncology API**. During the period under review, **Adley Lab Limited** achieved a turnover of **Rs 5332.59 lakhs** with a profitability of **Rs 686.40 lakhs**.
- **Beta Research Private Limited**, there is no operations till date.
Therefore **Adley Formulations Private Limited** and **Adley Lab Limited** played a significant role toward the increase in the overall profitability of the company.

❖ **REASONS FOR REVISION OF FINANCIAL STATEMENT OR REPORT:**

During the year, the financial statement or report was not revised. Hence further details are not applicable.

❖ **INCREASE IN AUTHORISED SHARE CAPITAL:**

During the year under review there is no change in the authorized Share capital of the company.

❖ **ALLOTMENT OF SHARES:**

During the financial year 2023-24 the Company has not allotted any shares

❖ **DEMATERIALIZATION OF EQUITY SHARES:**

The entire Shareholding of the Company is in Demat mode.

❖ **DEPOSITORY SYSTEM:**

As the Members are aware, your Company's shares are trade-able compulsorily in electronic form and your Company has established connectivity with both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). In view of the numerous advantages offered by the depository system, the members are requested to avail the facility of dematerialization of the Company's shares on NSDL & CDSL. The ISIN allotted to the Company's Equity shares is **INE351Y01019**.

❖ **DIRECTORS & KEY MANAGERIAL PERSONNEL:**

Pursuant to the provisions of Section 152 of the Companies Act, 2013 **Mr. Varun Batra (DIN: 02148383)** & **Mrs. Seema Chopra (DIN: 08510586)**, Directors of the Company retires by rotation at the ensuing Annual General Meeting and being eligible, has offered themselves to be re-appointed as Directors of the Company.

The Board recommends the re-appointment of **Mr. Balwant Singh (DIN: 01089968)** & **Mrs. Seema Chopra (DIN: 08510586)**, as Whole time Director of the Company, liable to retire by rotation.

Brief profile of the directors seeking appointment/re-appointment and other details including remuneration etc has been given in the **Annexure-2** of the notice of the ensuing AGM.

❖ **DIRECTORS' RESPONSIBILITY STATEMENT:**

Pursuant to the requirement of section 134(5) of the Companies Act, 2013, with respect to Directors' Responsibility Statement, it is hereby confirmed:

1. that in the preparation of the annual accounts, the applicable Indian accounting standards had been followed along with proper explanation relating to material departures;
2. that the Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for that period;



19TH ANNUAL REPORT

- 3. that the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- 4. that the Directors had prepared the annual accounts on a going concern basis; and
- 5. that the directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
- 6. that the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

❖ **FORMAL EVALUATION BY BOARD OF ITS OWN PERFORMANCE:**

The performance of the board was evaluated by the board after seeking inputs from all the directors on the basis of the criteria such as the board composition and structure, effectiveness of board processes, information and functioning, etc. The performance of the committees was evaluated by the board after seeking inputs from the committee members on the basis of the criteria such as the composition of committees, effectiveness of committee meetings, etc.

The Board and the Nomination and Remuneration Committee reviewed the performance of the individual directors on the basis of the criteria such as the contribution of the individual director to the board and committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings, etc. In addition, the chairman was also evaluated on the key aspects of his role.

In a separate meeting of independent directors, performance of non-independent directors, performance of the board as a whole and performance of the chairman was evaluated, taking into account the views of executive directors and non-executive directors. Performance evaluation of independent directors was done by the entire board, excluding the independent director being evaluated.

❖ **NUMBER OF MEETINGS OF BOARD:-**

During the FY 2023-24, the Board of Directors met eleven times viz. 1st April, 2023, 8th May, 2023, 20th June, 2023, 29th July, 2023, 1st September, 2023, 27th September, 2023, 20th October, 2023, 7th November, 2023, 4th January, 2024, 14th February, 2024 & 19th February, 2024.

Name of the Director	Number of Board Meetings Attended
Rahul Batra	11
Varun Batra	11
Balwant Singh	11
Rohit Parti	11
Manmohan Khanna	11
Seema Chopra	11
Ashutosh Shukla	11

Last Annual General Meeting of the company was held on 30th September, 2023.

During the Financial year 2023-24 no Extraordinary General Meeting was held. No item was required to be passed through postal ballot during the Financial year 2023-24.

❖ **DECLARATION BY INDEPENDENT DIRECTORS:**

The Company has received necessary Declaration from each Independent Director/s under section 149(7) of the Companies Act, 2013 that they meets the criteria of Independence laid down in section 149(6) of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Independent Directors have complied with the Code for Independent Directors prescribed in Schedule IV to the Companies Act, 2013.

❖ **ISSUE OF EQUITY SHARES WITH DIFFERENTIAL VOTING RIGHTS / SWEAT EQUITY SHARES / EMPLOYEE STOCK OPTION SCHEME:**

During the year, the Company has not issued any equity shares with differential voting rights or sweat equity shares or shares under employee stock option scheme. Hence disclosure regarding the same is not given.

❖ **AUDITORS' APPOINTMENT & REPORT:**

M/s Kalra Rai & Associates, Chartered Accountants, Chandigarh, Firm Registration Number **008859N** have issued their Report (Standalone & Consolidated) for the financial year ended on March 31, 2024 forms part of this Annual Report and the same does not contain any qualification, reservation or adverse remark hence no explanation or comments of the Board is required in this matter.

There have been no instances of fraud reported by the Auditors under Section 143(12) of the Companies Act, 2013.

M/s Kalra Rai & Associates, Chartered Accountants has completed his two consecutive terms of appointment as statutory auditor of the company and hence not eligible for re-appointment as statutory auditor of the company in terms of provisions u/s 139 (2) of the Companies Act, 2013. Therefore the Board of Directors of the company, on the recommendation made by the Audit Committee, has decided to appoint M/s Khurana Sharma & Co., (FRN-010920N), Chartered Accountant, Chandigarh as statutory Auditor of the company for a period of two years commencing from the conclusion of 19th Annual General Meeting till the conclusion of 21st Annual General Meeting of the company at a remuneration to be fixed by the Audit Committee and/or Board of Directors of the Company, in addition to the re-imburement of applicable taxes and actual out of pocket and travelling



expenses, etc. incurred in connection with the audit. The company has obtained consent cum eligibility certificate under section 139 & 141 of the Companies Act, 2013 from the proposed auditor.

❖ **COMMENTS ON AUDITOR'S REPORT:**

The notes referred to in the Auditor Report are self-explanatory and they do not call for any further explanation as required under section 134 of the Companies Act, 2013.

❖ **COST AUDITOR:**

The Board of Directors of your Company has appointed M/s Charu Jindal & Company, Cost Accountants, Dehradun as Cost Auditors to conduct audit of the Cost Records for Financial Year to be ended on March 31, 2025.

❖ **COST RECORDS:**

The Central Government has prescribed the maintenance of cost records under section 148(1) of the act, for the goods supplied by the Company. The Company had maintained proper cost accounts & records. Cost Audit Report for the financial year 2023-24 is being filed.

❖ **INTERNAL AUDITOR:**

The Board of Directors of your company has appointed M/s Srivastava V.K. & Associates, Chartered Accountants, Chandigarh as Internal Auditors to conduct Internal audit for Financial Year to be ended on March 31, 2025.

❖ **SECRETARIAL AUDIT:**

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company has appointed Mr. Dinesh Bhandari, Company Secretary to undertake the Secretarial Audit of the Company for Financial Year to be ended on March 31, 2025.

The Secretarial Audit Report for the FY 2023-24 is annexed herewith as “Annexure-3”.

❖ **MANAGEMENT COMMENTS TO THE SECRETARIAL AUDITOR QUALIFICATION/OBSERVATIONS:**

	Audit Qualifications/Observations	Management Comments
1.	Section 178 (1) of Companies Act, 2013 requires Composition of Nomination and remuneration committee of 3 or more non executive director, whereas Company has only 2 non executive directors in the Committee. It is also further drawn to your attention that there is a shortfall of one independent Director w.e.f. 20.1.2022 required u/s 149(4) of the Companies Act, 2013 as per strength of Board of Directors of Company.	The company is in the process of finding the suitable candidate and will fill the vacancy of Independent Director. After appointing the Independent Director, the composition of Nomination and Remuneration Committee will be as per the requirement of Section 178 (1) of Companies Act, 2013.
2.	a) Clause 33(3)(d) of LODR- Non submission of consolidated unaudited financial results as at 30.9.2023 to Stock Exchange with respect to non operative foreign subsidiary viz. Beta UBK International Pvt. Ltd. and compliance required u/s 129, 136 and other relevant provisions of Companies Act, 2013 not made. During the financial Year the Board of Directors of the Company at its meeting held on 7th November, 2023 has considered and approved to write off the total investment made by the company in Beta Ubk. International Private Limited (non operative subsidiary) and it ceased to be subsidiary of the company. However, no reporting of disinvestment / written off made to Reserve Bank of India till date. Further the Company has taken impact of above mentioned written off investment value in its half yearly financial results approved for the period ended 30 th September, 2023 in its board meeting held on 7.11.2023. b) Annual performance report (APR) for calendar year 2022, 2023 not filed to authorized dealer bank in respect of Beta UBK International Pvt. Ltd., foreign subsidiary.	a) Since the production facility in Beta UBK International Pvt. Ltd was not operational and the subsidiary is non operative since incorporation, therefore the Board of Directors of the Company at its meeting held on 7th November, 2023 has considered and approved to write off the total investment made by the company in Beta Ubk. International Private Limited and taken its impact in the financials of the company for the half year ended 30 th September, 2023. Therefore it ceased to be a subsidiary of the company. Further the company continues its operations of Sales & Marketing in Uzbekistan through its own sales team from India. All the MA's (Marketing Authorizations) belong to Beta Drugs Limited, India. Company is in process for reporting the same to RBI. b) The company is non-operative therefore APR is not yet filed.

❖ **INTERNAL AUDIT CONTROLS AND THEIR ADEQUACY:**

The Company has a proper and adequate system of internal controls, commensurate with the size scale and complexity of its operations. This ensures that all transactions are authorized, recorded and reported correctly, and assets are safeguarded and protected against loss from unauthorized use or disposition. In addition, there are operational controls and fraud risk controls, covering the entire spectrum of internal financial controls. To maintain its objectivity and independence, the Internal Audit function reports to the Chairman of the audit committee of the Board and to the Chairman and Managing



19TH ANNUAL REPORT

BETA DRUGS LIMITED

Director. The Internal Audit department monitors and evaluate the efficiency and adequacy of the internal control system in the Company, its compliance with operating systems, accounting procedures and policies at all locations of the Company. Based on the report of internal audit functions, process owner undertake corrective actions in their respective areas and thereby strengthen the controls. Significant audit observations and recommendations along with corrective actions thereon are presented to the Audit Committee of the Board.

❖ **ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS:-**

The Company has internal Auditors and the Audit Committee constituted are in place to take care of the same. During the year, the Company continued to implement their suggestions and recommendations to improve the control environment. Their scope of work includes review of processes for safeguarding the assets of the Company, review of operational efficiency, effectiveness of systems and processes, and assessing the internal control strengths in all areas. Internal Auditors findings are discussed with the process owners and suitable corrective actions taken as per the directions of Audit Committee on an ongoing basis to improve efficiency in operations.

❖ **AUDIT COMMITTEE:**

As required under the provisions of section 177 of the Companies Act, 2013 and Rules made there under the Board of Director constituted the Audit Committee.

The composition of the committee is as follows:-

1.	Mr.Manmohan Khanna	Chairman
2.	Mr.Rohit Parti	Member
4.	Mr.Rahul Batra	Member

During the year, Audit Committee has met five times details of the same are as follows:-

Sr. No	Date of Meeting	Strength of Committee	No. of Members Present
1.	1 st April, 2023	3	3
2.	8 th May, 2023	3	3
3.	20 th June, 2023	3	3
4.	1 st September, 2023	3	3
5.	7 th November, 2023	3	3

The term of references of audit committee are to recommend for appointment of statutory auditor, approve related party transactions, examination of financial statements and auditor's report, scrutinize inter corporate loans and investments, evaluation of internal financial control and risk management, review and monitor auditors independence and performance and effectiveness of audit process.

❖ **NOMINATION & REMUNERATION COMMITTEE:**

As required under the provisions of section 178 of the Companies Act, 2013 and Rules made there under the Board of Director constituted the Nomination and Remuneration Committee.

The composition of the committee is as follows:-

1.	Mr. Manmohan Khanna	Chairman
2.	Mr. Rohit Parti	Member
3.	Mr. Rahul Batra	Member

During the year, two meeting of the nomination and remuneration committee was held. Details of the Meeting are as follows:-

Sr. No	Date of Meeting	Strength of Committee	No. of Members Present
1.	8 th May, 2023	3	3
2.	20 th June, 2023	3	3

Remuneration Policy: Website link:-

<http://www.betadrugslimited.com>

(a) **Remuneration to Executive Directors:**

The remuneration paid to executive directors of the Company is recommended by the Nomination and Remuneration Committee of the Company and then Board of the Company approve in their duly held meeting. The remuneration of executive directors are decided by considering various criteria like qualification, experience, responsibilities, value addition to the Company and financial position of the Company. Board is taking permission of the members if required at any time for paying remuneration to executive directors.

(b) **Remuneration to Non-Executive Directors:**



Company is not paying any remuneration to non-executive and independent directors of the Company except sitting fees of Rs 3000/- per meeting.

❖ **STAKEHOLDERS RELATIONSHIP COMMITTEE:**

As required under the provisions of section 178 of the Companies Act, 2013 and Rules made there under the Board of Director constituted the Stakeholders Relationship Committee.

The composition of the committee is as follows:-

1.	Mr. Manmohan Khanna	Chairman
2.	Mr.Rohit Parti	Member
4.	Mr. Rahul Batra	Member

The Company has not received any complaints during the year. There was no valid request for transfer of shares pending as on 31st March, 2024.

Mrs.Rajni Brar, Company Secretary is the Compliance Officer for the above purpose.

During the year, two meeting of the Stakeholders Relationship Committee was held. Details of the Meeting are as follows:

Sr. No	Date of Meeting	Strength of Committee	No. of Members Present
1.	8 th May, 2023	3	3
2.	7 th November, 2023	3	3

❖ **POLICY ON PRESERVATION OF THE DOCUMENTS:**

The Company has formulated a Policy pursuant to Regulation 9 of the Securities Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015 (“Regulations”) on Preservation of the Documents to ensure safe keeping of the records and safeguard the Documents from getting mishandled, while at the same time avoiding superfluous inventory of Documents.

❖ **WHISTLE BLOWER POLICY/ VIGIL MECHANISM:**

The Vigil Mechanism/Whistle Blower Policy has been adopted to provide appropriate Avenues to the employees to bring to the attention of the management, the concerns about any unethical behaviour, by using the mechanism provided in the Policy. In cases related to financial irregularities, including fraud or suspected fraud, the employees may directly approach the Chairman of the Audit Committee of the Company. No director or employee has been denied access to the Audit Committee.

The Policy provides that no adverse action shall be taken or recommended against any employee in retaliation to his/her disclosure, if any, in good faith of any unethical and improper practices or alleged wrongful conduct. This Policy protects such employees from unfair or prejudicial treatment by anyone in the Company. The same is available on the Company’s Web www.betadrugslimited.com.

❖ **POLICY ON CRITERIA FOR DETERMINING MATERIALITY OF EVENTS:**

The Policy is framed in accordance with the requirements of the Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Regulations).The objective of the Policy is to determine materiality of events or information of the Company and to ensure that such information is adequately disseminated in pursuance with the Regulations and to provide an overall governance framework for such determination of materiality.

❖ **RISK MANAGEMENT POLICY/PLAN:**

It may please be noted that as our Company is not falling in the applicability criteria prescribed as mentioned in the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Hence, the company has not developed and implemented any risk management policy/plan but the Company has adequate internal control systems and procedures to combat the risk.

❖ **VIGIL MECHANISM:**

It may please be noted that as our Company is not falling in the applicability criteria prescribed as mentioned in the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Hence, there is no vigil mechanism in the company.

❖ **CODE OF BUSINESS CONDUCT AND ETHICS:**

Based on the requirements under SEBI (Prohibition of Insider Trading) Regulations, 1992 read with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the code of Internal Procedures and code for prevention of insider trading (“Code of Conduct”), as approved by the Board from time to time, are in force by the Company. The objective of this Code of Conduct is to protect the interest of shareholders at large, to prevent misuse of any price sensitive information and to prevent any insider trading activity by dealing in shares of the Company by its Directors, designated employees and other employees.

The Company also adopts the concept of Trading Window Closure, to prevent its Directors, Officers, designated employees and other employees from trading in the securities of Beta Drugs Limited at the time when there is unpublished price sensitive information.

The COC is available on the website of the Company www.betadrugslimited.com and the Directors and senior management personnel’s of the company has complied with the code of conduct.

**❖ DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORK PLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:**

The company has a policy in line with the requirement of applicable provision of the POSH Act, 2013 and it provides for protection against sexual harassment of woman at work place and for prevention and redressal of such complaints. The Company has zero tolerance on Sexual Harassment at workplace. During the year under review, no complaints were received/pending against the sexual harassment at workplace. The company has made compliance of all applicable provisions of the said Act. The Complaint Committee for Redressal of Sexual Harassment consists of the following members:-

1.	Mrs. Salita Chauhan,	Presiding Officer
2.	Mrs. Parul Thakur	Member
3.	Ms. Sonia Nawani,	Member
4.	Mr. Balwant Singh,	Member
5.	Mr. Rajeev Kumar Sharma, Advocate	Member

❖ REMUNERATION POLICY:

The Board has, on the recommendation of the Nomination & Remuneration Committee framed a policy for selection and appointment of Directors, Senior Management and their remuneration.

The Company's shareholders may refer the Company's website for the detailed Nomination & Remuneration Policy of the Company on the appointment and remuneration of Directors including criteria for determining qualifications, positive attributes, independence of a Director; and other matters provided under sub-section (3) of section 178.

The Company's remuneration policy is directed towards rewarding performance based on review of achievements periodically.

The remuneration policy is in consonance with the existing industry practice.

❖ ANALYSIS OF REMUNERATION:

Disclosure/details pursuant to provisions of Section 197(12) of the Companies Act 2013 read with Companies (appointment and Remuneration of managerial personnel) Rules, 2014 are given as follows:-

- 1) The percentage increase in Remuneration of each Director, Chief Financial Officer and Company Secretary in the financial year 2023-24 and ratio of remuneration of each key managerial personnel (KMP) against the performance are as under:-

Sr No.	Name of Director/KMP and Designation	Remuneration of Director/KMP for the Financial Year 2023-24 (In Rs.)	%age Increase in Remuneration for the Financial Year 2023-24	Ratio of Remuneration of each director to the Median Remuneration of Employees
1.	Mr. Varun Batra, Whole Time Director	1,21,00,000	Nil	64.70
2.	Mr. Rahul Batra, Whole Time Director	1,21,00,000	Nil	64.70
3.	Mr. Balwant Singh, Whole Time Director	29,79,860	11.96%	15.93
4.	Mr. Ashutosh Shukla, Whole Time Director	51,23,008	21.31%	27.39
5.	Mrs. Seema Chopra, Whole time Director	11,91,484	34.29%	6.37
6.	Mr. Manmohan Khanna, Independent Director	NIL	NIL	NIL
7.	Mr. Rohit Parti, Independent Director	NIL	NIL	NIL
8.	Mrs. Rajni Brar, Company Secretary	9,11,552	8.55%	4.87
9.	Mr. Nipun Arora, CFO	31,00,981	18.21%	16.58

2) The Median Remuneration of Employees of the Company during the financial year 2023-24 was Rs.1,87,000

3) There was an increase of 22.90% in median remuneration of employees during the financial year.

4) The number of permanent employees on the rolls of the Company is 371 for the year ended March 31, 2024.

5) There was an increase of 8.56% in salaries of employees other than the managerial personnel during the financial year 2023-24 while the increase in the remuneration of managerial personnel was 4.56%. The aggregate limit of remuneration of managerial personnel was reviewed and revised, keeping in view the need for leveraging experience and expertise as well as rewarding talent and the prevailing trend in the industry. Therefore increase in the managerial remuneration is justified.

6) It is affirmed that remuneration paid during the year ended March 31st, 2024 is as per the Remuneration Policy of the Company.

7) There is no employee withdrawing remuneration equal to or more than the limit prescribed in rule 5 (2) of The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

❖ PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES:

There was no employee drawing remuneration in excess of limits prescribed under section 197(12) of the Companies Act, 2013 read with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

❖ REGULATORY ORDERS:



During the year, there were no significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and Company's operations in future.

❖ **CSR COMMITTEE:**

As required under the provisions of section 135 of the Companies Act, 2013 and Rules made there under the Board of Director constituted the Stakeholders Relationship Committee.

The composition of the committee is as follows:-

1.	Mr. Rahul Batra	Chairman
2.	Mr. Varun Batra	Member
3.	Mr. Rohit Parti	Member

During the year, five meeting of the Corporate Social Responsibility Committee was held. Details of the Meeting are as follows:

Sr. No	Date of Meeting	Strength of Committee	No. of Members Present
1.	11 th April, 2023	3	3
2.	26 th October, 2023	3	3
3.	7 th November, 2023	3	3
4.	4 th January, 2024	3	3
	29 th March, 2024	3	3

The Committee has been entrusted with the responsibility of formulating and recommending to the Board, a Corporate Social Responsibility Policy (CSR Policy), indicating the activities to be undertaken by the Company, recommending the amount to be spent on CSR activities and monitoring the implementation of the framework of the CSR Policy.

The Company has provided for the corporate social responsibility as per Section 135 of the Companies Act 2013 i.e. **Rs. 41,27,644.21** during the year being 2% of the average net profits for the immediately preceding three Financial Years. The actual amount spent during the financial year was **Rs. 41,27,700.00** on eligible projects/ activities approved by the Board on the recommendation of the CSR Committee. Brief particulars of the CSR projects undertaken are given in **Annexure 4**, forming part of the Board's Report.

❖ **DETAILS ON CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:**

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo stipulated under Section 134(3)(m) of the Companies Act, 2013 read with Rule, 8 of The Companies (Accounts) Rules, 2014.

(A) CONSERVATION OF ENERGY:

(i)	the steps taken or impact on conservation of energy	The Company accords high priority to conservation of energy. However, there are no specific steps taken in this regard.
(ii)	the steps taken by the company for utilizing alternate sources of energy	The Company is not utilizing alternate sources of energy.
(iii)	the capital investment on energy conservation equipments	NIL

(B) TECHNOLOGY ABSORPTION:

(i)	the efforts made towards technology absorption	NIL
(ii)	the benefits derived like product improvement, cost reduction, product development or import substitution	NIL
(iii)	in case of imported technology (imported during the last three years reckoned from the beginning of the financial year) (a) the details of technology imported; (b) the year of import; (c) whether the technology been fully absorbed; (d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof; and	The Company has not imported any technology during the year. Hence, there are no details to be furnished under this clause.
(iv)	the expenditure incurred on Research and Development	Rs 1,45,74,778.79

(C) Foreign exchange earnings and Outgo:

The Foreign Exchange earned in terms of actual inflows during the year and the Foreign Exchange outgo during the year in terms of actual outflows are given below:

Particulars	Amt. as on 31.3.2024	Amt. as on 31.3.2023
Earnings in Foreign Exchange	44,48,15,702.67	27,82,93,667.94
Foreign Exchange Outgo	(4,580.55)	4,79,58,756.36



19TH ANNUAL REPORT

BETA DRUGS LIMITED

❖ **INTERNAL FINANCIAL CONTROL:**

The Company has a well placed, proper and adequate internal financial control system which ensures that all the assets are safeguarded and protected and that the transactions are authorized recorded and reported correctly.

The internal audit covers a wide variety of operational matters and ensures compliance with specific standard with regards to availability and suitability of policies and procedures. During the year no reportable material weakness in the design or operation were observed.

The Directors has laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and have been operating effectively.

❖ **COMPLIANCE WITH SECRETARIAL STANDARDS ON BOARD AND ANNUAL GENERAL MEETINGS:**

The Company has complied with Secretarial Standards issued by the Institute of Company Secretaries of India on Board meetings and Annual General Meetings.

❖ **AGREEMENTS THAT SUBSIST AS ON THE DATE OF NOTIFICATION OF CLAUSE 5A TO PARA A OF PART A OF SCHEDULE III, THEIR SALIENT FEATURES, INCLUDING THE LINK TO THE WEBPAGE WHERE THE COMPLETE DETAILS OF SUCH AGREEMENTS ARE AVAILABLE- N.A.**

❖ **DEPOSITS:**

The Company has not invited/ accepted any deposits from the public during the year ended **March 31, 2024**. There were no unclaimed or unpaid deposits outstanding as on **March 31, 2024**. No unsecured loan has been received from the Directors of the company.

❖ **DETAILS OF DEPOSITS WHICH ARE NOT IN COMPLIANCE WITH THE REQUIREMENTS OF CHAPTER V OF THE ACT;- N.A.**

❖ **CORPORATE GOVERNANCE:**

It may please be noted that as our Company is not falling in the applicability criteria prescribed as mentioned in the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Hence, the Report on Corporate Governance is not forming part of the Directors' Report.

❖ **TRANSFER OF AMOUNTS TO INVESTOR EDUCATION AND PROTECTION FUND:**

Your Company did not have any funds lying unpaid or unclaimed for a period of seven years. Therefore, there were no funds which were required to be transferred to Investor Education and Protection Fund (IEPF).

❖ **ANNUAL RETURN:**

Annual Return is available on the Company's website at www.betadrugslimited.com.

❖ **PARTICULARS OF LOANS, INVESTMENTS OR GUARANTEES UNDER SECTION 186 OF THE COMPANIES ACT, 2013:**

Company has provided the following loans, investments or guarantees under section 186 of the Companies Act, 2013 as on 31st March, 2023:-

PARTICULARS	During the financial year 2023-24	Amount as on 31 st March, 2024
LOANS GIVEN BY COMPANY		
LOAN TO ADLEY LAB LIMITED (Wholly-owned Subsidiary)	35,00,000.00	2,50,94,764.00
LOAN TO ADLEY FORMULATIONS PRIVATE LIMITED (AFPL) (Wholly-owned Subsidiary)	1,80,60,000.00	4,95,99,060.00
TOTAL	2,15,60,000.00	7,46,93,824.00
INVESTMENTS MADE BY COMPANY		
INVESTMENT IN BETA UBK INTERNATIONAL PVT. LTD.	-77,89,905.49	Nil
INVESTMENT IN ADLEY FORMULATION PVT. LTD.	Nil	1,26,00,000.00
INVESTMENT IN ADLEY LAB LTD.	Nil	4,50,40,000.00
INVESTMENT IN BETA RESEARCH PVT. LTD.	Nil	1,00,000.00
TOTAL	-77,89,905.49	5,77,40,000.00
GUARANTEES GIVEN BY COMPANY		
GUARANTEE GIVEN TO ICICI BANK FOR ADLEY FORMULATIONS PRIVATE LIMITED (Wholly-owned Subsidiary)	Nil	11,49,00,000.00
GUARANTEE GIVEN TO HDFC BANK FOR ADLEY LAB LIMITED (Wholly-owned Subsidiary)	Nil	11,25,00,000.00
GUARANTEE GIVEN TO SIDBI FOR ADLEY LAB LIMITED (Wholly-owned Subsidiary)	Nil	80,00,000.00
TOTAL	Nil	23,54,00,000.00



❖ **RELATED PARTY TRANSACTIONS:** The particulars of every contract or arrangements entered into by the Company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso Form No. AOC -2, given below:

Related Party Transactions:

Particulars of contracts or arrangements with related parties referred to in sub-section (1) of section 188 in the form AOC-2:All related party transactions that were entered into during the financial year were on an arm's length basis and were in the ordinary course of business.

Information Pursuant to *clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014:*

1. Details of contracts or arrangements or transactions not at Arm's length basis.

SL. No.	Particulars	Details
a)	Name (s) of the related party & nature of relationship	NIL
b)	Nature of contracts/arrangements/transaction	-
c)	Duration of the contracts/arrangements/transaction	-
d)	Salient terms of the contracts or arrangements or transaction including the value, if any	-
e)	Justification for entering into such contracts or arrangements or transactions'	-
f)	Date of approval by the Board	-
g)	Amount paid as advances, if any	-
h)	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	-

2. Details of material contracts or arrangements or transactions at Arm's length basis.

SL. No.	Particulars		
a)	Name (s) of the related party & nature of relationship	Adley Lab Limited (wholly owned subsidiary)	Adley Formulations Private Limited (wholly owned subsidiary)
			BT Associates Pvt Ltd.
b)	Nature of contracts/Arrangements /transaction	i) Purchase of Goods: Rs 17,89,96,195.00 ii) Interest received on unsecured loan: Rs 19,42,788.00 iii) Unsecured Loan given to subsidiary: Rs 35,00,000.00 iv) Purchase of Machinery: Rs 1,00,000.00	i) Sale of Goods: Rs 3,09,35,849.06 ii) Purchase of Goods: Rs 5,27,75,471.80 iii) Sale of Fixed assets: Rs 4,77,970.00 iv) Interest received on Unsecured Loan :Rs 32,40,302.00 v) Unsecured Loan given to subsidiary: Rs 1,80,60,000
			Payment of Building Rent: Rs 28,88,640.00
c)	Duration of the Contracts/Arrangements /transaction	Regular	Regular
d)	Salient terms of the contracts or arrangements or transaction including the value, if any	Transactions are at Arm's length basis and in the ordinary course of business	Transactions are at Arm's length basis and in the ordinary course of business
e)	Date of approval by the Board	1 st April, 2023	1 st April, 2023
f)	Amount paid as advances, if any	-	-



❖ **MANAGEMENT DISCUSSION AND ANALYSIS:**

As per Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015, the Management Discussion and Analysis Report is given in Annexure - 5.

❖ **THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (31 OF 2016) DURING THE YEAR ALONGWITH THEIR STATUS AS AT THE END OF THE FINANCIAL YEAR.** N.A.

❖ **THE DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE-TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OF FINANCIAL INSTITUTIONS**

During the period under review there was no instance of one time settlement with any Banker Financial Institution.

❖ **APPRECIATION:**

Your Directors wish to place on record their sincere appreciation for significant contribution made by the employees at all the levels through their dedication, hard work and commitment, thereby enabling the Company to boost its performance during the year under report.

Your Directors also take this opportunity to place on record the valuable co-operation and continuous support extended by its valued business associates, Practicing Company Secretary, Auditors, Supplier, Customers, Banks / Financial Institutions, Government authorities and the shareholders for their continuously reposed confidence in the Company and look forward to having the same support in all its future endeavors.

Dated: 31.08.2024

Place: Panchkula

By Order of the Board of Directors

sd/-

Rahul Batra

Chairman & Managing Director

(DIN: 02229234)



Secretarial Audit Report for the Financial Year Ended March 31, 2024

To

The Members of

BETA DRUGS LIMITED (CIN : L24230HP2005PLC028969)

Regd. Office : Village Nandpur, Baddi, Himachal Pradesh-174101.

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **BETA DRUGS LIMITED** (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/ statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on March 31, 2024 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2024 according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the rules made thereunder;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- (iii) The Depositories Act, 1996 and the Regulations and Byelaws framed thereunder to the extent of Regulation 55A;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):
 - a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and The Securities Exchange Board of India (SEBI) (Substantial Acquisition of Shares and Takeovers (Amendment) Regulations, 2013;
 - b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and amended thereon.;
 - d) SEBI (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999
 - e) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client to the extent of securities issued;
 - f) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and amendment thereon;
 - g) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018.
- (vi) The other laws, as informed and certified by the management of the Company which are specifically applicable to the Company based on their sectors/ industry are:-
 - (a) Drugs & Cosmetics Act, 1940
 - (b) Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954
 - (c) Narcotic Drugs and Psychotropic Substances Act, 1985
 - (d) Conservations of Foreign Exchange And Prevention of Smuggling Activities Act, 1974
 - (e) The Medicinal & toilet Preparations Substances (Excise Duties) Act, 1955
 - (f) The Environment (Protection) Act, 1986
 - (g) Hazardous Waste Management Rules, 2016
 - (h) The Indian Copyright Act, 1957
 - (i) The Patents Act, 1970
 - (j) The Trade Marks Act, 1999

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.
- (ii) The Listing Agreements entered into by the Company with NSE Limited (SME segment) and SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations mentioned above in this report except the following:-



1. Section 178 (1) of Companies Act, 2013 requires Composition of Nomination and remuneration committee of 3 or more non executive director, whereas Company has only 2 non executive directors in the Committee. It is also further drawn to your attention that there is a shortfall of one independent Director w.e.f. 20.1.2022 required u/s 149(4) of the Companies Act, 2013 as per strength of Board of Directors of Company.
2. a) Clause 33(3)(d) of LODR- Non submission of consolidated unaudited financial results as at 30.9.2023 to Stock Exchange with respect to non operative foreign subsidiary viz. Beta UBK International Pvt. Ltd. and compliance required u/s 129, 136 and other relevant provisions of Companies Act, 2013 not made. During the financial Year the Board of Directors of the Company at its meeting held on 7th November, 2023 has considered and approved to write off the total investment made by the company in Beta Ubk. International Private Limited (non operative subsidiary) and it ceased to be subsidiary of the company. However, no reporting of disinvestment / written off made to Reserve Bank of India till date. Further the Company has taken impact of above mentioned written off investment value in its half yearly financial results approved for the period ended 30th September, 2023 in its board meeting held on 7.11.2023.
b) Annual performance report (APR) for calendar year 2022, 2023 not filed to authorized dealer bank in respect of Beta UBK International Pvt. Ltd., foreign subsidiary.

We further report that compliance by the Company of applicable financial laws like direct and indirect tax laws and maintenance of financial record and books of accounts has not been reviewed in this Audit, since the same has been subject to review by statutory financial audit and other designated professionals.

We further report that:-

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors subject to above. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all Directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions at Board Meetings and Committee Meetings are carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committee of the Board, as the case may be.

We further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period no specific events / actions took place that having a major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards.

Place: Chandigarh

Date: 31.08.2024

Sd/-

CS. Dinesh Bhandari / Proprietor

Practising Company Secretary

Membership No. FCS No.: 5887

Certificate of Practice No.: 10300

UDIN: F005887F001090377

Peer Review Cert No. 814/2020

Note: This report is to be read with our letter of even date which is annexed as Annexure A and forms an integral part of this report.



Annexure –A

The Members

BETA DRUGS LIMITED (CIN:L24230HP2005PLC028969)

Regd. Office : Village Nandpur,

Baddi,

Himachal Pradesh-174101.

1. Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on the random test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Wherever required, we have obtained the Management representation about the compliance of laws, rules and regulations and major events during the audit period.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on the random test basis for the purpose of the Secretarial Audit Report.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

Place: Chandigarh

Date: 31.08.2024

Sd/-

CS. Dinesh Bhandari / Proprietor

Practising Company Secretary

Membership No. FCS No.: 5887

Certificate of Practice No.: 10300

UDIN: F005887F001090377

Peer Review Cert No. 814/2020



ANNEXURE-4

ANNEXURE TO BOARD'S REPORT

1. A brief outline on CSR Policy of the Company:-

The Company's CSR Policy is in adherence to the updated Section 135 of the Companies Act, 2013 read with rules framed thereunder and provides for carrying out CSR activities and Initiate projects that benefit communities, encourage an increased commitment from employees towards CSR activities and volunteering and contribution towards some specific project being undertaken by any of the organizations or directly by the Company.

2.Composition of CSR Committee:

Sr. No.	Name of Director	Designation / Nature of Directorship	Number of meetings of CSR Committee held during the year	Number of meetings of CSR Committee attended during the year
1.	Mr. Rahul Batra	Managing Director	5	5
2.	Mr. Varun Batra	Joint Managing Director	5	5
3.	Mr. Rohit Parti	Independent Director	5	5

3.Web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the company:-<http://www.betadrugslimited.com/>

4.Executive summary along with web-link(s) of Impact Assessment of CSR Projects carried out in pursuance of sub-rule (3) of rule 8, if applicable- Not applicable

4.Details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014, if applicable (attach the report):- **Not Applicable**

5.(a)Average net profit of the company as per sub section (5) of section 135: **Rs. 20,63,82,210.37**

(b) Two percent of average net profit of the company as per section 135(5): **Rs.41,27,644.21**

(c) Surplus arising out of the CSR projects or programmes or activities of the previous financial years: : Nil

(d) Amount required to be set off for the financial year, if any: **Rs 10,907.82**

(e) Total CSR obligation for the financial year (b+c-d): **Rs.41,16,736.39**

6. (a)Amount spent on CSR Projects (both Ongoing Project and other than Ongoing Project):**Rs. 41,27,700.00**

(b) Amount spent in Administrative Overheads: **NIL**

(c) Amount spent on Impact Assessment, if applicable: **NOT APPLICABLE**

(d) **Total amount spent for the Financial Year (a+b+c): Rs.41,27,700**

(e)CSR amount spent or unspent for the financial year:

Total Amount Spent for the Financial Year. (in Rs.)	Amount Unspent (in Rs.)				
	Total Amount transferred to Unspent CSR Account as per section 135(6).		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5).		
	Amount.	Date of transfer.	Name of the Fund	Amount.	Date of transfer.
Rs. 41,27,700.00	Nil	-	Nil	-	-



(f) Excess amount for set off, if any:

Sr. No.	Particular	Amount (in Rs.)
(i)	Two percent of average net profit of the company as per section 135(5)	41,27,644.21
(ii)	Total amount spent for the Financial Year	41,38,607.82*
(iii)	Excess amount spent for the financial year [(ii)-(i)]	10,963.61
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	Nil
(v)	Amount available for set off in succeeding financial years [(iii)-(iv)]	10,963.61

(*Including excess amount of `Rs 10,907.81 spent during the previous FYs 2021-22 & 2022-23)

7. Details of Unspent CSR amount for the preceding three financial years:

Sr. No.	Preceding Financial Year.	Amount transferred to Unspent CSR Account under section 135 (6) (in Rs.)	Balance Amount in Unspent CSR Account under subsection (6) of section 135 (in Rs.)	Amount spent in the reporting Financial Year (in Rs.).	Amount transferred to a fund as specified under Schedule VII as per second proviso to subsection (5) of section 135, if any.		Amount remaining to be spent in succeeding financial years. (in Rs.)	Deficiency, if any
					Amount (in Rs).	Date of transfer.		
1.	2020-21	NIL	NIL	NIL	-	-	NIL	NIL
2.	2021-22	NIL	NIL	NIL	-	-	NIL	NIL
3.	2022-23	NIL	NIL	NIL	-	-	NIL	NIL
	Total	NIL	NIL	NIL			NIL	NIL

8. Whether any capital assets have been created or acquired through Corporate Social Responsibility amount spent in the Financial Year:

No

9. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per section 135(5):-N.A.

Sd/- Rahul Batra Chairman CSR Committee	Sd/- Varun Batra Joint Managing Director
------------------------------------------------------	-------------------------------------------------------



MANAGEMENT DISCUSSION AND ANALYSIS

In terms of Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 the Management Discussion and Analysis Report (MDAR) is structured as follows:

❖ **INDUSTRY STRUCTURE, DEVELOPMENTS, OPPORTUNITIES & THREATS:**

The global medicine market is expected to continue its growth trajectory over the next five years, fueled by increased spending in regions such as the US, Europe, and key emerging markets. Growth in these regions will be driven by the introduction of new branded products, greater adoption of original medicines, and the uptake of novel therapies.

As per IQVIA, global medicine market is expected to grow at 3–6% CAGR through 2027, reaching about \$1.9Tn in total market size. Oncology is forecasted to grow the fastest in terms of global spending at a CAGR of 13–16% through 2027. Oncology is projected to add 100 new treatments over five years, contributing to an increase in spending of \$184Bn to a total of more than \$370Bn in 2027 and facing limited new losses of exclusivity. While most major therapy areas have seen growth in medicine use in the last decade, oncology usage has far exceeded the others with a 10-year CAGR as of 2021 of 15.3%.

The increase in oncology spending is expected to be driven by early diagnoses of patients, continued introduction of new drugs, and wider access to novel cancer drugs in more countries beyond the major developed countries where they often launch first and longer treatments for medicines with survival benefits.

The oncology market in India is experiencing stronger growth compared to the overall pharmaceutical industry. As the second leading cause of death in the country, cancer drives significant demand for oncology drugs. The market is highly fragmented, with numerous foreign and domestic players competing. Factors contributing to market growth include a sharp rise in cancer cases—particularly lung and breast cancers—shifts in treatment approaches, the development of alternative therapies, expanded cancer health insurance coverage, and increasing foreign direct investment (FDI). The growing prevalence of cancer is largely attributed to unhealthy lifestyles and an aging population. However, the high cost of treatments remains a barrier to further market expansion.

Beta has identified four pillars for sustainable future growth and build strong defensible moats in the oncology space. The four pillars are:-

1. Building compelling brand equity for leading products through strong clinical differentiation
2. Launching innovative products addressing unmet needs through novel formulation development
3. Integrated manufacturing with best-in-class quality accreditations
4. Leveraging world class Indian manufacturing infrastructure to penetrate export geographies.

Beta has been able to build a significant presence in branded oncology business in India and is ranked among the top 10 oncology companies. Many of the key products of the company are ranked among the Top 5 in their respective categories. We have built a solid credibility among prescribers of being high quality suppliers of life saving oncology formulations who have made cancer medicines affordable to large sections of the society. Going forward Beta will continue to focus on building a solid franchise in the domestic market through robust brand building initiatives focusing on patient outcomes and strong clinical differentiation

We have a large pipeline of new product launches which address the white spaces in oncology. We are on track to offer innovative products through novel formulation development to provide clinicians with better solutions and improve patient outcomes. Over the next three years Beta would be launching oncology formulations in novel NDDS platforms which would be the first of its kind in the Indian oncology market. Beta Drugs is continuously increasing its spend on R&D and is building its capabilities so as to become nimble and responsive to market needs. Beta's R&D strengths are in developing novel molecules that are going off patent in non-infringing processes, scaling complex chemistry challenges and novel formulation development. The company is in the midst of developing new drug delivery systems, new dosage formulations and applying the latest technology for better processes. The Research centre is proficient in developing, scaling up and commercializing various dosage forms spread across tablets, capsules, oral liquids and injectables (solutions, suspensions, lyophilized, etc.)

To achieve leadership position in the cytotoxic market the company is focused on building Rs 10 Cr & above brands. It is also strengthening its Hemato & Uro Oncology presence and is trying to increase customer base by launching new NDDS formulations and supportive care products. d in-house is already in advanced stages.



We started with the API business in 2018-2019 as it was our firm belief that improving efficiency and quality are only possible if we have control over the entire supply chain. The backward integration into API has provided us with better margins, higher yields, reduced reliance on external suppliers and improved the quality of our products. Going forward API development will be core to launching of new products and maintaining market leadership in select products. We also plan to export APIs to improve the operating leverage in the API business. 70% of API for formulations is manufactured in-house. Beta has increased its API production capacity and is continuously improving manufacturing processes to meet customer requirements

Beta is well positioned to leverage its Indian low-cost manufacturing expertise to gain traction in the above-mentioned countries and capture significant market share. We will continue to grow our exports business both in formulations and API over the next three years to become a leading supplier of high-quality oncology drugs across developing countries.

❖ **RISK MANAGEMENT FRAMEWORK:**

During the last three years, the company has increased its focus on building its innovative product pipeline in the oncology space and be ready to realize significant growth opportunities both domestically and globally. Your Company has continued to be the preferred supplier of many leading OEMS's and has been successful in expanding its approval base, adding leading players from the industry. Therefore, we expect that your Company will continue to be in a position to gradually expand its market reach and improve its market share. The Company regularly insures all its assets to enable itself in case of any mis-happening. The Company has formed a risk management team which constantly monitors the Indian and international markets and guides the management of any sort of prevailing risk to the company. The commodities prices being internationally traded are affected by the global market demand and supply forces and the dollar rate. The risk management team plays a major role here. Moreover, the industry is labour oriented and business operations of the Company may be materially affected by strikes, lock outs or work stoppage.

❖ **SEGMENT WISE OR PRODUCT WISE PERFORMANCE:**

Your company has only one segment that is trading and manufacturing of pharmaceutical products.

❖ **OVERVIEW & OUTLOOK:**

The Indian pharmaceutical market will likely grow substantially, with medicine spending expected to reach US\$38-42 Billion by 2028, reflecting a CAGR of 7-10% between 2024 and 2028. Acute therapies like anti-infectives and vitamins/minerals saw improved volumes in 2023, while chronic therapies, including cardiac and respiratory segments, continue to perform well.

Oncology and immunology are expected to lead growth across therapy areas, driven by the introduction of new treatments and the expansion of patient populations. Oncology drugs market is expected to grow at a fast clip across the world primarily driven by an ageing population and lifestyle changes making population susceptible to cancer. In India the Oncology drugs market is expected market to grow in double digits for the next many years to come. Therefore, Beta Drugs being a leader in the oncology segment has long runaway ahead both in terms of opportunities and growth.

Our multiple segments of revenue provide us diversification benefits and substantial financial strength. Our financial strength enables us to reinvest in two key areas: building commercial capabilities both domestic and international and building a robust pipeline while expanding our technology capabilities.

❖ **RISK AND CONCERNS:**

During the last three years, the company has increased its focus on building its innovative product pipeline in the oncology space and be ready to realize significant growth opportunities both domestically and globally. Your Company has continued to be the preferred supplier of many leading OEMS's and has been successful in expanding its approval base, adding leading players from the industry. Therefore, we expect that your Company will continue to be in a position to gradually expand its market reach and improve its market share. The Company regularly insures all its assets to enable itself in case of any mis-happening.

The Company has formed a risk management team which constantly monitors the Indian and international markets and guides the management of any sort of prevailing risk to the company. The commodities prices being internationally traded are affected by the global market demand and supply forces and the dollar rate. The risk management team plays a major role here. Moreover, the industry is labour oriented and business operations of the Company may be materially affected by strikes, lock outs or work stoppage.

❖ **INTERNAL CONTROL SYSTEM:**

The Company has in place an adequate system of internal control commensurate with its size and nature of its business. These have been designed to provide reasonable assurance that all assets are safeguarded and protected against loss from unauthorized use or disposition and that all transactions are authorized, recorded and reported correctly and the business operations are conducted as per the prescribed policies and procedures of the Company. The Audit committee and the management have reviewed the adequacy of the internal control systems and suitable steps are taken to improve the same.

❖ **FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE:**

During the year, Revenue of the Company increased by 25.44% i.e. from Rs 15,891.74 lakhs to Rs 19,935.01 lakhs .Profit before tax increased by 16.95% i.e. from Rs. 2,520.95 lakhs to Rs.2,948.30 lakhs. Profit after tax increased by 16.58% i.e. from Rs. 1881.61 lakhs to Rs.2193.66 lakhs.

❖ **HUMAN RESOURCES DEVELOPMENT AND INDUSTRIAL RELATIONS:**

Your Company firmly believes that its human resources are the key enablers for the growth of the Company and important asset. Hence, the success of the Company is closely aligned to the goals of the human resources of the Company. Taking into this account, your Company continued to Invest in developing its human capital and establishing its brand on the market to attract and retain the best talent. Employee relations during the period under review continued to be healthy, cordial and harmonious at all levels and your Company is committed to maintain good relations with the employees.

❖ **KEY FINANCIAL RATIOS:**

Following are ratios for the current financial year and their comparison with preceding financial year:

Sr. No.	Ratios	As at March 31, 2024	As at March 31, 2023	Variance	Explanation for any change in the ratio by more than 25% as compared to the preceding year
1	Debtor Turnover	4.20	4.21	-0.29%	
2	Inventory turnover	7.27	8.91	-18.42%	
3	Interest coverage ratio	29.15	31.13	-6.37%	
4	Current Ratio	2.38	2.70	-11.69%	
5	Debt-Equity Ratio	0.047	0.054	-12.50%	
6	Operating Profit Margin(%)	15.45%	16.50%	-6.36%	
7	Net Profit Margin (%)	11.10%	11.92%	-6.86%	

❖ **CAUTIONARY STATEMENT:**

Statement in this Management Discussion and Analysis Report, describing the Company's objectives, estimates and expectations may constitute 'Forward Looking Statements' within the meaning of applicable laws or regulations. Actual results might differ materially from those either expressed or implied.

Dated: 31.08.2024

Place: Panchkula

By Order of the Board of Directors

sd/-

Rahul Batra

Chairman & Managing Director

(DIN: 02229234)

STANDALONE FINANCIAL

STATEMENTS

OF

“BETA DRUGS LIMITED”

FOR THE FINANCIAL YEAR

2023-24



KALRA RAI & ASSOCIATES
CHARTERED ACCOUNTANTS

Head Office: Kothi No. 667, 1st floor, Sector-43-A
Chandigarh-160022

Independent Auditors' Report

Members of Beta Drugs Limited

Report on the Standalone Financial Statements

We have audited the accompanying standalone Ind-AS financial statements of Beta Drugs Limited ('the Company'), which comprise the Balance Sheet as at March 31, 2024, the Statement of Profit and Loss, including the statement of Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ('the Act') with respect to the preparation of these standalone Ind-AS financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with accounting principles generally accepted in India, including the Indian Accounting Standards (Ind-AS) specified under Section 133 of the Act., read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial control that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind-AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these standalone Ind-AS financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under. We conducted our audit of the standalone Ind-AS financial statements in accordance with the Standards on Auditing, issued by the Institute of Chartered Accountants of India, as specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone Ind-AS financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the standalone Ind-AS financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the standalone Ind-AS financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone Ind AS financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the standalone Ind-AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as

at March 31, 2024, its profit including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's report) Order, 2016 ('the Order') issued by the Central Government of India in terms of subsection (11) of Section 143 of the Act, we give in the Annexure 1 a statement on the matters specified in paragraphs 3 and 4 of the Order.

2. As required by Section 143 (3) of the Act, we report that:

- a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
- b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- c. The Balance Sheet, Statement of Profit and Loss including the Statement of Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account;
- d. In our opinion, the aforesaid standalone Ind-AS financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act, read with Companies (Indian Accounting Standards) Rules, 2015, as amended;
- e. On the basis of written representations received from the directors as on March 31, 2024, and taken on record by the Board of Directors, none of the Director is disqualified as on March 31, 2024, from being appointed as a director in terms of Section 164 (2) of the Act.
- f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refers to our separate Report in "Annexure B";
- g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2020, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements.
- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
- iii. There has been no amounts available which is required to be transferred, to the Investor Education and Protection Fund by the Company;

Place:- Chandigarh
Date: 14/05/2024
UDIN:24087438BJZXBA3692

For KALRA RAI & ASSOCIATES

Chartered Accountants

Sd/-
(Lajpat Rai Kalra)
Partner
M. No- 087438
FRN: 008859N



CARO

Annexure 1 referred to in paragraph 1 of our report of even date

Re: Beta Drugs Limited ('the Company')

To the best of our information and according to the explanations provided to us by the Company and the books of account and records examined by us in the normal course of audit, we state that:

i. In respect of the Company's Property, Plant and Equipment and Intangible Assets:

(a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The Company has maintained proper records showing full particulars of intangible assets.

(b) The Company has a program of physical verification of Property, Plant and Equipment so to cover all the assets once every three years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. According to the information and explanations given to us, no material discrepancies were noticed on such verification.

(c) Based on our examination of the property tax receipts and lease agreement for land on which building is constructed, registered sale deed / transfer deed / conveyance deed provided to us, we report that, the title in respect of self-constructed buildings and title deeds of all other immovable properties, disclosed in the financial statements included under Property, Plant and Equipment are held in the name of the Company as at the balance sheet date.

(d) The Company has not revalued any of its Property, Plant and Equipment and intangible assets during the year.

(e) No proceedings have been initiated during the year or are pending against the Company as at March 31, 2024 for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.

ii. (a) As explained to us, the inventories were physically verified during the year by the Management at reasonable intervals, except goods-in-transit. The coverage and procedure adopted by the Management is appropriate according to the size and scale of the Company. No discrepancies of 10% or more were observed in any class of inventories.

(b) The Company has been sanctioned working capital limits of Rs.10 crores, in aggregate, from banks or financial institutions and the monthly statements filed by the Company with such banks or financial institutions are in agreement with the books of accounts of the Company

iii. The Company has made investments in and granted unsecured loans, to companies or any other parties during the year, in respect of which:



(a) The Company has provided loans during the year and details of which are given below:

	Loan (Rs. in lakhs)
A. Aggregate amount granted / provided during the year:	
- Subsidiaries	215.60
- Others	0.00
B. Balance outstanding as at balance sheet date:*	
- Subsidiaries	746.94
- Others	0.00

* The amounts reported are at gross amounts, without considering provisions made.

The Company has not provided any advances in nature of loan, guarantee or security to Subsidiaries or any other parties during the year.

(b) In our opinion, the investments made and the terms and conditions of the grant of loans, during the year are, prima facie, not prejudicial to the Company's interest.

(c) In respect of loans granted by the Company, the schedule of repayment of principal and payment of interest has been stipulated and the repayments of principal amounts and receipts of interest are generally been regular as per stipulation.

(d) In respect of loans granted by the Company, there is no overdue amount remaining outstanding as at the balance sheet date.

(e) No loan granted by the Company which has fallen due during the year, has been renewed or extended or fresh loans granted to settle the overdues of existing loans given to the same parties.

(f) The Company has granted Loans which are repayable on demand details of which are given below:

	(Rs. in lakhs)		
	All Parties*	Related Parties*	Others*
Aggregate of loans/advances in nature of loans - Repayable on demand (A)	215.60	215.60	-
Percentage of loans/advances in nature of loans to the total loans	100%	100%	-

iv. The Company has complied with the provisions of Sections 185 and 186 of the Companies Act, 2013 in respect of loans granted, investments made and guarantees and securities provided, as applicable.

v. The Company has not accepted any deposit or amounts which are deemed to be deposits. Hence, reporting under clause 3(v) of the Order is not applicable.

vi. The maintenance of cost records has not been specified by the Central Government under sub-section (1) of section 148 of the Companies Act, 2013 for the business activities carried out by the Company. Hence, reporting under clause (vi) of the Order is not applicable to the Company.

vii. In respect of statutory dues:

(a) In our opinion, the Company has generally been regular in depositing undisputed statutory dues, including Goods and Services tax, Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, Cess and other material statutory dues applicable to it with



the appropriate authorities except advance tax. There were no undisputed amounts payable in respect of Goods and Service tax, Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, Cess and other material statutory dues in arrears as at March 31, 2024 for a period of more than six months from the date they became payable.

- (b) Disputed Income tax demand amounting to Rs.12,122/- for A.Y 2020-21 and Rs.90,64,680/- for A.Y 2021-22 is outstanding and appeal filed against the same is under process as on 31.03.2024. The said demand was raised by the department on account of non-compliance of notice u/s 133(6) issued to the third parties, however, the said third parties had duly filed the response to the notices received by them. The company has filed an appeal providing acknowledgements of the replies filed by those third parties.

viii. There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).

ix. (a) The Company has not defaulted in repayment of loans or other borrowings or in payment of interest thereon to any lender.

- (b) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (c) According to the explanations provided by the Company and overall examination of the financial statements of the Company, the term loans were prima facie applied for the purpose for which they were obtained.
- (d) On an overall examination of the financial statements of the Company, funds raised on short-term basis have, prima facie, not been used during the year for long-term purposes by the Company.
- (e) On an overall examination of the financial statements of the Company, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries.
- (f) The Company has not raised any loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies and hence reporting on clause 3(ix)(f) of the Order is not applicable.

x. (a) The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under clause 3(x)(a) of the Order is not applicable.

(b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause 3(x)(b) of the Order is not applicable.

xi. (a) No fraud by the Company and no material fraud on the Company has been noticed or reported during the year.

(b) No report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.

(c) The Company has not received any whistle-blower complaints during the year.

xii. The Company is not a Nidhi Company and hence reporting under clause (xii) of the Order is not applicable.

xiii. In our opinion, the Company is in compliance with Section 177 and 188 of the Companies Act, 2013 with respect to applicable transactions with the related parties and the details of related party transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.



xiv. (a) In our opinion the Company has an adequate internal audit system commensurate with the size and the nature of its business.

(b) We have considered, the internal audit reports for the year under audit, issued to the Company during the year and till date, in determining the nature, timing and extent of our audit procedures.

xv. In our opinion during the year the Company has not entered into any non-cash transactions with its Directors or persons connected with its directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.

xvi. (a) In our opinion, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause 3(xvi)(a), (b), (c) and (d) of the Order is not applicable.

xvii. The Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.

xviii. There has been no resignation of the statutory auditors of the Company during the year.

xix. On the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

xx. The Company has fully spent the required amount towards Corporate Social Responsibility (CSR) and there are no unspent CSR amount for the year requiring a transfer to a Fund specified in Schedule VII to the Companies Act or special account in compliance with the provision of sub-section (6) of section 135 of the said Act. Accordingly, reporting under clause (xx) of paragraph 3 of the order is not applicable for the year.

Place:- Chandigarh
Date: 14/05/2024
UDIN:24087438BJZXBA3692

For KALRA RAI & ASSOCIATES

Chartered Accountants

Sd/-
(Lajpat Rai Kalra)
Partner
M. No- 087438
FRN: 008859N



“ANNEXURE-B” TO THE AUDITORS’ REPORT

Referred to in Paragraph 7 of Our Report of Even Date

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of **Beta Drugs Limited** (“the Company”) as of 31 March 2024 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (“the Guidance Note”) issued by the Institute of Chartered Accountants of India (“ICAI”). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (“the Act”).

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (“the Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to

permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March 2024, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Place:- Chandigarh
Date: 14/05/2024
UDIN:24087438BJZXBA3692

For KALRA RAI & ASSOCIATES

Chartered Accountants

Sd/-
(Lajpat Rai Kalra)
Partner
M. No- 087438
FRN: 008859N

BETA DRUGS LIMITED				
VILLAGE NANDPUR, BADDI, SOLAN 174101				
CIN: L24230HP2005PLC028969				
BALANCE SHEET AS AT 31 March' 2024				
	Particulars	Note No.	As at 31 March' 2024	As at 31 March' 2023
			Amount in Rs. Lakhs	Amount in Rs. Lakhs
A	EQUITY AND LIABILITIES			
1	Shareholders' funds			
	(a) Share capital	1	961.38	961.38
	(b) Reserves and surplus	2	10,639.65	8,664.14
	(c) Money received against share warrants		-	-
			11,601.03	9,625.52
2	Share application money pending allotment		-	-
3	Non-current liabilities			
	(a) Long-term borrowings	3	361.98	372.88
	(b) Deferred tax liabilities (net)		-	-
	(c) Other long-term liabilities	5 (a)	189.97	150.50
	(d) Long-term provisions	5 (b)	127.77	108.12
			679.72	631.50
4	Current liabilities			
	(a) Short-term borrowings		-	-
	(b) Trade payables	6	3,579.84	2,321.25
	(c) Other current liabilities	7	999.78	531.94
	(d) Short-term provisions	4 (a)	186.79	294.28
			4,766.41	3,147.48
	TOTAL		17,047.15	13,404.49
B	ASSETS			
1	Non-current assets			
	(a) Property, Plant and Equipment and Intangible Assets			
	(i) Property, Plant and Equipment	8	3,410.47	3,324.87
	(ii) Intangible assets	8	237.62	152.31
	(iii) Capital work-in-progress	8	-	-
	(iv) Intangible assets under development		-	-
	(v) Fixed assets held for sale		-	-
			3,648.08	3,477.18
	(b) Non-current investments	9	577.40	655.30
	(c) Deferred tax assets (net)	4	81.30	89.23
	(d) Long-term loans and advances	10 (a)	1,368.04	677.72
	(e) Other non-current assets	10 (b)	5.00	5.00
			2,031.74	1,427.25
2	Current assets			
	(a) Current investments		-	-
	(b) Inventories	11	2,193.53	1,366.35
	(c) Trade receivables	12	5,049.20	4,359.48
	(d) Cash and cash equivalents	13	2,719.74	1,779.41
	(e) Short-term loans and advances	14	384.44	285.01
	(f) Other current assets	15	1,020.42	709.82
			11,367.33	8,500.07
	TOTAL		17,047.15	13,404.49
	See accompanying notes forming part of the financial statements	24		
In terms of our report attached.				
For KALRA RAI AND ASSOCIATES Chartered Accountants (FRN: 008859N)			For and on the behalf of the Board of Directors	
Sd/- LAJPAT RAI KALRA Partner MEMBERSHIP NO. 087438 UDIN: 24087438BJZXBA3692 Place : Chandigarh Date : 14/05/2024	Sd/- NIPUN ARORA C.F.O	Sd/- RAJNI BRAR C.S.	Sd/- VARUN BATRA DIRECTOR DIN: 02148383	Sd/- RAHUL BATRA MANAGING DIRECTOR DIN: 02229234

Particulars	Note No.	As at 31 March' 2024	As at 31 March' 2023
		Amount in Rs. Lakhs	Amount in Rs. Lakhs
A CONTINUING OPERATIONS			
1 Revenue from operations (gross)	16	19,762.07	15,787.46
Less: Excise duty		-	
Revenue from operations (net)		19,762.07	15,787.46
2 Other income	17	172.94	104.28
3 Total revenue (1+2)		19,935.01	15,891.74
4 Expenses			
(a) Cost of materials consumed	18	11,927.19	8,646.84
(b) Purchases of stock-in-trade		-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	19	-697.50	-316.95
(d) Other manufacturing expenses	20	1,715.29	1,521.88
(d) Employee benefits expense	21	1,431.58	1,342.08
(e) Finance costs	22	104.73	83.66
(f) Depreciation and amortisation expense	8	472.47	619.48
(g) Other expenses	23	2,032.96	1,473.81
Total expenses		16,986.71	13,370.79
5 Profit / (Loss) before exceptional and extraordinary items and tax		2,948.30	2,520.95
6 Exceptional items		-	-
7 Profit / (Loss) before extraordinary items and tax (5 ± 6)		2,948.30	2,520.95
8 Extraordinary items/Prior period items		-	-
9 Profit / (Loss) before tax (7 ± 8)		2,948.30	2,520.95
10 Tax expense:			
(a) Current tax expense for current year		746.71	668.39
(b) (Less): MAT credit (where applicable)		-	-
(c) Tax expense relating to prior years		-	-
(d) Net current tax expense		746.71	668.39
(e) Deferred tax		7.93	-29.05
		754.64	639.34
11 Profit / (Loss) from continuing operations (9 ±10)		2,193.66	1,881.61
B DISCONTINUING OPERATIONS			
12 Profit / (Loss) from discontinuing operations (B.i ± B.ii ± B.iii)		-	-
C TOTAL OPERATIONS		2,193.66	1,881.61
13 Profit / (Loss) for the year (11 ± 12)		2,193.66	1,881.61
14 Earnings per share (of Rs. 10/- each):			
(a) Basic			
(i) Continuing operations		22.82	19.57
(ii) Total operations		22.82	19.57
(b) Diluted			
(i) Continuing operations		22.82	19.57
(ii) Total operations		22.82	19.57
See accompanying notes forming part of the financial statements	24		

In terms of our report attached.

For KALRA RAI AND ASSOCIATES
Chartered Accountants
(FRN: 008859N)

For and on the behalf of the Board of Directors

Sd/-
LAJPAT RAI KALRA
Partner

Sd/- Sd/-
NIPUN ARORA RAJNI BRAR
C.F.O C.S.

Sd/-
VARUN BATRA
DIRECTOR
DIN: 02148383

Sd/-
RAHUL BATRA
MANAGING DIRECTOR
DIN: 02229234

MEMBERSHIP NO. 087438
UDIN: 24087438BJZXA3692
Place : Chandigarh
Date : 14/05/2024

BETA DRUGS LIMITED		
VILLAGE NANDPUR, BADDI, SOLAN 174101		
CIN: L24230HP2005PLC028969		
CASHFLOW STATEMENT FOR THE PERIOD ENDED 31 March' 2024		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
A CASHFLOW FROM OPERATING ACTIVITIES		
Net Profit before tax and extraordinary items(as per Statement of Profit & Loss)	2,948.30	2,520.95
Adjustments for non Cash/Non trade items:		
Depreciation & Amortization Expenses	472.47	619.48
Finance Cost	104.73	83.66
Interest received	(153.59)	(98.84)
Other inflows/(outflows) of cash	(1,052.69)	(561.84)
Operating profits before Working Capital Changes	2,319.23	2,563.41
Adjusted For:		
(Increase)/Decrease in trade receivables	(689.72)	(1,224.06)
Increase/(Decrease) in trade payables	1,258.59	354.97
(Increase)/Decrease in inventories	(827.18)	(519.33)
Increase/(Decrease) in other current liabilities	467.84	107.31
(Increase)/Decrease in short term loans and advances	(99.43)	(94.75)
(Increase)/Decrease in other current assets	(310.60)	(164.91)
Working Capital Changes	(200.51)	(1,540.77)
Net cashflow from Operating Activities (A)	2,118.72	1,022.64
B CASHFLOW FROM INVESTING ACTIVITIES		
Purchase of tangible/intangible assets	(643.38)	(690.95)
Sale of Tangible Assets	-	-
Interest received	153.59	98.84
Cash used for Non Current Investment	77.90	(1.00)
Cash used for Long Term Loans/ Advances	(690.32)	11.13
Net cash used in Investing Activities (B)	(1,102.22)	(581.99)
C CASHFLOW FROM FINANCING ACTIVITIES		
Finance Cost	(104.73)	(83.66)
Increase in/(Repayment) of Short term Borrowings	-	-
Increase in/(Repayment) of Long term Borrowings	28.56	(135.65)
Increase/ (Decrease) in Share capital	-	-
Increase/ (Decrease) in Share premium	-	-
Other Inflows/ (Outflows) of cash	-	-
Net cash used in Financing Activities (C)	(76.17)	(219.31)
D Net Increase/(Decrease) in cash & cash equivalents (A+B+C)	940.33	221.34
E Cash & Cash equivalents at beginning of period	1,779.41	1,558.07
F Cash & Cash equivalents at end of period	2,719.74	1,779.41
G Net Increase/(Decrease) in cash & cash equivalents (F-E)	940.33	221.34
In terms of our report attached.		
For KALRA RAI AND ASSOCIATES Chartered Accountants (ERN: 008859N)	For and on the behalf of the Board of Directors	
Sd/- LAJPAT RAI KALRA Partner MEMBERSHIP NO. 087438 UDIN: 24087438BJZXBA3692 Place : Chandigarh Date : 14/05/2024	Sd/- NIPUN ARORA C.F.O	Sd/- RAJNI BRAR C.S.
	Sd/- VARUN BATRA DIRECTOR DIN: 02148383	Sd/- RAHUL BATRA MANAGING DIRECTOR DIN: 02229234

BETA DRUGS LIMITED
Notes forming part of the financial statements

Note 1 Share capital

Particulars	As at 31 March' 2024		As at 31 March' 2023	
	Number of shares	Amount in Rs. Lakhs	Number of shares	Amount in Rs. Lakhs
(a) Authorised - Equity shares of Rs. 10 each	1,00,00,000.00	1,000.00	1,00,00,000.00	1,000.00
	-	-	-	-
(b) Issued - Equity shares of Rs. 10 each	96,13,790.00	961.38	96,13,790.00	961.38
	96,13,790.00	961.38	96,13,790.00	961.38
(c) Subscribed and fully paid up - Equity shares of Rs.10 each	96,13,790.00	961.38	96,13,790.00	961.38
	96,13,790.00	961.38	96,13,790.00	961.38
(d) Subscribed but not fully paid up	-	-	-	-
	-	-	-	-
Total	96,13,790.00	961.38	96,13,790.00	961.38

Note 1(a) Reconciliation of number of shares outstanding is set out below:

Particulars	Equity Shares March' 2024		Equity Shares March' 2023	
	Number	Amount in (Rs. Lakhs)	Number	Amount in (Rs. Lakhs)
Shares outstanding at the beginning of the year	96,13,790.00	961.38	96,13,790.00	961.38
Shares Issued during the year	-	-	-	-
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	96,13,790.00	961.38	96,13,790.00	961.38

Note 1(b) Shares held by promoters at the end of the year 31st March 2024

Name of Shareholder	As at 31 March' 2024		
	No. of Shares held	% of Holding	% Changes
Mrs. Neeraj Batra	63,41,663.00	65.96%	
Mr. Varun Batra	33,230.00	0.35%	
Mr. Rahul Batra	39,650.00	0.41%	
Mrs. Heena Batra	590.00	0.01%	
Mrs. Aditi Batra	590.00	0.01%	

Note 1(b) Shares held by promoters at the end of the year 31st March 2023

Name of Shareholder	As at 31 March' 2023		
	No. of Shares held	% of Holding	% Changes
Mrs. Neeraj Batra	63,41,663.00	65.96%	0.28%
Mr. Varun Batra	33,230.00	0.35%	
Mr. Rahul Batra	39,650.00	0.41%	0.02%
Mrs. Heena Batra	590.00	0.01%	
Mrs. Aditi Batra	590.00	0.01%	

Note 1(c) Details of shares held by each shareholder holding more than 5% shares:

Class of shares / Name of shareholder	As at 31 March' 2024		As at 31 March' 2023	
	Number of shares held	% holding in that class of shares	Number of shares held	% holding in that class of shares
Equity shares with voting rights				
Mrs. Neeraj Batra	63,41,663.00	65.96%	63,41,663.00	65.96%

BETA DRUGS LIMITED
Notes forming part of the financial statements

Notes: Long-term borrowings

Particulars	As at 31 March' 2024			As at 31 March' 2023		
	Amount in Rs. Lakhs			Amount in Rs. Lakhs		
	Non- Current	Current Maturities	Total	Non- Current	Current Maturities	Total
Term loans						
From banks						
Secured						
HDFC Bank (Covid WCTL)	-	-	-	8.31	28.98	37.29
SIDBI (Machinery Loan-1)	-	-	-	17.47	14.76	32.23
SIDBI (Machinery Loan-2)	-	37.40	37.40	37.40	88.80	126.20
HDFC Bank (Car Loan)	11.05	12.49	23.54	23.54	11.54	35.08
SIDBI (Covid WCTL)	83.20	43.20	126.40	130.00	-	130.00
SIDBI (Machinery Loan)	46.00	45.60	91.60	91.60	45.60	137.20
HDFC (Machinery Loan)	-	-	-	28.95	15.68	44.63
Axis Bank Vehicle Loan	17.48	18.13	35.61	35.61	16.89	52.50
Federal Bank - Vehicle Loan	53.13	23.16	76.30	-	-	-
SIDBI (PCS Gold)	139.26	20.74	160.00	-	-	-
Tata Motors Finance	11.86	5.14	17.00	-	-	-
	361.98	205.87	567.84	372.88	222.25	595.13
From other parties						
Unsecured (From Related Parties)	-	-	-	-	-	-
Secured	-	-	-	-	-	-
Total - A	-	-	-	-	-	-
Unsecured (From Unrelated Parties)	-	-	-	-	-	-
Total - B	-	-	-	-	-	-
	-	-	-	-	-	-
The Above Amount Includes						
Secured Borrowings	361.98	205.87	567.84	372.88	222.25	595.13
Unsecured Borrowings	-	-	-	-	-	-
Amount disclosed under "Other Current Liabilities"	-	-205.87	-205.87	-	-222.25	-222.25
Total	361.98	-	361.98	372.88	-	372.88

BETA DRUGS LIMITED		
Notes forming part of the financial statements		
Note 2 Reserves and surplus		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a) Capital reserve		
Opening balance	-	-
Closing balance	-	-
(b) Securities premium account		
Opening balance	2,394.01	2,394.01
Closing balance	2,394.01	2,394.01
(c) Surplus / (Deficit) in Statement of Profit and Loss		
Opening balance	6,270.13	4,390.77
	6,270.13	4,390.77
Add: Profit / (Loss) for the year	2,193.66	1,881.61
Less: Investment w/off/ Prov for tax and other prior period adjustments	218.14	2.25
Closing balance	8,245.64	6,270.13
Total	10,639.65	8,664.14
Note 3 Long-term borrowings		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Term loans		
From banks		
Secured		
HDFC Bank (Covid WCTL)	-	8.31
SIDBI (Machinery Loan -1)	-	17.47
SIDBI (Machinery Loan -2)	-	37.40
HDFC (Machinery Loan)	-	28.95
HDFC Bank Car Loan	11.05	23.54
SIDBI (Covid WCTL)	83.20	130.00
SIDBI (Machinery Loan)	46.00	91.60
Axis Bank (Vehicle Loan)	17.48	35.61
Federal Bank - Vehicle Loan	53.13	-
SIDBI (PCS Gold)	139.26	-
Tata Motors Finance	11.86	-
	361.98	372.88
From other parties		
Unsecured (From Related Parties)	-	-
Secured	-	-
Total - A	-	-
Unsecured (From Unrelated Parties)	-	-
Total - B	-	-
	-	-
The Above Amount Includes		
Secured Borrowings	361.98	372.88
Unsecured Borrowings	-	-
Total	361.98	372.88

BETA DRUGS LIMITED		
Notes forming part of the financial statements		
BETA DRUGS LIMITED		
Note 4 Deferred Tax		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Deferred tax assets		
Deferred tax on depreciation	-12.45	25.53
Deferred tax on provision of gratuity	4.95	2.08
Deferred tax on provision of bonus	-0.43	1.44
		-
Less: Deferred tax liability opening	89.23	60.18
Net Deferred tax liabilities/assets	-81.30	-89.23
Note 4 (a) Current tax Provision		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Current Year Tax	746.71	668.39
Less :- MAT Credit Utilised	-	-
Less :- Advance Tax Including TDS	-559.93	-374.11
Short term Provision	186.79	294.28
Net Current Tax provision	186.79	294.28

BETA DRUGS LIMITED		
Note 5 (a) Other long-term liabilities		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Others:		
(i) Payables on purchase of fixed assets	89.39	88.89
(ii) Security received from customers	100.58	61.61
Total	189.97	150.50

Note 5 (b) Long Term-provisions

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a) Provision for Gratuity	127.77	108.12
Total	127.77	108.12

BETA DRUGS LIMITED		
Note 6 Trade payables		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Trade payables:		
Micro Enterprises And Small Enterprises	261.99	1,460.36
Others	3,317.85	860.89
Total	3,579.84	2,321.25
Note 7 Other current liabilities		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a) Other payables	388.59	284.69
(i) Current Maturities of Long Term Debt (Note No. 3)	205.87	222.25
(b) Cheque issued yet not presented for Payment	249.49	13.62
Advances From Customers	155.83	11.38
Total	999.78	531.94
Note 7 (a) Other Payables		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
PF Payable	16.30	12.38
ESI payable	0.56	0.70
Labour Welfare Payable	0.39	0.25
TDS/TCS payable	23.55	17.60
Interest Accrued But Not Due	3.85	4.13
Salary & wages Payable	155.26	135.73
Other Creditors	162.55	86.06
Bonus Payable	26.13	27.85
Total	388.59	284.69

Note No. 8 Property, Plant & Equipment and Intangible Assets as at 31st March 2024

Assets	Useful Life (In Years)	Shift	Gross Block				Accumulated Depreciation/ Amortisation				Net Block			
			Balance as at 1st April 2023	Additions during the year	Addition on account of business acquisition	Deletion during the year	Balance as at 31st March 2024	Balance as at 1st April 2023	Provided during the year	Deletion / adjustments during the year	Balance as at 31st March 2024	Balance as at 31st March 2024	Balance as at 31st March 2023	
A Property, Plant & Equipment														
Own Assets														
LAND		Single	159.09				159.09						159.09	159.09
BUILDING	30	Single	1,646.04	165.39			1,811.43	502.68	115.08			617.76	1,193.68	1,143.37
PLANT AND MACHINERY	15	Single	2,933.68	411.31			2,955.34	1,211.85	131.53	25.25		1,418.15	1,537.16	1,621.79
FURNITURE AND FIXTURES	10	Single	157.58	49.76			207.36	52.81	32.48			85.29	122.07	104.77
COMPUTER	3	Single	67.82	18.10			85.92	51.21	14.77			65.92	20.01	16.61
VEHICLE	8	Single	389.84	163.82		100.93	452.73	255.74	66.03	90.60		231.17	221.56	134.10
ELECTRICAL EQUIPMENTS	5	Single	145.81	64.12			209.94	102.06	30.39			132.44	77.50	43.76
LAB EQUIPMENTS	10	Single	80.30	3.18			83.48	59.18	5.88			65.06	18.42	21.12
R&D LAB BUILDING	30	Single	12.90				12.90	3.57	0.89			4.45	8.44	9.33
R&D LAB EQUIPMENTS	10	Single	170.67				170.67	100.74	18.14			118.90	51.76	69.93
R&D LAB FURNITURE	10	Single	2.62				2.62	1.62	0.26			1.88	0.74	1.00
Total (A)			5,766.34	875.71		490.58	6,151.48	2,441.48	415.39	115.89		2,741.01	3,410.47	3,324.87
P.Y Total			5,240.01	683.21		156.88	5,766.34	1,947.87	586.36	92.76		2,441.48	3,324.87	3,292.14
B Capital work in progress														
BUILDING														
PLANT AND MACHINERY														
SOFTWARE DEVELOPMENT														
R&D Lab Building														
R&D Lab Equipment														
R&D Lab Furniture														
Total (B)			-	-	-	-	-	-	-	-	-	-	-	-
P.Y Total														
C Intangible Assets														
Registration Fee			196.99	142.38			339.37	60.86	52.89			113.77	225.67	136.13
Software			21.09				21.09	4.91	4.23			9.14	11.95	16.16
Total (C)			218.08	142.38	-	-	360.47	65.77	57.08	-	-	122.85	237.62	152.31
P.Y Total			146.22	71.86	-	-	218.08	32.65	33.12	-	-	65.77	152.31	113.57
Current Year Total (A+B+C)			5,984.43	1,018.10	-	490.58	6,511.95	2,507.25	472.47	115.89	-	2,863.86	3,648.09	3,477.18
Previous Year Total			5,386.24	755.07	-	156.88	5,984.43	1,980.53	619.48	92.76	-	2,507.25	3,477.18	3,405.71

BETA DRUGS LIMITED		
Note 9 Non Current investments		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Investment In Beta UBK International Pvt. Ltd. (Uzbekistan)	-	77.90
Investment In Adley Formulation Pvt. Ltd. (Wholly Owned Subsidiary)	126.00	126.00
Investment In Adley Lab Ltd. (Wholly Owned Subsidiary)	450.40	450.40
Investment in Beta Research Pvt. Ltd. (Wholly Owned Subsidiary)	1.00	1.00
Total	577.40	655.30
Note 10 (a) Long-term loans and advances		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Security Deposit		
Secured, considered good	105.16	82.40
	105.16	82.40
Others		
Capital Advances	515.94	110.63
loan and advances to related parties		
Unsecured, considered good		
Adley Lab Ltd.	250.95	198.46
Adley Formulations Pvt. Ltd.	495.99	286.23
Total	1,368.04	677.72
Note 10 (b) Other Non Current Assets		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Amount deposited with Approved Gratuity Fund	5.00	5.00
Total	5.00	5.00
Note 11 Inventories		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(Valued at cost or NRV unless otherwise stated)		
(a) Finished goods (other than those acquired for trading)	421.63	361.45
(b) Raw Material	366.73	293.74
(c) WIP	1,018.71	381.40
(d) Others	386.46	329.76
Total	2,193.53	1,366.35
Note 12 Trade receivables		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Exceeding six months		
Secured, considered good	545.75	484.20
Total	545.75	484.20
Less than six months		
Secured, considered good	4,503.46	3,875.28
Total	4,503.46	3,875.28
Grand Total	5,049.20	4,359.48

BETA DRUGS LIMITED**Note 12 (a) Trade receivables ageing Schedule As at 31st March'2024**

Particulars	Outstanding for following periods from					Total
	Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	4,503.46	119.67	39.49	169.59	135.60	4,967.80
(ii) Undisputed Trade receivables - considered doubtful	-	-	-	-	-	-
(iii) Disputed trade receivables considered good	-	-	-	-	-	-
(iv) Disputed trade receivables considered doubtful	-	-	29.73	6.96	44.71	81.40

Note 12 (b) Trade receivables ageing Schedule As at 31st March'2023

Particulars	Outstanding for following periods from					Total
	Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	3,798.94	21.86	165.86	78.20	206.21	4,271.07
(ii) Undisputed Trade receivables - considered doubtful	-	-	-	-	-	-
(iii) Disputed trade receivables considered good	-	-	-	-	-	-
(iv) Disputed trade receivables considered doubtful	-	15.01	22.62	25.87	24.90	88.41

BETA DRUGS LIMITED		
Note 13 Cash and cash equivalents		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
CASH oN HAND		
(a) Cash on hand	10.29	9.91
Balance with Imprest a/c	5.87	3.92
Total	16.16	13.82
(b) Balances with banks		
(i) In current accounts		
-Bank of Baroda	0.46	1.60
-HDFC Bank	830.17	454.11
(c) Others (specify nature)		
FDR with Axis Bank_No Lien	126.23	119.31
FDR with Bank of Baroda_No Lien	1,259.75	1,061.97
FDR with Bank of Baroda_Marked as Lien	16.78	16.78
FDR with SIDBI_No Lien	91.79	86.74
FDR with ICICI Bank_Marked as Lien	10.69	10.69
FDR with HDFC Bank	104.18	1.78
FDR with HDFC Bank_Marked as Lien	12.60	12.61
FDR with IndusInd_No Lien	250.94	-
Total	2,703.59	1,765.58
Grand Total	2,719.74	1,779.41
Note 14 Short-term loans and advances		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a) Loans and advances to related parties	-	-
(b) Loans and advances		
Advances To Supplier	349.29	251.89
Other Advances (Staff)	35.15	33.12
Total	384.44	285.01
Note 15 Other current assets		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Other Assets		
Income Tax Refund due A.Y 2021-22	0.64	0.64
Cheque Deposited Yet not Cleared	-	58.11
Prepaid Insurance	33.09	25.25
GST Recoverable	986.70	625.83
Total	1,020.42	709.82

BETA DRUGS LIMITED			
Note 16 Revenue from operations			
	Particulars	For the year ended 31 March' 2024	For the year ended 31 March' 2023
		Amount in Rs. Lakhs	Amount in Rs. Lakhs
	Sale Of Products		
	Indirect Export Sales	25.34	79.64
	Export Sales	4,448.16	2,703.29
	Sales Exempt	-256.34	0.49
	GST Sales 12%	12,357.34	10,823.85
	GST Sales 5%	2,091.78	1,504.07
	GST Sales 18%	1,095.79	676.11
	Total	19,762.07	15,787.46
Note 17 Other income			
	Particulars	For the year ended 31 March' 2024	For the year ended 31 March' 2023
		Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a)	Interest Income	153.59	98.84
(b)	Other non-operating income (net of expenses directly attributable to such income)	19.36	5.44
	Total	172.94	104.28

BETA DRUGS LIMITED		
Note 18 Cost of materials consumed		
Particulars	For the year ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Opening stock	623.50	421.12
Add: Purchases	12,056.87	8,849.22
Less: Closing stock	753.18	623.50
Cost of material consumed	11,927.19	8,646.84
Total	11,927.19	8,646.84
Note 19 Changes in inventories of finished goods, work-in-progress and stock-in-trade		
Particulars	For the year ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
<u>Inventories at the end of the year:</u>		
Finished goods	421.63	361.45
Work In Progress	1,018.71	381.40
	1,440.35	742.85
<u>Inventories at the beginning of the year:</u>		
Finished goods	361.45	246.99
Work In Progress	381.40	178.90
	742.85	425.90
(Increase)/ decrease in Inventory		
Finished goods	-60.18	-114.46
Work In Progress	-637.31	-202.50
	-697.50	-316.95
Note 20 Other Manufacturing Expenses		
Particulars	For the year ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Consumable Stores	161.13	99.69
R&D Consumable Stores	53.36	132.35
Generator running expenses	138.24	103.50
Power & Fuel	245.22	202.85
Direct labour	858.60	768.95
Repairs & maintenance (machinery & Building)	156.70	106.40
Freight Inward	16.18	13.10
Factory Expenses	26.99	23.77
Solid Waste Pollution expenses	1.43	1.17
Housekeeping Expenses	10.71	10.95
Testing Charges	46.74	59.14
Total	1,715.29	1,521.88

BETA DRUGS LIMITED		
Note 21 Employee benefits expense		
Particulars	For the year ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Salaries and wages		
Director	323.56	311.52
Employees	893.22	803.51
R&D Staff	27.90	47.87
Employer Share of ESI	5.52	6.94
Employer Share of PF	76.35	71.29
Employer Share of LWF	0.84	1.08
Bonus	28.21	36.52
Staff welfare expenses	47.71	43.90
Staff Uniform Expenses	4.22	0.18
Gratuity Provision	24.05	19.27
Total	1,431.58	1,342.08
Note 22 Finance costs		
Particulars	For the year ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a) Interest expense on:		
(i) Borrowings		
Bank Interest CC	1.04	1.66
Interest on Term Loan	33.65	44.17
Interest on Vehicle Loan	10.00	5.76
Interest on PCFC Loan	12.57	6.53
(ii) Others	40.85	21.03
(b) Other borrowing costs (Processing Fees)		
Bank charges	6.62	4.52
Total	104.73	83.66

BETA DRUGS LIMITED		
Note 23 Other expenses		
Particulars	For the year ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Advertisement Expenses	2.13	2.63
Audit Fee	8.88	8.88
Business Promotion Expenses	115.57	98.53
Daily Pooja Expenses	1.36	0.75
Commission Paid	336.31	179.20
Conference Expenses	259.23	119.70
Convenyance Expenses	77.83	66.39
Corporate Social Responsibility Expenses	41.28	29.28
Donation A/C	8.85	5.78
Diwali Expenses	10.25	16.16
Expired & damages Goods Return	6.34	12.76
Freight Outward	224.58	165.05
Foreign Travel	175.67	102.90
Foreign Exchange	0.05	-
Insurance Apportion Cost	59.22	28.55
Legal & Professional Expenses	231.55	183.74
Medical Expenses	-0.00	3.57
Office Expenses	19.46	18.02
Packing & Forwarding expense	3.22	13.69
Printing & Stationary	65.63	35.04
Rate Fee & taxes	48.28	61.72
Rent	32.40	32.37
Repair & maintenance (Vehicle)	8.30	10.17
Round Off	-0.00	-0.01
Software Expenses	21.10	22.14
Telephone & Postage	3.68	3.38
Trade Discount Expenses	25.78	25.21
Travelling Expenses	246.04	228.20
Total	2,032.96	1,473.81



BETA DRUGS LIMITED
NOTE '24': SIGNIFICANT ACCOUNTING POLICIES
(Forming part of Accounts)
FOR THE YEAR ENDED 31ST MARCH' 2024

24.1. Basis of Accounting

The financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India under the historical convention on accrual basis. These financial statements have been prepared to comply, in all material aspects, with the accounting standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and the presentation requirements as prescribed by the Schedule III of the Companies Act, 2013 to the extent applicable.

24.2. Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires that management makes estimates and assumptions that affect the reported amounts of income and expenses of the year, the reported balance of assets and liabilities and the disclosure relating to contingent liabilities as at the date of the financial statements. These estimates are based upon management's best knowledge of current events and actions. The difference between the actual results and estimates are recognized in the period in which the results are known / materialized.

24.3. Property, Plant and Equipment and Intangible assets

-Property, Plant and Equipment

Tangible Assets are stated at cost of acquisition or construction less accumulated depreciation and impairment of assets, if any. The cost comprises purchase price, borrowing costs if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. The company has a policy of physical verification of all the assets once in a year, the last verification was done on 26th March 2024 and no discrepancies were noticed during such verification.

The company has also got the physical verification conducted from external agency dated 16.09.2023.

-Capital Work-in-Progress

Expenses incurred during construction/installation period are included under capital work-in-progress and allocated to relevant fixed assets in the ratio of cost of the respective assets on completion of construction/installation. There is no work in progress for the financial year ending 31-March-2024.

24.4. Depreciation/Amortization

Depreciation on tangible assets is provided, on Written down Value method, over the useful life of assets estimated by the management in accordance with Schedule-II of the Companies Act, 2013.

-Residual value of assets has been considered at 5% of the original cost of the assets.

-Depreciation on additions to fixed assets is calculated on date of put to use as certified by the management.

-Depreciation on assets sold & scrapped, during the year, is provided up-to the date on which such fixed assets are sold or scrapped.

24.5. Impairment of Assets

The carrying amounts of assets are reviewed at each balance sheet date if there is any indication of impairment based on internal/external factors. An asset is treated as impaired when the carrying cost of the assets exceeds its recoverable value. An impairment loss, if any, is charged to the Statement of Profit & Loss in the year in which an asset is identified as impaired. Reversal of impairment losses recognized in prior years is recorded when there is an indication that the impairment losses recognized for the assets no longer exist or have decreased.

24.6. Valuation of Inventories

-Raw Material Chemicals & Salts,

-Packing Material,



-Finished Goods Oncology products comprise of injections, tablets and capsules,
-Work In Progress (Semi Finished Goods).

Is valued at cost or estimated realizable value, whichever is lower. The company has determined the cost of inventory using the First-In, First-Out method.

The company has appointed cost auditor to ascertain and verify the authenticity of cost records maintained by the company. The valuation of Finished Goods as well as Work in Process material has been taken as certified by the cost auditor. The value of raw material and packing material has been taken at cost.

The company has a policy of physical verification of the entire available inventory once every month, no material discrepancies were noticed during such verification. Last stock verification was done on 3rd April 2024.

24.7. Revenue Recognition

-Revenue from sale of goods is recognized when risk and rewards of ownership are transferred to the customers.

-Revenue from services is recognized when services are rendered and related costs are incurred.

-Other income is recognized on accrual basis unless otherwise stated.

-Insurance and other claims are accounted for on settlement of claims/on receipt.

-Revenue from sales/services are shown net of taxes, as applicable.

24.8. Employee Benefits

a) Short-term Employee Benefits:

-Leave Encashment, on the basis of actual computation, is accounted for on payment basis, after the cessation of employment, the payment in respect thereof is made by the Company from its own funds as per the past practice consistently followed by the Company.

-Payment of Bonus – This year the company has incurred the expenditure of Rs. 28,20,568.00 as per The Payment of Bonus Act, 1965.

b) Post-Employment Benefits

(i) Defined Contribution Plans:

Contributions as required under the Statute/Rule are made to Employees State Insurance & Provident Fund and charged to the Statement of Profit & Loss of the year when the contributions to the respective funds are due.

(ii) Defined Benefit Plans:

Gratuity is accounted for on accrual basis -the Company has opened an Employees' Gratuity Trust with Aditya Birla Sun Life Insurance Company Ltd. and has taken the Group Cap Secure Plan. The Gratuity payable to any employee will be paid out of funds deposited in this plan.

The company has got the Actual Valuation done by independent consultant for FY 2023-24 to determine the projected benefit obligation for Gratuity Benefit and the accounting expenses associated with Gratuity Benefit on 31-03-2024.

Detailed Calculation of Gratuity Provision as per Certified Actuary.

Particulars	Amount (₹)
Present Value of Benefit Obligation as on 01.04.2023	1,08,12,022.00
Current Service Cost	27,34,137.00
Interest Cost	7,67,654.00
Benefits paid	(4,39,221.00)
Net Actuarial Losses (Gains) recognized in the year	(10,97,184.00)
Present Value of Benefit Obligation on 31.03.2024	1,27,77,408.00

Gratuity Provision in FY 2023-24 was provided for Rs. 24,04,607.04 and Rs. 19,26,992.00 in FY 2022-23.

c) **Termination Benefits:** Termination benefits are recognized as an expense as and when incurred.



24.9 Foreign Currency Transactions

- i.) Functional and Reporting Currency: The standalone financial statements are presented in Indian Rupee ('INR') which is also the functional and presentation currency of the Company.
 - ii.) Initial Recognition: Foreign currency transactions are recorded in the functional currency, by applying to the exchange rate between the functional currency and the foreign currency at the date of the transaction.
 - iii.) Conversion on Reporting Date: Transactions in foreign currencies are initially recorded by the Company at its functional currency spot rates at the date the transaction first qualifies for recognition. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.
 - iv.) Exchange Differences: Exchange differences arising on monetary items on settlement, or restatement as at reporting date, at rates different from those at which they were initially recorded, are recognized in the statement of profit and loss in the year in which they arise.
- Net amount of Rs. 4,580.55 is recognized as expense for the year due to foreign exchange fluctuation.

24.10. Borrowing Costs

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalized as part of the cost of such assets to the extent that they relate to the period till such assets are ready to use. A qualifying asset is one that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are charged to the Statement of Profit & Loss.

During the year, the Company has not capitalized any borrowing cost this year (Previous year Rs. Nil) relating to credit facility availed for installation of Plant and Machinery.

24.11. Investments

- Current Investments are carried at cost or fair market value whichever is lower.
- Non-Current Investments are carried at cost. Provision for diminution in value of non-current Investments is made only, if a decline is other than temporary.

24.12. Operating Lease

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased assets are classified as operating leases. Operating lease charges are recognized as an expense in the Statement of Profit & Loss on monthly due basis. The company has taken following premises on lease:

- 1.) Administrative office located at Panchkula-SCO 184, First floor, Sector 5, Panchkula -134114. The lease is entered into with M/s B.T. Associates, Panchkula for 10 years with monthly rent of Rs. 2,40,720.00 plus GST@18 percent.

24.13. Taxes on Income

- Current Tax is measured at the amount expected to be paid to the tax authorities in accordance with the Indian Income Tax Act, 1961.
- Deferred tax is recognized, subject to the consideration of prudence in respect of deferred tax assets, on timing differences, being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods.
- Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off assets against liabilities.

24.14. Earnings Per Share (EPS)

- Annualized basic earnings per equity share is arrived at based on net profit/(loss) attributable to equity shareholders to the basic weighted average number of equity shares outstanding.
- Annualized diluted earnings per equity share is arrived at based on adjusted net profit/(loss) attributable to equity shareholders to the adjusted weighted average number of equity shares outstanding, for the effects of all dilutive potential equity shares; except where the results are anti-dilutive. At present the Company does not have any dilutive potential equity shares.



24.15. Cash Flow Statement:

- The Cash Flow Statement is prepared by the indirect method set out in Accounting Standard (Ind AS) 7 on Cash Flow Statements and presents the cash flows by operating, investing and financing activities of the Company.
- Cash and cash equivalents presented in the Cash Flow Statement consists of balance in current accounts and cash balances.

24.16. Contingencies and Provisions

A provision is recognized when the Company has a present obligation as a result of past events. It is probable that an outflow of resources embodying economic benefit will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on the best estimate of the expenditure required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimate.

A contingent liability is disclosed, unless the possibility of an outflow of resources embodying the economic benefit is remote.

Bank Name	Bank Guarantee No	Opening Date	Expiry Date	In Favor	Bank Guarantee Amount (Rs.)
ICICI BANK	0043BGFD003118	02-09-2017	31-08-2025	The President Of India Through The Deputy Asst Commissioner Of Customs, Air Cargo Complex, New Delhi	8,22,770.00
BANK OF BARODA	8304IGISS190060	04-10-2019	31-01-2024	President Of India Through Office Of DGAFMS, New Delhi	1,68,400.00
BANK OF BARODA	8304IGISS200012	10-09-2020	30-10-2022	President Of India Through Office Of DGAFMS, New Delhi	4,70,600.00
BANK OF BARODA	2488IGP000733520	23-09-2020	30-11-2024	President Of India Through Office Of DGAFMS, New Delhi	2,71,200.00
HDFC BANK	03GT02203400002	05-12-2020	28-02-2026	President Of India Through Office Of DGAFMS, New Delhi	3,13,000.00
BANK OF BARODA	8304IGISS190075	27-12-2019	28-02-2023	Managing Director RMSCL, Jaipur	4,43,944.00
BANK OF BARODA	FD NO - 49A064337	18-09-2020	18-09-2022	Medical Superintendent, KGMU Lucknow	2,00,000.00
HDFC BANK	03GT02212300004	18-08-2021	30-08-2023	Odisha State Medical Corp Bhubaneshwar	65,900.00
HDFC BANK	03GT02220110002	11-01-2022	31-01-2024	State Health Society Assam	1,39,388.00
HDFC BANK	03GT02221450001	25.05.2022	30.04.2025	Chitranjan National Cancer Kolkata	2,00,000.00
HDFC BANK	035GT0222180008	30.06.2022	30.06.2025	State Health Society Assam	1,16,160.00
HDFC BANK	BG NO 035GT02222300001	18.08.2022	28.02.2023	AIIMS Kalyani Procurement Cell , Delhi	10,00,000.00
HDFC BANK	035GT02222850004	12.10.2022	31.12.2026	The Dy Director Health Services E&S West Bengal	2,86,650.00
HDFC BANK	035GT02222980001	25.10.2022	31.12.2026	The Dy Director Health Services E&S West Bengal	2,32,200.00
HDFC BANK	035GT02222980002	25.10.2022	31.12.2026	The Dy Director Health Services E&S West Bengal	2,86,650.00



HDFC BANK	035GT02230440002	13.02.2023	17.01.2025	Punjab Health Systems Corp, Punjab	6,00,000.00
HDFC BANK	035GT02230470004	16.02.2023	31.12.2025	Odisha State Medical Corp Bhubaneswar	19,98,000.00
HDFC BANK	035GT02231780006	27.06.2023	30.06.2026	B.G OSMCL Bhubaneswar	4,29,749.00
HDFC BANK	035GT02231240020	04.05.2023	31.01.2025	B.G. KMSCL Kerala	8,42,100.00
HDFC BANK	035GT02233080009	04.11.2023	30.04.2026	The Gujarat Cancer Research Institute	2,91,336.00
HDFC BANK	035GT02240200010	20.01.2024	31.07.2026	Regional Cancer Centre Medical College	7,76,029.00
				TOTAL AMOUNT	99,54,076.00

24.17 **Internal Control Policy and BCP Management:** The Company has a comprehensive system of Internal Controls to safeguard its assets against loss from unauthorized use and to ensure reliability of financial reporting. The management assesses the operating effectiveness of these controls on regular basis. All the required security checks i.e., physical security of the company premises and its database are properly installed, daily backup is being done for all the accounting and related data. The internal auditor in his quarterly report, also confirms about the effectiveness of the internal control measures. The company maintains a system of internal controls designed for effectiveness and efficiency of operations, compliance and regulations. The company has a cloud-based ERP system (maintained by TATA Consultancy Services) in which the data remains safe on cloud and can be accessed and updated on real time basis from anywhere with defined access user rights.

The system of internal controls monitors and ensures process for:

- Effectiveness and efficiency of operations;
- Reliability of financial reporting;
- Compliance with applicable laws and regulations.



NOTE 25 : OTHER NOTES TO ACCOUNTS
(Forming part of Accounts)
FOR THE YEAR ENDED 31ST MARCH, 2024

25.1. **Contingent Liabilities & Commitments:**

- a) Estimated amount of contracts remaining to be executed and not provided for in the books of account- Nil (previous year- Nil).
- b) Contingent Liabilities: Rs. 99,54,076.00
 - . Claims against the Company not acknowledged as debt -Nil (previous year - Nil).
 - . Liabilities in respect of Income Tax, Service Tax, Sales Tax and other material statutory dues have been accounted for on the basis of respective returns filed with the relevant authorities. Additional demand, if any, arising at the time of assessments will be accounted for in the year in which assessments are completed.

25.2. **Issued, Subscribed & Paid-up Capital:**

Issued, Subscribed and Paid-up capital of the company is Rs. 9,61,37,900.00 (Divided into 96,13,790.00 shares of Rs. 10 each). During the financial year 2023-24, the company has no further issue of capital.

25.3. **Reserves & Surplus:**

-The amount shown in the Reserve & Surplus represents only surplus carried forward from the earlier year plus the surplus earned during the year. Total amount of surplus outstanding as on 31.03.2024 is Rs. 1,06,39,65,140.20 which includes share premium of Rs. 23,94,01,048.98 and Free Reserves of Rs. 82,45,64,091.22.

25.4. **Long-term Borrowings**

Secured :

Term Loan:

S.NO	Lender	Nature of facility	Loan	Amount outstanding as at March 31, 2024	Sanctioned Rate of Interest (%)	Repayment Terms	Security / Principal terms and conditions
		Vehicle Loan of Rs. 5 Lakhs	Term Loan	Rs. 2.86 Lakhs	8.25%	Total Installments of Rs 0.15 Lakhs P.M. divided into 39 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.
		Vehicle Loan of Rs. 35 Lakhs	Term Loan	Rs. 20.68 Lakhs	7.90%	Total Installments of Rs 1.01 Lakhs P.M. divided into 39 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.



	SIDBI	Term Loan of Rs. 400.00 Lakhs SIDBI term loan new	Term Loan	Rs. 37.40 Lakhs	8.09%	Fixed principal repayment of Rs 7.40 Lakhs P.M. after moratorium of 6 months divided into 53 Equated monthly installment. Last Installment i.e. 54 th Installment is of Rs. 7.80 Lakh.	<p>1) Pari-Passu (Second Charge) of Equitable Mortgage of Industrial Property situated at Lodhimajra, comprising of Khasra No 733/465 (0-5), 466(0-2), 735/467(2-0), Khatoni No 78, comprising of Khasra No 368(1-17). Land measuring 4 Bigha 4 Biswa, Village Nandpur, HB No 170, Tehsil Baddi, Distt Solan (HP) and Khata No 70min/90 comprising Khasra No 369(1-15), 370(0-2-0), 371 (1-6-0), 379/1(2-8-0), Kitte-4. Land measuring 5 Bigha 11 Biswa, village Nandpur, HB NO 170, Tehsil Baddi, Distt Solan (HP)</p> <p>2) HYP of Machinery amounted Rs. 829.00 Lakhs.</p>
	SIDBI	Term Loan of Rs. 130.00 Lakhs SIDBI Covid Working Capital Term Loan	Working Capital Term Loan	Rs. 126.40 Lakhs	6.00%	Fixed principal repayment of Rs 3.60 Lakhs P.M. after moratorium of 24 months divided into 35 Equated monthly installment. Last Installment i.e.36 th Installment is of Rs. 4 Lakh.	<p>1) Second charge by way of hypothecation in favour of SIDBI of all the movables including; plant, machinery spares, tools & accessories, office equipment, computers, furniture and fixtures.</p> <p>2) Second charge by way of pledge of FDR with SIDBI of Rs. 34 Lakh</p> <p>3) Second charge by way of mortgage on the Industrial Plot in Vill Nandpur comprised in Khewat/Khatoni No. 114/157 measuring 9 Bigha 15 Biswa owned by Beta Drugs Ltd.</p>



	SIDBI	Term Loan of Rs. 160.00 Lakhs SIDBI Machinery Loan	Term Loan	Rs. 91.60 Lakhs	5.65%	Fixed principal repayment of Rs 3.80 Lakhs P.M. after moratorium of 6 months divided into 41 Equated monthly installment. Last Installment i.e.42 nd Installment is of Rs. 4.2 Lakh.	<p>1) First charge by way of hypothecation in favour of SIDBI of the plant, machinery, equipment, tools, spares, accessories, misc fixed assets and all other current assets.</p> <p>2) Extension of pledge of FDR of Rs. 34 Lakh and pledge of FDR of Rs. 40 Lakh.</p> <p>3) Extension of first pari passu charge by way of mortgage on Industrial Plot in Vill. Nandpur measuring 9 Bigha 15 Biswa owned by Beta Drugs Ltd.</p>
3	Axis Bank	Vehicle Loan of Rs. 69.72 Lakhs	Term Loan	Rs. 35.61 Lakhs	7.10%	Total Installments of Rs 1.67 Lakhs P.M. divided into 48 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.
3	Federal Bank	Vehicle Loan of Rs. 60 Lakhs	Term Loan	Rs. 50.03 Lakhs	8.55%	Total Installments of Rs 1.48 Lakhs P.M. divided into 48 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.
3	Federal Bank	Vehicle Loan of Rs. 17 Lakhs	Term Loan	Rs. 14.87 Lakhs	8.60%	Total Installments of Rs 0.54 Lakhs P.M. divided into 36 Equated	1) HYP of Motor Vehicles from the bank in the name of Company.



						monthly installment.	
3	Federal Bank	Vehicle Loan of Rs. 12 Lakhs	Term Loan	Rs. 11.39 Lakhs	8.70%	Total Installments of Rs 0.38 Lakhs P.M. divided into 36 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.
3	SIDBI	PCS Gold of Rs. 160.00 Lakhs	Term Loan	Rs. 160.00 Lakhs	8.40%	Total principal payment of Rs 2.96 Lakhs P.M. plus interest for 54 months after 6 months moratorium period from the date of sanction.	<p>(i.) Primary Security: Hypothecation for creating charge over existing movable assets charged to SIDBI and movable assets proposed to be acquired out of the loan.</p> <p>Collateral Security:</p> <p>1.) Extension of First Pari passu Charge with HDFC Bank Ltd. by way of mortgage on the Industrial Plot in village Nandpur comprised in Khawat/Khatoni No. 114/157 in Khasra No. 733/465 (00-05), 466 (00-02), 735/467 (02-00), village Nandpur, Tehsil Nalagarh, Dist. Baddi, measuring 2 Bigha 7 Biswa and at plot 47/69 in Khasra Number 368(01-17) admeasuring 1 Bigha 17 Biswas (i.e total 4 Bigha 04 Biswas) owned by Mis Beta Drugs Ltd. ,</p> <p>2.) Extension of First Pari passu Charge with HDFCF Bank Ltd. by way of mortgage on the Industrial Plot situated at Khata No. 70min/90 (as per jamabandi for the year 2017-18) Khasra No.369(1-15), 370(0-2-0), 371(1-6-0),, 379/1(2-8-0), Kitte -4, Village Nandpur, HB No. 170, Tehsil Baddi, Distt. Solan (HP) admeasuring 5 Bigha 11 Biswas owned by Beta Dmgs Limited.</p> <p>3.) Extension of pledge of FDR ofRs.40 Lakh with SIDBI</p> <p>4.) Extension of pledge of FDR ofRs.34 Lakh with SIDBI.</p> <p>5.) Extension of First charge by way of hypothecation in favour of SIDBI of the plant, machinery, equipment, tools,</p>



							spares, accessories, miscellaneous fixed assets and all other assets (save and except book debts & current assets) acquired/ proposed to be acquired under the project/ scheme. 6.) .GUARANTEE(S): Irrevocable, unconditional guarantee of Smt Neeraj Batra, Shri Rahul Batra, Shri Varun Batra.
3	Tata Motors Finance	Vehicle Loan of Rs. 17.00 Lakhs	Term Loan	Rs. 17.00 Lakhs	9.28%	Total Installments of Rs 0.54 Lakhs P.M. divided into 36 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.

Interest on the above term loans is payable on monthly basis.

25.5. In the opinion of the Directors, “Current Assets” and “Loans &Advances” are approximately of the value stated in the Balance Sheet, if realized in the ordinary course of business and to the best of their knowledge. Provisions for all the known liabilities have been made and, *as certified*, all the contractual and statutory obligations have been duly complied with.

25.6. **Depreciation/Amortization**

The management estimates the useful life of existing fixed assets as follows:-

Building	30 years
Furniture & Fixtures	10 years
Machinery	15 years
Lab Equipment	10 years
Equipment (Other)	5 years
Vehicles	8 years

For these class of assets, based on internal assessment and independent technical evaluation carried out by external valuers, the management believes that the useful lives as given above best represent the period over which management expects to use these assets.

25.7. **Earnings Per Share (Ind AS-33)**

	Year ended 31 st March, 2024	Year ended 31 st March, 2023
Numerator		
Net Profit/(Loss)		
Attributable to Equity shareholders	21,93,65,854.27	18,81,60,708.34
Denominator		
Number of Equity shares	No.'s 96,13,790	No.'s 96,13,790
Number of Weighted avg. shares	No.'s 96,13,790	No.'s 96,13,790
Nominal		
Value per Equity share	10	10
Earnings per Equity share	22.82	19.57
- Basic and diluted		

**25.8. Non-Current Investments:**

Investment in Joint ventures and Associates are accounted for using the equity method of accounting. Under the equity method of accounting, the investments are initially recognized at cost and adjusted thereafter to recognize Dividends received or receivable from associates or joint ventures are recognized as a reduction in the carrying amount of the investment.

Equity shares have been stated at cost; provision for appreciation/diminution in the value of shares has not been made and no dividend was received during the year.

The provisions of Section 186 of the Companies Act 2013 have been complied with.

The company has the following investments as on 31.03.2024 in entities as mentioned below:

(a) Beta Drugs has an investment in Adley Formulations Private Limited (CIN: U24303HR2018PTC076347) amounting Rs.1,26,00,000.00

(b) Beta Drugs has an investment in Adley Lab Limited (CIN: U24231PB1992PLC051220) amounting Rs. 4,50,40,000.00.

(c) Beta Drugs has an investment in Beta Research Pvt. Ltd. (CIN: U24303HR2022PTC104598) amounting Rs. 1,00,000.00.

The company had investment in Beta UBK International Pvt. Ltd. (Uzbekistan) till November 2023. The Board of Directors of the Company at its meeting held on 7th November, 2023, inter alia, had considered and approved to write off the total investment made by the company in Beta UBK International Private Limited and it ceased to be subsidiary of the company.

25.9. Taxes

- The exact liability of CST/VAT, Service Tax, GST, Income Tax and other statutory dues is indeterminate, till finalization of assessments no undisputed dues or amounts were outstanding or remaining unpaid as at 31st March, 2024.
- Disputed Income tax demand amounting to Rs. 12,122/- for A.Y 2020-21 and Rs. 90,64,680/- for A.Y 2021-22 is outstanding and appeal filed against the same is under process as on 31.03.2024. The said demand was raised by the department on account of non-compliance of notice u/s 133(6) issued to the third parties, however, the said third parties had duly filed the response to the said notices received by them. The company has filed an appeal providing acknowledgements of the replies filed by those third parties.

-The current tax provision shown in the Balance Sheet is Rs. 1,86,78,501.27 after utilization of the advance tax and TDS of Rs. 5,59,92,646.82.

25.10. Segment Reporting

Since the Company primarily operates in one segment (i.e., Manufacturing of Oncology medicines), therefore segment reporting as required under Ind AS – 108 is not applicable. Regarding the geographical segments, the company has an export turnover of Rs. 44,48,15,702.67 (Including Direct and Indirect Exports) and the domestic turnover of Rs. 1,53,13,91,321.04.

25.11. Related Party Disclosures (Ind AS-24)

Related parties & their relationship and related party's transactions.



BETA DRUGS LTD				
S. NO.	Related Party	Nature of Relationship	Nature of Transaction	Amount Involved During the year 2024 (Rs.)
1	Adley Lab Limited	Wholly Owned Subsidiary	-Purchase of Goods	17,89,96,195.00
			-Sale of Goods	-
			-Interest received on Unsecured Loan	19,42,788.00
			-Unsecured Loan given to subsidiary	35,00,000.00
			- Sale of Machinery	-
			- Purchase of Machinery	1,00,000.00
2	Adley Formulations Private Limited	Wholly Owned Subsidiary	-Sale of Goods	3,09,35,849.06
			-Purchase of goods	5,27,75,471.80
			-Interest received on Unsecured Loan	32,40,302.00
			-Unsecured Loan given to subsidiary	1,80,60,000.00
			-Sale of Fixed Assets	4,77,970.00
3	B.T. Associates Private Limited	Share holder are common (Holding more than 50 % shares)	Payment of Building Rent	28,88,640.00
4	Varun Batra	Director	Salary (including bonus)	1,21,00,000.00
5	Balwant Singh	Director	Salary (including bonus)	29,79,860.00
6	Rahul Batra	Director	Salary (including bonus)	1,21,00,000.00
7	Ashutosh Shukla	Director	Salary (including bonus and incentive)	51,23,008.00
8	Seema Chopra	Director	Salary (including bonus)	11,91,484.00
9	Nipun Arora	Chief Financial Officer	Salary (including bonus)	31,00,981.00
10	Rajni Brar	Company Secretary	Salary (including bonus)	9,11,552.00

The above disclosure of the related party and the transactions entered have been made as per Ind AS-24. The transactions have been carried at arm's length price (ALP).

*Rs. 35.00 Lakh has been further provided to M/s Adley Lab Limited and Rs. 180.60 Lakhs has been further provided to M/s Adley Formulations Pvt Ltd during F.Y 2023-24 for working capital requirements. The loan has an outstanding



balance of Rs. 2,50,94,764.00 provided to Adley Lab Ltd and Rs. 4,95,99,060.00 provided to Adley Formulations Pvt. Ltd. as on 31st March 2024. The rate of interest on these loans has been taken at yield method i.e. 9% as computed.

25.12 Ratios

Beta Drugs Limited- Ratios							
Sr. No.	Ratios	Numerator	Denominator	As at March 31' 2024	As at March 31' 2023	Variance	Explanation for any significant change in ratios as compared to the preceding financial year
1	Current Ratio	Current Assets	Current liabilities	2.38	2.70	-11.69%	Trade Payables increased by 12.60 Cr. vis-a-vis Trade Receivables which increased by 6.90 Cr. However, the operating cash flow has been increased by 13.70Cr
2	Debt-Equity Ratio	Total Debt	Shareholders' equity	0.047	0.054	-12.50%	Due to increase in Reserves.
3	Debt Service Coverage Ratio	Earnings available for debt service	Debt service	9.15	12.77	-28.38%	Due to the increase in loan repayment from Rs. 2.52 Cr. in FY 23 to Rs. 3.85 Cr. in FY 24. The company has voluntarily repaid additional principal of Rs. 84.50 lac and interest cost of Rs.21 lacs.
4	Return on Equity Ratio	Net profit after taxes Less preference dividend (if any)	Shareholder's equity	18.91%	19.55%	-3.27%	
5	Inventory Turnover ratio	Cost of goods sold or sales	Average inventory	7.27	8.91	-18.42%	Due to increase in COGS by 31.22% vis a vis increase in average inventory by 60.84%
6	Trade Receivables turnover ratio	Net Sales	Average Trade Receivables	4.20	4.21	-0.29%	
7	Trade Payables turnover ratio	Net Purchases	Average Trade Payables	4.09	4.13	-1.01%	
8	Net capital turnover ratio	Net Sales	Net working capital	2.99	2.95	1.50%	
9	Net Profit ratio	Net Profit after taxes	Net Sales	11.10%	11.92%	-6.86%	
10	Return on capital employed	Earnings before interest and taxes	Capital employed	0.249	0.254	-2.10%	



11	Return on investment	Income generated from investments	Total Current Investments	0.054	0.047	15.72%
12	Operating Profit Margin	Earnings before interest and taxes	Net Sales	15.45%	16.50%	-6.36%
13	Interest Coverage Ratio	Earnings before interest and taxes	Interest Expense	29.15	31.13	-6.37%

25.13 **Particulars relating to corporate social responsibility**

The Company has provided for the corporate social responsibility as per Section 135 of the Companies Act 2013 i.e., Rs. 41,27,644.00 during the year. The actual amount spent during the financial year was Rs. 41,27,700.00 and there is no outstanding provision as on 31st March 2024.

25.14. **Impairment of Assets**

During the year, the Company has undertaken a review of all the fixed assets in line with the requirements of Ind AS-36 on “Impairment of Assets” as notified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014, based on such review, no provision for impairment is required to be recognized for the year.

25.15. **Property, Plant and Equipment and Intangible assets:**

- During the financial Year 2023-24 there was no addition under the head Land.
- During the financial Year 2023-24 there was an addition of Rs. 1,65,38,815.93 under the head Building.
- During the financial year, there was net additions of Rs 5,82,81,119.58 to Plant & Machinery, Furniture & Fixtures, Office Equipment, Vehicles & Computers including the assets transferred from WIP. The company has received capital grant of Rs. 3,63,06,653.00 from The Government of India under Industrial Development Scheme for capital subsidy in October -23 which was reduced from the Gross Block of Plant and Machinery.
- During the financial Year 2023-24 there was an addition of Rs. 1,42,38,441.82 under the head Intangible Assets.

25.16. **Deferred Tax Assets & Liabilities**

During the FY 2023-24 the company has made Deferred Tax Provision (Asset) as follows:

Calculation of Deferred Tax Asset / Liability	Amount (‘)
Deferred Tax on Depreciation	(12,44,526.47)
Deferred Tax on provision of Gratuity	4,94,645.83
Deferred Tax on provision of Bonus	(43,216.22)
Total Deferred Asset Created for the financial year in Profit and Loss Account.	7,93,096.86
Add: Deferred Tax Asset as on 31.03.2023 (Opening)	89,23,345.75
Balance Deferred Tax Asset recognized in Balance Sheet	(81,30,248.89)

25.17. **Micro, Small & Medium Enterprises**

Based on the information presently available, total outstanding as on 31.03.2024 is Rs.2,61,98,873.17 to micro or small enterprises under the Micro, Small and Medium Enterprises Development Act, 2006.

25.18. **Auditor's Remuneration**

(Exclusive of GST)

	31st March, 2024	31st March, 2023
	AMOUNT	AMOUNT
As Statutory Auditors	4,02,500.00	4,02,500.00
- Taxation Matters	-	
- Certification	-	-
-Other Services	-	-
As Internal Auditor	3,60,000.00	3,60,000.00
- Taxation Matters	-	-
- Certification-	-	-
-Other Services	-	-
- Cost Audit	1,25,000.00	1,25,000.00
- Reimbursement of out of pocket expenses	-	-
TOTAL	<u>8,87,500.00</u>	<u>8,87,500.00</u>

25.19. **Other additional information**

<u>Particulars</u>	<u>31st March, 2024</u>	<u>31st March, 2023</u>
	<u>AMOUNT</u>	<u>AMOUNT</u>
“A” Revenue from operations		
(Under broad heads)		
-Export Sales	44,48,15,702.67	27,82,93,667.94
-Sales With in India	1,53,13,91,321.04	1,30,04,52,205.51
-Total	<u>1,97,62,07,023.71</u>	<u>1,57,87,45,873.45</u>
“B” Purchases		
-Raw Material, Excipients & Packing Material	1,20,56,86,993.36	88,49,21,760.72



25.20. Expenditure In Foreign Currency (On Accrual Basis): - Following Expenses were incurred by the company during the year 2023-24.

	31st March, 2024	31st March, 2023
	AMOUNT	AMOUNT
-Import of Capital Goods	29,74,835.03	1,60,11,850.26
-Import of Capital Services	1,03,93,677.59	50,36,026.99
-Revenue Expenses (Others)	2,77,65,287.60	1,66,21,367.85
-Revenue Expenses (Travel)	0.00	1,02,89,511.26
TOTAL	<u>4,11,33,800.22</u>	<u>4,79,58,756.36</u>

25.21. Earning in Foreign Currency Particulars

	For the Year Ended	For the year Ended
	(31.03.2024)	(31.03.2023)
FOB Value of Export	44,48,15,702.67	27,82,93,667.94
Foreign Exchange Gain/(Loss)	(4,580.55)	1,87,278.27

25.22. **Other statutory information**

- i. No proceedings have been initiated during the year or are pending against the Company as at March 31, 2024 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.
- ii. The Company does not have any trading in Crypto Currency or Virtual Currency.
- iii. The Company does not have any transactions or balances with a Companies struck off under section 248 of the Companies Act, 2013 or Section 560 of the Companies Act 1956.
- iv. The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessment under the Income Tax Act, 1961.
- v. Company has not advanced or loaned or invested funds to any other person(s) or entity(is), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- vi. The Company has not received any fund from any person(s) or entity(is), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- vii. No charge is pending to be registered beyond statutory period with ROC.
- viii. The company has not used the borrowings from banks and financial institutions for any other purpose other than for the specific purpose for which it was taken.
- ix. The Company have defined agreement with the Debtors regarding the credit payment period given and ageing is done accordingly in Financial Statement.



-
- x. As there are no specific agreements with the creditors, hence the creditors ageing is done as per the date of invoice received.
- 25.23. Total count of debtors in M/s Beta Drugs Limited is 156, and creditors count is 404, Balance confirmations were sent to all and confirmation reply came from more than 50% of the total count.
- 25.24. Figures for previous year have been regrouped/rearranged where necessary to confirm to the current year's presentation.

In terms of our attached report of even date.

For KALRA RAI AND ASSOCIATES

CHARTERED ACCOUNTANTS

F R No. -008859N

**Sd/-
LAJPAT RAI KALRA
PARTNER
M No. -087438
Dated: 14/05/2024
Place: Chandigarh
UDIN: 24087438BJZXBA3692**

For and on behalf of the Board of Directors

**sd/-
Rahul Batra
(Director)
DIN:02229234**

**sd/-
Varun Batra
(Director)
DIN:02148383**

CONSOLIDATED FINANCIAL STATEMENTS

OF

“BETA DRUGS LIMITED”

&

ITS WHOLLY –OWNED SUBSIDIARIES

“ADLEY FORMULATIONS PRIVATE LIMITED”

“ADLEY LAB LIMITED”

&

“BETA RESEARCH PRIVATE LIMITED”

FOR THE FINANCIAL YEAR

2023-24



**KALRA RAI & ASSOCIATES
CHARTERED ACCOUNTANTS**

**Head Office: Kothi No. 667, 1st floor, Sector-43-A
Chandigarh-160022**

Independent Auditors' Report

Members of Beta Drugs Limited

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated Ind-AS financial statements of Beta Drugs Limited ('the Holding Company'), and its subsidiary (Holding company and its subsidiary together referred to as "the Group"), which comprise the Consolidated Balance Sheet as at March 31, 2024, the Consolidated Statement of Profit and Loss, including the statement of Other Comprehensive Income, the Consolidated Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Holding Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ('the Act') with respect to the preparation of these consolidated Ind-AS financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Group in accordance with accounting principles generally accepted in India, including the Indian Accounting Standards (Ind-AS) specified under Section 133 of the Act., read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial control that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind-AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated Ind-AS financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under. We conducted our audit of the consolidated Ind-AS financial statements in accordance with the Standards on Auditing, issued by the Institute of Chartered Accountants of India, as specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated Ind-AS financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Group's preparation of the consolidated Ind-AS financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Holding Company's Directors, as well as evaluating the overall presentation of the consolidated Ind-AS financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the consolidated Ind AS financial statements.



Opinion

In our opinion and to the best of our information and according to the explanations given to us, the consolidated Ind-AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Group as at March 31, 2024, its profit including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143 (3) of the Act, we report that:

- a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
- b. In our opinion, proper books of account as required by law have been kept by the Group so far as it appears from our examination of those books;
- c. The Consolidated Balance Sheet, Consolidated Statement of Profit and Loss including the Statement of Other Comprehensive Income, the Consolidated Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account;
- d. In our opinion, the aforesaid consolidated Ind-AS financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act, read with Companies (Indian Accounting Standards) Rules, 2015, as amended;
- e. On the basis of written representations received from the directors of holding company as on March 31, 2024, and taken on record by the Board of Directors, none of the Directors in the Group is disqualified as on March 31, 2024.
- f. With respect to the adequacy of the internal financial controls over financial reporting of the Group and the operating effectiveness of such controls, refers to our separate Report in “Annexure A”;
- g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Group has disclosed the impact of pending litigations on its financial position in its financial statements.
- ii. The Group did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
- iii. There have been no amounts available which is required to be transferred, to the Investor Education and Protection Fund by the Group;

2. With respect to the matters specified in paragraphs 3(xxi) and 4 of the Companies (Auditor's Report) Order, 2020 (the “Order”/ “CARO”) issued by the Central Government in terms of Section 143(11) of the Act, to be included in the Auditor's report, according to the information and explanations given to us, and based on the CARO reports issued by us for the Parent Company and CARO reports issued by the respective auditors of its subsidiaries included in the consolidated financial statements, to which reporting under CARO is applicable, we report that there are no qualifications or adverse remarks by the respective auditors in the CARO reports of the said companies included in the consolidated financial statements

Place:- Chandigarh
Date: 14/05/2024
UDIN:24087438BJZXAZ9600

For KALRA RAI & ASSOCIATES

Chartered Accountants

Sd/-
(Lajpat Rai Kalra)
Partner
M. No- 087438
FRN: 008859N

“ANNEXURE-A” TO THE AUDITORS’ REPORT

Referred to in Paragraph 7 of Our Report of Even Date

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of **Beta Drugs Limited** (“the Group”) as of 31 March 2024 in conjunction with our audit of the financial statements of the Group for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The respective Board of Directors of the Holding Company and its subsidiary companies, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (“the Guidance Note”) issued by the Institute of Chartered Accountants of India (‘ICAI’). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (“the Act”).

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (“the Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to

permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Companies have, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2024, based on the internal control over financial reporting criteria established by the Companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Place:- Chandigarh
Date: 14/05/2024
UDIN:24087438BJXAZ9600

For KALRA RAI & ASSOCIATES

Chartered Accountants

Sd/-
(Lajpat Rai Kalra)
Partner
M. No- 087438
FRN: 008859N

BETA DRUGS LIMITED (CONSOLIDATED)			
VILLAGE NANDPUR, BADDI, SOLAN 174101			
CIN : L24230HP2005PLC028969			
BALANCE SHEET AS AT 31st March' 2024			
Particulars	Note No.	As at 31 March' 2024	As at 31 March' 2023
		Amount in Rs. Lakhs	Amount in Rs. Lakhs
A			
EQUITY AND LIABILITIES			
1 Shareholders' funds			
(a) Share capital	1	961.38	961.38
(b) Reserves and surplus	2	14,750.31	11,327.04
(c) Money received against share warrants		-	-
		15,711.69	12,288.42
2 Share application money pending allotment		-	-
3 Non-current liabilities			
(a) Long-term borrowings	3	604.07	697.38
(b) Deferred tax liabilities (net)	4	-	-
(c) Other long-term liabilities	5 (a)	409.31	371.89
(d) Long-term provisions	5 (b)	217.90	182.87
		1,231.28	1,252.14
4 Current liabilities			
(a) Short-term borrowings	6	495.74	906.85
(b) Trade payables	7	5,927.32	4,024.04
(c) Other current liabilities	8	1,764.17	953.69
(d) Short-term provisions		279.66	417.01
		8,466.89	6,301.59
TOTAL		25,409.86	19,842.15
B			
ASSETS			
1 Non-current assets			
(a) Property, Plant and Equipment and Intangible Assets			
(i) Property, Plant and Equipment	9	5,920.26	5,809.46
(ii) Intangible assets	9	538.79	466.23
(iii) Capital work-in-progress	9	-	-
(iv) Intangible assets under development		-	-
(v) Fixed assets held for sale		-	-
		6,459.04	6,275.69
(b) Non-current investments	10	-	77.90
(c) Deferred tax assets (net)	4	141.10	120.06
(d) Long-term loans and advances	11 (a)	1,016.92	595.03
(e) Other non-current assets	11 (b)	6.00	5.00
		1,164.02	797.99
2 Current assets			
(a) Current investments		-	-
(b) Inventories	12	4,981.22	3,061.87
(c) Trade receivables	13	7,923.99	6,272.27
(d) Cash and cash equivalents	14	2,863.25	1,916.40
(e) Short-term loans and advances	15	715.23	609.02
(f) Other current assets	16	1,303.10	908.91
		17,786.79	12,768.47
TOTAL		25,409.86	19,842.15
See accompanying notes forming part of the financial statements	25		
In terms of our report attached.			
For KALRA RAI AND ASSOCIATES		For and on the behalf of the Board of Directors	
Chartered Accountants			
(FRN: 008859N)			
Sd/-	Sd/-	Sd/-	Sd/-
LAJPAT RAI KALRA	NIPUN ARORA	RAJNI BRAR	VARUN BATRA
Partner	C.F.O	C.S.	DIRECTOR
MEMBERSHIP NO. 087438			RAHUL BATRA
UDIN: 24087438BJXAZ9600			MANAGING DIRECTOR
Place : Chandigarh			DIN: 02229234
Date :- 14/05/2024			

Particulars	Note No.	As at 31 March' 2024	As at 31 March' 2023
		Amount in Rs. Lakhs	Amount in Rs. Lakhs
A CONTINUING OPERATIONS			
1 Revenue from operations (gross)	17	29,571.38	22,711.36
Less: Excise duty		-	-
Revenue from operations (net)		29,571.38	22,711.36
2 Other income	18	135.89	75.35
3 Total revenue (1+2)		29,707.26	22,786.71
4 Expenses			
(a) Cost of materials consumed	19	16,764.73	11,040.22
(b) Purchases of stock-in-trade		-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	20	-1,823.78	-471.28
(d) Other manufacturing expenses	21	3,178.83	2,381.61
(d) Employee benefits expense	22	2,588.68	2,269.68
(e) Finance costs	23	281.99	241.48
(f) Depreciation and amortisation expense	9	978.23	1,041.00
(g) Other expenses	24	2,863.16	2,178.35
Total expenses		24,831.83	18,681.06
5 Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)		4,875.43	4,105.65
6 Exceptional items		-	-
7 Profit / (Loss) before extraordinary items and tax (5 ± 6)		4,875.43	4,105.65
8 Extraordinary items/Prior period items		-	-
9 Profit / (Loss) before tax (7 ± 8)		4,875.43	4,105.65
10 Tax expense:			
(a) Current tax expense for current year		1,252.77	1,085.85
(b) (Less): MAT credit (where applicable)		-	-
(c) Current tax expense relating to prior years		-	-
(d) Net current tax expense		1,252.77	1,085.85
(e) Deferred tax		-21.04	-52.07
		1,231.73	1,033.78
11 Profit / (Loss) from continuing operations (9 ± 10)		3,643.70	3,071.87
B DISCONTINUING OPERATIONS			
12 Profit / (Loss) from discontinuing operations (B.i ± B.ii ± B.iii)		-	-
C TOTAL OPERATIONS		3,643.70	3,071.87
13 Profit / (Loss) for the year (11 ± 12)		3,643.70	3,071.87
14 Earnings per share (of Rs. 10/- each):			
(a) Basic			
(i) Continuing operations		37.90	31.95
(ii) Total operations		37.90	31.95
(b) Diluted			
(i) Continuing operations		37.90	31.95
(ii) Total operations		37.90	31.95
See accompanying notes forming part of the financial statements	25		

In terms of our report attached.

For KALRA RAI AND ASSOCIATES
Chartered Accountants
(FRN: 008859N)

For and on the behalf of the Board of Directors

Sd/-
LAJPAT RAI KALRA
Partner

Sd/-
NIPUN ARORA
C.F.O

Sd/-
RAJNI BRAR
C.S.

Sd/-
VARUN BATRA
DIRECTOR

Sd/-
RAHUL BATRA
MANAGING DIRECTOR

MEMBERSHIP NO. 087438
UDIN: 24087438BJXAZ9600
Place : Chandigarh
Date :- 14/05/2024

DIN: 02148383

DIN: 02229234

BETA DRUGS LIMITED (CONSOLIDATED)
VILLAGE NANDPUR, BADDI, SOLAN 174101
CIN : L24230HP2005PLC028969
CASHFLOW STATEMENT FOR THE PERIOD ENDED 31st March' 2024

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
A CASHFLOW FROM OPERATING ACTIVITIES		
Net Profit before tax and extraordinary items(as per Statement of Profit & Loss)	4,875.43	4,105.65
Adjustments for non Cash/Non trade items:		
Depreciation & Amortization Expenses	978.23	1,041.00
Finance Cost	281.99	241.48
Interest received	(108.39)	(66.30)
Other inflows/(outflows) of cash	(1,576.52)	(1,014.23)
Operating profits before Working Capital Changes	4,450.74	4,307.61
Adjusted For:		
(Increase)/Decrease in trade receivables	(1,651.72)	(1,754.08)
Increase/(Decrease) in trade payables	1,903.29	828.84
(Increase)/Decrease in inventories	(1,919.35)	(813.72)
Increase/(Decrease) in other current liabilities	810.47	90.40
(Increase)/Decrease in short term loans and advances	(106.21)	(161.33)
(Increase)/Decrease in other current assets	(394.19)	(159.46)
Working Capital Changes	(1,357.71)	(1,969.36)
Net cashflow from Operating Activities (A)	3,093.03	2,338.25
B CASHFLOW FROM INVESTING ACTIVITIES		
Purchase of tangible/intangible assets	(1,161.58)	(1,821.19)
Interest received	108.39	66.30
Cash used for Non Current Investments	77.90	-
Cash used for Long Term Loans/Advances	(421.89)	(152.01)
Net cash used in Investing Activities (B)	(1,397.19)	(1,906.89)
C CASHFLOW FROM FINANCING ACTIVITIES		
Finance Cost	(281.99)	(241.48)
Increase in/(Repayment) of Short term Borrowings	(411.11)	431.42
Increase in/(Repayment) of Long term Borrowings	(55.89)	(437.31)
Increase/ (Decrease) in share capital	-	-
Increase/ (Decrease) in share premium	-	-
Other Inflows/ (Outflows) of cash	-	-
Net cash used in Financing Activities (C)	(748.99)	(247.36)
D Net Increase/(Decrease) in cash & cash equivalents (A+B+C)	946.86	183.99
E Cash & Cash equivalents at beginning of period	1,916.40	1,732.40
F Cash & Cash equivalents at end of period	2,863.25	1,916.40
G Net Increase/(Decrease) in cash & cash equivalents (F-E)	946.86	183.99

In terms of our report attached.

For KALRA RAI AND ASSOCIATES
Chartered Accountants
(FRN: 008859N)

For and on the behalf of the Board of Directors

Sd/-
LAJPAT RAI KALRA
Partner
MEMBERSHIP NO. 087438
UDIN: 24087438BJXAZ9600
Place : Chandigarh
Date :- 14/05/2024

Sd/-
NIPUN ARORA
C.F.O

Sd/-
RAJNI BRAR
C.S.

Sd/-
VARUN BATRA
DIRECTOR
DIN: 02148383

Sd/-
RAHUL BATRA
MANAGING DIRECTOR
DIN: 02229234

BETA DRUGS LIMITED (CONSOLIDATED)
Notes forming part of the financial statements

Note 1 Share capital

Particulars	As at 31 March' 2024		As at 31 March' 2023	
	Number of shares	Amount in Rs. Lakhs	Number of shares	Amount in Rs. Lakhs
(a) Authorised - Equity shares of Rs. 10 each	1,00,00,000.00	1,000.00	1,00,00,000.00	1,000.00
	-	-	-	-
(b) Issued - Equity shares of Rs. 10 each	96,13,790.00	961.38	96,13,790.00	961.38
	96,13,790.00	961.38	96,13,790.00	961.38
(c) Subscribed and fully paid up - Equity shares of Rs.10 each	96,13,790.00	961.38	96,13,790.00	961.38
	96,13,790.00	961.38	96,13,790.00	961.38
(d) Subscribed but not fully paid up	-	-	-	-
	-	-	-	-
Total	96,13,790.00	961.38	96,13,790.00	961.38

Note 1(a) Reconciliation of number of shares outstanding is set out below:

Particulars	Equity Shares March'2024		Equity Shares March' 2023	
	Number	Amount in (Rs. Lakhs)	Number	Amount in (Rs. Lakhs)
Shares outstanding at the beginning of the year	96,13,790.00	961.38	96,13,790.00	961.38
Shares Issued during the year	-	-	-	-
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	96,13,790.00	961.38	96,13,790.00	961.38

Note 1(b) Shares held by promoters at the end of the year 31st March 2024

Name of Shareholder	As at 31 March' 2024		
	No. of Shares held	% of Holding	% Changes
Mrs. Neeraj Batra	63,41,663.00	65.96%	0.00%
Mr. Varun Batra	33,230.00	0.35%	
Mr. Rahul Batra	39,650.00	0.41%	0.00%
Mrs. Heena Batra	590.00	0.01%	
Mrs. Aditi Batra	590.00	0.01%	

Note 1(b) Shares held by promoters at the end of the year 31st March 2023

Name of Shareholder	As at 31 March' 2023		
	No. of Shares held	% of Holding	% Changes
Mrs. Neeraj Batra	63,41,663.00	65.96%	0.28%
Mr. Varun Batra	33,230.00	0.35%	
Mr. Rahul Batra	39,650.00	0.41%	0.02%
Mrs. Heena Batra	590.00	0.01%	
Mrs. Aditi Batra	590.00	0.01%	

Note 1(c) Details of shares held by each shareholder holding more than 5% shares:

Class of shares / Name of shareholder	As at 31 March' 2024		As at 31 March' 2023	
	Number of shares held	% holding in that class of shares	Number of shares held	% holding in that class of shares
Equity shares with voting rights				
Mrs. Neeraj Batra	63,41,663.00	65.96%	63,41,663.00	65.96%

BETA DRUGS LIMITED (CONSOLIDATED)		
Notes forming part of the financial statements		
Note 2 Reserves and surplus		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a) Capital reserve		
Opening balance	-	-
Closing balance	-	-
(b) Securities premium account		
Opening balance	2,394.01	2,394.01
Closing balance	2,394.01	2,394.01
(c) Surplus / (Deficit) in Statement of Profit and Loss		
Opening balance	8,933.03	5,878.87
Less :- B/f balance on a/c of acquisition	-	-
Less :- Provision for insurance claim recoverable	-	-
	8,933.03	5,878.87
Add: Profit / (Loss) for the year	3,643.70	3,071.87
Less: Investment w/off/ Prov for tax and other prior period adjustments	220.43	17.71
Closing balance	12,356.30	8,933.03
Total	14,750.31	11,327.04
Note 3 Long-term borrowings		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Term loans		
From banks		
Secured		
HDFC (Covid WCTL)	-	8.31
HDFC Bank (Machinery Loan)	26.50	89.92
HDFC Bank (Machinery Loan 2)	100.58	147.30
HDFC Bank (Machinery Loan 3)	-	28.95
SIDBI (Machinery Loan-1)	-	17.47
SIDBI (Machinery Loan 2)	-	37.40
HDFC Bank (Car Loan)	23.88	37.96
Federal Bank (Vehicle Loan)	92.69	60.62
Tata Motors Finance	11.86	-
SIDBI (Covid WCTL)	83.20	130.00
SIDBI (PCS Gold)	46.00	-
SIDBI (Machinery Loan)	139.26	91.60
Axis Bank Vehicle Loan	17.48	35.61
ICICI Bank (Covid WCTL)	-	12.24
ICICI Bank (LAP)	4.97	-
SIDBI (Plant and Machinery Loan)	57.65	-
	604.07	697.38
From other parties		
<u>Unsecured (From Related Parties)</u>	-	-
<u>Secured</u>	-	-
Total - A	-	-
Unsecured (From Unrelated Parties)		
Total - B	-	-
	-	-
The Above Amount Includes		
Secured Borrowings	604.07	697.38
Unsecured Borrowings	-	-
Total	604.07	697.38

BETA DRUGS LIMITED (CONSOLIDATED)		
Notes forming part of the financial statements		
BETA DRUGS LIMITED (CONSOLIDATED)		
Note 4 Deferred Tax		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Deferred tax liabilities		
Deferred tax on depreciation	-	-
Deferred tax assets		
Deferred tax on unabsorbed depreciation	12.49	41.73
Deferred tax on loss on sale of asset	-	-
Deferred tax on provision of gratuity	8.98	8.91
Deferred tax on provision of bonus	-0.43	1.44
Deferred tax on a/c of acquisition	-	-
Less: Opening Deferred Tax	120.06	67.99
Net Deferred tax liabilities/assets	141.10	120.06
Continue Note 4 Current tax Provision		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Current Year Tax	1,252.77	1,085.85
Less :-MAT Credit Utilised	-	-
Less :- Advance Tax Including TDS	-973.11	-668.84
Short term Provision	279.66	417.01
Net Current Tax provision	279.66	417.01

BETA DRUGS LIMITED (CONSOLIDATED)
Notes forming part of the financial statements

Notes: Long-term borrowings

Particulars	As at 31 March' 2024			As at 31 March' 2023		
	Amount in Rs. Lakhs			Amount in Rs. Lakhs		
	Non- Current	Current Maturities	Total	Non- Current	Current Maturities	Total
Term loans						
From banks						
Secured						
HDFC Bank (Covid WCTL)	-	-	-	8.31	28.98	37.29
HDFC Bank (Machinery Loan)	26.50	63.73	90.23	89.92	58.87	148.79
HDFC Bank (Machinery Loan 2)	100.58	47.36	147.94	147.30	44.17	191.47
HDFC Bank (Machinery Loan 3)	-	-	-	28.95	15.68	44.63
SIDBI (Machinery Loan 1)	-	-	-	17.47	14.76	32.23
SIDBI (Machinery Loan 2)	-	37.40	37.40	37.40	88.80	126.20
HDFC Bank (Vehicle Loan)	23.88	32.28	56.16	37.96	31.40	69.37
Federal Bank (Vehicle Loan)	92.69	37.18	129.88	60.62	18.95	79.57
Tata Motors Finance	11.86	5.14	17.00	-	-	-
SIDBI (Covid WCTL)	83.20	43.20	126.40	130.00	-	130.00
SIDBI (Machinery Loan)	46.00	45.60	91.60	91.60	45.60	137.20
SIDBI (PCS Gold)	139.26	20.74	160.00	-	-	-
Axis Bank (Vehicle Loan)	17.48	18.13	35.61	35.61	16.89	52.50
ICICI Bank (Covid WCTL)	-	-	-	12.24	36.72	48.96
ICICI Bank (Vehicle Loan)	4.97	2.63	7.60	-	-	-
Yes Bank (Vehicle Loan)	-	-	-	-	0.59	0.59
SIDBI (Term Loan)	-	-	-	-	23.14	23.14
SIDBI (Smile Scheme)	-	-	-	-	2.18	2.18
SIDBI (Liquid Scheme)	-	-	-	-	2.28	2.28
SIDBI (Plant and Machinery Loan)	57.65	17.88	75.53	-	-	-
	604.07	371.27	975.34	697.38	429.02	1,126.40
From other parties						
Unsecured (From Related Parties)						
Secured						
Total - A	-	-	-	-	-	-
Unsecured (From Unrelated Parties)						
Total - B	-	-	-	-	-	-
	-	-	-	-	-	-
The Above Amount Includes						
Secured Borrowings	604.07	371.27	975.34	697.38	429.02	1,126.40
Unsecured Borrowings	-	-	-	-	-	-
Amount disclosed under "Other Current Liabilities"		-371.27	-371.27		-429.02	-429.02
Total	604.07	-	604.07	697.38	-	697.38

BETA DRUGS LIMITED (CONSOLIDATED)**Note 5 Other long-term liabilities**

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Others:		
(i) Payables on purchase of fixed assets	233.34	234.88
(ii) Security received from customers	175.97	137.00
Total	409.31	371.89

Note 5 (b) Long Term-provisions

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a) Provision for Gratuity	217.90	182.87
Total	217.90	182.87

BETA DRUGS LIMITED (CONSOLIDATED)		
Note 6 Short-term borrowings		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Other loans and advances		
- HDFC Bank CC Limit (Beta Drugs) Secured	-	-
- HDFC Bank CC Limit (Adley Lab) Secured	109.49	220.21
- ICICI Bank CC Limit Secured	87.05	258.39
-ICICI Bank OD Account	299.21	428.25
Total	495.74	906.85
Note 7 Trade payables		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Trade payables:		
Micro Enterprises And Small Enterprises	386.89	1,887.06
Others	5,540.44	2,136.97
Total	5,927.32	4,024.04
Note 8 Other current liabilities		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a) Other payables	693.03	483.37
(i) Current Maturities of Long Term Debt (Note No. 3)	371.27	429.02
(b) Cheque issued yet not presented for Payment	524.00	20.46
Advances From Customers	175.86	20.85
Total	1,764.17	953.69
Note 8 (a) Other current liabilities		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
PF Payable	27.87	20.82
ESI payable	1.25	1.33
Labour Welfare payable	0.78	0.50
TCS payable	-	-
TDS/TCS Payable payable	41.95	33.36
Interest Accrued But Not Due	6.76	7.65
Salary & wages Payable	286.32	235.13
Other Expenses payable	294.87	156.74
Bonus Payable	26.13	27.85
Electricity Expenses Payable	7.11	-
Total	693.03	483.37

Note No. 9 Property, Plant & Equipment and Intangible Assets as at 31st March'2024

Assets		Gross Block						Accumulated Depreciation/ Amortisation					Net Block	
	Useful Life (In Years)	Shift	Balance as at 1st April 2023	Additions during the year	Addition on account of business acquisition	Deletion during the year	Balance as at 31st March' 2024	Balance as at 1st April 2023	Addition on account of business acquisition	Provided during the year	Deletion / adjustments during the year	Balance as at 31st March' 2024	Balance as at 31st March' 2024	Balance as at 31st March 2023
A Property, Plant & Equipment														
Own Assets														
LAND		Single	194.93				194.93						194.93	194.93
BUILDING	30	Single	2,796.52	334.49			3,131.01	801.2		204.0		1,005.22	2,125.79	1,995.30
PLANT AND MACHINERY	15	Single	4,540.84	619.55		420.5	4,739.89	1,804.2		354.1	51.0	2,107.33	2,632.56	2,736.60
FURNITURE AND FIXTURES	10	Single	213.85	80.18			294.03	68.6		47.7		116.3	177.68	145.22
COMPUTER	3	Single	86.83	28.7			115.53	60.8		24.3		85.1	30.4	25.9
VEHICLE	8	Single	739.30	207.35		119.5	827.1	431.0		125.5	98.9	457.6	369.5	308.2
ELECTRICAL EQUIPMENTS	5	Single	278.63	128.55			407.2	167.3		77.6		245.0	162.2	111.2
LAB EQUIPMENTS	10	Single	343.76	10.4			354.1	132.1		55.7		187.9	166.2	211.6
R&D LAB BUILDING	30	Single	12.9				12.9	3.5		0.8		4.4	8.4	9.3
R&D LAB EQUIPMENTS	10	Single	170.6				170.6	100.7		18.1		118.9	51.7	69.9
R&D LAB FURNITURE	10	Single	2.6				2.6	1.6		0.2		1.8	0.7	1.0
Total (A)			9,380.95	1,409.2		540.1	10,250.10	3,571.4		908.4	150.0	4,329.85	5,920.2	5,809.44
P.Y Total			7,743.12	1,808.2		170.3	9,380.95	2,676.3		996.3	101.2	3,671.45	5,809.4	5,066.77
B Capital work in progress														
BUILDING														
PLANT AND MACHINERY														
SOFTWARE DEVELOPMENT														
R&D Lab Building														
Lab Equipment														
R&D Lab Furniture														
Total (B)														
P.Y Total														
C Intangible Assets														
Registration Fee			260.5	142.3			402.9	85.0		65.5		150.6	252.2	175.4
Software			21.0				21.0	4.91		4.23		9.1	11.9	16.1
Goodwill on consolidation			274.6				274.6						274.6	274.6
Total (C)			556.23	142.3			698.62	90.01		69.8		159.83	538.75	466.2
P.Y Total			474.1	82.1			556.2	45.3		44.6		90.0	466.2	426.7
Current Year Total (A+B+C)			9,937.15	1,551.6		540.1	10,948.7	3,661.4		978.2	150.0	4,489.6	6,459.0	6,275.6
Previous Year Total			8,217.2	1,890.3		170.3	9,937.1	2,721.7		1,041.0	101.2	3,661.4	6,275.6	5,495.5

BETA DRUGS LIMITED (CONSOLIDATED)		
Note 10 Non Current investments		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Investment In Beta UBK International Pvt. Ltd. (Uzbekistan)	-	77.90
Total	-	77.90
Note 11 (a) Long-term loans and advances		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Security Deposit Secured, considered good	237.41	195.71
Others Capital Advances	779.51	399.32
loan and advances to realted parties Unsecured, considered good	-	-
Total	1,016.92	595.03
Note 11 (b) Other Non Current Assets		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
MAT Credit Entitlement	-	-
Insurance Claim Receivable	-	-
Amount deposited in approved Gratuity fund	6.00	5.00
Total	6.00	5.00
Note 12 Inventories		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(Valued at cost or NRV unless otherwise stated)		
(a) Finished goods (other than those acquired for trading)	1,134.92	879.51
(b) Raw Material	1,011.21	797.66
(c) WIP	2,090.89	522.52
(d) Others	744.20	862.18
Total	4,981.22	3,061.87
Note 13 Trade receivables		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Exceeding six months Secured, considered good	729.87	718.77
Total	729.87	718.77
Less than six months Secured, considered good	7,194.12	5,553.50
Total	7,194.12	5,553.50
Grand Total	7,923.99	6,272.27

BETA DRUGS LIMITED (CONSOLIDATED)**Note 13 (a) Trade receivables ageing Schedule As at 31st March'2024**

Particulars	Outstanding for following periods from					Total
	Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	7,118.70	112.02	94.38	219.74	181.48	7,726.33
(ii) Undisputed Trade receivables - considered doubtful	-	-	-	-	-	-
(iii) Disputed trade receivables considered good	-	-	-	-	-	-
(iv) Disputed trade receivables considered doubtful	75.41	-	29.73	6.96	85.56	197.66

Note 13 (b) Trade receivables ageing Schedule As at 31st March'2023

Particulars	Outstanding for following periods from					Total
	Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	5,553.50	38.21	215.04	92.32	242.95	6,142.02
(ii) Undisputed Trade receivables - considered doubtful	-	-	-	-	-	-
(iii) Disputed trade receivables considered good	-	-	-	-	-	-
(iv) Disputed trade receivables considered doubtful	-	15.01	22.62	25.87	66.75	130.25

BETA DRUGS LIMITED (CONSOLIDATED)		
Note 14 Cash and cash equivalents		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
CASH ON HAND		
(a) Cash on hand	33.07	28.72
(b) Balance with Imprest a/c	6.90	6.09
(c) Wallet (Custom Duty)	0.12	
Total	40.08	34.81
(b) Balances with banks		
(i) In current accounts		
ICICI Bank	0.01	0.01
Bank of Baroda	0.52	1.72
HDFC Bank	830.17	454.11
HDFC Bank - Beta Research Pvt. Ltd.	1.00	1.00
Indusind Bank	-	-
Kotak Mahindra Bank	2.37	0.46
(c) Others (specify nature)		
FDR With Axis Bank	126.23	119.31
FDR With Bank of Baroda	1,276.53	1,078.74
FDR With SIDBI	91.79	86.74
FDR With ICICI Bank	10.69	10.69
FDR With HDFC Bank	131.85	14.39
FDR With Indusind Bank	250.94	-
FDR (Against Bank Guarantees)	101.07	114.40
Total	2,823.17	1,881.59
Grand Total	2,863.25	1,916.40
Note 15 Short-term loans and advances		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a) Loans and advances to related parties	-	-
(b) Loans and advances		
Advances To Supplier	657.75	557.77
Other Advances (Staff)	57.48	51.26
Total	715.23	609.02
Note 16 Other current assets		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Other Assets		
Income Tax Refund due	0.72	0.72
Cheque Deposited yet not cleared	-	58.11
Prepaid Insurance	52.39	32.74
GST Recoverable	1,249.98	817.33
Total	1,303.10	908.91

BETA DRUGS LIMITED (CONSOLIDATED)**Note 17 Revenue from operations**

	Particulars	For the year ended 31 March' 2024	For the year ended 31 March' 2023
		Amount in Rs. Lakhs	Amount in Rs. Lakhs
	Sale Of Products		
	Other Export Sales	295.40	104.74
	Export Sales	4,928.65	2,864.86
	Sales Exempt	-553.97	2.23
	GST Sales 12%	18,459.80	14,872.78
	GST Sales 5%	3,577.81	2,527.80
	GST Sales 18%	2,863.69	2,338.95
	Total	29,571.38	22,711.36

Note 18 Other income

	Particulars	For the year ended 31 March' 2024	For the year ended 31 March' 2023
		Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a)	Interest Income	108.39	66.30
(b)	Rental Income	-	-
(c)	Other non-operating income (net of expenses directly attributable to such income)	27.50	9.05
(d)	Foreign Currency Exchange Gain	-	-
(e)	Gain on sale of asset	-	-
	Total	135.89	75.35

BETA DRUGS LIMITED (CONSOLIDATED)**Note 19 Cost of materials consumed**

Particulars	For the year ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Opening stock	1,659.84	1,317.40
Add: Purchases	16,860.30	11,382.66
Less: Closing stock	1,755.41	1,659.84
Cost of material consumed	16,764.73	11,040.22
Total	16,764.73	11,040.22

Note 20 Changes in inventories of finished goods, work-in-progress and stock-in-trade

Particulars	For the year ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
<u>Inventories at the end of the year:</u>		
Finished goods	1,134.92	879.51
Work In Progress	2,090.89	522.52
	3,225.81	1,402.03
<u>Inventories at the beginning of the year:</u>		
Finished goods	879.51	664.26
Work In Progress	522.52	266.49
	1,402.03	930.75
<u>(Increase)/ decrease in Inventory</u>		
Finished goods	-255.41	-215.25
Work In Progress	-1,568.37	-256.03
	-1,823.78	-471.28

Note 21 Other Manufacturing Expenses

Particulars	For the year ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Consumeable Stores	310.50	206.48
R&D Consumable Stores	98.55	132.35
Generator running expenses	186.51	135.99
Power & Fuel	448.36	343.12
Direct labour	1,682.43	1,212.55
Repairs & maintenance (machinery & Building)	279.57	186.47
Freight Inward	26.07	29.55
Factory Expenses	46.73	33.29
Solid Waste Pollution expenses	2.46	2.44
Housekeeping expenses	15.01	12.48
Testing Charges	82.65	86.89
Total	3,178.83	2,381.61

BETA DRUGS LIMITED (CONSOLIDATED)		
Note 22 Employee benefits expense		
Particulars	For the year ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Salaries and wages		
Director	575.13	561.80
Employees	1,661.20	1,372.14
R&D Staff	27.90	47.87
Employer Share of ESI	12.10	11.63
Employer Share of PF	137.55	100.31
Employer Share of Welfare Fund	1.66	13.83
Bonus	52.12	55.14
Staff welfare expenses	72.62	59.67
Staff Uniform Expenses	7.47	0.90
Gratuity Provision	40.93	46.40
Total	2,588.68	2,269.68
Note 23 Finance costs		
Particulars	For the year ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a) Interest expense on:		
(i) Borrowings		
Bank Interest CC	116.37	80.36
Interest on Term Loan	66.56	90.87
Interest on Vehicle Loan	17.53	16.49
Interest on PCFC Loan	12.57	6.53
(ii) Others	7.76	5.03
(iii) Interest on income tax	46.95	28.72
(b) Other borrowing costs (Processing Fees)		
Bank charges	14.23	13.49
Total	281.99	241.48

BETA DRUGS LIMITED (CONSOLIDATED)**Note 24 Other expenses**

Particulars	For the year ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Advertisement Expenses	5.72	5.85
Audit Fee- Stat Audit	5.03	5.03
Audit Fee- Internal Audit	3.60	3.60
Audit Fees- Cost Audit	2.00	1.25
Business Promotion Expenses	139.93	119.89
Daily Pooja Expenses	2.17	1.54
Commission Paid	482.82	304.57
Conference Expenses	285.15	125.01
Convenyance Expenses	109.54	80.78
Corporate Social Responsibility Expenses	68.87	47.44
Donation A/C	9.10	5.78
Diwali Expenses	10.25	16.16
Expired & damages Goods Return	25.47	44.84
Freight Outward	268.52	202.78
Foreign Travel	188.30	120.39
Foreign Exchange Loss	-8.43	30.87
Insurance Apportion Cost	86.09	46.55
Legal & Professional Expenses	263.55	196.64
Loss on sale of Assets	0.34	-
Medical Expenses	0.44	4.45
Office Expenses	39.27	27.45
Packing & Forwarding expense	41.80	51.24
Printing & Stationary	80.98	45.59
Preliminary expenses w/off	-	0.44
Rate Fee & taxes	72.74	92.86
Rent	32.40	32.37
Repair & maintenance (Vehicle)	17.85	16.15
Round Off	-0.00	0.01
Software Expenses	26.05	28.70
Telephone & Postage	9.84	11.32
Trade Discount Expenses	27.40	27.53
Travelling Expenses	566.37	481.29
Total	2,863.16	2,178.35

NOTES TO CONSOLIDATED FINANCIAL STATEMENT
BETA DRUGS LIMITED**NOTE '25': SIGNIFICANT ACCOUNTING POLICIES****(Forming part of Accounts)****FOR THE YEAR ENDED 31ST MARCH, 2024****25.1. i) Basis of Accounting**

The consolidated financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India under the historical convention on accrual basis. These financial statements have been prepared to comply, in all material aspects, with the accounting standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and the presentation requirements as prescribed by the Schedule III of the Companies Act, 2013 to the extent applicable.

The Separate financial statements are presented in addition to the consolidated financial statements presented by the Company.

ii) Principles of consolidation**a) Subsidiaries:**

Subsidiaries are all entities over which the group has control. Control is achieved when the Group has power over the investee, is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to use its power to affect its returns.

The group combines the financial statements of the parent and its subsidiaries line by line adding together like items of assets, liabilities, equity, income and expenses. Inter Company transactions, balances and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset.

Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the group non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated statement of profit and loss, consolidated statement of changes in equity and balance sheet respectively.

Common control transactions

Business combinations involving entities that are controlled by the group are accounted for using the pooling of interests' method as follows:

- 1) The assets and liabilities of the combining entities are reflected at their carrying amounts.
- 2) No adjustments are made to reflect fair values or recognize any new assets or liabilities. Adjustments are only made to harmonize accounting policies.

The company had investment in Beta UBK International Pvt. Ltd. (Uzbekistan) till November 2023. The Board of Directors of the Company at its meeting held on 7th November, 2023, inter alia, had considered and approved to write off the total investment made by the company in Beta UBK International Private Limited and it ceased to be subsidiary of the company.

25.2. Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires that management makes estimates and assumptions that affect the reported amounts of income and expenses of the year, the reported balance of assets and liabilities and the disclosure relating to contingent liabilities as at the date of the financial statements. These estimates are based upon management's best knowledge of current events and actions. The difference between the actual results and estimates are recognized in the period in which the results are known/materialized.

**25.3. Property, Plant and Equipment and Intangible assets****- Property, Plant and Equipment**

Tangible Assets are stated at cost of acquisition or construction less accumulated depreciation and impairment of assets, if any. The cost comprises purchase price, borrowing costs if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use reflecting in each standalone financials of holding and subsidiaries companies. The company has a policy of physical verification of all the assets once in a year, the last verification was done on 26th March 2024 for M/s Beta Drugs Limited, 27th March 2024 for M/s Adley Lab Limited , and 28th March 2024 for M/s Adley Formulation Private Limited and no discrepancies were noticed during such verification.

Also physical verification of assets was conducted by independent external agency dated 16.09.2023 for M/s Beta Drugs Limited and dated 25.09.2023 for M/s Adley Formulations Private Limited.

Following Immovable assets were in name of M/s Adley Formulations (Prop. Sh. Vijay Kumar Batra) which were required to be transferred in the name of M/s Adley Formulations Private Limited, post-acquisition of business in FY 2018-19.

Particulars	Address of Property
1. LAND	Village Kotla, Barotiwala, Tehsil Baddi, Dist. Solan, HP
2. BUILDING	Village Kotla, Barotiwala, Tehsil Baddi, Dist. Solan, HP
3. BUILDING SHOWROOM	SCO 42, Sector 12, Panchkula

* A Writ Petition was filed by M/s Adley Formulations Private Limited bearing CWP No. 1464 of 2023 titled M/s Adley Formulations Private Limited Vs State of Himachal Pradesh & anr before the Hon'ble H.P. High Court at Shimla for issuance of nature of mandamus, directing/ commanding the Department of Revenue to change the name of the Petitioner Company from M/s Adley Formulations to M/s Adley Formulations Private Limited consequent upon conversion from a Proprietorship Firm to a Private Limited Company without foisting any condition to pay Stamp Duty or Registration Fee.

The Hon'ble High Court vide Order dated 18-12-2023, disposed of the said petition in terms of judgment the Hon'ble High Court in in CWP No.4019 of 2020, titled as M/s Sozin Flora Pharma LLP vs. State of Himachal Pradesh and another, decided on 07.01.2021 and CWP No.3331 of 2021, titled as M/s Indorama India Pvt. Ltd. & another vs. State of HP & others, decided on 31.07.2023. apart from that a direction was issued to the effect that the petitioner shall not be forced to pay the stamp duty for the transfer of the Unit in issue.

Now the Execution Petition No 729 of 2024 has been filed before the Hon'ble High Court, Shimla and the same is pending for 09-09-2024.

- Capital Work-in-Progress

Expenses incurred during construction/installation period are included under capital work-in-progress and allocated to relevant fixed assets in the ratio of cost of the respective assets on completion of construction/installation. There is no work in progress for the financial year ending 31-March-2024.

- Intangible Assets

Intangible assets comprise of product registration fees paid in different countries and goodwill generated on consolidation of the accounts.

25.4. Depreciation / Amortization

- Depreciation on tangible assets is provided, on Written Down Value method, over the useful life of assets estimated by the management in accordance with Schedule-II of the Companies Act, 2013.
- Residual value of assets has been considered at 5% of the original cost of the assets.
- Depreciation on additions to fixed assets is calculated on date of put to use as certified by the management.
- Depreciation on assets sold & scrapped, during the year, is provided up-to the month in which such fixed assets are sold or scrapped.

**25.5. Impairment of Assets**

The carrying amounts of assets are reviewed at each balance sheet date if there is any indication of impairment based on internal/external factors. An asset is treated as impaired when the carrying cost of the assets exceeds its recoverable value. An impairment loss, if any, is charged to the Statement of Profit & Loss in the year in which an asset is identified as impaired. Reversal of impairment losses recognized in prior years is recorded when there is an indication that the impairment losses recognized for the assets no longer exist or have decreased.

25.6. Valuation of Inventories

- Raw Material Chemicals & Salts
- Packing Material
- Finished Goods Oncology products comprise of Injections, Tablets & Capsules
- Work In Progress (Semi Finished Goods)
- Is valued at cost or estimated realizable value, whichever is lower. The company has determined the cost of inventory using the First-In, First-Out method.
- The company has a policy of physical verification of the entire available inventory once every month, no material discrepancies were noticed during such verification. The last verification was done on 03rd April 2024 for M/s Beta Drugs Limited, 04th April 2024 for M/s Adley Formulations Private Limited & 05th April 2024 for M/s Adley Lab Limited.

25.7. Revenue Recognition

- Revenue from sale of goods is recognized when risk and rewards of ownership are transferred to the customers.
- Revenue from services is recognized when services are rendered and related costs are incurred.
- Other income is recognized on accrual basis unless otherwise stated.
- Revenue from sales/services are shown net of taxes, as applicable.

25.8. Employee Benefits**a) Short-term Employee Benefits:**

- Leave Encashment, on the basis of actual computation, is accounted for on payment basis, after the cessation of employment the payment in respect thereof is made by the Company from its own funds as per the past practice consistently followed by the Company.
- Payment of Bonus – This year the company has incurred an expenditure of Rs. 52,12,182.00 as per The Payment of Bonus Act, 1965.

b) Post-Employment Benefits**(i) Defined Contribution Plans:**

Contributions as required under the Statute/Rule are made to Employees State Insurance & Provident Fund and charged to the Statement of Profit & Loss of the year when the contributions to the respective funds are due.

(ii) Defined Benefit Plans:

Gratuity is accounted for on accrual basis -the Company has opened an Employees' Gratuity Trust with Aditya Birla Sun Life Insurance Company Ltd. and has taken the Group Cap Secure Plan. The Gratuity payable to any employee will be paid out of funds deposited in this plan.

The company has got the Actual Valuation done by independent consultant for FY 2023-24 to determine the projected benefit obligation for Gratuity Benefit and the accounting expenses associated with Gratuity Benefit on 31-03-2024.

GRATUITY PROVISION FOR HOLDING COMPANY – BETA DRUGS LIMITED

Detailed Calculation of Gratuity Provision as per Certified Actuary.

Particulars	Amount (₹)
Present Value of Benefit Obligation as on 01.04.2023	1,08,12,022.00
Current Service Cost	27,34,137.00
Interest Cost	7,67,654.00
Benefits paid	(4,39,221.00)
Net Actuarial Gain (Loss) recognized in the year	(10,97,184.00)
Present Value of Benefit Obligation on 31.03.2024	1,27,77,408.00

Gratuity Provision in FY 2023-24 was provided for Rs. 24,04,607.04 and Rs. 19,26,992.00 in FY 2022-23.

GRATUITY PROVISIONS FOR SUBSIDIARY – ADLEY FORMULATIONS PRIVATE LIMITED

The company has paid Gratuity of Rs. 84,889.00 during the year, made a further provision of Rs. 14,77,117.00 and the closing balance of the provision for Gratuity as on 31.03.2024 is Rs. 68,05,361.00.

GRATUITY PROVISIONS FOR SUBSIDIARY – ADLEY LAB LIMITED

The company has got the Actual Valuation done by independent consultant for FY 2023-24 to determine the projected benefit obligation for Gratuity Benefit and the accounting expenses associated with Gratuity Benefit on 31-03-2024.

Gratuity Provision in FY 2023-24 was provided for Rs. 22,07,142.00.

c) Termination Benefits: Termination benefits are recognized as an expense as and when incurred.

25.9. Foreign Currency Transactions

- i.) Functional and Reporting Currency: The standalone financial statements are presented in Indian Rupee ('INR') which is also the functional and presentation currency of the Company.
- ii.) Initial Recognition: Foreign currency transactions are recorded in the functional currency, by applying to the exchange rate between the functional currency and the foreign currency at the date of the transaction.
- iii.) Conversion on Reporting Date: Transactions in foreign currencies are initially recorded by the Company at its functional currency spot rates at the date the transaction first qualifies for recognition. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.
- iv.) Exchange Differences: Exchange differences arising on monetary items on settlement, or restatement as at reporting date, at rates different from those at which they were initially recorded, are recognized in the statement of profit and loss in the year in which they arise.
- v.) Net amount of Rs. 8,43,417.83 is recognized as other income for the year due to foreign exchange Gain.

25.10. Borrowing Costs

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalized as part of the cost of such assets to the extent that they relate to the period till such assets are ready to use. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use. All other borrowing costs are charged to the Statement of Profit & Loss.

During the year, the Company has not capitalized any borrowing cost this year (Previous year Rs. Nil) relating to credit facility availed for installation of Plant and Machinery.



25.11. Investments

- Current Investments are carried at cost or fair value whichever is lower.
- Non-Current Investments are carried at cost. Provision for diminution in value of non-current investments is made only, if a decline is other than temporary.

25.12. Operating Lease

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased assets are classified as operating leases. Operating lease charges are recognized as an expense in the Statement of Profit & Loss on monthly due basis. The company has taken following premises on lease:

- 1.) Administrative office located at Panchkula-SCO 184, First floor, Sector 5, Panchkula -134114. The lease is entered into with M/s B.T. Associates, Panchkula for 10 years with monthly rent of Rs. 2,40,720.00 plus GST@18 percent.

25.13. Taxes on Income

- Current Tax is measured at the amount expected to be paid to the tax authorities in accordance with the Indian Income Tax Act, 1961.
- Deferred tax is recognized, subject to the consideration of prudence in respect of deferred tax assets, on timing differences, being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods.
- Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off assets against liabilities.

25.14. Earnings Per Share (EPS)

- Annualized basic earnings per equity share is arrived at based on net profit/(loss) attributable to equity shareholders to the basic weighted average number of equity shares outstanding.
- Annualized diluted earnings per equity share is arrived at based on adjusted net profit/(loss) attributable to equity shareholders to the adjusted weighted average number of equity shares outstanding, for the effects of all dilutive potential equity shares; except where the results are anti-dilutive. At present the Company does not have any dilutive potential equity shares.

25.15. Cash Flow Statement:

- The Cash Flow Statement is prepared by the indirect method set out in Accounting Standard (Ind AS) 7 on Cash Flow Statements and presents the cash flows by operating, investing and financing activities of the Company.
- Cash and cash equivalents presented in the Cash Flow Statement consists of balance in current accounts and cash balances.

25.16. Contingencies and Provisions

A provision is recognized when the Company has a present obligation as a result of past events. It is probable that an outflow of resources embodying economic benefit will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on the best estimate of the expenditure required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimate.

A contingent liability is disclosed, unless the possibility of an outflow of resources embodying the economic benefit is remote.

The Consolidated Contingent Liability in the form of Bank Guarantee as on 31.03.2024 is Rs. 1,54,61,575/-. Details of contingent liabilities are separately mentioned in standalone financials statement of each enterprise.

- 25.17 Internal Control Policy and BCP Management:** The Company has a comprehensive system of Internal Controls to safeguard its assets against loss from unauthorized use and to ensure reliability of financial reporting. The management assesses the operating effectiveness of these controls on regular basis. All the required security



checks i.e., physical security of the company premises and its database are properly installed, daily backup is being done for all the accounting and related data. The company maintains a system of internal controls designed for effectiveness and efficiency of operations, compliance and regulations. The company has a cloud-based ERP system (maintained by TATA Consultancy Services) in which the data remains safe on cloud and can be accessed and updated on real time basis from anywhere with defined access user rights.

The system of internal controls monitors and ensures process for:

- Effectiveness and efficiency of operations;
- Reliability of financial reporting;
- Compliance with applicable laws and regulations.



NOTE 26: OTHER NOTES TO ACCOUNTS
(Forming part of Accounts)
FOR THE YEAR ENDED 31ST MARCH, 2024

26.1. Contingent Liabilities & Commitments:

- a) Estimated amount of contracts remaining to be executed and not provided for in the books of account - Nil (previous year - Nil).
- b) Contingent Liabilities: Rs. 1,54,61,575/-
 - Claims against the Company not acknowledged as debt- Nil (previous year - Nil).
 - Liabilities in respect of Income Tax, Service Tax, Sales Tax and other material statutory dues have been accounted for on the basis of respective returns filed with the relevant authorities. Additional demand, if any, arising at the time of assessments will be accounted for in the year in which assessments are completed.

26.2. Issued, Subscribed & Paid-up Capital:

Issued, Subscribed and Paid-up capital of the company are separately mentioned in standalone financials statement of each enterprise.

26.3. Reserves & Surplus:

-The amount shown in the Reserve & Surplus represents only surplus carried forward from the earlier year plus the surplus earned during the year. Total amount of surplus outstanding as on 31.03.2024 is Rs. 1,47,50,31,214.11 which includes Share Premium of Rs. 23,94,01,048.98 and Free Reserves of Rs. 1,23,56,30,165.13.

26.4. Long-term Borrowings

Secured: Details of Consolidated Term Loan is mentioned below.

Term Loan:

DETAILS OF TERM LOAN - M/S BETA DRUGS LIMITED

S.NO	Lender	Nature of facility	Loan	Amount outstanding as at March 31, 2024	Sanctioned Rate of Interest (%)	Repayment Terms	Security / Principal terms and conditions
		Vehicle Loan of Rs. 5 Lakhs	Term Loan	Rs. 2.86 Lakhs	8.25%	Total Installments of Rs 0.15 Lakhs P.M. divided into 39 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.
		Vehicle Loan of Rs. 35 Lakhs	Term Loan	Rs. 20.68 Lakhs	7.90%	Total Installments of Rs 1.01 Lakhs P.M. divided into 39 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.



	SIDBI	Term Loan of Rs. 400.00 Lakhs SIDBI term loan new	Term Loan	Rs. 37.40 Lakhs	8.09%	Fixed principal repayment of Rs 7.40 Lakhs P.M. after moratorium of 6 months divided into 53 Equated monthly installment. Last Installment i.e. 54 th Installment is of Rs. 7.80 Lakh.	<p>1) Pari-Passu (Second Charge) of Equitable Mortgage of Industrial Property situated at Lodhimajra, comprising of Khasra No 733/465 (0-5), 466(0-2), 735/467(2-0), Khatoni No 78, comprising of Khasra No 368(1-17). Land measuring 4 Bigha 4 Biswa, Village Nandpur, HB No 170, Tehsil Baddi, Distt Solan (HP) and Khata No 70min/90 comprising Khasra No 369(1-15), 370(0-2-0), 371 (1-6-0), 379/1(2-8-0), Kitte-4. Land measuring 5 Bigha 11 Biswa, village Nandpur, HB NO 170, Tehsil Baddi, Distt Solan (HP)</p> <p>2) HYP of Machinery amounted Rs. 829.00 Lakhs.</p>
	SIDBI	Term Loan of Rs. 130.00 Lakhs SIDBI Covid Working Capital Term Loan	Working Capital Term Loan	Rs. 126.40 Lakhs	6.00%	Fixed principal repayment of Rs 3.60 Lakhs P.M. after moratorium of 24 months divided into 35 Equated monthly installment. Last Installment i.e.36 th Installment is of Rs. 4 Lakh.	<p>1) Second charge by way of hypothecation in favour of SIDBI of all the movables including; plant, machinery spares, tools & accessories, office equipment, computers, furniture and fixtures.</p> <p>2) Second charge by way of pledge of FDR with SIDBI of Rs. 34 Lakh</p> <p>3) Second charge by way of mortgage on the Industrial Plot in Vill Nandpur comprised in Khewat/Khatoni No. 114/157 measuring 9 Bigha 15 Biswa owned by Beta Drugs Ltd.</p>



	SIDBI	Term Loan of Rs. 160.00 Lakhs SIDBI Machinery Loan	Term Loan	Rs. 91.60 Lakhs	5.65%	Fixed principal repayment of Rs 3.80 Lakhs P.M. after moratorium of 6 months divided into 41 Equated monthly installment. Last Installment i.e.42 nd Installment is of Rs. 4.2 Lakh.	<p>1) First charge by way of hypothecation in favour of SIDBI of the plant, machinery, equipment, tools, spares, accessories, misc fixed assets and all other current assets.</p> <p>2) Extension of pledge of FDR of Rs. 34 Lakh and pledge of FDR of Rs. 40 Lakh.</p> <p>3) Extension of first pari passu charge by way of mortgage on Industrial Plot in Vill. Nandpur measuring 9 Bigha 15 Biswa owned by Beta Drugs Ltd.</p>
3	Axis Bank	Vehicle Loan of Rs. 69.72 Lakhs	Term Loan	Rs. 35.61 Lakhs	7.10%	Total Installments of Rs 1.67 Lakhs P.M. divided into 48 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.
3	Federal Bank	Vehicle Loan of Rs. 60 Lakhs	Term Loan	Rs. 50.03 Lakhs	8.55%	Total Installments of Rs 1.48 Lakhs P.M. divided into 48 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.
3	Federal Bank	Vehicle Loan of Rs. 17 Lakhs	Term Loan	Rs. 14.87 Lakhs	8.60%	Total Installments of Rs 0.54 Lakhs P.M. divided into 36 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.



3	Federal Bank	Vehicle Loan of Rs. 12 Lakhs	Term Loan	Rs. 11.39 Lakhs	8.70%	Total Installments of Rs 0.38 Lakhs P.M. divided into 36 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.
3	SIDBI	PCS Gold of Rs. 160.00 Lakhs	Term Loan	Rs. 160.00 Lakhs	8.40%	Total principal payment of Rs 2.96 Lakhs P.M. plus interest for 54 months after 6 months moratorium period from the date of sanction.	<p>(i.) Primary Security: Hypothecation for creating charge over existing movable assets charged to SIDBI and movable assets proposed to be acquired out of the loan.</p> <p>Collateral Security: 1.) Extension of First Pari passu Charge with HDFC Bank Ltd. by way of mortgage on the Industrial Plot in village Nandpur comprised in Khewat/Khatoni No. 114/157 in Khasra No. 733/465 (00-05), 466 (00-02), 735/467 (02-00), village Nandpur, Tehsil Nalagarh, Dist. Baddi, measuring 2 Bigha 7 Biswa and at plot 47/69 in Khasra Number 368(01-17) admeasuring 1 Bigha 17 Biswas (i.e total 4 Bigha 04 Biswas) owned by Mis Beta Drugs Ltd. ,</p> <p>2.) Extension of First Pari passu Charge with HDFCF Bank Ltd. by way of mortgage on the Industrial Plot situated at Khata No. 70min/90 (as per jamabandi for the year 2017-18) Khasra No.369(1-15), 370(0-2-0), 371(1-6-0),, 379/1(2-8-0), Kitte -4, Village Nandpur, HB No. 170, Tehsil Baddi, Distt. Solan (HP) admeasuring 5 Bigha 11 Biswas owned by Beta Dmgs Limited.</p> <p>3.) Extension of pledge of FDR ofRs.40 Lakh with SIDBI</p> <p>4.) Extension of pledge of FDR ofRs.34 Lakh with SIDBI.</p> <p>5.) Extension of First charge by way of hypothecation in favour of SIDBI of the plant, machinery, equipment, tools, spares, accessories, miscellaneous fixed</p>



19TH ANNUAL REPORT

BETA DRUGS LIMITED

							assets and all other assets (save and except book debts & current assets) acquired/ proposed to be acquired under the project/ scheme.
							6.) .GUARANTEE(S): Irrevocable, unconditional guarantee of Smt Neeraj Batra, Shri Rahul Batra, Shri Varun Batra.
3	Tata Motors Finance	Vehicle Loan of Rs. 17.00 Lakhs	Term Loan	Rs. 17.00 Lakhs	9.28%	Total Installments of Rs 0.54 Lakhs P.M. divided into 36 Equated monthly installment.	1) HYP of Motor Vehicles from the bank in the name of Company.

Interest on the above term loans is payable on monthly basis.

DETAILS OF TERM LOAN - M/S ADLEY FORMUATIONS PVT. LTD.

S.NO	Lender	Nature of facility	Loan	Amount outstanding as at March 31, 2024	Rate of interest (%)	Repayment Terms	Security / Principal terms and conditions
1	HDFC BANK (VEHICLE LOAN)	Term Loan of Rs 60 Lakhs	Term Loan	Rs 9.91 Lakhs	7.50%	Total Installments of Rs 1.45 Lakhs P.M. divided into 48 Equated monthly instalment.	HYP of Motor Vehicles from the bank.
2	HDFC BANK (VEHICLE LOAN)	Term Loan of Rs 15 Lakhs	Term Loan	Rs 4.51 Lakhs	7.50%	Total Installments of Rs 0.36 Lakhs P.M. divided into 48 Equated monthly instalment.	HYP of Motor Vehicles from the bank.
3	HDFC BANK (VEHICLE LOAN)	Term Loan of Rs 20 Lakhs	Term Loan	Rs 18.20 Lakhs	8.80%	Total Installments of Rs 0.59 Lakhs P.M. divided into 39 Equated monthly instalment.	HYP of Motor Vehicles from the bank.
4	Federal Bank (Vehicle Loan)	Term Loan of Rs. 25 Lakh	Term Loan	Rs. 13.36 Lakhs	7.25%	Total Installments of Rs 0.50 Lakhs P.M. divided into 60 Equated monthly instalment.	HYP of Motor Vehicles from the bank.
5	Federal Bank (Vehicle Loan)	Term Loan of Rs. 15 Lakh	Term Loan	Rs. 2.04 Lakhs	7.25%	Total Installments of Rs 0.46 Lakhs P.M. divided into 36 Equated monthly instalment.	HYP of Motor Vehicles from the bank.



6	Federal Bank (Vehicle Loan)	Term Loan of Rs. 50 Lakh	Term Loan	Rs. 38.18 Lakhs	9.34%	Total Installments of Rs 0.86 Lakhs P.M. divided into 76 Equated monthly instalment.	HYP of Motor Vehicles from the bank.
7	ICICI Bank Ltd (Vehicle Loan)	Term Loan of Rs. 9.00 Lakh	Term Loan	Rs. 7.60 Lakhs	9.35%	Total Installments of Rs 0.27 Lakhs P.M. divided into 39 Equated monthly instalment.	HYP of Motor Vehicles from the bank.

DETAILS OF TERM LOAN - M/S ADLEY LAB LTD.

Lender	Nature of Facility	Loan	Amount outstanding as at 31 March'2024	Rate of Interest	Repayment Terms	Conditions
SIDBI	PCS Gold of Rs. 80.00 Lakhs	Term Loan	Rs.75.53 Lakhs	8.30% (Floating)	Total principal payment of Rs 1.49 Lakhs P.M. plus interest for 54 months after 6 months moratorium period from the date of sanction.	<p>1.) Primary security: Extension of first charge by way of equitable mortgage in favor of SIDBI of all those piece and parcel of land admeasuring 2500 sq yard bearing Plot No. D-27 situated at Industrial Area, Focal Point , Derabassi,PUNJAB.</p> <p>2.) Collateral security : EXTENSION OF First charge by way of hypothecation in favour of SIDBI of the plant, machinery , equipment , tools , spares , accessories , miscellaneous fixed assets and all other assets (save and except book debt & current assets) acquired / proposed to be acquired under the project / scheme .</p> <p>3. GUARANTESS(S): Irrevocable , unconditional guarantee of Shri Rahul Batra , Shri Varun Batra , and Corporate Guarantee from Beta Drugs Limited.</p>
HDFC	Plant and Machinery Loan of Rs. 225 Lakhs	Term Loan	Rs. 147.94 Lakhs	7.36% (Floating)	Installments of Rs. 5.77 lakh per month.	<p>First Charge in Favour of bank by way of Hypothecation of company's entire stock of RM, WIP, Semi Finished Goods and Finished Goods, consumable stores spares including book debts, bills whether documentary or clean, outstanding monies, receivables, both present and future, in a form and manner satisfactory to the Bank and as specified by CAM.</p> <p>Equitable mortgage of Plot No. D-27, Derabassi, Industrial Focal Point owned by company. (First Pari-passu charge with SIDBI.</p>



	Plant and Machinery Loan of Rs. 200 Lakhs	Term Loan	Rs. 90.22 Lakhs	8.35% (Floating)	Installments of Rs. 4.89 lakh per month.	Corporate Guarantee by M/s Beta Drugs Limited.
--	-------------------------------------------	-----------	-----------------	------------------	------------------------------------------	------------------------------------------------

26.5. In the opinion of the Directors, “Current Assets” and “Loans & Advances” are approximately of the value stated in the Balance Sheet, if realized in the ordinary course of business and to the best of their knowledge. Provisions for all the known liabilities have been made and, *as certified*, all the contractual and statutory obligations have been duly complied with.

26.6. Party balances have been incorporated in the financial statements at the value as per the books of accounts & are considered hopeful of recovery/good for payment. The balance confirmation letter for both debtor and creditors are sent by the company through registered post/email, and in many cases balance confirmation is received from them.

26.7. **Depreciation/Amortization**

The management estimates the useful life of existing fixed assets as follows:-

Building	30 years
Furniture & Fixtures	10 years
Machinery	15 years
Lab Equipment	10 years
Equipment (Other)	5 years
Vehicles	8 years

For this class of assets, based on internal assessment and independent technical evaluation carried out by external valuers the management believes that the useful lives as given above best represent the period over which management expects to use these assets. The useful lives for these assets are same as the useful lives as prescribed under Part-C of Schedule-II of the Companies Act, 2013.

26.8. **Earnings Per Share**

	Year ended 31 st March, 2024	Year ended 31 st March, 2023
Numerator		
Net Profit / (Loss)		
Attributable to Equity shareholders	36,43,70,111.63	30,71,87,173.47
Denominator		
Number of Equity shares	No.'s 96,13,790	No.'s 96,13,790
Nominal		
Value per Equity share	10	10
Earnings per Equity share		
- Basic and diluted	37.90/37.90	31.95/31.95

26.9. **Non-Current Investments:**

Investment in Joint ventures and Associates are accounted for using the equity method of accounting. Under the equity method of accounting, the investments are initially recognized at cost and adjusted thereafter to



recognize Dividends received or receivable from associates or joint ventures are recognized as a reduction in the carrying amount of the investment.

Equity shares have been stated at cost; provision for appreciation/diminution in the value of shares has not been made and no dividend was received during the year.

The provisions of Section 186 of the Companies Act, 2013 have been complied with.

The company has the following investments as on 31.03.2024 in entities as mentioned below:

(a) Beta Drugs has an investment in Adley Formulations Private Limited (CIN: U24303HR2018PTC076347) amounting Rs.1,26,00,000.00

(b) Beta Drugs has an investment in Adley Lab Limited (CIN: U24231PB1992PLC051220) amounting Rs. 4,50,40,000.00.

(c) Beta Drugs made an investment in Beta Research Pvt. Ltd. (CIN: U24303HR2022PTC104598) amounting Rs. 1,00,000.00.

The company had investment in Beta UBK International Pvt. Ltd. (Uzbekistan) till November 2023. The Board of Directors of the Company at its meeting held on 7th November, 2023, inter alia, had considered and approved to write off the total investment made by the company in Beta UBK International Private Limited and it ceased to be subsidiary of the company.

26.10. **Taxes**

- The exact liability of CST/VAT, Service Tax, GST, Income Tax and other statutory dues is indeterminate pending finalization of assessments and no undisputed dues or amounts were outstanding or remaining unpaid as at 31st March, 2024.

- **M/S Beta Drugs Limited** -Disputed Income tax demand amounting to Rs. 12,122/- for A.Y 2020-21 and Rs. 90,64,680/- for A.Y 2021-22 is outstanding and appeal filed against the same is under process as on 31.03.2023. The said demand was raised by the department on account of non-compliance of notice u/s 133(6) issued to the third parties, however, the said third parties had duly filed the response to the said notices received by them. The company has filed an appeal providing acknowledgements of the replies filed by those third parties.

- **M/s Adley Formulations Pvt. Ltd**- Disputed Income tax demand amounting to Rs. 72,350/- for A.Y 2021-22 is outstanding and appeal filed against the same is under process as on 31.03.2024. The said demand was due to wrong double disallowance by the department u/s 36 for which appeal has been filed by the company.

-The amount of tax credit determined shall be carried forward up-to fifteen assessment years immediately succeeding the assessment year in which tax credit becomes allowable.

-The tax provision has been disclosed in the separate Notes to Accounts respectively.

26.11 **Ratios**

Beta Drugs Ltd. (Consolidated)- Ratios							
Sr. No.	Ratios	Numerator	Denominator	As at March 31' 2024	As at March 31' 2023	Variance	Explanation for significant changes in ratio as



							compared to the preceding year
1	Current Ratio	Current Assets	Current liabilities	2.10	2.03	3.68%	-
2	Debt-Equity Ratio	Total Debt	Shareholders' equity	0.10	0.16	-40.27%	Due to increase in reserves by Rs. 34.2 cr. and reduction in debt by Rs. 4.7 cr.
3	Debt Service Coverage Ratio	Earnings available for debt service	Debt service	7.79	5.15	51.32%	Due to reduction of yearly repayment of loans from Rs. 10.47 cr. to Rs. 7.88 cr. and increase in profits.
4	Return on Equity Ratio	Net profit after taxes less preference dividend (if any)	Shareholder's equity	23.19%	25.00%	-7.23%	
5	Inventory turnover ratio	Cost of goods sold or sales	Average inventory	4.51	4.90	-7.97%	
6	Trade Receivables turnover ratio	Net Sales	Average Trade Receivables	4.17	4.21	-1.03%	
7	Trade Payables turnover ratio	Net Purchases	Average Trade Payables	3.39	3.15	7.46%	
8	Net capital turnover ratio	Net Sales	Net working capital	3.17	3.51	-9.65%	
9	Net Profit ratio	Net Profit after taxes	Net Sales	0.12	0.14	-8.90%	



10	Return on capital employed	Earnings before interest and taxes	Capital employed	0.30	0.32	-5.19%	
11	Return on investment	Net Profit after taxes	Total Current Investments	5.45%	4.65%	17.06%	
12	Operating Profit Margin	Earnings before interest and taxes	Net Sales	17.44%	19.14%	-8.88%	
13	Interest Coverage Ratio	Earnings before interest and taxes	Interest Expense	18.29	18.00	1.60%	

26.12. Segment Reporting

Since the Company primarily operates in one segment (i.e., Manufacturing of Oncology medicines), therefore segment reporting as required under Ind AS – 108 is not applicable. Regarding the geographical segments, the company has an export turnover of Rs. 46,03,44,297.39 and the domestic turnover of Rs. 2,49,67,93,296.49.

26.13. Related Party Disclosures

Related Party disclosures are made in separate standalone audited financials of each enterprise.

26.14. Impairment of Assets

During the year, the Company has undertaken a review of all the fixed assets in line with the requirements of Ind AS-36 on “Impairment of Assets” as notified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014, based on such review, no provision for impairment is required to be recognized for the year.

26.15 Property, Plant and Equipment and Intangible assets:

- During the financial Year 2023-24 there was no addition under the head Land.
- During the financial Year 2023-24 there was an addition of Rs 3,34,49,231.75 under the head Building.
- During the financial year, there was net addition of Rs. 8,97,72,910.10 to Plant & Machinery, Furniture & Fixtures, Office Equipment, Vehicles & Computers including the assets transferred from WIP.
- The No additions was made to the R&D Block.
- During the financial year 2021-22 there was an addition of Rs 1,42,38,441.82 under the head Intangible Asset.

26.16. Deferred Tax Assets & Liabilities

At the end of financial year 2023-24 the company has Consolidated Deferred Tax Provision (Asset) of Rs. 1,41,10,278.60. Details of Calculation in mentioned below.

Calculation of Deferred Tax Asset / Liability	Amount in Rs.
Deferred Tax Asset on provision of gratuity	8,98,236.61
Deferred Tax Asset on provision of CSR	-
Deferred Tax Asset on depreciation	12,48,762.14



Deferred Tax Asset on sale of Asset	-
Deferred Tax Asset on provision of bonus	(43,216.22)
Total Deferred Tax Asset Created for the financial year 2023-24 in Profit and Loss Account.	21,03,782.53
Add: Deferred Tax Asset as on 01.04.2023 (Opening)	1,20,06,496.08
Balance Deferred Tax Asset recognized in Balance Sheet	1,41,10,278.60

26.17. **Government Grants:**

Government grants are recognized when there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is deducted from the related expense. When the grant relates to an asset, it is recognized as deferred income and amortized over the useful life of such assets. No Government Grant received during the financial year 2023-2024.

26.18. **Micro, Small & Medium Enterprises**

Based on the information presently available, total outstanding as on 31.03.2024 is Rs.3,86,88,924.77 to micro or small enterprises under the Micro, Small and Medium Enterprises Development Act, 2006.

26.19. **Auditor's Remuneration**

(Exclusive of GST)

	31st March, 2024	31st March, 2023
	AMOUNT	AMOUNT
-As Statutory Auditors	5,02,500.00	5,02,500.00
- Taxation Matters	-	-
- Certification	-	-
-Other Services	-	-
-As Internal Auditor	3,60,000.00	3,60,000.00
- Taxation Matters	-	-
- Certification	-	-
-Other Services	-	-
- Cost Audit	2,00,000.00	1,25,000.00
- Reimbursement of out-of-pocket expenses	-	-
TOTAL	<u>10,62,500.00</u>	<u>9,87,500.00</u>

26.20 **Other additional information**

<u>Particulars</u>	<u>31st March, 2024</u>	<u>31st March, 2023</u>
	<u>AMOUNT</u>	<u>AMOUNT</u>
Revenue from "A" operations		



19TH ANNUAL REPORT

BETA DRUGS LIMITED

(Under broad heads)		
Sales		
-Sales With in India	2,49,67,93,296.49	1,97,41,76,278.71
-Export Sales	<u>46,03,44,297.39</u>	<u>29,69,59,715.54</u>
	<u>2,95,71,37,593.88</u>	<u>2,27,11,35,994.25</u>
“B” Purchases		
-Chemicals, Bulk Drugs & Packing Material		
	1,68,60,30,040.18	1,13,82,65,990.26

26.21. **Expenditure in Foreign Currency (On Accrual Basis): - Following Expenses were incurred by the company during the year 2023-24.**

	<u>31st March, 2024</u> <u>AMOUNT</u>	<u>31st March, 2023</u> <u>AMOUNT</u>
Import of Capital Goods	29,74,835.03	1,81,02,850.26
Import of Capital Services	1,03,93,677.59	50,36,026.99
Revenue Expenses (Travel)	-	1,20,38,899.79
Revenue Expenses (RM Purchase)	18,53,51,037.87	12,60,34,964.18
Revenue Expenses (others)	2,79,15,104.05	1,97,08,019.56
TOTAL	<u><u>22,66,34,654.54</u></u>	<u><u>18,09,20,760.78</u></u>

26.22. **Earning in Foreign Currency Particulars**

	For the Year Ended (31.03.2024)	For the year Ended (31.03.2023)
FOB Value of Export	46,03,44,297.39	29,69,59,715.54*
Foreign Exchange Gain / (Loss)	8,43,417.83	1,87,278.27

26.23. **Other statutory information**

- i. No proceedings have been initiated during the year or are pending against the Company as at March 31, 2024 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.
- ii. The Company does not have any trading in Crypto Currency or Virtual Currency.
- iii. The Company does not have any transactions or balances with a Companies struck off under section 248 of the Companies Act, 2013 or Section 560 of the Companies Act 1956.
- iv. The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessment under the Income Tax Act, 1961.
- v. Company has not advanced or loaned or invested funds to any other person(s) or entity(is), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner



- whatsoever by or on behalf of the company (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- vi. The Company has not received any fund from any person(s) or entity(is), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - vii. No charge is pending to be registered beyond statutory period with ROC.
 - viii. The company has not used the borrowings from banks and financial institutions for any other purpose other than for the specific purpose for which it was taken.
 - ix. The Company have defined agreement with the Debtors regarding the credit payment period given and ageing is done accordingly in Financial Statement.
 - x. As there is no specific agreements with the creditors, hence the creditors ageing is done as per the date of invoice received.

.26.24 Additional Information, as required under Schedule III to the Companies Act, 2013 in respect of subsidiaries whose accounts are consolidated.

Amount in Rs.

Name of the Enterprise	Net Assets i.e., Total assets minus total liabilities		Share in profit or (loss)	
	As % of consolidated net assets	Amount	As % of consolidated net profit	Amount
Parent				
Beta Drugs Limited	73.84%	116,01,03,040.20	60.20%	21,93,65,854.27
Subsidiary				
Adley Formulations Private Limited	15.36%	24,12,92,980.85	20.96%	7,63,69,755.83
Adley Lab Limited	12.73%	19,99,58,593.04	18.83%	6,86,39,501.52
Beta Research Private Limited	0.01%	95,000.00	-0.01%	-5000.00
Inter-Company Elimination	(1.93%)	-3,02,80,499.98	-	-
Total	100.00%	1,57,11,69,114.11	100.00%	36,43,70,111.63



Annexure-6

26.25 SALIENT FEATURES OF FINANCIAL STATEMENTS OF SUBSIDIARIES / ASSOCIATES / JOINT VENTURES AS PER COMPANIES ACT, 2013	
ADLEY FORMULATIONS PRIVATE LIMITED	
[Pursuant to Section 129(3) of the Companies Act, 2013 and Rule 5 of the Companies (Accounts) Rules, 2014 –AOC 1]	
Sr. No.	I
Name of Subsidiary Company	Adley Formulations Private Limited
Date since when Subsidiary was acquired	09/10/2018
Reporting Period	01 st April 2023 to 31 st March 2024
Reporting Currency	Rupees (Rs.)
Share Capital	1,26,00,000.00
Reserves & Surplus	22,86,92,980.85
Total Assets	66,67,08,367.09
Total Liabilities	66,67,08,367.08
Investments	-
Turnover / Total Income	85,80,70,668.77
Profit/ (Loss) Before Taxation	10,14,76,051.29
Provision for Taxation	2,67,83,370.33
Profit / (Loss) After Taxation	7,63,69,755.83
Proposed Dividend	Nil
% of Shareholding	99.99%

26.26 SALIENT FEATURES OF FINANCIAL STATEMENTS OF SUBSIDIARIES / ASSOCIATES / JOINT VENTURES AS PER COMPANIES ACT, 2013	
ADLEY LAB LIMITED	
[Pursuant to Section 129(3) of the Companies Act, 2013 and Rule 5 of the Companies (Accounts) Rules, 2014 -AOC 1]	
Sr. No.	II
Name of Subsidiary Company	Adley Lab Limited
Date since when Subsidiary was acquired	30/10/2019
Reporting Period	01 st April 2023 to 31 st March 2024
Reporting Currency	Rupees (Rs.)
Share Capital	1,75,80,500.00
Reserves & Surplus	18,23,78,093.04
Total Assets	45,80,58,385.70
Total Liabilities	45,80,58,385.70
Investments	-
Turnover / Total Income	53,32,59,588.86
Profit/ (Loss) Before Taxation	9,12,41,843.18
Provision for Taxation*	2,38,22,146.23
Profit / (Loss) After Taxation	6,86,39,501.52
Proposed Dividend	-
% of Shareholding	99.99%



*Deferred Tax Provision

26.27 SALIENT FEATURES OF FINANCIAL STATEMENTS OF SUBSIDIARIES / ASSOCIATES / JOINT VENTURES AS PER COMPANIES ACT, 2013	
BETA RESEARCH PRIVATE LIMITED	
[Pursuant to Section 129(3) of the Companies Act, 2013 and Rule 5 of the Companies (Accounts) Rules, 2014 -AOC 1]	
Sr. No.	III
Name of Subsidiary Company	Beta Research Private Limited
Date since when Subsidiary was acquired	22/06/2022
Reporting Period	1 st April 2023 to 31 st March 2024
Reporting Currency	Rupees (Rs.)
Share Capital	1,00,000.00
Reserves & Surplus	-
Total Assets	1,00,000.00
Total Liabilities	1,00,000.00
Investments	-
Turnover / Total Income	-
Profit/ (Loss) Before Taxation	(5,000.00)
Provision for Taxation*	-
Profit / (Loss) After Taxation	(5,000.00)
Proposed Dividend	-
% of Shareholding	99.99%

26.28. Corporate Social Responsibility:

The Company has provided for the corporate social responsibility as per Section 135 of the Companies Act 2013 i.e., Rs.68,87,205.00 during the year. The actual amount spent during the financial year was Rs. 68,87,305.00 and there is no outstanding provision as on 31st March 2024.

26.29. Balance confirmation has been sent to all the Debtors and Creditors by way of electronic mail. Total count of debtors in M/s Beta Drugs Limited is 156 and creditors count is 404, Total count of debtors in M/s Adley Formulations Private Limited Limited is 93 and creditors count is 189 & Total count of debtors in M/s Adley Lab Limited Limited is 26 and creditors count is 151 and confirmation reply came from more than 50% of the total count.

26.30. Figures for previous year have been regrouped / rearranged where necessary to conform to the current year's presentation.

In terms of our attached report of even date.

For and on behalf of the Board of Directors

For KALRA RAI & ASSOCIATES
CHARTERED ACCOUNTANTS
FR No. -008859N

SD/-

SD/-

Sd/-
LAJPAT RAI KALRA
PARTNER
M. No.087438
Dated: 14/05/2024
Place: Chandigarh
UDIN: 24087438BJZXAZ9600

Rahul Batra
(Director)
DIN:02229234

Varun Batra
(Director)
DIN:02148383

STANDALONE FINANCIAL

STATEMENTS

OF

“ADLEY FORMULATIONS PRIVATE LIMITED”

(WHOLLY-OWNED SUBSIDIARY)

FOR THE FINANCIAL YEAR

2023-24



**KALRA RAI & ASSOCIATES
CHARTERED ACCOUNTANTS**

**Head Office: Kothi No. 667, 1st floor, Sector-43-A
Chandigarh-160022**

Independent Auditors' Report

Members of Adley Formulations Private Limited

Report on the Standalone Financial Statements

We have audited the accompanying standalone Ind-AS financial statements of Adley Formulations Private Limited ('the Company'), which comprise the Balance Sheet as at March 31, 2024, the Statement of Profit and Loss, including the statement of Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ('the Act') with respect to the preparation of these standalone Ind-AS financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with accounting principles generally accepted in India, including the Indian Accounting Standards (Ind-AS) specified under Section 133 of the Act., read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial control that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind-AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these standalone Ind-AS financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under. We conducted our audit of the standalone Ind-AS financial statements in accordance with the Standards on Auditing, issued by the Institute of Chartered Accountants of India, as specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone Ind-AS financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the standalone Ind-AS financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the standalone Ind-AS financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone Ind AS financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the standalone Ind-AS financial statements give the information required by the Act in the manner so required and give a true and fair



view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024, its profit including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's report) Order, 2016 ('the Order') issued by the Central Government of India in terms of subsection (11) of Section 143 of the Act, we give in the Annexure 1 a statement on the matters specified in paragraphs 3 and 4 of the Order.

2. As required by Section 143(3) of the Act, we report that:

- a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
- b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- c. The Balance Sheet, Statement of Profit and Loss including the Statement of Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account;
- d. In our opinion, the aforesaid standalone Ind-AS financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Companies (Indian Accounting Standards) Rules, 2015, as amended;
- e. On the basis of written representations received from the directors as on March 31, 2024, and taken on record by the Board of Directors, none of the Directors is disqualified as on March 31, 2024, from being appointed as a director in terms of Section 164 (2) of the Act;
- f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refers to our separate Report in "Annexure B";
- g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2020, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
 - iii. There have been no amounts available which is required to be transferred to the Investor Education and Protection Fund by the Company;

Place:- Chandigarh
Date: 14/05/2024
UDIN:24087438BJZXBC6851

For KALRA RAI & ASSOCIATES

Chartered Accountants

Sd/-

(Lajpat Rai Kalra)
Partner
M. No- 087438
FRN: 008859N

**CARO****Annexure 1 referred to in paragraph 1 of our report of even date****Re: Adley Formulations Private Limited ('the Company')**

To the best of our information and according to the explanations provided to us by the Company and the books of account and records examined by us in the normal course of audit, we state that:

i. In respect of the Company's Property, Plant and Equipment and Intangible Assets:

(a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The Company has maintained proper records showing full particulars of intangible assets.

(b) The Company has a program of physical verification of Property, Plant and Equipment so to cover all the assets once every three years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. According to the information and explanations given to us, no material discrepancies were noticed on such verification.

(c) Based on our examination of the property tax receipts and lease agreement for land on which building is constructed, registered sale deed / transfer deed / conveyance deed provided to us, we report that, the title in respect of self-constructed buildings and title deeds of all other immovable properties, except for the following, disclosed in the financial statements included under Property, Plant and Equipment are held in the name of the Company as at the balance sheet date.

Following Immovable assets are currently in the name of M/s Adley Formulations, post-acquisition of business, the title deed is to be transferred in M/s Adley Formulations Private Limited.

Description of Property	Gross carrying value	Held in name of	Whether promoter, director or their relative or employee	Period held- indicate range, where applicable	Reasons for not being held in name of company
Land at Village kotla, Barotiwala, Tehsil Baddi, Dist. Solan, HP	3,58,750/-	M/s Adley Formulations (Proprietorship firm of Mr. Vijay Kumar Batra)		Since 09/10/2018	*as details below
Building at Village kotla, Barotiwala, Tehsil Baddi, Dist. Solan, HP	6,76,45,511.83/-	M/s Adley Formulations (Proprietorship firm of Mr. Vijay Kumar Batra)		Since 09/10/2018	*as details below
Showroom at SCO 42, Sector 12, Panchkula	1,13,18,424.58/-	M/s Adley Formulations (Proprietorship firm of Mr. Vijay Kumar Batra)		Since 09/10/2018	*as details below



- * A Writ Petition was filed by M/s Adley Formulations Private Limited bearing CWP No. 1464 of 2023 titled M/s Adley Formulations Private Limited Vs State of Himachal Pradesh & anr before the Hon'ble H.P. High Court at Shimla for issuance of nature of mandamus, directing/ commanding the Department of Revenue to change the name of the Petitioner Company from M/s Adley Formulations to M/s Adley Formulations Private Limited consequent upon conversion from a Proprietorship Firm to a Private Limited Company without foisting any condition to pay Stamp Duty or Registration Fee.

The Hon'ble High Court vide Order dated 18-12-2023, disposed of the said petition in terms of judgment the Hon'ble High Court in in CWP No.4019 of 2020, titled as M/s Sozin Flora Pharma LLP vs. State of Himachal Pradesh and another, decided on 07.01.2021 and CWP No.3331 of 2021, titled as M/s Indorama India Pvt. Ltd. & another vs. State of HP & others, decided on 31.07.2023. apart from that a direction was issued to the effect that the petitioner shall not be forced to pay the stamp duty for the transfer of the Unit in issue.

Now the Execution Petition No 729 of 2024 has been filed before the Hon'ble High Court, Shimla and the same is pending for 09.09.2024.

(d) The Company has not revalued any of its Property, Plant and Equipment and intangible assets during the year.

(e) No proceedings have been initiated during the year or are pending against the Company as at March 31, 2024 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.

ii. (a) As explained to us, the inventories were physically verified during the year by the Management at reasonable intervals, except goods-in-transit. The coverage and procedure adopted by the Management is appropriate according to the size and scale of the Company. No discrepancies of 10% or more were observed in any class of inventories.

(b) The Company has been sanctioned working capital limits of Rs. 10.70 crores, in aggregate, from banks or financial institutions and the monthly statements filed by the Company with such banks or financial institutions are in agreement with the books of accounts of the Company.

iii. (a) The Company has not provided any loans or advances in the nature of loans or stood guarantee, or provided security to any other entity during the year, and hence reporting under clause 3(iii)(a) of the Order is not applicable.

(b) The company has not made any investments, or provided any guarantees, loans or advances. Hence, clause 3(iii)(b) is not applicable.

(c) The company has not provided any loans and hence, clause 3(iii)(c) is not applicable.

(d) The company has not granted any loans and hence, clause 3(iii)(d) is not applicable.

(e) The company has not granted any loan and hence, clause 3(iii)(e) is not applicable.

(f) The Company has not granted any loans or hence, reporting under clause 3(iii)(f) is not applicable.

iv. The Company has complied with the provisions of Sections 185 and 186 of the Companies Act, 2013 in respect of loans granted, investments made and guarantees and securities provided, as applicable.



BETA DRUGS LIMITED

19TH ANNUAL REPORT

v. The Company has not accepted any deposit or amounts which are deemed to be deposits. Hence, reporting under clause 3(v) of the Order is not applicable.

vi. The maintenance of cost records has not been specified by the Central Government under sub-section (1) of section 148 of the Companies Act, 2013 for the business activities carried out by the Company. Hence, reporting under clause (vi) of the Order is not applicable to the Company.

vii. In respect of statutory dues:

- (a) In our opinion, the Company has generally been regular in depositing undisputed statutory dues, including Goods and Services tax, Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, Cess and other material statutory dues applicable to it with the appropriate authorities except advance tax. There were no undisputed amounts payable in respect of Goods and Service tax, Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, Cess and other material statutory dues in arrears as at March 31, 2024 for a period of more than six months from the date they became payable.
- (b) Disputed Income tax demand amounting to Rs.72,350/- for A.Y 2021-22 is outstanding and appeal filed against the same is under process as on 31.03.2024. The said demand was due to wrong double disallowance by the department u/s 36 for which appeal has been filed by the company.

viii. There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).

ix. (a) The Company has not defaulted in repayment of loans or other borrowings or in payment of interest thereon to any lender.

- (b) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (c) According to the explanations provided by the Company and overall examination of the financial statements of the Company, the term loans were prima facie applied for the purpose for which they were obtained.
- (d) On an overall examination of the financial statements of the Company, funds raised on short-term basis have, prima facie, not been used during the year for long-term purposes by the Company.
- (e) On an overall examination of the financial statements of the Company, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries.
- (f) The Company has not raised any loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies and hence reporting on clause 3(ix)(f) of the Order is not applicable.

x. (a) The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under clause 3(x)(a) of the Order is not applicable.

(b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause 3(x)(b) of the Order is not applicable.

xi. (a) No fraud by the Company and no material fraud on the Company has been noticed or reported during the year.

(b) No report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.

(c) The Company has not received any whistle-blower complaints during the year.



xii. The Company is not a Nidhi Company and hence reporting under clause (xii) of the Order is not applicable.

xiii. In our opinion, the Company is in compliance with Section 177 and 188 of the Companies Act, 2013 with respect to applicable transactions with the related parties and the details of related party transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.

xiv. (a) In our opinion the Company has an adequate internal audit system commensurate with the size and the nature of its business.

(b) We have considered, the internal audit reports for the year under audit, issued to the Company during the year and till date, in determining the nature, timing and extent of our audit procedures.

xv. In our opinion during the year the Company has not entered into any non-cash transactions with its Directors or persons connected with its directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.

xvi. (a) In our opinion, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause 3(xvi)(a), (b), (c) and (d) of the Order is not applicable.

xvii. The Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.

xviii. There has been no resignation of the statutory auditors of the Company during the year.

xix. On the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

xx. The Company has fully spent the required amount towards Corporate Social Responsibility (CSR) and there are no unspent CSR amount for the year requiring a transfer to a Fund specified in Schedule VII to the Companies Act or special account in compliance with the provision of sub-section (6) of section 135 of the said Act. Accordingly, reporting under clause (xx) of paragraph 3 of the order is not applicable for the year.

Place:- Chandigarh
Date: 14/05/2024
UDIN: 24087438BJZXBC6851

For KALRA RAI & ASSOCIATES

Chartered Accountants

Sd/-

(Lajpat Rai Kalra)

Partner

M. No- 087438

FRN: 008859N

“ANNEXURE-B” TO THE AUDITORS’ REPORT

Referred to in Paragraph 7 of Our Report of Even Date

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of **Adley Formulations Private Limited** (“the Company”) as of 31 March 2024 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (“the Guidance Note”) issued by the Institute of Chartered Accountants of India (“ICAI”). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (“the Act”).

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (“the Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to

permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March 2024, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Place:- Chandigarh**Date: 14/05/2024****UDIN:24087438BJZXBC6851****For KALRA RAI & ASSOCIATES****Chartered Accountants****Sd/-****(Lajpat Rai Kalra)****Partner****M. No- 087438****FRN: 008859N**

ADLEY FORMULATIONS PRIVATE LIMITED			
Cabin No. 1, 1ST FLOOR SCO-184, SECTOR-5 PANCHKULA Panchkula HR 134114 IN			
CIN : U24303HR2018PTC076347			
BALANCE SHEET AS AT 31 March' 2024			
Particulars	Note No.	As at 31 March' 2024	As at 31 March' 2023
		Amount in Rs. Lakhs	Amount in Rs. Lakhs
A EQUITY AND LIABILITIES			
1 Shareholders' funds			
(a) Share capital	1	126.00	126.00
(b) Reserves and surplus	2	2,286.93	1,524.66
(c) Money received against share warrants		-	-
		2,412.93	1,650.66
2 Share application money pending allotment		-	-
3 Non-current liabilities			
(a) Long-term borrowings	3	553.36	366.47
(b) Deferred tax liabilities (net)	4	-	-
(c) Other long-term liabilities	5 (a)	167.27	167.11
(d) Long-term provisions	5 (b)	68.05	54.13
		788.69	587.72
4 Current liabilities			
(a) Short-term borrowings	6	386.25	686.64
(b) Trade payables	7	2,671.54	1,426.46
(c) Other current liabilities	8	381.71	209.11
(d) Short-term provisions		25.97	80.34
		3,465.47	2,402.56
TOTAL		6,667.08	4,640.93
B ASSETS			
1 Non-current assets			
(a) Property, Plant and Equipment and Intangible Assets			
(i) Property, Plant and Equipment	9	1,437.99	1,423.22
(ii) Intangible assets	9	7.38	13.31
(iii) Capital work-in-progress		-	-
(iv) Intangible assets under development		-	-
(v) Fixed assets held for sale		-	-
		1,445.37	1,436.53
(b) Non-current investments		-	-
(c) Deferred tax assets (net)	4	44.69	27.92
(d) Long-term loans and advances	10 (a)	343.01	330.16
(e) Other non-current assets	10 (b)	1.00	-
		388.70	358.08
2 Current assets			
(a) Current investments		-	-
(b) Inventories	11	1,401.66	834.79
(c) Trade receivables	12	2,757.71	1,427.22
(d) Cash and cash equivalents	13	83.68	108.04
(e) Short-term loans and advances	14	316.95	292.47
(f) Other current assets	15	273.01	183.81
		4,833.01	2,846.33
TOTAL		6,667.08	4,640.93
See accompanying notes forming part of the financial statements	24		
In terms of our report attached.			
For KALRA RAI AND ASSOCIATES Chartered Accountants (FRN: 008859N)		For and on the behalf of the Board of Directors	
Sd/- LAJPAT RAI KALRA Partner MEMBERSHIP NO. 087438 UDIN: 24087438BJZXC6851 Place : Chandigarh Date : 14/05/2024		Sd/- RAHUL BATRA DIRECTOR DIN: 02229234	Sd/- VARUN BATRA DIRECTOR DIN: 02148383

ADLEY FORMULATIONS PRIVATE LIMITED				
Cabin No. 1, 1ST FLOOR SCO-184, SECTOR-5 PANCHKULA Panchkula HR 134114 IN				
CIN : U24303HR2018PTC076347				
STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED 31 March' 2024				
	Particulars	Note No.	As at 31 March' 2024	As at 31 March' 2023
			Amount in Rs. Lakhs	Amount in Rs. Lakhs
A	CONTINUING OPERATIONS			
1	Revenue from operations (gross)	16	8,580.71	5,820.54
	Less: Excise duty		-	-
	Revenue from operations (net)		8,580.71	5,820.54
2	Other income	17	5.19	7.32
3	Total revenue (1+2)		8,585.90	5,827.86
4	Expenses			
	(a) Cost of materials consumed	18	5,431.30	2,767.84
	(b) Purchases of stock-in-trade		-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	19	-710.29	6.51
	(d) Other manufacturing expenses	20	741.46	448.88
	(d) Employee benefits expense	21	1,007.21	812.83
	(e) Finance costs	22	139.23	132.74
	(f) Depreciation and amortisation expense	9	281.62	252.00
	(g) Other expenses	23	680.61	549.08
	Total expenses		7,571.14	4,969.89
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)		1,014.76	857.96
6	Exceptional items		-	-
7	Profit / (Loss) before extraordinary items and tax (5 ± 6)		1,014.76	857.96
8	Extraordinary items/Prior period items		-	-
9	Profit / (Loss) before tax (7 ± 8)		1,014.76	857.96
10	Tax expense:			
	(a) Current tax expense for current year		267.83	228.63
	(b) (Less): MAT credit (where applicable)		-	-
	(c) Tax expense relating to prior years		-	-
	(d) Net current tax expense		267.83	228.63
	(e) Deferred tax		(16.77)	(15.09)
			251.06	213.54
11	Profit / (Loss) from continuing operations (9 ± 10)		763.70	644.42
B	DISCONTINUING OPERATIONS			
12	Profit / (Loss) from discontinuing operations (B.i ± B.ii ± B.iii)		-	-
C	TOTAL OPERATIONS		763.70	644.42
13	Profit / (Loss) for the year (11 ± 12)		763.70	644.42
14	Earnings per share (of Rs. 10/- each):			
	(a) Basic			
	(i) Continuing operations		60.61	51.14
	(ii) Total operations		60.61	51.14
	(b) Diluted			
	(i) Continuing operations		60.61	51.14
	(ii) Total operations		60.61	51.14
	See accompanying notes forming part of the financial statements	24		
In terms of our report attached.				
For KALRA RAI AND ASSOCIATES Chartered Accountants (FRN: 008859N)			For and on the behalf of the Board of Directors	
Sd/- LAJPAT RAI KALRA Partner MEMBERSHIP NO. 087438 UDIN: 24087438BJXBC6851 Place : Chandigarh Date : 14/05/2024			Sd/- RAHUL BATRA DIRECTOR DIN: 02229234	Sd/- VARUN BATRA DIRECTOR DIN: 02148383

ADLEY FORMULATIONS PRIVATE LIMITED
Cabin No. 1, IST FLOOR SCO-184, SECTOR-5 PANCHKULA Panchkula HR 134114 IN
CIN : U24303HR2018PTC076347
CASHFLOW STATEMENT FOR THE PERIOD ENDED 31 March' 2024

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
A CASHFLOW FROM OPERATING ACTIVITIES		
Net Profit before tax and extraordinary items (as per Statement of Profit & Loss)	1,014.76	857.96
Adjustments for non Cash/Non trade items:		
Depreciation & Amortization Expenses	281.62	252.00
Finance Cost	139.23	132.74
Interest received	(4.90)	(4.17)
Other inflows/(outflows) of cash	(310.71)	(203.73)
Operating profits before Working Capital Changes	1,119.99	1,034.80
Adjusted For:		
(Increase)/Decrease in trade receivables	(1,330.50)	(389.58)
Increase/(Decrease) in trade payables	1,245.07	409.00
(Increase)/Decrease in inventories	(566.87)	(124.17)
Increase/(Decrease) in other current liabilities	172.60	(37.09)
(Increase)/Decrease in short term loans and advances	(24.48)	(43.96)
(Increase)/Decrease in other current assets	(89.19)	8.87
Working Capital Changes	(593.37)	(176.92)
Net cashflow from Operating Activities (A)	526.62	857.88
B CASHFLOW FROM INVESTING ACTIVITIES		
Purchase of tangible/intangible assets	(290.47)	(627.48)
Interest received	4.90	4.17
Cash used for Long Term Loans/Advances	(12.86)	(193.60)
Net cash used in Investing Activities (B)	(298.42)	(816.91)
C CASHFLOW FROM FINANCING ACTIVITIES		
Finance Cost	(139.23)	(132.74)
Increase/(Decrease) in short term borrowings	(300.39)	391.25
Increase in/(Repayment) of Long term Borrowings	186.89	(335.50)
Increase in/(Repayment) of Other Long term Liabilities	0.16	(0.12)
Increase/ (Decrease) in share capital	-	-
Other Inflows/ (Outflows) of cash	-	-
Net cash used in Financing Activities (C)	(252.56)	(77.12)
D Net Increase/(Decrease) in cash & cash equivalents (A+B+C)	(24.36)	-36.15
E Cash & Cash equivalents at beginning of period	108.04	144.19
F Cash & Cash equivalents at end of period	83.68	108.04
G Net Increase/(Decrease) in cash & cash equivalents (F-E)	(24.36)	-36.15

In terms of our report attached.

For KALRA RAI AND ASSOCIATES
Chartered Accountants
(FRN: 008859N)

For and on the behalf of the Board of Directors

Sd/-
LAJPAT RAI KALRA
Partner
MEMBERSHIP NO. 087438
UDIN: 24087438BJZXBC6851
Place : Chandigarh
Date : 14/05/2024

Sd/-
RAHUL BATRA
DIRECTOR
DIN: 02229234

Sd/-
VARUN BATRA
DIRECTOR
DIN: 02148383

ADLEY FORMULATIONS PRIVATE LIMITED
Notes forming part of the financial statements

Note 1 Share capital

Particulars	As at 31 March' 2024		As at 31 March' 2023	
	Number of shares	Amount in Rs. Lakhs	Number of shares	Amount in Rs. Lakhs
(a) Authorised - Equity shares of Rs. 10 each	13,00,000.00	130.00	13,00,000.00	130.00
(b) Issued - Equity shares of Rs. 10 each	12,60,000.00	126.00	12,60,000.00	126.00
(c) Subscribed and fully paid up - Equity shares of Rs.10 each	12,60,000.00	126.00	12,60,000.00	126.00
(d) Subscribed but not fully paid up	-	-	-	-
Total	12,60,000.00	126.00	12,60,000.00	126.00

Note 1(a) Reconciliation of number of shares outstanding is set out below:

Particulars	Equity Shares 31 March' 2024		Equity Shares 31 March' 2023	
	Number	Amount in (Rs. Lakhs)	Number	Amount in (Rs. Lakhs)
Shares outstanding at the beginning of the year	12,60,000.00	126.00	12,60,000.00	126.00
Shares Issued during the year	-	-	-	-
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	12,60,000.00	126.00	12,60,000.00	126.00

Note 1(b) Shares held by promoters at the end of the year 31st Mar 2024

Name of Shareholder	As at 31 March' 2024		
	No. of Shares held	% of Holding	% Changes
Beta Drugs Limited	12,59,999.00	99.9999%	
Mr. Rahul Batra	1.00	0.0001%	

Note 1(b) Shares held by promoters at the end of the year 31st March 2023

Name of Shareholder	As at 31 March' 2023		
	No. of Shares held	% of Holding	% Changes
Beta Drugs Limited	12,59,999.00	99.9999%	
Mr. Rahul Batra	1.00	0.0001%	

Note 1(c) Details of shares held by each shareholder holding more than 5% shares:

Class of shares / Name of shareholder	As at 31 March' 2024		As at 31 March' 2023	
	Number of shares held	% holding in that class of shares	Number of shares held	% holding in that class of shares
Equity shares with voting rights				
Beta Drugs Limited	12,59,999	100%	12,59,999	100%
Mr. Rahul Batra	1	0%	1	0%

ADLEY FORMULATIONS PRIVATE LIMITED
Notes forming part of the financial statements

Note 2 Reserves and surplus

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a) Securities premium account		
Opening balance	-	-
Closing balance	-	-
(b) Surplus / (Deficit) in Statement of Profit and Loss		
Opening balance	1,524.66	888.51
Less: Provision for Insurance claim recoverable		-
Less: Provision for Income Tax	1.43	8.27
Add: Profit / (Loss) for the year	763.70	644.42
Closing balance	2,286.93	1,524.66
Total	2,286.93	1,524.66

Note 3 Long-term borrowings

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Term loans		
From banks		
Secured		
Federal Bank (Vehicle Loan)	39.56	53.58
ICICI Bank Ltd (LAP)	4.97	-
ICICI Covid Loan	-	12.24
HDFC Bank (Vehicle Loan)	12.84	14.42
Yes Bank Loan (Vehicle Loan)	-	-
	57.37	80.24
From other parties		
Secured		
Unsecured (From Related Parties)		
M/s Beta Drugs Ltd.	495.99	286.23
Total - A	495.99	286.23
Unsecured (From Unrelated Parties)	-	-
Total - B	-	-
	495.99	286.23
The Above Amount Includes		
Secured Borrowings	57.37	80.24
Unsecured Borrowings	495.99	286.23
	-	-
Total	553.36	366.47

ADLEY FORMULATIONS PRIVATE LIMITED
Notes forming part of the financial statements

ADLEY FORMULATIONS PRIVATE LIMITED
Note 4 Deferred Tax

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Deferred tax Asset		
Opening Deferred Tax Asset	27.92	12.83
Deferred tax on depreciation	13.27	9.71
Deferred tax on Gratuity	3.50	5.39
Deferred tax on loss on sale of asset	-	-
Deferred tax asset for the year	16.77	15.09
Net Deferred tax asset	44.69	27.92

Continue Note 4 Current tax Provision

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Current Year Tax	267.83	228.63
Less: Advance Tax/TDS/TCS	-241.86	-148.29
Current Year Tax Provision	25.97	80.34
Short term provisions	25.97	80.34

ADLEY FORMULATIONS PRIVATE LIMITED
Notes forming part of the financial statements

Notes: Long-term borrowings

Particulars	As at 31 March' 2024			As at 31 March' 2023		
	Amount in Rs. Lakhs			Amount in Rs. Lakhs		
	Non- Current	Current Maturities	Total	Non- Current	Current Maturities	Total
Term loans						
From banks						
Secured						
Federal Bank (Vehicle Loan)	39.56	14.02	53.58	53.58	15.99	69.57
HDFC Bank (Vehicle Loan)	12.84	19.78	32.62	14.42	19.86	34.28
Yes Bank (Vehicle Loan)	-	-	-	-	0.59	0.59
ICICI Bank (Vehicle Loan)	4.97	2.63	7.60	-	-	-
ICICI Covid Loan	-	-	-	12.24	36.72	48.96
	57.37	36.44	93.81	80.24	73.17	153.41
From other parties						
Secured	-	-	-	-	-	-
Unsecured (From Related Parties)						
M/s Beta Drugs Ltd.	495.99	-	495.99	286.23	-	286.23
Total - A	495.99	-	495.99	286.23	-	286.23
Unsecured (From Unrelated Parties)	-	-	-	-	-	-
Total - B	-	-	-	-	-	-
	495.99	-	495.99	286.23	-	286.23
The Above Amount Includes						
Secured Borrowings	57.37	36.44	93.81	80.24	73.17	153.41
Unsecured Borrowings	495.99	-	495.99	286.23	-	286.23
Amount disclosed under "Other Current Liabilities"		(36.44)	(36.44)		(73.17)	(73.17)
Total	553.36	-	553.36	366.47	-	366.47

ADLEY FORMULATIONS PRIVATE LIMITED
Notes forming part of the financial statements

Note 5 (a) Other long-term liabilities		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Others:		
(i) Payables on purchase of fixed assets	91.88	91.72
(ii) Contractually reimbursable expenses	-	-
(iii) Security received from customers	75.40	75.40
Total	167.27	167.11

Note 5 (b) Long Term-provisions		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a) Provision for Gratuity	68.05	54.13
Total	68.05	54.13

ADLEY FORMULATIONS PRIVATE LIMITED

Notes forming part of the financial statements

Note 6 Short-term borrowings

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Other loans and advances Secured		
- ICICI Bank CC against hypothecation of stock, Debtors and movable assets	87.05	258.39
-ICICI Bank OD Account	299.21	428.25
Total	386.25	686.64

Note 7 Trade payables

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Trade payables:		
Micro Enterprises And Small Enterprises	83.37	1,113.16
Others	2,588.17	313.31
Total	2,671.54	1,426.46

Note 8 Other current liabilities

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a) Other payables	174.09	126.64
(i) Current Maturities of Long Term Debt	36.44	73.17
(b) Cheque issued yet not presented for Payment	151.15	0.03
Advances From Customers	20.03	9.27
Total	381.71	209.11

Note 8(a) Other current liabilities

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
PF Payable	7.58	5.87
ESI payable	0.43	0.37
TDS payable	14.72	12.39
Labour Welfare payable	0.23	0.15
Interest Accrued But Not Due	0.71	0.78
Salary & wages Payable	90.79	79.17
Income Tax Payable	-	-
Other Expenses payable	59.62	27.91
Total	174.09	126.64

Note No. 9 Property, Plant & Equipment and Intangible Assets as at 31st March'2024

Assets		Gross Block						Accumulated Depreciation/ Amortisation				Net Block	
	Useful Life (In Years)	Shift	Balance as at 1st April 2023	Additions during the year	Addition on account of business acquisition	Deletion during the year	Balance as at 31st March' 2024	Balance as at 1st April 2023	Provided during the year	Deletion / adjustments during the year	Balance as at 31st March' 2024	Balance as at 31st March' 2024	Balance as at 31st March 2023
A Property, Plant & Equipment													
Own Assets													
LAND		Single	3.59	-	-	-	3.59	-	-	-	-	3.59	3.59
SHOWROOM LAND		Single	26.20	-	-	-	26.20	-	-	-	-	26.20	26.20
BUILDING	30	Single	573.57	102.89	-	-	676.46	91.94	50.85	-	142.79	533.67	481.63
SHOWROOM SCO 42	30	Single	86.98	-	-	-	86.98	30.93	5.34	-	36.27	50.72	56.06
PLANT AND MACHINERY	15	Single	798.47	86.12	-	9.81	874.77	181.34	119.79	5.75	295.38	579.39	617.13
FURNITURE AND FIXTURES	10	Single	47.67	20.73	-	-	68.40	11.32	12.68	-	24.00	44.40	36.35
ELECTRICAL EQUIPMENTS	5	Single	82.38	36.60	-	-	118.98	44.30	26.56	-	70.86	48.11	38.08
COMPUTER	3	Single	7.15	4.65	-	-	11.80	3.74	4.09	-	7.83	3.97	3.41
VEHICLE	8	Single	330.85	43.54	-	-	374.39	170.06	56.38	-	226.44	147.95	160.79
Total (A)			1,956.85	294.53	-	9.81	2,241.56	533.63	275.69	5.75	803.57	1,437.99	1,423.22
P.Y Total			1,332.53	629.99	-	5.66	1,956.85	290.70	246.09	3.16	533.63	1,423.22	1,041.82
B Capital work in progress													
BUILDING			-	-	-	-	-	-	-	-	-	-	-
PLANT AND MACHINERY			-	-	-	-	-	-	-	-	-	-	-
SOFTWARE DEVELOPMENT			-	-	-	-	-	-	-	-	-	-	-
EUGMP Fee			-	-	-	-	-	-	-	-	-	-	-
Total (B)			-	-	-	-	-	-	-	-	-	-	-
P.Y Total			-	-	-	-	-	-	-	-	-	-	-
C Intangible Assets													
REGISTRATION FEE			29.55	-	-	-	29.55	16.25	5.93	-	22.17	7.38	13.31
Total (C)			29.55	-	-	-	29.55	16.25	5.93	-	22.17	7.38	13.31
P.Y Total			29.55	-	-	-	29.55	10.33	5.91	-	16.25	13.31	19.22
Current Year Total (A+B+C)			1,986.40	294.53	-	9.81	2,271.11	549.87	281.62	5.75	825.74	1,445.37	1,436.53
Previous Year Total			1,362.08	629.99	-	5.66	1,986.40	301.04	252.00	3.16	549.87	1,436.53	1,061.04

ADLEY FORMULATIONS PRIVATE LIMITED

Note 10 (a) Long-term loans and advances

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
Security Deposit		
Secured, considered good	120.06	101.12
Others		
Advances to Capital Suppliers	222.95	229.04
Total	343.01	330.16

Note 10 (b) Other Non Current Assets

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
Amount deposited with Approved Gratuity Fund	1.00	-
Total	1.00	-

Note 11 Inventories

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
(Valued at cost or NRV unless otherwise stated)		
(a) Finished goods (other than those acquired for trading)	217.38	120.55
(b) Raw Material	170.97	133.77
(c) WIP	661.51	48.05
d) Others	351.80	532.43
Total	1,401.66	834.79

Note 12 Trade receivables

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
Exceeding six months		
Secured, considered good	197.36	155.58
Total	197.36	155.58
Less than six months		
Secured, considered good	2,560.36	1,271.64
Total	2,560.36	1,271.64
Total	2,757.71	1,427.22

ADLEY FORMULATIONS PRIVATE LIMITED

Note 12 (a) Trade receivables ageing Schedule As at 31st March'2024

Particulars	Outstanding for following periods from					Total
	Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	2,560.36	9.58	50.89	50.15	45.88	2,716.87
(ii) Undisputed Trade receivables - considered doubtful	-	-	-	-	-	-
(iii) Disputed trade receivables considered good	-	-	-	-	-	-
(iv) Disputed trade receivables considered doubtful	-	-	-	-	40.84	40.84

Note 12 (b) Trade receivables ageing Schedule As at 31st March'2023

Particulars	Outstanding for following periods from					Total
	Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	1,271.64	16.34	46.53	14.11	36.75	1,385.37
(ii) Undisputed Trade receivables - considered doubtful	-	-	-	-	-	-
(iii) Disputed trade receivables considered good	-	-	-	-	-	-
(iv) Disputed trade receivables considered doubtful	-	-	-	-	41.84	41.84

ADLEY FORMULATIONS PRIVATE LIMITED		
Note 13 Cash and cash equivalents		
Particulars	As at 31 March'	As at 31 March'
	2024	2023
	Amount in Rs.	Amount in Rs.
	Lakhs	Lakhs
CASH ON HAND		
(a) Cash on hand	9.07	7.28
(b) Imprest A/c	1.03	1.97
Total	10.10	9.26
(b) Balances with banks		
(i) In current accounts		
-ICICI Bank	0.01	0.01
-Kotak Mohindra Bank	2.37	0.46
(ii) In earmarked accounts		
(c) Others (specify nature)		
FDRs (Margin Money against B.G)	71.20	98.31
Total	73.58	98.78
Grand Total	83.68	108.04
Note 14 Short-term loans and advances		
Particulars	As at 31 March'	As at 31 March'
	2024	2023
	Amount in Rs.	Amount in Rs.
	Lakhs	Lakhs
(a) Loans and advances to related parties	-	-
(b) Loans and advances others		
Advances To Supplier	298.93	278.98
Other Advances (Staff)	18.01	13.49
Total	316.95	292.47
Note 15 Other current assets		
Particulars	As at 31 March'	As at 31 March'
	2024	2023
	Amount in Rs.	Amount in Rs.
	Lakhs	Lakhs
Other Assets		
Prepaid Insurance	12.71	4.59
GST Recoverable	260.21	168.17
GST-Under Protest	-	10.96
Income Tax Refund A.Y 2022-23	0.09	0.09
Cheque deposited not cleared	-	-
Total	273.01	183.81

ADLEY FORMULATIONS PRIVATE LIMITED**Note 16 Revenue from operations**

	Particulars	For the period ended	For the period ended
		31 March' 2024	31 March' 2023
		Amount in Rs.	Amount in Rs.
		Lakhs	Lakhs
	Sale Of Products		
	GST Sales 18%	387.44	199.83
	Export Sales	155.29	86.32
	Sales Exempt	-298.47	1.74
	GST Sales 12%	6,489.16	4,361.80
	GST Sales 5%	1,577.24	1,145.75
	GST Sales 0.1%	270.06	25.10
	Total	8,580.71	5,820.54

Note 17 Other income

	Particulars	For the period ended	For the period ended
		31 March' 2024	31 March' 2023
		Amount in Rs.	Amount in Rs.
		Lakhs	Lakhs
(a)	Interest Income	4.90	4.17
(b)	Other non-operating income	0.29	3.15
(c)	Foreign Currency Exchange Gain	-	-
	Total	5.19	7.32

ADLEY FORMULATIONS PRIVATE LIMITED**Note 18 Cost of materials consumed**

Particulars	For the period ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Opening stock	666.19	535.51
Add: Purchases	5,287.87	2,898.52
Less: Closing stock	522.77	666.19
Cost of material consumed	5,431.30	2,767.84
Total	5,431.30	2,767.84

Note 19 Changes in inventories of finished goods, work-in-progress and stock-in-trade

Particulars	For the period ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
<u>Inventories at the end of the year:</u>		
Finished goods	217.38	120.55
Work In Progress	661.51	48.05
	878.88	168.60
<u>Inventories at the beginning of the year:</u>		
Finished goods	120.55	87.52
Work In Progress	48.05	87.59
	168.60	175.11
(Increase)/ decrease in Inventory		
Finished goods	-96.83	-33.03
Work In Progress	-613.46	39.54
	-710.29	6.51

Note 20 Other Manufacturing Expenses

Particulars	For the period ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Consumeable Stores	77.46	50.39
Generator running expenses	14.93	7.72
Power & Fuel	89.62	55.32
Direct labour	453.96	248.64
Repairs & maintenance (machinery & Building)	67.87	62.10
Freight Inward	3.31	7.98
Factory Expenses	12.17	6.06
Solid Waste Pollution expenses	1.03	1.26
Housekeeping Expenses	4.30	1.53
Testing Charges	16.81	7.90
Total	741.46	448.88

ADLEY FORMULATIONS PRIVATE LIMITED**Note 21 Employee benefits expense**

Particulars	For the period ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Salaries and wages		
Director	251.57	250.29
Employees	662.38	486.46
Employer Share of ESI	3.98	2.58
Employer Share of PF	40.48	28.86
Employer Share of LWF	0.59	0.46
Bonus	14.87	11.97
Staff welfare expenses	15.33	10.10
Staff Uniform Expenses	3.24	0.73
Gratuity	14.77	21.40
Total	1,007.21	812.83

Note 22 Finance costs

Particulars	For the period ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a) Interest expense on:		
(i) Borrowings		
Bank Interest CC	82.46	62.76
Interest on Term Loan	2.49	18.89
Interest on Term Loan (Vehicle)	6.91	9.84
(ii) Others	13.37	12.04
(iii) Interest on Loan (Holding Co.)	32.40	24.28
(b) Other borrowing costs (Processing Fees)		
Bank charges	1.59	4.93
Total	139.23	132.74

ADLEY FORMULATIONS PRIVATE LIMITED**Note 23 Other expenses**

Particulars	For the period ended 31 March' 2024	For the year ended 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Advertisement Expenses	1.85	0.61
Audit Fees- Statutory	0.50	0.50
Audit Fees- Cost Audit	0.75	-
Business Promotion Expenses	23.02	16.61
Commission Paid	123.01	96.87
Conference Expenses	21.55	5.30
Convenyance Expenses	20.46	9.12
Corporate Social Responsibility Expenses	16.00	11.36
Expired & damages Goods Return	16.53	32.07
Foreign Exchange Gain/Loss	0.72	0.19
Foreign Travelling	4.94	10.11
Freight Outward	32.69	30.50
Insurance Apportion Cost	19.67	13.10
Legal & Professional Expenses	5.17	5.26
Medical Expenses	0.45	0.88
Office Expenses	15.74	3.85
Packing & Forwarding expense	22.68	23.11
Printing & Stationary	8.51	5.92
Preliminary expenses w/off	-	0.44
Rate Fee & taxes	12.23	13.32
Repair & maintenance (Vehicle)	9.46	5.82
Round Off	-0.00	-0.00
Software Expenses	4.64	6.14
Telephone & Postage	4.73	7.10
Trade Discount Expenses	1.55	2.32
Travelling Expenses	313.79	248.58
Total	680.61	549.08

NOTES TO ACCOUNTS OF STANDALONE FINANCIALS OF M/S ADLEY FORMULATIONS PRIVATE LIMITED

NOTE '24': SIGNIFICANT ACCOUNTING POLICIES

(Forming part of Accounts)

FOR THE YEAR ENDED 31ST MARCH, 2024

24.1. Basis of Accounting

The financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India under the historical convention on accrual basis. These financial statements have been prepared to comply, in all material aspects, with the accounting standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and the presentation requirements as prescribed by the Schedule III of the Companies Act, 2013 to the extent applicable.

24.2. Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires that management makes estimates and assumptions that affect the reported amounts of income and expenses of the year, the reported balance of assets and liabilities and the disclosure relating to contingent liabilities as at the date of the financial statements. These estimates are based upon management's best knowledge of current events and actions. The difference between the actual results and estimates are recognised in the period in which the results are known / materialized.

24.3. Property, Plant and Equipment and Intangible assets

- Property, Plant and Equipment

Tangible Assets are stated at cost of acquisition or construction less accumulated depreciation and impairment of assets, if any. The cost comprises purchase price, borrowing costs if capitalisation criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. The company has a policy of physical verification of all the assets once in a year, the last verification was done on 28th March 2024 and no discrepancies were noticed during such verification.

The company has also got the physical verification conducted from external agency dated 25.09.2023.

Following Immovable assets were in name of M/s Adley Formulations (Prop. Sh. Vijay Kumar Batra) which were required to be transferred in the name of M/s Adley Formulations Private Limited, post-acquisition of business in FY 2018-19.

Particulars	Address of Property
1. LAND	Village Kotla, Barotiwala, Tehsil Baddi, Dist. Solan, HP
2. BUILDING	Village Kotla, Barotiwala, Tehsil Baddi, Dist. Solan, HP
3. BUILDING SHOWROOM	SCO 42, Sector 12, Panchkula

* A Writ Petition was filed by M/s Adley Formulations Private Limited bearing CWP No. 1464 of 2023 titled M/s Adley Formulations Private Limited Vs State of Himachal Pradesh & anr before the Hon'ble H.P. High Court at Shimla for issuance of nature of mandamus, directing/ commanding the Department of Revenue to change the name of the Petitioner Company from M/s Adley Formulations to M/s Adley Formulations Private Limited consequent upon conversion from a Proprietorship Firm to a Private Limited Company without foisting any condition to pay Stamp Duty or Registration Fee.

The Hon'ble High Court vide Order dated 18-12-2023, disposed of the said petition in terms of judgment the Hon'ble High Court in in CWP No.4019 of 2020, titled as M/s Sozin Flora Pharma LLP vs. State of Himachal Pradesh and another, decided on 07.01.2021 and CWP No.3331 of 2021, titled as M/s Indorama India Pvt. Ltd. & another vs. State of HP & others, decided on 31.07.2023. apart from that a direction was issued to the effect that the petitioner shall not be forced to pay the stamp duty for the transfer of the Unit in issue.

Now the Execution Petition No 729 of 2024 has been filed before the Hon'ble High Court, Shimla and the same is pending for 09-09-2024.

- Capital Work-in-Progress

Expenses incurred during construction/installation period are included under capital work-in-progress and allocated to relevant fixed assets in the ratio of cost of the respective assets on completion of construction/installation. There is no work in progress for the financial year ending 31-March-2024.

24.4. Depreciation/Amortisation

- Depreciation on tangible assets is provided, on Written Down Value method, over the useful life of assets estimated by the management in accordance with Schedule-II of the Companies Act, 2013.



- Residual value of assets has been considered at 5% of the original cost of the assets.
- Depreciation on additions to fixed assets is calculated on date of put to use as certified by the management.
- Depreciation on assets sold & scrapped, during the year, is provided up-to the month in which such fixed assets are sold or scrapped.

24.5. Impairment of Assets

The carrying amounts of assets are reviewed at each balance sheet date if there is any indication of impairment based on internal/external factors. An asset is treated as impaired when the carrying cost of the assets exceeds its recoverable value. An impairment loss, if any, is charged to the Statement of Profit & Loss in the year in which an asset is identified as impaired. Reversal of impairment losses recognised in prior years is recorded when there is an indication that the impairment losses recognised for the assets no longer exist or have decreased.

24.6. Valuation of Inventories

- Raw Material Chemicals & Salts
- Packing Material
- Finished Goods Oncology products comprise of Injections, Tablets & Capsules
- Work In Progress (Semi Finished Goods)
- The value of raw material and packing material has been taken at cost.
- The value of Finished Goods and Work in Progress has been taken on allocation of labour and manufacturing overheads and is valued at cost or net realizable value whichever is lower.
- The company has a policy of physical verification of the entire available inventory once every month, no material discrepancies were noticed during such verification. The last verification was done on 4th April 2024.

24.7. Revenue Recognition

- Revenue from sale of goods is recognised when risk and rewards of ownership are transferred to the customers.
- Revenue from services is recognised when services are rendered and related costs are incurred.
- Other income is recognised on accrual basis unless otherwise stated.
- Revenue from sales/services are shown net of taxes, as applicable.

24.8. Employee Benefits

a) Short-term Employee Benefits:

- Leave Encashment, on the basis of actual computation, is accounted on payment basis, after retirement of the employees, the payment in respect thereof is made by the Company from its own funds as per the past practice consistently followed by the Company.
- Payment of Bonus – This year the company has paid Rs. 14,86,998.00 as per The Payment of Bonus Act, 1965.

b) Post-Employment Benefits

(i) Defined Contribution Plans:

Contributions as required under the Statute/Rule are made to Employees State Insurance & Provident Fund and charged to the Statement of Profit & Loss of the year when the contributions to the respective funds are due.

(ii) Defined Benefit Plans:

Gratuity is accounted for on accrual basis.

The company has paid Gratuity of Rs. 84,889.00 during the year, made a further provision of Rs. 14,77,117.00 and the closing balance of the provision for Gratuity as on 31.03.2024 is Rs. 68,05,361.00.

- c) **Termination Benefits:** Termination benefits are recognized as an expense as and when incurred.

24.9. Foreign Currency Transactions

- Functional and Reporting Currency:** The standalone financial statements are presented in Indian Rupee ('INR') which is also the functional and presentation currency of the Company.
- Initial Recognition:** Foreign currency transactions are recorded in the functional currency, by applying to the exchange rate between the functional currency and the foreign currency at the date of the transaction.
- Conversion on Reporting Date:** Transactions in foreign currencies are initially recorded by the Company at its functional currency spot rates at the date the transaction first qualifies for recognition. Monetary assets



and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.

iv.) Exchange Differences: Exchange differences arising on monetary items on settlement, or restatement as at reporting date, at rates different from those at which they were initially recorded, are recognized in the statement of profit and loss in the year in which they arise.

-Net amount of Rs. 71,986.38 is recognized as expense for the year due to foreign exchange fluctuation.

24.10. Borrowing Costs

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalized as part of the cost of such assets to the extent that they relate to the period till such assets are ready to use. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use. All other borrowing costs are charged to the Statement of Profit & Loss.

24.11. Investments

-Current Investments are carried at cost or fair value whichever is lower.

-Non-Current Investments are carried at cost. Provision for diminution in value of non-current investments is made only, if a decline is other than temporary.

24.12. Operating Lease

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased assets are classified as operating leases. Operating lease charges are recognised as an expense in the Statement of Profit & Loss on monthly due basis.

24.13. Taxes on Income

- Current Tax is measured at the amount expected to be paid to the tax authorities in accordance with the Indian Income Tax Act, 1961.

- Deferred tax is recognised, subject to the consideration of prudence in respect of deferred tax assets, on timing differences, being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods.

- Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off assets against liabilities.

24.14. Earnings Per Share (EPS)

- Annualised basic earnings per equity share is arrived at based on net profit/(loss) attributable to equity shareholders to the basic weighted average number of equity shares outstanding.

- Annualised diluted earnings per equity share is arrived at based on adjusted net profit/(loss) attributable to equity shareholders to the adjusted weighted average number of equity shares outstanding, for the effects of all dilutive potential equity shares; except where the results are anti-dilutive. At present the Company does not have any dilutive potential equity shares.

24.15. Cash Flow Statement:

- The Cash Flow Statement is prepared by the indirect method set out in Accounting Standard (Ind AS) 7 on Cash Flow Statements and presents the cash flows by operating, investing and financing activities of the Company.

- Cash and cash equivalents presented in the Cash Flow Statement consists of balance in current accounts and cash balances.

24.16. Contingencies and Provisions

A provision is recognised when the Company has a present obligation as a result of past events. It is probable that an outflow of resources embodying economic benefit will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on the best estimate of the expenditure required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimate.

A contingent liability is disclosed, unless the possibility of an outflow of resources embodying the economic benefit is remote.

Details of Contingent Liabilities in the form of Bank Guarantee as on 31.03.2024.



Bank Name	Bank Guarantee No	Opening Date	Expiry Date	In Favour	Bank Guarantee Amount (Rs.)
ICICI BANK	0043BGFD003519	19-12-2018	31-12-2021	THE MANAGING DIRECTOR UTTAR PRADESH MEDICAL SUPPLIES CORP LTD	13,004.00
KOTAK	0281IGP190065684	26-12-2019	26-12-2021	STATE HEALTH SOCIETY, ASSAM O/O	69,418.00
KOTAK	0259OBG18010100	23-05-2018	31-03-2021	THE DY DIR HEALTH SERVICES ,WEST BENGAL	1,20,000.00
KOTAK	503LG1347/14	20-11-2014	30-11-2020	THE ASSISTANT/DEP COMMISSIONER OF CUSTOM	1,18,745.00
KOTAK	503LG1412/13	09-12-2013	08-12-2020	THE ASSISTANT/DEP COMMISSIONER OF CUSTOM	1,15,000.00
ICICI BANK	FD NO - 16736502	23-10-2019	23-10-2021	FA/CAO JKMSCL JAMMU	1,00,000.00
ICICI BANK	FD NO - 004313028150	14-07-2020	14-07-2022	FA/CAO JKMSCL JAMMU	1,00,000.00
KOTAK	0259OBG18001568	23-01-2018	22-01-2021	MANAGING DIRECTOR,RMSCL JAIPUR	22,08,435.00
KOTAK	0259OBG18003057	13-02-2018	13-02-2021	MANAGING DIRECTOR,RMSCL JAIPUR	2,46,592.00
KOTAK	0281IGP190063972	19-12-2019	11-01-2024	MANAGING DIRECTOR,RMSCL JAIPUR	14,91,497.00
ICICI BANK	0043NDDG00006222	07-08-2021	31-03-2024	THE DY DIR HEALTH SERVICES ,WEST BENGAL	30,000.00
ICICI BANK	0043NDDG00014822	15-02-2021	28-02-2024	THE DY DIR HEALTH SERVICES ,WEST BENGAL	2,58,685.00
ICICI BANK	0043NDDG00016622	24-03-2022	23-03-2024	MANAGING DIR JAMMU AND KASHMIR	52,507.00
ICICI BANK	0043NDDG00046722	24-03-2022	23-03-2024	MANAGING DIR JAMMU AND KASHMIR	72,330.00
ICICI BANK	0043NDDG00001323	26-05-2022	30-04-2026	DIRECTOR GENERAL ARMED FORCES MEDICAL SERVICES.	1,11,500.00
ICICI BANK	0043NDDG00013223	02-02-2023	16-08-2026	ALL INDIA INSTITUTE OF MEDICAL SCIENCES , AIIMS PATNA, BIHAR	3,00,000.00
ICICI BANK	0043NDDG00018024	14-02-2024	30-05-2025	THE DIRECTOR HBCH/MPMMCC TATA MEMORIAL CENTRE VARANASI UP	99,786.00
				TOTAL AMOUNT	55,07,499.00

24.17 **Internal Control Policy and BCP Management:** The Company has a comprehensive system of Internal Controls to safeguard its assets against loss from unauthorized use and to ensure reliability of financial reporting. The management assesses the operating effectiveness of these controls on regular basis. All the required security checks i.e., physical security of the company premises and its database are properly installed, daily backup is being done for all the accounting and related data. The company has a cloud-based ERP system (maintained by TATA Consultancy Services) in which the data remains safe on cloud and can be accessed and updated on real time basis from anywhere with defined access user rights. The company maintains a system of internal controls designed for effectiveness and efficiency of operations, compliance and regulations.

The system of internal controls monitors and ensures process for:

- Effectiveness and efficiency of operations;
- Reliability of financial reporting;
- Compliance with applicable laws and regulations.



NOTE 25 : OTHER NOTES TO ACCOUNTS
(Forming part of Accounts)
FOR THE YEAR ENDED 31ST MARCH, 2024

25.1. Contingent Liabilities & Commitments:

a) Estimated amount of contracts remaining to be executed and not provided for in the books of account- Nil (previous year- Nil).

b) Contingent Liabilities: Rs. 55,07,499.00

. Claims against the Company not acknowledged as debt -Nil (previous year - Nil).

. Liabilities in respect of Income Tax, Service Tax, Sales Tax and other material statutory dues have been accounted for on the basis of respective returns filed with the relevant authorities. Additional demand, if any, arising at the time of assessments will be accounted for in the year in which assessments are completed.

25.2. Issued, Subscribed & Paid up Capital:

Issued Subscribed and paid up capital of the company is Rs. 1,26,00,000.00 (divided into 12,60,000 shares of Rs, 10 each)

25.3. Reserves & Surplus:

The amount shown in the Reserve & Surplus represents only surplus carried forward from the earlier years plus the surplus earned during the year. Total amount of surplus outstanding as on 31.03.2024 is Rs. 22,86,92,980.85.

25.4. Long Term Borrowings

Secured :

Term Loan:

S.NO	Lender	Nature of facility	Loan	Amount outstanding as at March 31, 2024	Rate of interest (%)	Repayment Terms	Security / Principal terms and conditions
1	HDFC BANK (VEHICLE LOAN)	Term Loan of Rs 60 Lakhs	Term Loan	Rs 9.91 Lakhs	7.50%	Total Installments of Rs 1.45 Lakhs P.M. divided into 48 Equated monthly instalment.	HYP of Motor Vehicles from the bank.
2	HDFC BANK (VEHICLE LOAN)	Term Loan of Rs 15 Lakhs	Term Loan	Rs 4.51 Lakhs	7.50%	Total Installments of Rs 0.36 Lakhs P.M. divided into 48 Equated monthly instalment.	HYP of Motor Vehicles from the bank.
3	HDFC BANK (VEHICLE LOAN)	Term Loan of Rs 20 Lakhs	Term Loan	Rs 18.20 Lakhs	8.80%	Total Installments of Rs 0.59 Lakhs P.M. divided into 39 Equated monthly instalment.	HYP of Motor Vehicles from the bank.
4	Federal Bank (Vehicle Loan)	Term Loan of Rs. 25 Lakh	Term Loan	Rs. 13.36 Lakhs	7.25%	Total Installments of Rs 0.50 Lakhs P.M. divided into 60 Equated monthly instalment.	HYP of Motor Vehicles from the bank.



5	Federal Bank (Vehicle Loan)	Term Loan of Rs. 15 Lakh	Term Loan	Rs. 2.04 Lakhs	7.25%	Total Installments of Rs 0.46 Lakhs P.M. divided into 36 Equated monthly instalment.	HYP of Motor Vehicles from the bank.
6	Federal Bank (Vehicle Loan)	Term Loan of Rs. 50 Lakh	Term Loan	Rs. 38.18 Lakhs	9.34%	Total Installments of Rs 0.86 Lakhs P.M. divided into 76 Equated monthly instalment.	HYP of Motor Vehicles from the bank.
7	ICICI Bank Ltd (Vehicle Loan)	Term Loan of Rs. 9.00 Lakh	Term Loan	Rs. 7.60 Lakhs	9.35%	Total Installments of Rs 0.27 Lakhs P.M. divided into 39 Equated monthly instalment.	HYP of Motor Vehicles from the bank.

25.5. In the opinion of the Directors, “Current Assets” and “Loans & Advances” are approximately of the value stated in the Balance Sheet, if realized in the ordinary course of business and to the best of their knowledge, provisions for all the known liabilities have been made and, as certified, all the contractual and statutory obligations have been duly complied with.

25.6. Party balances have been incorporated in the financial statements at the value as per the books of accounts & are considered hopeful of recovery/good for payment. The balance confirmation letter for both debtor and creditors are sent by the company through registered post/email, and in many cases balance confirmation is received from them.

25.7. Depreciation/Amortization

The management estimates the useful life of existing fixed assets as follows:

Building	30 years
Furniture & Fixtures	10 years
Machinery	15 years
Equipment	5 years
Lab Equipment	10 years
Vehicles	8 years

For this class of assets, based on internal assessment and independent technical evaluation carried out by external valuers the management believes that the useful lives as given above best represent the period over which management expects to use these assets and the useful lives for these assets is same as the useful lives as prescribed under Part.C of Schedule.II of the Companies Act, 2013. **(Refer note 3.4).**

25.8. Earnings Per Share (IND AS 33)

	<u>Year ended</u> 31st March, 2024	<u>Year ended</u> 31st March, 2023
Numerator		
Net Profit/(Loss) attributable to Equity shareholders	7,63,69,755.83	6,44,42,439.77
Denominator		
Number of Equity shares Nominal	No.'s 12,60,000	No.'s 12,60,000
Value per Equity share	10	10
Earnings per Equity share Basic and diluted	60.61	51.14



25.9. Non Current Investments:

Equity shares have been stated at cost; provision for appreciation/diminution in the value of shares has not been made and no dividend was received during the year.

The provisions of Section 186 of the Companies Act, 2013 have been complied with.

25.10. Taxes

-The exact liability of CST/VAT, Service Tax, GST, Income Tax and other statutory dues is indeterminate pending finalisation of assessments and no undisputed dues or amounts were outstanding or remaining unpaid as at 31st March, 2024.

-Disputed Income tax demand amounting to Rs. 72,350/- for A.Y 2021-22 is outstanding and appeal filed against the same is under process as on 31.03.2024. The said demand was due to wrong double disallowance by the department u/s 36 for which appeal has been filed by the company.

-The current tax provision shown in the Balance Sheet is Rs. 25,96,924.96 after utilization of the advance tax and TDS of Rs. 2,41,86,445.37

25.11. Segment Reporting

Since the Company primarily operates in one segment (i.e., Manufacturing of Oncology medicines), therefore segment reporting as required under Ind AS 108 is not applicable.

25.12. Related Party Disclosures (Ind AS-24)

Related parties & their relationship and related parties' transactions:

S.	Related Party	Nature of Relationship	Nature of Transaction	Amount Involved During the year (₹)
1.	Beta Drugs Limited	100% Holding	Purchase of Goods	3,09,35,849.06
	Beta Drugs Limited	100% Holding	Sale of Goods	5,27,75,471.80
	Beta Drugs Limited	100% Holding	Interest on Unsecured Loan	32,40,302.00
	Beta Drugs Limited	100% Holding	Purchase of Fixed Assets	4,77,970.00
	Beta Drugs Limited	100% Holding	Unsecured Loan Taken	1,80,60,000.00
2.	Adley Lab Limited	Common Subsidiary	Purchase of Goods	14,76,92,171.00
3.	Rishi Herbal Products	Partnership Firm of Directors	Purchase of Goods	42,12,800.00
4.	Rahul Batra	Director	Salary (including bonus)	1,21,00,000.00
5.	Varun Batra	Director	Salary (including bonus)	1,21,00,000.00
6.	Ram Chander Jha	Common Director	Salary (including bonus)	11,87,172.00

The above disclosure of the related party and the transactions entered have been made as per Ind AS.24.

The transactions have been carried at arm's length price (ALP).

25.13. Ratios

Adley Formulations Pvt. Ltd.- Ratios							
Sr. No.	Ratios	Numerator	Denominator	As at March 31' 2024	As at March 31' 2023	Variance	Explanation for significant changes in the ratio as compared to the preceding year
1	Current Ratio	Current Assets	Current liabilities	1.39	1.18	17.72%	-
2	Debt-Equity Ratio	Total Debt	Shareholders' equity	0.46	0.74	-37.94%	Due to increase in reserves by Rs. 7.62 Cr. and



							decrease in debt by 1.13 Cr.
3	Debt Service Coverage Ratio	Earnings available for debt service	Debt service	6.39	2.25	184.20%	Due to reduction of yearly repayment of loans from Rs. 5.52 Cr to Rs. 2.76 Cr and increase in profits.
4	Return on Equity Ratio	Net profit after taxes less preference dividend (if any)	Shareholder's equity	0.32	0.39	-18.93%	Due to increase in reserves by Rs. 7.62 Cr.
5	Inventory turnover ratio	Cost of goods sold or sales	Average inventory	4.88	4.20	16.27%	
6	Trade Receivables turnover ratio	Net Sales	Average Trade Receivables	4.10	4.72	-13.17%	
7	Trade Payables turnover ratio	Net Purchases	Average Trade Payables	2.58	2.37	8.80%	
8	Net capital turnover ratio	Net Sales	Net working capital	6.27	13.12	-52.16%	Due to increase in turnover by Rs. 27.60 crores.
9	Net Profit ratio	Net Profit after taxes	Net Sales	8.90%	11.07%	-19.61%	
10	Return on capital employed	Earnings before interest and taxes	Capital employed	0.36	0.44	-18.56%	Due to increase in reserves by Rs. 7.62 Cr. and Increase in Non-Current Liabilities by 2 Cr.
11	Return on investment	Income generated from investments	Total Current Investments	0.07	0.04	62.19%	Due to reduction of investment as compared to reduction of income from Investment.
12	Operating Profit Margin	Earnings before interest and taxes	Net Sales	13.45%	17.02%	-20.99%	
13	Interest Coverage Ratio	Earnings before interest and taxes	Interest Expense	8.29	7.46	11.06%	

**25.14. Particulars relating to corporate social responsibility**

The Company has provided for the corporate social responsibility as per Section 135 of the Companies Act 2013 i.e., Rs. 15,99,505.00 during the year. The actual amount spent during the financial year was Rs. 15,99,505.00 and there is no outstanding provision as on 31st March 2024.

25.15. Impairment of Assets

During the year, the Company has undertaken a review of all the fixed assets in line with the requirements of Ind AS 36 on "Impairment of Assets" as notified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014, based on such review, no provision for impairment is required to be recognized for the year.

25.16. Property, Plant and Equipment and Intangible assets:

- During the financial Year 2023-24 there was an addition of Rs. Nil under the head Intangible Asset.
- During the financial Year 2023-24 there was an addition of Rs. 1,02,88,806.82 under the head Building.
- During the financial year, there was net addition of Rs. 1,81,82,683.92 made to Plant & Machinery. Furniture & Fixtures, Office Equipment, Vehicles & Computers

25.17. Deferred Tax Assets & Liabilities

During the FY 2023-24 the company has made Deferred Tax Asset. Details of Calculation is mentioned below:

Calculation of Deferred Tax Asset / Liability	Amount (₹)
Deferred Tax Asset on Depreciation	13,26,678.93
Deferred Tax Asset on Gratuity	3,50,395.94
Deferred tax on loss on Sale of Asset	.
Total Deferred Tax Asset Created for the financial year 2023-24 in Profit and Loss Account.	16,77,074.87
Add: Deferred Tax Asset as on 01.04.2023 (Opening)	27,92,174.46
Balance Deferred Tax Asset recognized in Balance Sheet	44,69,243.33

25.18. Micro, Small & Medium Enterprises

Based on the information presently available, total outstanding as on 31.03.2024 is Rs. 83,37,101.60 to micro or small enterprises under the Micro, Small and Medium Enterprises Development Act, 2006.

25.19. Auditor's Remuneration

(Exclusive of GST)

	<u>31st March, 2024</u> <u>AMOUNT</u>	<u>31st March, 2023</u> <u>AMOUNT</u>
. As Auditors	50,000.00	50,000.00
. Taxation Matters	.	.
. Certification	.	.
. Other Services	.	.
. Reimbursement of out.of pocket expenses	.	.
TOTAL	<u>50,000.00</u>	<u>50,000.00</u>

**25.20 Other additional information**

	31st March 2024	31st March 2023
<u>Particulars</u>	<u>AMOUNT</u>	<u>AMOUNT</u>
“A” Revenue from operations		
(under broad heads)		
Sales		
Sales With in India	84,25,42,074.05	57,09,11,759.21
Export Sales	1,55,28,594.72	1,11,41,826.85*
Total	85,80,70,668.77	58,20,53,586.06
“B” Purchases		
.Chemicals, Bulk Drugs & Packing Material	52,87,87,406.81	28,98,52,382.26

25.21. Expenditure In Foreign Currency (On Accrual Basis):
Following Expenses were incurred by the company during the year 2023-24.

	<u>31st March, 2024</u>	<u>31st March, 2023</u>
	<u>AMOUNT</u>	<u>AMOUNT</u>
. Import of Capital Goods	0.00	0.00
. Import of Raw Material	0.00	74,35,273.64
. Revenue Expenses (Travel)	0.00	10,11,375.00
. Revenue Expenses (Others)	0.00	18,507.19
TOTAL	0.00	84,65,155.83

25.22. Earning in Foreign Currency

Particulars	For the Year Ended (31.03.2024)	For the year Ended (31.03.2023)
FOB Value of Export	1,55,28,594.72	1,11,41,826.85

25.23. Other statutory information

- i. No proceedings have been initiated during the year or are pending against the Company as at March 31, 2024 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.
- ii. The Company does not have any trading in Crypto Currency or Virtual Currency.



- iii. The Company does not have any transactions or balances with a Companies struck off under section 248 of the Companies Act, 2013 or Section 560 of the Companies Act 1956.
- iv. The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessment under the Income Tax Act, 1961.
- v. Company has not advanced or loaned or invested funds to any other person(s) or entity(is), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- vi. The Company has not received any fund from any person(s) or entity(is), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- vii. No charge is pending to be registered beyond statutory period with ROC.
- viii. The company has not used the borrowings from banks and financial institutions for any other purpose other than for the specific purpose for which it was taken.
- ix. The Company have defined agreement with the Debtors regarding the credit payment period given and ageing is done accordingly in Financial Statement.
- x. As there is no specific agreements with the creditors, hence the creditors ageing is done as per the date of invoice received.

25.24 Total count of debtors in M/s Adley Formulations Private Limited is 93, and creditors count is 189, Balance confirmation were sent to all and confirmation reply came from more than 50% of the total count.

25.25. Figures for previous year have been regrouped / rearranged where necessary to conform to the current year's presentation.

In terms of our attached report of even date.

For and on behalf of the Board of Directors

**For KALRA RAI AND ASSOCIATES
CHARTERED ACCOUNTANTS
F R No. – 008859**

**Sd/-
LAJPAT RAI KALRA
PARTNER
M No. 087438
Dated: 14/05/2024
Place: Chandigarh
UDIN: 24087438BJZXC6851**

sd/-	sd/-
Rahul Batra	Varun Batra
(Director)	(Director)
DIN: 02229234	DIN:02148383

**STANDALONE FINANCIAL
STATEMENTS
OF
“ADLEY LAB LIMITED”
(WHOLLY-OWNED SUBSIDIARY)
FOR THE FINANCIAL YEAR
2023-24**



**KALRA RAI & ASSOCIATES
CHARTERED ACCOUNTANTS**

**Head Office: Kothi No. 667, 1st floor, Sector-43-A
Chandigarh-160022**

Independent Auditors' Report

Members of Adley Lab Limited

Report on the Standalone Financial Statements

We have audited the accompanying standalone Ind-AS financial statements of Adley Lab Limited ('the Company'), which comprise the Balance Sheet as at March 31, 2024, the Statement of Profit and Loss, including the statement of Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ('the Act') with respect to the preparation of these standalone Ind-AS financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with accounting principles generally accepted in India, including the Indian Accounting Standards (Ind-AS) specified under Section 133 of the Act., read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial control that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind-AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these standalone Ind-AS financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under. We conducted our audit of the standalone Ind-AS financial statements in accordance with the Standards on Auditing, issued by the Institute of Chartered Accountants of India, as specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone Ind-AS financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the standalone Ind-AS financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the standalone Ind-AS financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone Ind AS financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the standalone Ind-AS financial statements give the information required by the Act in the manner so required and give a true and fair



view inconformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024, its profit including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's report) Order, 2016 ('the Order') issued by the Central Government of India in terms of subsection(11) of Section 143 of the Act, we give in the Annexure 1 a statement on the matters specified in paragraphs 3 and 4 of the Order.

2. As required by Section 143 (3) of the Act, we report that:

a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;

b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;

c. The Balance Sheet, Statement of Profit and Loss including the Statement of Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account;

d. In our opinion, the aforesaid standalone Ind-AS financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Companies (Indian Accounting Standards) Rules, 2015, as amended;

e. On the basis of written representations received from the directors as on March 31, 2024, and taken on record by the Board of Directors, none of the Directors is disqualified as on March 31, 2024, from being appointed as a director in terms of Section 164 (2) of the Act;

f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refers to our separate Report in "Annexure B";

g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2020, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements.

ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;

iii. There has been no amount available which is required to be transferred to the Investor Education and Protection Fund by the Company;

Place:- Chandigarh
Date: 14/05/2024
UDIN:24087438BJZXBB2970

For KALRA RAI & ASSOCIATES

Chartered Accountants

Sd/-
(Lajpat Rai Kalra)
Partner
M. No- 087438
FRN: 008859N



CARO

Annexure 1 referred to in paragraph 1 of our report of even date

Re: Adley Lab Limited ('the Company')

To the best of our information and according to the explanations provided to us by the Company and the books of account and records examined by us in the normal course of audit, we state that:

i. In respect of the Company's Property, Plant and Equipment and Intangible Assets:

(a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The Company has maintained proper records showing full particulars of intangible assets.

(b) The Company has a program of physical verification of Property, Plant and Equipment so to cover all the assets once every three years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. According to the information and explanations given to us, no material discrepancies were noticed on such verification.

(c) Based on our examination of the property tax receipts and lease agreement for land on which building is constructed, registered sale deed / transfer deed / conveyance deed provided to us, we report that, the title in respect of self-constructed buildings and title deeds of all other immovable properties, disclosed in the financial statements included under Property, Plant and Equipment are held in the name of the Company as at the balance sheet date.

(d) The Company has not revalued any of its Property, Plant and Equipment and intangible assets during the year.

(e) No proceedings have been initiated during the year or are pending against the Company as at March 31, 2024 for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.

ii. (a) As explained to us, the inventories were physically verified during the year by the Management at reasonable intervals, except goods-in-transit. The coverage and procedure adopted by the Management is appropriate according to the size and scale of the Company. No discrepancies of 10% or more were observed in any class of inventories.

(b) The Company has been previously sanctioned working capital limits of Rs. 5 crore, in aggregate, from banks or financial institutions and the monthly statements filed by the Company with such banks or financial institutions are in agreement with the books of accounts of the Company.

iii. (a) The Company has not provided any loans or advances in the nature of loans or stood guarantee, or provided security to any other entity during the year, and hence reporting under clause 3(iii)(a) of the Order is not applicable.

(b) The company has not made any investments, or provided any guarantees, loans or advances. Hence, clause 3(iii)(b) is not applicable.

(c) The company has not provided any loans and hence, clause 3(iii)(c) is not applicable.

(d) The company has not granted any loans and hence, clause 3(iii)(d) is not applicable.

(e) The company has not granted any loan and hence, clause 3(iii)(e) is not applicable.

(f) The Company has not granted any loans or advances Hence, reporting under clause 3(iii)(f) is not applicable.



iv. The Company has complied with the provisions of Sections 185 and 186 of the Companies Act, 2013 in respect of loans granted, investments made and guarantees and securities provided, as applicable.

v. The Company has not accepted any deposit or amounts which are deemed to be deposits. Hence, reporting under clause 3(v) of the Order is not applicable.

vi. The maintenance of cost records has not been specified by the Central Government under sub-section (1) of section 148 of the Companies Act, 2013 for the business activities carried out by the Company. Hence, reporting under clause (vi) of the Order is not applicable to the Company.

vii. In respect of statutory dues:

- (a) In our opinion, the Company has generally been regular in depositing undisputed statutory dues, including Goods and Services tax, Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, Cess and other material statutory dues applicable to it with the appropriate authorities except advance tax. There were no undisputed amounts payable in respect of Goods and Service tax, Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, Cess and other material statutory dues in arrears as at March 31, 2024 for a period of more than six months from the date they became payable.
- (b) There are no disputed amounts in respect of statutory dues referred to in sub-clause (a) above and therefore reporting under sub-clause (b) is not applicable.

viii. There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).

ix. (a) The Company has not defaulted in repayment of loans or other borrowings or in payment of interest thereon to any lender.

- (b) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (c) According to the explanations provided by the Company and overall examination of the financial statements of the Company, the term loans were prima facie applied for the purpose for which they were obtained.
- (d) On an overall examination of the financial statements of the Company, funds raised on short-term basis have, prima facie, not been used during the year for long-term purposes by the Company.
- (e) On an overall examination of the financial statements of the Company, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries.
- (f) The Company has not raised any loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies and hence reporting on clause 3(ix)(f) of the Order is not applicable.

x. (a) The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under clause 3(x)(a) of the Order is not applicable.

(b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause 3(x)(b) of the Order is not applicable.

xi. (a) No fraud by the Company and no material fraud on the Company has been noticed or reported during the year.

(b) No report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.



- (c) The Company has not received any whistle-blower complaints during the year.
- xii. The Company is not a Nidhi Company and hence reporting under clause (xii) of the Order is not applicable.
- xiii. In our opinion, the Company is in compliance with Section 177 and 188 of the Companies Act, 2013 with respect to applicable transactions with the related parties and the details of related party transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.
- xiv. (a) In our opinion the Company has an adequate internal audit system commensurate with the size and the nature of its business.
- (b) We have considered, the internal audit reports for the year under audit, issued to the Company during the year and till date, in determining the nature, timing and extent of our audit procedures.
- xv. In our opinion during the year the Company has not entered into any non-cash transactions with its Directors or persons connected with its directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.
- xvi. (a) In our opinion, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause 3(xvi)(a), (b) (c) and (d) of the Order is not applicable.
- xvii. The Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.
- xviii. There has been no resignation of the statutory auditors of the Company during the year.
- xix. On the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- xx. The Company has fully spent the required amount towards Corporate Social Responsibility (CSR) and there are no unspent CSR amount for the year requiring a transfer to a Fund specified in Schedule VII to the Companies Act or special account in compliance with the provision of sub-section (6) of section 135 of the said Act. Accordingly, reporting under clause (xx) of paragraph 3 of the order is not applicable for the year.

Place:- Chandigarh
Date: 14/05/2024
UDIN:24087438BJZXBB2970

For KALRA RAI & ASSOCIATES

Chartered Accountants

Sd/-
(Lajpat Rai Kalra)
Partner
M. No- 087438
FRN: 008859N

**“ANNEXURE-B” TO THE AUDITORS’ REPORT**

Referred to in Paragraph 7 of Our Report of Even Date

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of **Adley Lab Limited** (“the Company”) as of 31 March 2024 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (“the Guidance Note”) issued by the Institute of Chartered Accountants of India (“ICAI”). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (“the Act”).

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (“the Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to

permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March 2024, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Place:- Chandigarh
Date: 14/05/2024
UDIN:24087438BJZXBB2970

For KALRA RAI & ASSOCIATES

Chartered Accountants

Sd/-
(Lajpat Rai Kalra)
Partner
M. No- 087438
FRN: 008859N

ADLEY LAB LIMITED			
D-27, INDUSTRIAL AREA FOCAL POINT DERABASSI Mohali PB, 140507 IN			
CIN NUMBER U24231PB1992PLC051220			
BALANCE SHEET AS AT 31ST MARCH' 2024			
Particulars	Note No.	As at 31 March' 2024	As at 31 March' 2023
		Amount in Rs. Lakhs	Amount in Rs. Lakhs
A EQUITY AND LIABILITIES			
1 Shareholders' funds			
(a) Share capital	1	175.81	175.81
(b) Reserves and surplus	2	1,823.78	1,138.24
(c) Money received against share warrants		-	-
		1,999.59	1,314.05
2 Share application money pending allotment		-	-
3 Non-current liabilities			
(a) Long-term borrowings	3	435.67	442.72
(b) Deferred tax liabilities (net)	4	-	-
(c) Other long-term liabilities	5 (a)	52.07	54.27
(d) Long-term provisions	5 (b)	22.07	20.62
		509.82	517.61
4 Current liabilities			
(a) Short-term borrowings	6	109.49	220.21
(b) Trade payables	7	1,512.11	1,288.92
(c) Other current liabilities	8	382.68	212.64
(d) Short-term provisions		66.91	42.39
		2,071.18	1,764.16
TOTAL		4,580.58	3,595.82
B ASSETS			
1 Non-current assets			
(a) Property, Plant and Equipment and Intangible Assets			
(i) Property, Plant and Equipment	9	1,071.80	1,061.38
(ii) Intangible assets		19.19	26.01
(iii) Capital work-in-progress		-	-
(iv) Intangible assets under development		-	-
(v) Fixed assets held for sale		-	-
		1,090.99	1,087.39
(b) Non-current investments		-	-
(c) Deferred tax assets (net)	4	15.11	2.91
(d) Long-term loans and advances	10	52.81	71.85
(e) Other non-current assets		-	-
		67.92	74.76
2 Current assets			
(a) Current investments		-	-
(b) Inventories	11	1,386.04	860.73
(c) Trade receivables	12	1,953.24	1,498.17
(d) Cash and cash equivalents	13	58.83	27.95
(e) Short-term loans and advances	14	13.89	31.55
(f) Other current assets	15	9.67	15.27
		3,421.67	2,433.67
TOTAL		4,580.58	3,595.82
See accompanying notes forming part of the financial statements	24 & 25		
In terms of our report attached.			
For KALRA RAI AND ASSOCIATES Chartered Accountants (FRN: 008859N)		For and on the behalf of the Board of Directors	
Sd/- LAJPAT RAI KALRA Partner MEMBERSHIP NO. 087438 UDIN: 24087438BJZXB2970 Place : Chandigarh Date : 14/05/2024		Sd/- RAHUL BATRA DIRECTOR DIN: 02229234	Sd/- JAYANT KUMAR DIRECTOR DIN: 02172627

ADLEY LAB LIMITED			
D-27, INDUSTRIAL AREA FOCAL POINT DERABASSI Mohali PB, 140507 IN			
CIN NUMBER U24231PB1992PLC051220			
STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED 31ST MARCH' 2024			
Particulars	Note No.	As at 31 March' 2024	As at 31 March' 2023
		Amount in Rs. Lakhs	Amount in Rs. Lakhs
A CONTINUING OPERATIONS			
1 Revenue from operations (gross)	16	5,332.60	4,276.94
Less: Excise duty		-	-
Revenue from operations (net)		5,332.60	4,276.94
2 Other income	17	9.58	1.09
3 Total revenue (1+2)		5,342.18	4,278.03
4 Expenses			
(a) Cost of material consumed	18	3,510.24	2,799.12
(b) Purchases of stock-in-trade		-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	19	-416.00	-160.84
(d) Other Manufacturing expense	20	722.08	410.84
(d) Employee benefits expense	21	149.89	114.78
(e) Finance costs	22	89.86	62.41
(f) Depreciation and amortisation expense	9	224.14	169.52
(g) Other expenses	23	149.54	155.45
		-	-
Total expenses		4,429.76	3,551.29
5 Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)		912.42	726.74
6 Exceptional items		-	-
7 Profit / (Loss) before extraordinary items and tax (5 ± 6)		912.42	726.74
8 Extraordinary items/Prior period items		-	-
9 Profit / (Loss) before tax (7 ± 8)		912.42	726.74
10 Tax expense:			
(a) Current tax expense for current year		238.22	188.83
(b) (Less): MAT credit (where applicable)		-	-
(c) Current tax expense relating to prior years		-	-
(d) Net current tax expense		238.22	188.83
(e) Deferred tax		-12.20	-7.93
		226.02	180.90
11 Profit / (Loss) from continuing operations (9 ± 10)		686.40	545.84
B DISCONTINUING OPERATIONS			
12 Profit / (Loss) from discontinuing operations (B.i ± B.ii ± B.iii)		-	-
C TOTAL OPERATIONS		686.40	545.84
13 Profit / (Loss) for the year (11 ± 12)		686.40	545.84
14 Earnings per share (of Rs. Lakhs 10/- each):			
(a) Basic			
(i) Continuing operations		39.04	31.05
(ii) Total operations		39.04	31.05
(b) Diluted			
(i) Continuing operations		39.04	31.05
(ii) Total operations		39.04	31.05
See accompanying notes forming part of the financial statements	24 & 25		
In terms of our report attached. For KALRA RAI AND ASSOCIATES Chartered Accountants (FRN: 008859N)		For and on the behalf of the Board of Directors	
Sd/- LAJPAT RAI KALRA Partner MEMBERSHIP NO. 087438 UDIN: 24087438BJZXB2970 Place : Chandigarh Date : 14/05/2024		Sd/- RAHUL BATRA DIRECTOR DIN: 02229234	Sd/- JAYANT KUMAR DIRECTOR DIN: 02172627

ADLEY LAB LIMITED			
D-27, INDUSTRIAL AREA FOCAL POINT DERABASSI Mohali PB, 140507 IN			
CIN NUMBER U24231PB1992PLC051220			
CASHFLOW STATEMENT FOR THE PERIOD ENDED ON 31ST MARCH' 2024			
Particulars		As at 31 March' 2024	As at 31 March' 2023
		Amount in Rs. Lakhs	Amount in Rs. Lakhs
A	CASHFLOW FROM OPERATING ACTIVITIES		
	Net Profit before tax and extraordinary items (as per Statement of Profit & Loss)	912.42	726.74
	Adjustments for non Cash/Non trade items:		
	Depreciation & Amortization Expenses	224.14	169.52
	Finance Cost	89.86	62.41
	Interest received	(1.73)	(0.63)
	Other inflows/(outflows) of cash	(213.11)	(248.66)
	Operating profits before Working Capital Changes	1,011.58	709.40
	Adjusted For:		
	(Increase)/Decrease in trade receivables	(455.07)	(321.51)
	Increase/(Decrease) in trade payables	223.19	245.93
	(Increase)/Decrease in inventories	(525.31)	(170.21)
	Increase/(Decrease) in other current liabilities	170.04	20.18
	(Increase)/Decrease in short term loans and advances	17.66	(22.62)
	(Increase)/Decrease in other current assets	5.60	(3.42)
	Working Capital Changes	(563.89)	(251.66)
	Net cashflow from Operating Activities (A)	447.70	457.74
B	CASHFLOW FROM INVESTING ACTIVITIES		
	Purchase of fixed assets	(227.74)	-502.75
	Interest received	1.73	0.63
	Cash used for Long Term Loans/Advances	19.03	-50.64
	Net cash used in Investing Activities (B)	(206.98)	(552.77)
C	CASHFLOW FROM FINANCING ACTIVITIES		
	Finance Cost	(89.86)	(62.41)
	Increase/(Decrease) in short term borrowings	(110.73)	40.17
	Increase in/(Repayment) of Long term Borrowings	(7.05)	73.58
	Increase in/(Repayment) of Other Long term Liabilities	(2.20)	41.49
	Increase/ (Decrease) in share capital	-	-
	Other Inflows/ (Outflows) of cash	-	-
	Net cash used in Financing Activities (C)	(209.83)	92.83
D	Net Increase/(Decrease) in cash & cash equivalents (A+B+C)	30.88	(2.20)
E	Cash & Cash equivalents at beginning of period	27.95	30.15
F	Cash & Cash equivalents at end of period	58.83	27.95
G	Net Increase/(Decrease) in cash & cash equivalents (F-E)	30.88	(2.20)
In terms of our report attached.			
For KALRA RAI AND ASSOCIATES		For and on the behalf of the Board of Directors	
Chartered Accountants			
(FRN: 008859N)			
Sd/-		Sd/-	Sd/-
LAJPAT RAI KALRA		RAHUL BATRA	JAYANT KUMAR
Partner		DIRECTOR	DIRECTOR
MEMBERSHIP NO. 087438		DIN: 02229234	DIN: 02172627
UDIN: 24087438BJXBB2970			
Place : Chandigarh			
Date : 14/05/2024			

ADLEY LAB LIMITED
D-27, INDUSTRIAL AREA FOCAL POINT DERABASSI Mohali PB, 140507 IN
CIN NUMBER U24231PB1992PLC051220
Note 1 Share capital

Amount In Rupees

Particulars	As at 31 March' 2024		As at 31 March' 2023	
	Number of shares	Amount in Rs. Lakhs	Number of shares	Amount in Rs. Lakhs
(a) Authorised	3,000,000.00	300.00	3,000,000.00	300.00
- Equity shares of Rs. Lakhs 10 each	-	-	-	-
(b) Issued				
- Equity shares of Rs. Lakhs 10 each	1,758,050.00	175.81	1,758,050.00	175.81
	1,758,050.00	175.81	1,758,050.00	175.81
(c) Subscribed and fully paid up				
- Equity shares of Rs. Lakhs10 each	1,758,050.00	175.81	1,758,050.00	175.81
	1,758,050.00	175.81	1,758,050.00	175.81
(d) Subscribed but not fully paid up	-	-	-	-
	-	-	-	-
Total	1,758,050.00	175.81	1,758,050.00	175.81

Note 1(a) Reconciliation of number of shares outstanding is set out below:

Particulars	Equity Shares March' 2024		Equity Shares March' 2023	
	Number	Amount in (Rs. Lakhs)	Number	Amount in (Rs. Lakhs)
Shares outstanding at the beginning of the year	1,758,050.00	175.81	1,758,050.00	175.81
Shares Issued during the year	-	-	-	-
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	1,758,050.00	175.81	1,758,050.00	175.81

Note 1(b) Shares held by promoters at the end of the year 31 March' 2024

Name of Shareholder	As at 31 March' 2024		
	No. of Shares held	% of Holding	% Changes
Beta Drugs Limited	1,758,044.00	99.9997%	
MRs. Lakhs Neeraj Batra	1.00	0.0001%	
Mr. Varun Batra	1.00	0.0001%	
Mr. Rahul Batra	1.00	0.0001%	
MRs. Lakhs Heena Batra	1.00	0.0001%	
Mr. Balwant Singh	1.00	0.0001%	
MRs. Lakhs Aditi Batra	1.00	0.0001%	

Note 1(b) Shares held by promoters at the end of the year 31st March 2023

Name of Shareholder	As at 31 March' 2023		
	No. of Shares held	% of Holding	% Changes
Beta Drugs Limited	1,758,044.00	99.9997%	
MRs. Lakhs Neeraj Batra	1.00	0.0001%	0.0001%
Mr. Varun Batra	1.00	0.0001%	
Mr. Rahul Batra	1.00	0.0001%	
MRs. Lakhs Heena Batra	1.00	0.0001%	
Mr. Balwant Singh	1.00	0.0001%	
MRs. Lakhs Aditi Batra	1.00	0.0001%	

Note 1(c) Details of shares held by each shareholder holding more than 5% shares:

Class of shares / Name of shareholder	As at 31 March' 2024		As at 31 March' 2023	
	Number of shares held	% holding in that class of shares	Number of shares held	% holding in that class of shares
Equity shares with voting rights				
Mr. Vijay Kumar Batra	1	0.00	1	0.00
Mr. Varun Batra	1	0.00	1	0.00
Mr. Rahul Batra	1	0.00	1	0.00
MRs. Lakhs Neeraj Batra	1	0.00	1	0.00
MRs. Lakhs Heena Batra	1	0.00	1	0.00
Mr. Balwant Singh	1	0.00	1	0.00
Beta Drugs Limited	1,758,044	100.00	1,758,044	100.00
Total	1,758,050	100.00	1,758,050	100.00

Note 2 Reserves and surplus

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
(a) Capital reserve		
Opening balance	-	-
Closing balance	-	-
(b) Securities premium account		
Opening balance	-	-
Closing balance	-	-
(c) Surplus / (Deficit) in Statement of Profit and Loss		
Opening balance	1,138.24	599.58
	1,138.24	599.58
Add: Profit / (Loss) for the year	686.40	545.84
Less: Last Year Provision Diff	0.86	7.18
Closing balance	1,823.78	1,138.24
Total	1,823.78	1,138.24

Note 3 Long-term borrowings

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
Term loans		
From banks		
Secured		
SIDBI (Plant and Machinery Loan)	-	-
SIDBI Smile (Plant and Machinery)	-	-
SIDBI Covid Loan	-	-
SIDBI (Plant and Machinery Loan)	57.65	-
HDFC TERM LOAN (CAPEX) NEW	100.58	147.30
HDFC New Loan-P&M	26.50	89.92
Federal Bank- Vehicle Loan	-	7.04
	184.73	244.26
From other parties		
Secured		
Unsecured (From Related Parties)		
M/s Beta Drugs Limited	250.95	198.46
Total - A	250.95	198.46
Unsecured (From Related Parties)	-	-
Total - B	-	-
	250.95	198.46
The Above Amount Includes	-	-
Secured Borrowings	184.73	244.26
Unsecured Borrowings	250.95	198.46
Total	435.67	442.72

ADLEY LAB LIMITED

Note 4 Deferred Tax

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
Deferred tax assets		
Deferred tax on depreciation	12.20	7.93
Add: Deferred tax asset opening	2.91	-5.02
Net Deferred assets/(liability)	15.11	2.91

Continue Note 4 Current tax Provision

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
Current Year Tax	238.22	188.83
Less :- Advance Tax Including TDS	171.32	146.42
Less :- TCS recoverable	-	0.02
Current Year Tax Provision	66.91	42.39
Short Term Provisions	66.91	42.39

ADLEY LAB LIMITED
D-27, INDUSTRIAL AREA FOCAL POINT DERABASSI Mohali PB, 140507 IN
CIN NUMBER U24231PB1992PLC051220
Notes 3: Long-term borrowings

Particulars	As at 31 March' 2024			As at 31 March' 2023		
	Amount in Rs. Lakhs			Amount in Rs. Lakhs		
	Non- Current	Current Maturities	Total	Non- Current	Current Maturities	Total
Term loans						
From banks						
Secured						
SIDBI (Plant and Machinery Loan)	-	-	-	-	23.14	23.14
SIDBI Smile (Plant and Machinery)	-	-	-	-	2.18	2.18
SIDBI Covid Loan	-	-	-	-	2.28	2.28
SIDBI (Plant and Machinery Loan)	57.65	17.88	75.53	-	-	-
HDFC TERM LOAN (CAPEX) NEW	100.58	47.36	147.94	147.30	44.17	191.47
HDFC New Loan-P&M	26.50	63.73	90.23	89.92	58.87	148.79
Federal Bank Vehicle Loan	-	-	-	7.04	2.96	10.00
	184.73	128.97	313.69	244.26	133.60	377.86
From other parties						
Secured	-	-	-	-	-	-
Unsecured (From Related Parties)						
M/s Beta Drugs Limited	250.95	-	250.95	198.46	-	198.46
Total - A	250.95	-	250.95	198.46	-	198.46
Unsecured (From Unrelated Parties)	-	-	-	-	-	-
Total - B	-	-	-	-	-	-
	250.95	-	250.95	198.46	-	198.46
The Above Amount Includes						
Secured Borrowings	184.73	128.97	313.69	244.26	133.60	377.86
Unsecured Borrowings	250.95	-	250.95	198.46	-	198.46
Amount disclosed under "Other Current Liabilities"		(128.97)	(128.97)		(133.60)	(133.60)
Total	435.67	-	435.67	442.72	-	442.72

ADLEY LAB LIMITED

Notes forming part of the financial statements

Note 5 Other long-term liabilities		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Others:		
(i) Payables on purchase of fixed assets	52.07	54.27
Total	52.07	54.27

Note 5 (b) Long-term provisions

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a) Provision for Gratuity	22.07	20.62
Total	22.07	20.62

Note 6 Short-term borrowings

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Other loans and advances		
Secured		
HDFC BANK CC A/C against hypothecation of stock, Debtors and movable assets	109.49	220.21
Total	109.49	220.21

Note 7 Trade payables

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Trade payables:		
MSME	41.53	326.15
Others	1,470.58	962.77
Total	1,512.11	1,288.92

Note 8 Other current liabilities

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Other payables	130.35	72.03
(i) Current Maturities of Long Term Debt (Note No. 3)	128.97	133.60
Cheques issued but not yet presented	123.36	6.80
Advances From Customers	-	0.20
Total	382.68	212.64

Note 8(a) Other current liabilities

Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
PF Payable	3.98	2.57
ESI payable	0.27	0.26
TDS payable	3.68	3.37
Interest Accrued But Not Due	2.20	2.74
Salary & wages Payable	40.27	20.23
Welfare Payable	0.16	0.10
Electricity Expenses Payable	7.11	-
Expenses payable	72.69	42.77
Total	130.35	72.03

Note 9 Property, Plant & Equipment and Intangibl

D-2 Assets			Gross Block					Accumulated Depreciation/ Amortisation				Net Block	
CIN	Useful Life (In Years)	Shift	Balance as at 1st April 2023	Additions during the year	Addition on account of business acquisition	Deletion during the year	Balance as at 31st March 2024	Balance as at 1st April 2023	Provided during the year	Deletion / adjustments during the year	Balance as at 31st March 2024	Balance as at 31st March 2024	Balance as at 31st March 2023
A Property, Plant & Equipment													
Own Assets													
		Single	6.05				6.05					6.05	6.05
	30	Single	489.92	66.22			556.14	175.67	32.74		208.41	347.73	314.26
	15	Single	808.15	122.13		21.10	909.17	311.02	102.82	20.05	393.79	515.38	497.13
	10	Single	9.19	9.66			18.85	4.53	2.56		7.09	11.76	4.66
	3	Single	11.88	5.96			17.83	5.91	5.50		11.41	6.42	5.97
	5	Single	50.49	27.84			78.32	21.03	20.69		41.72	36.61	29.46
	10	Single	263.46	7.23			270.69	72.98	49.86		122.84	147.85	190.48
	8	Single	18.62			18.62	-	5.24	3.15	8.39	0.00	-0.00	13.38
			1,657.76	239.03	-	39.72	1,857.06	596.38	217.32	28.44	785.26	1,071.80	1,061.38
			1,170.58	495.01	-	7.83	1,657.76	437.77	163.93	5.32	596.38	1,061.38	732.81
B Capital work in progress													
				-			-				-	-	-
							-				-	-	-
							-				-	-	-
							-				-	-	-
							-				-	-	-
							-				-	-	-
C Intangible Asseta													
			34.00				34.00	7.99	6.82		14.81	19.19	26.01
			34.00	-			34.00	7.99	6.82		14.81	19.19	26.01
			23.75	10.25			34.00	2.40	5.59		7.99	26.01	21.35
			1,691.76	239.03	-	39.72	1,891.06	604.37	224.14	28.44	800.07	1,090.99	1,087.39
			1,194.33	505.26	-	7.83	1,691.76	440.17	169.52	5.32	604.37	1,087.39	754.16

ADLEY LAB LIMITED

D-27, INDUSTRIAL AREA FOCAL POINT DERABASSI Mohali PB, 140507 IN

CIN NUMBER U24231PB1992PLC051220

Note 10 Long-term loans and advances

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
Security Deposit		
Secured, considered good	12.20	12.20
Others		
Advances to Capital Suppliers	40.61	59.65
Total	52.81	71.85

Note 11 Inventories

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
(Valued at cost or NRV unless otherwise stated)		
(a) Finished goods (other than those acquired for trading)	495.91	397.51
(b) Raw Material	473.51	370.15
(c) WIP	410.67	93.08
(d) Others	5.94	-
Total	1,386.04	860.73

Note 12 Trade receivables

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
Exceeding six months-		
Secured, considered good	4.00	2.65
Total	4.00	2.65
Less than six months-		
Secured, considered good	1,949.24	1,495.52
Total	1,949.24	1,495.52
Total	1,953.24	1,498.17

ADLEY LAB LIMITED**Note 12 (a) Trade receivables ageing Schedule As at As at 31st March'2024**

Particulars	Outstanding for following periods from					Total
	Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	1,873.83	-	4.00	-	-	1,877.83
(ii) Undisputed Trade receivables - considered doubtful	-	-	-	-	-	-
(iii) Disputed trade receivables considered good	-	-	-	-	-	-
(iv) Disputed trade receivables considered doubtful	75.41	-	-	-	-	75.41

Note 12 (b) Trade receivables ageing Schedule As at 31st March'2023

Particulars	Outstanding for following periods from					Total
	Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	1,495.52	-	2.65	-	-	1,498.17
(ii) Undisputed Trade receivables - considered doubtful	-	-	-	-	-	-
(iii) Disputed trade receivables considered good	-	-	-	-	-	-
(iv) Disputed trade receivables considered doubtful	-	-	-	-	-	-

ADLEY LAB LIMITED

D-27, INDUSTRIAL AREA FOCAL POINT DERABASSI Mohali PB, 140507 IN

CIN NUMBER U24231PB1992PLC051220

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
Note 13 Cash and cash equivalents		
CASH ON HAND		
(a) Cash on hand	13.70	11.53
(b) Imprest A/c	-	0.20
(c) Wallet (Custom Duty)	0.12	
Total	13.83	11.73
(b) Balances with banks		
(i) In current accounts		
Bank of Baroda	0.06	0.13
(iv) In earmarked accounts		
(c) Others (specify nature)		
FDRs against BG	29.88	16.09
FDR with HDFC Bank_No Lien	15.07	-
Total	45.00	16.22
Total	58.83	27.95

Note 14 Short-term loans and advances

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
(a) Loans and advances to related parties		
(b) Loans and advances others		
Advances To Supplier	9.55	26.90
Other Advances (Staff)	4.34	4.65
Total	13.89	31.55

Note 15 Other current assets

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
Prepaid Insurance	6.59	2.91
GST Recoverable	3.08	12.37
Total	9.67	15.27

ADLEY LAB LIMITED

D-27, INDUSTRIAL AREA FOCAL POINT DERABASSI Mohali PB, 140507 IN

CIN NUMBER U24231PB1992PLC051220

Particulars	For the period ended 31 March' 2024 Amount in Rs. Lakhs	For the period ended 31 March' 2023 Amount in Rs. Lakhs
Note 16 Revenue from operations (gross)		
Sale Of Products		
Domestic Sale	5,005.72	4,201.70
Export Sale	326.88	75.24
Total	5,332.60	4,276.94

Note 17 Other income

Particulars	For the period ended 31 March' 2024 Amount in Rs. Lakhs	For the period ended 31 March' 2023 Amount in Rs. Lakhs
(a) Interest Income	1.73	0.63
(b) Other non-operating income	7.85	0.47
Total	9.58	1.09

ADLEY LAB LIMITED

D-27, INDUSTRIAL AREA FOCAL POINT DERABASSI Mohali PB, 140507 IN

CIN NUMBER U24231PB1992PLC051220

Note 18 Cost of material consumed

Particulars	For the period ended 31 March' 2024 Amount in Rs. Lakhs	For the period ended 31 March' 2023 Amount in Rs. Lakhs
Opening stock	370.15	360.77
Add: Other items (Direct Expenses) to services provided :	-	-
Purchases	3,619.55	2,808.49
Total	3,989.70	3,169.27
Less: Closing stock	479.46	370.15
Cost of material consumed	3,510.24	2,799.12
Total	3,510.24	2,799.12

Note 19 Changes in inventories of finished goods, work-in-progress and stock-in-trade

Particulars	For the period ended 31 March' 2024 Amount in Rs. Lakhs	For the period ended 31 March' 2023 Amount in Rs. Lakhs
Inventories at the end of the year:		
Finished goods	495.91	397.51
Work In Progress	410.67	93.08
	906.58	490.58
Inventories at the beginning of the year:		
Finished goods	397.51	329.74
Work In Progress	93.08	-
	490.58	329.74
(Increase)/ decrease in Inventory		
Finished goods	-98.40	-67.77
Work In Progress	-317.59	-93.08
	-416.00	-160.84

Note 20 Other Manufacturing expense

Particulars	For the period ended 31 March' 2024 Amount in Rs. Lakhs	For the period ended 31 March' 2023 Amount in Rs. Lakhs
Consumable Stores	71.91	56.40
R & D Consumable Stores	45.19	-
Direct Labour	369.87	194.96
Factory Expenses	7.57	3.46
Freight Inward	6.57	8.48
Generator Running Expenses	33.34	24.77
Power & Fuel	113.52	84.95
Repair & maintenance (Electricity)	9.78	6.19
Repair & maintenance (Machinery and Building)	45.21	11.79
Testing Charges	19.11	19.85
Total	722.08	410.84

ADLEY LAB LIMITED

D-27, INDUSTRIAL AREA FOCAL POINT DERABASSI Mohali PB, 140507 IN

CIN NUMBER U24231PB1992PLC051220

Note 21 Employee benefits expense

	For the period ended 31 March' 2024	For the period ended 31 March' 2023
Particulars	Amount in Rs. Lakhs	Amount in Rs. Lakhs
Salaries and wages		
Employees	105.61	82.16
Employer Share of ESI	2.60	2.12
Employer Share of PF	20.72	12.30
Welfare Fund	0.23	0.16
Staff welfare expenses	9.57	5.67
Gratuity	2.11	5.73
Bonus	9.05	6.64
Total	149.89	114.78

Note 22 Finance costs

	For the period ended 31 March' 2024	For the period ended 31 March' 2023
Particulars	Amount in Rs. Lakhs	Amount in Rs. Lakhs
(a) Interest expense on:		
(i) Borrowings		
Interest on CC	32.87	15.94
Interest on Term Loan	30.42	27.82
Interest on Vehicle Loan	0.63	0.88
(ii) Others	0.49	0.68
(iii) Interest on Loan (Holding Co.)	19.43	13.06
(b) Other borrowing costs (Processing Fees)		
Bank charges	6.02	4.04
Total	89.86	62.41

ADLEY LAB LIMITED
D-27, INDUSTRIAL AREA FOCAL POINT DERABASSI Mohali PB, 140507 IN
CIN NUMBER U24231PB1992PLC051220

Note 23 Other Expenses

Particulars	For the period ended 31 March' 2024 Amount in Rs. Lakhs	For the period ended 31 March' 2023 Amount in Rs. Lakhs
Advertisement Expenses	1.74	2.61
Audit Fee	0.50	0.50
Business Promotion	1.35	4.75
Commission	23.50	28.49
Conveyance Expenses	11.25	5.27
Corporate Social Responsibility Expenses	11.60	6.80
Conference Expenses	4.37	-
Donation Expense	0.25	-
Expired & damages Goods Return	2.60	-
Freight Outward	11.25	7.22
Foreign Travelling	7.69	7.38
Foreign Currency Exchange Loss	-9.20	30.68
Insurance Apportion Cost	7.20	4.90
Legal & Professional Expenses	26.79	7.64
Loss on Sale of Assets	0.34	-
Office Expenses	4.88	6.37
Packing & Forwarding Expenses	15.90	14.43
Printing & Stationary	6.85	4.63
Rate Fee & taxes	12.24	17.82
Repair & maintenance (Vehicles)	0.10	0.16
Round Off	0.00	0.02
Software Expenses	0.30	0.43
Telephone & Postage	1.43	0.84
Trade Discount Expenses	0.08	-
Travelling Expenses	6.54	4.51
Total	149.54	155.45

NOTES TO ACCOUNTS OF STANDALONE FINANCIALS OF M/S ADLEY LAB LIMITED
NOTE '24': SIGNIFICANT ACCOUNTING POLICIES
(Forming part of Accounts)
FOR THE YEAR ENDED 31ST MARCH, 2024
24.1. Basis of Accounting

The financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India under the historical convention on accrual basis. These financial statements have been prepared to comply, in all material aspects, with the accounting standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and the presentation requirements as prescribed by the Schedule III of the Companies Act, 2013 to the extent applicable.

24.2. Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires that management makes estimates and assumptions that affect the reported amounts of income and expenses of the year, the reported balance of assets and liabilities and the disclosure relating to contingent liabilities as at the date of the financial statements. These estimates are based upon management's best knowledge of current events and actions. The difference between the actual results and estimates are recognised in the period in which the results are known / materialized.

24.3. Property, Plant and Equipment and Intangible assets
- Property, Plant and Equipment

Tangible Assets are stated at cost of acquisition or construction less accumulated depreciation and impairment of assets, if any. The cost comprises purchase price, borrowing costs if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. The company has a policy of physical verification of all the assets once in a year, the last verification was done on 27th March 2024 and no discrepancies were noticed during such verification.

- Capital Work-in-Progress

Expenses incurred during construction/installation period are included under capital work-in-progress and allocated to relevant fixed assets in the ratio of cost of the respective assets on completion of construction/installation. There is no work in progress for the financial year ending 31-March-2024.

24.4. Depreciation/Amortisation

- Depreciation on tangible assets is provided, on Written Down Value method, over the useful life of assets estimated by the management in accordance with Schedule-II of the Companies Act, 2013.
- Residual value of assets has been considered at 5% of the original cost of the assets.
- Depreciation on additions to fixed assets is calculated on date of put to use as certified by the management.
- Depreciation on assets sold & scrapped, during the year, is provided up-to the date on which such fixed assets are sold or scrapped.

24.5. Impairment of Assets

The carrying amounts of assets are reviewed at each balance sheet date if there is any indication of impairment based on internal/external factors. An asset is treated as impaired when the carrying cost of the assets exceeds its recoverable value. An impairment loss, if any, is charged to the Statement of Profit & Loss in the year in which an asset is identified as impaired. Reversal of impairment losses recognised in prior years is recorded when there is an indication that the impairment losses recognised for the assets no longer exist or have decreased.

24.6. Valuation of Inventories

- Raw Material Chemicals & Salts
- Packing Material
- Finished Goods products comprises of Active Pharmaceutical Ingredients and Pharmaceutical Formulation Intermediates
- Work In Progress (Semi Finished Goods)
- The value of Finished Goods and Work in Progress has been taken on allocation of labour and manufacturing overheads and is valued at cost or net realizable value whichever is lower.



- The company has a policy of physical verification of the entire available inventory once every month, no material discrepancies were noticed during such verification. The last verification was done on 5th April 2024.

24.7. Revenue Recognition

- Revenue from sale of goods is recognized when risk and rewards of ownership are transferred to the customers.
- Revenue from services is recognised when services are rendered and related costs are incurred.
- Other income is recognised on accrual basis unless otherwise stated.
- Insurance and other claims are accounted for on settlement of claims/on receipt.
- Revenue from sales/services are shown net of taxes, as applicable.

24.8. Employee Benefits

b) Short-term Employee Benefits:

- Leave Encashment, on the basis of actual computation, is accounted for on accrual basis, during the tenure of employment the payment in respect thereof is made by the Company from its own funds as per the past practice consistently followed by the Company.
- Payment of Bonus – This year the company has paid Rs. 9,04,616.00 as per The Payment of Bonus Act, 1965.

c) Post-Employment Benefits

(i) Defined Contribution Plans:

Contributions as required under the Statute/Rule are made to Employees State Insurance & Provident Fund and charged to the Statement of Profit & Loss of the year when the contributions to the respective funds are due.

(ii) Defined Benefit Plans:

The company has got the Actual Valuation done by independent consultant for FY 2023-24 to determine the projected benefit obligation for Gratuity Benefit and the accounting expenses associated with Gratuity Benefit on 31-03-2024. The company has made a further provision of Rs. 2,11,359 and the closing balance of the Gratuity Provision in FY 2023-24 was provided for Rs. 22,07,142.00

- d) **Termination Benefits:** Termination benefits are recognized as an expense as and when incurred.

24.9. Foreign Currency Transactions

- Functional and Reporting Currency:** The standalone financial statements are presented in Indian Rupee ('INR') which is also the functional and presentation currency of the Company.
 - Initial Recognition:** Foreign currency transactions are recorded in the functional currency, by applying to the exchange rate between the functional currency and the foreign currency at the date of the transaction.
 - Conversion on Reporting Date:** Transactions in foreign currencies are initially recorded by the Company at its functional currency spot rates at the date the transaction first qualifies for recognition. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.
 - Exchange Differences:** Exchange differences arising on monetary items on settlement, or restatement as at reporting date, at rates different from those at which they were initially recorded, are recognized in the statement of profit and loss in the year in which they arise.
- Net amount of Rs. 9,19,984.76 is recognized as Other Income for the year due to foreign exchange gains.

24.10. Borrowing Costs

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalized as part of the cost of such assets to the extent that they relate to the period till such assets are ready to use. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use. All other borrowing costs are charged to the Statement of Profit & Loss.

24.11. Investments

- Current Investments are carried at cost or fair value whichever is lower.



- Non-Current Investments are carried at cost. Provision for diminution in value of non-current investments is made only, if a decline is other than temporary.

24.12. Operating Lease

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased assets are classified as operating leases. Operating lease charges are recognised as an expense in the Statement of Profit & Loss on monthly due basis.

24.13. Taxes on Income

- Current Tax is measured at the amount expected to be paid to the tax authorities in accordance with the Indian Income Tax Act, 1961.
- Deferred tax is recognised, subject to the consideration of prudence in respect of deferred tax assets, on timing differences, being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods.
- Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off assets against liabilities.

24.14. Earnings Per Share (EPS)

- Annualised basic earnings per equity share is arrived at based on net profit/(loss) attributable to equity shareholders to the basic weighted average number of equity shares outstanding.
- Annualised diluted earnings per equity share is arrived at based on adjusted net profit/(loss) attributable to equity shareholders to the adjusted weighted average number of equity shares outstanding, for the effects of all dilutive potential equity shares; except where the results are anti-dilutive. At present the Company does not have any dilutive potential equity shares.

24.15. Cash Flow Statement:

- The Cash Flow Statement is prepared by the indirect method set out in Ind AS 7 on Cash Flow Statements and presents the cash flows by operating, investing and financing activities of the Company.
- Cash and cash equivalents presented in the Cash Flow Statement consists of balance in current accounts and cash balances.

24.16. Contingencies and Provisions

A provision is recognized when the Company has a present obligation as a result of past events. It is probable that an outflow of resources embodying economic benefit will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on the best estimate of the expenditure required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimate.

A contingent liability is disclosed, unless the possibility of an outflow of resources embodying the economic benefit is remote.

24.17 Internal Control Policy and BCP Management: The Company has a comprehensive system of Internal Controls to safeguard its assets against loss from unauthorized use and to ensure reliability of financial reporting. The management assesses the operating effectiveness of these controls on regular basis. All the required security checks i.e., physical security of the company premises and its database are properly installed, daily backup is being done for all the accounting and related data. The company maintains a system of internal controls designed for effectiveness and efficiency of operations, compliance and regulations.

The system of internal controls monitors and ensures process for:

- Effectiveness and efficiency of operations;
- Reliability of financial reporting;
- Compliance with applicable laws and regulations.



NOTE 25: OTHER NOTES TO ACCOUNTS
(Forming part of Accounts)
FOR THE YEAR ENDED 31ST MARCH, 2024

25.1. Issued, Subscribed & Paid-up Capital:

Issued, Subscribed and paid-up capital of the company is Rs. 1,75,80,500.00 (divided into 17,58,050 shares of Rs, 10 each)

25.2. Reserves & Surplus:

- The amount shown in the Reserve & Surplus represents profits generated during the year amounting Rs. 6,86,39,501.52. Total amount of Reserves & Surplus as on 31.03.2024 is Rs. 18,23,78,093.04.

25.3. Long-term Borrowings

Secured:

Term Loan:

Lender	Nature of Facility	Loan	Amount outstanding as at 31 March'2024	Rate of Interest	Repayment Terms	Conditions
SIDBI	PCS Gold of Rs. 80.00 Lakhs	Term Loan	Rs.75.53 Lakhs	8.30% (Floating)	Total principal payment of Rs 1.49 Lakhs P.M. plus interest for 54 months after 6 months moratorium period from the date of sanction.	1.) Primary security: Extension of first charge by way of equitable mortgage in favor of SIDBI of all those piece and parcel of land admeasuring 2500 sq yard bearing Plot No. D-27 situated at Industrial Area, Focal Point, Derabassi, PUNJAB. 2.) Collateral security: EXTENSION OF First charge by way of hypothecation in favour of SIDBI of the plant, machinery, equipment, tools, spares, accessories, miscellaneous fixed assets and all other assets (save and except book debt & current assets) acquired / proposed to be acquired under the project / scheme. 3. GUARANTESS(S): Irrevocable, unconditional guarantee of Shri Rahul Batra, Shri Varun Batra, and Corporate Guarantee from Beta Drugs Limited.
HDFC	Plant and Machinery Loan of Rs. 225 Lakhs	Term Loan	Rs. 147.94 Lakhs	7.36% (Floating)	Installments of Rs. 5.77 lakh per month.	First Charge in Favour of bank by way of Hypothecation of company's entire stock of RM, WIP, Semi Finished Goods and Finished Goods, consumable stores spares including book debts, bills whether documentary or clean, outstanding monies, receivables, both present and future, in a form and manner satisfactory to the Bank and as specified by CAM. Equitable mortgage of Plot No. D-27, Derabassi, Industrial Focal Point owned by company. (First Pari-passu charge with SIDBI.
	Plant and Machinery Loan of Rs. 200 Lakhs	Term Loan	Rs. 90.22 Lakhs	8.35% (Floating)	Installments of Rs. 4.89 lakh per month.	Corporate Guarantee by M/s Beta Drugs Limited.



25.4. In the opinion of the Directors, "Current Assets" and "Loans & Advances" are approximately of the value stated in the Balance Sheet, if realized in the ordinary course of business and to the best of their knowledge, provisions for all the known liabilities have been made and, as certified, all the contractual and statutory obligations have been duly complied with.

25.5. Depreciation/Amortisation

- The management estimates the useful life of existing fixed assets as follows: -

Building	30 years
Furniture & Fixtures	10 years
Machinery	15 years
Equipment	5 years
Lab Equipment	10 years

For this class of assets, based on internal assessment and independent technical evaluation carried out by external valuers the management believes that the useful lives as given above best represent the period over which management expects to use these assets. The useful lives for these assets are same as prescribed under Part-C of Schedule-II of the Companies Act, 2013. (Refer note 3.4)

25.6. Earnings Per Share (AS-20)

	<u>Year ended</u> <u>31st March, 2024</u>	<u>Year ended</u> <u>31st March, 2023</u>
Numerator		
Net Profit/(Loss) attributable to Equity shareholders	6,86,39,501.52	5,45,84,025.34
Denominator		
Number of Equity shares	No.'s 17,58,050	No.'s 17,58,050
Nominal		
Value per Equity share	10	10
Earnings per Equity share		
- Basic and diluted	39.04	31.05

25.7. Non. Current Investments:

Equity shares have been stated at cost; provision for appreciation/diminution in the value of shares has not been made and no dividend was received during the year.

The provisions of Section 186 of the Companies Act, 2013 have been complied with.

25.8. Taxes

The exact liability of CST/VAT, Service Tax, GST, Income Tax and other statutory dues is indeterminate pending finalization of assessments and no undisputed dues or amounts were outstanding or remaining unpaid as at 31st March, 2024.

The current tax provision shown in the Balance Sheet is Rs. 66,90,561.39 after utilization of the advance tax and TDS of Rs. 1,71,31,584.85.

25.9. Segment Reporting

Since the Company primarily operates in one segment (i.e., Manufacturing of API/PFI), therefore segment reporting as required under Ind AS - 108 is not applicable.

25.10. Related Party Disclosures (Ind AS-24)

Related parties & their relationship and related parties' transactions.



S. No.	Related Party	Nature of Relationship	Nature of Transaction	Amount Involved During the year (₹)
1.	Beta Drugs Limited	100% Holding	Finished Goods Sold	17,89,96,195.00
	Beta Drugs Limited	100% Holding	Interest on Unsecured Loan	19,42,788.00
	Beta Drugs Limited	100% Holding	Unsecured Loan Taken	35,00,000.00
	Beta Drugs Limited	100% Holding	Sale of Machinery	1,00,000.00
2.	Adley Formulations Pvt Ltd	Common Subsidiary	Sale of Goods	14,76,92,171.00

The above disclosure of the related party and the transactions entered has been made as per Ind AS-24. The transactions have been carried at arm's length price (ALP).

25.11. Ratios

Adley Lab Ltd.- Ratios							
Sr. No.	Ratios	Numerator	Denominator	As at March 31' 2024	As at March 31' 2023	Variance	Explanation for significant changes in ratio as compared to the preceding year.
1	Current Ratio	Current Assets	Current liabilities	1.65	1.38	19.76%	-
2	Debt-Equity Ratio	Total Debt	Shareholders' equity	0.30	0.55	-45.28%	Due to increase in reserves by 6.86 Cr and debt is reduced by Rs. 1.2 Cr.
3	Debt Service Coverage Ratio	Earnings available for debt service	Debt service	5.34	3.71	43.81%	Due to increase in reserves by 6.86 Cr and debt is reduced by Rs. 1.2 Cr.
4	Return on Equity Ratio	Net profit after taxes less preference dividend (if any)	Shareholder's equity	0.34	0.42	-17.36%	
5	Inventory turnover ratio	Cost of goods sold or sales	Average inventory	3.40	3.95	-13.89%	
6	Trade Receivables turnover ratio	Net Sales	Average Trade Receivables	3.09	3.20	-3.37%	
7	Trade Payables turnover ratio	Net Purchases	Average Trade Payables	2.58	2.41	7.29%	



8	Net capital turnover ratio	Net Sales	Net working capital	3.95	6.39	-38.19%	Due to increase in Working Capital by 1.01 times however sales increased by 24.68%.
9	Net Profit ratio	Net Profit after taxes	Net Sales	0.129	0.128	0.86%	
10	Return on capital employed	Earnings before interest and taxes	Capital employed	0.40	0.43	-7.30%	
11	Return on investment	Income generated from investments	Total Current Investments	0.038	0.039	-1.11%	
12	Operating Profit Margin	Earnings before interest and taxes	Net Sales	18.80%	18.45%	1.86%	
13	Interest Coverage Ratio	Earnings before interest and taxes	Interest Expense	11.15	12.64	-11.78%	

25.12. Particulars relating to corporate social responsibility

The Company has provided for the corporate social responsibility as per Section 135 of the Companies Act 2013 i.e., Rs. 11,60,056.00 during the year. The actual amount spent during the financial year was Rs. 11,60,100.00 and there is no outstanding provision as on 31st March 2024.

25.13. Property, Plant and Equipment and Intangible assets:

- During the financial Year 2023-24 there was no addition under the head Land.
- During the financial Year 2023-24, there was addition of Rs. 66,21,609.00 under the head Building. During the financial year 2023-24, there was net addition of Rs. 1,33,09,106.60 made to Plant & Machinery, Furniture & Fixtures, Office Equipment, Vehicles & Computers.
- During the financial Year 2023-24 there was Nil addition under the head Intangible Assets.

25.14. Deferred Tax Assets & Liabilities

During the FY 2023-24 the company has made Deferred Tax Asset. Details of Calculation mentioned below.

Calculation of Deferred Tax Asset / Liability	Amount (‘)
Deferred Tax Asset/(Liability) on Depreciation	12,19,804.58
Total Deferred Tax Asset/(Liability) Created for the financial year 2023-24 in Profit and Loss Account.	12,19,804.58
Add: Deferred Tax Asset/(Liability) as on 01.04.2023 (Opening)	2,90,975.81
Net Deferred Tax Asset/(Liability)	15,10,780.39

**25.15. Other additional information**

<u>Particulars</u>	<u>31st March, 2024</u> <u>AMOUNT</u>	<u>31st March, 2023</u> <u>AMOUNT</u>
“A” Revenue from operations (under broad heads)		
Sales		
-Sales With in India	50,05,71,568.00	42,01,69,804.00
-Export Sales	3,26,88,020.86	75,24,220.75
Total	53,32,59,588.86	42,76,94,024.75
“B” Purchases		
-Chemicals,excipients& Packing Material	36,19,55,326.87	28,08,49,337.29

25.16. Expenditure In Foreign Currency (On Accrual Basis): - Following Expenses were incurred by the company during the year 2023-24.

	<u>31st March, 2024</u> <u>AMOUNT</u>	<u>31st March, 2023</u> <u>AMOUNT</u>
- Import of Capital Goods	0.00	20,91,000.00
- Import of raw material (including R&D Material)	18,53,51,037.87	11,85,99,690.54
- Revenue Expenses (Travel)	0.00	7,38,013.53
- Revenue Expenses (Others)	1,49,816.45	30,68,144.52
TOTAL	18,55,00,854.32	12,44,96,848.59

25.17. Micro, Small & Medium Enterprises

Based on the information presently available, total outstanding as on 31.03.2024 is Rs.41,52,950.00 to micro or small enterprises under the Micro, Small and Medium Enterprises Development Act, 2006.

25.18. Other statutory information

- i. No proceedings have been initiated during the year or are pending against the Company as at March 31, 2024 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.
- ii. The Company does not have any trading in Crypto Currency or Virtual Currency.
- iii. The Company does not have any transactions or balances with a Companies struck off under section 248 of the Companies Act, 2013 or Section 560 of the Companies Act 1956.
- iv. The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessment under the Income Tax Act, 1961.
- v. Company has not advanced or loaned or invested funds to any other person(s) or entity(is), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- vi. The Company has not received any fund from any person(s) or entity(is), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the



Company shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

- vii. No charge is pending to be registered beyond statutory period with ROC.
- viii. The company has not used the borrowings from banks and financial institutions for any other purpose other than for the specific purpose for which it was taken.
- ix. The Company have defined agreement with the Debtors regarding the credit payment period given and ageing is done accordingly in Financial Statement.
- x. As there is no specific agreements with the creditors, hence the creditors ageing is done as per the date of invoice received.

25.19. Total count of debtors in M/s Adley Lab Limited is 26, and creditors count is 151, Balance confirmations were sent to all and confirmation reply came from more than 50% of the total count.

25.20. Figures for previous year have been regrouped / rearranged where necessary to conform to the current year's presentation.

In terms of our attached report of even date.

For and on behalf of the Board of Directors

**For KALRA RAI AND ASSOCIATES
CHARTERED ACCOUNTANTS
F R No. – 008859N**

**Sd/-
LAJPAT RAI KALRA
PARTNER
M No. -087438
Dated: 14/05/2024
Place: Chandigarh
UDIN: 24087438BJZXBB2970**

sd/-	sd/-
Rahul Batra	Jayant Kumar
(Director)	(Director)
DIN:02229234	DIN:02172627

**STANDALONE FINANCIAL
STATEMENTS
OF
“BETA RESEARCH PRIVATE LIMITED”
(WHOLLY-OWNED SUBSIDIARY)
FOR THE FINANCIAL YEAR
2023-24**



**KALRA RAI & ASSOCIATES
CHARTERED ACCOUNTANTS**

**Head Office: Kothi No. 667, 1st floor, Sector-43-A
Chandigarh-160022**

Independent Auditors' Report

Members of Beta Research Pvt. Ltd.

Report on the Standalone Financial Statements

We have audited the accompanying standalone Ind-AS financial statements of Beta Research Pvt. Ltd. ('the Company'), which comprise the Balance Sheet as at March 31, 2024, the Statement of Profit and Loss, including the statement of Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ('the Act') with respect to the preparation of these standalone Ind-AS financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with accounting principles generally accepted in India, including the Indian Accounting Standards (Ind-AS) specified under Section 133 of the Act., read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial control that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind-AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these standalone Ind-AS financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under. We conducted our audit of the standalone Ind-AS financial statements in accordance with the Standards on Auditing, issued by the Institute of Chartered Accountants of India, as specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone Ind-AS financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the standalone Ind-AS financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the standalone Ind-AS financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone Ind AS financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the standalone Ind-AS financial statements give the information required by the Act in the manner so required and give a true and fair

view inconformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024, its profit including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's report) Order, 2016 ('the Order') issued by the Central Government of India in terms of subsection(11) of Section 143 of the Act, regarding statement on the matters specified in paragraphs 3 and 4 of the Order, this is not applicable..

2. As required by Section 143 (3) of the Act, we report that:

a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;

b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;

c. The Balance Sheet, Statement of Profit and Loss including the Statement of Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account;

d. In our opinion, the aforesaid standalone Ind-AS financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Companies (Indian Accounting Standards) Rules, 2015, as amended;

e. On the basis of written representations received from the directors as on March 31, 2024, and taken on record by the Board of Directors, none of the Directors is disqualified as on March 31, 2024, from being appointed as a director in terms of Section 164 (2) of the Act;

f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refers to our separate Report in "Annexure A";

g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2020, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements.

ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;

iii. There has been no amount available which is required to be transferred to the Investor Education and Protection Fund by the Company;

Place:- Chandigarh
Date: 14/05/2024
UDIN:24087438BJZXBX9025

For KALRA RAI & ASSOCIATES

Chartered Accountants

Sd/-
(Lajpat Rai Kalra)
Partner
M. No- 087438
FRN: 008859N



“ANNEXURE-A” TO THE AUDITORS’ REPORT

Referred to in Paragraph 7 of Our Report of Even Date

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of **Beta Research Pvt. Ltd.** (“the Company”) as of 31 March 2024 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (“the Guidance Note”) issued by the Institute of Chartered Accountants of India (“ICAI”). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (“the Act”).

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (“the Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to

permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March 2024, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Place:- Chandigarh
Date: 14/05/2024
UDIN:24087438BJZXBX9025

For KALRA RAI & ASSOCIATES

Chartered Accountants

Sd/-
(Lajpat Rai Kalra)
Partner
M. No- 087438
FRN: 008859N

BETA RESEARCH PRIVATE LIMITED SCO-184 1ST FLOOR SECTOR-5 PANCHKULA Panchkula HR 134114 IN CIN NUMBER U24303HR2022PTC104598 BALANCE SHEET AS AT 31 March' 2024			
Particulars	Note No.	As at 31 March' 2024	As at 31 March' 2023
		Amount in Rs. Lakhs	Amount in Rs. Lakhs
A EQUITY AND LIABILITIES			
1 Shareholders' funds			
(a) Share capital	1	1.00	1.00
(b) Reserves and surplus	2	-0.05	-
(c) Money received against share warrants		-	-
		0.95	1.00
2 Share application money pending allotment		-	-
3 Non-current liabilities			
(a) Long-term borrowings		-	-
(b) Deferred tax liabilities (net)		-	-
(c) Other long-term liabilities		-	-
(d) Long-term provisions		-	-
4 Current liabilities			
(a) Short-term borrowings		-	-
(b) Trade payables		-	-
(c) Other current liabilities	3	0.05	-
(d) Short-term provisions		-	-
		0.05	-
TOTAL		1.00	1.00
B ASSETS			
1 Non-current assets			
(a) Property, Plant and Equipment and Intangible assets			
(i) Property, Plant and Equipment		-	-
(ii) Intangible assets		-	-
(iii) Capital work-in-progress		-	-
(iv) Intangible assets under development		-	-
(v) Fixed assets held for sale		-	-
(b) Non-current investments		-	-
(c) Deferred tax assets (net)		-	-
(d) Long-term loans and advances		-	-
(e) Other non-current assets		-	-
2 Current assets			
(a) Current investments		-	-
(b) Inventories		-	-
(c) Trade receivables		-	-
(d) Cash and cash equivalents	4	1.00	1.00
(e) Short-term loans and advances		-	-
(f) Other current assets		-	-
		1.00	1.00
TOTAL		1.00	1.00
See accompanying notes forming part of the financial statements	6		
In terms of our report attached.			
For KALRA RAI AND ASSOCIATES Chartered Accountants (FRN: 008859N)		For and on the behalf of the Board of Directors	
Sd/- LAJPAT RAI KALRA Partner MEMBERSHIP NO. 087438 UDIN: 24087438BJZBX9025 Place : Chandigarh Date : 14-05-2024		Sd/- RAHUL BATRA DIRECTOR DIN: 02229234	Sd/- VARUN BATRA DIRECTOR DIN: 02148383

BETA RESEARCH PRIVATE LIMITED
SCO-184 1ST FLOOR SECTOR-5 PANCHKULA Panchkula HR 134114 IN
CIN NUMBER U24303HR2022PTC104598
STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED 31ST MARCH 2024

Particulars	Note No.	As at 31 March' 2024	As at 31 March' 2023
		Amount in Rs. Lakhs	Amount in Rs. Lakhs
A CONTINUING OPERATIONS			
1 Revenue from operations (gross)		-	-
Less: Excise duty		-	-
Revenue from operations (net)		-	-
2 Other income		-	-
3 Total revenue (1+2)		-	-
4 Expenses			
(a) Cost of material consumed		-	-
(b) Purchases of stock-in-trade		-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade		-	-
(d) Other Manufacturing expense		-	-
(d) Employee benefits expense		-	-
(e) Finance costs		-	-
(f) Depreciation and amortisation expense		-	-
(g) Other expenses	5	0.05	-
Total expenses		0.05	-
5 Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)		-0.05	-
6 Exceptional items		-	-
7 Profit / (Loss) before extraordinary items and tax (5 ± 6)		-0.05	-
8 Extraordinary items/Prior period items		-	-
9 Profit / (Loss) before tax (7 ± 8)		-0.05	-
10 Tax expense:			
(a) Current tax expense for current year		-	-
(b) (Less): MAT credit (where applicable)		-	-
(c) Current tax expense relating to prior years		-	-
(d) Net current tax expense		-	-
(e) Deferred tax		-	-
11 Profit / (Loss) from continuing operations (9 ± 10)		-0.05	-
B DISCONTINUING OPERATIONS			
12 Profit / (Loss) from discontinuing operations (B.i ± B.ii ± B.iii)		-	-
C TOTAL OPERATIONS		-0.05	-
13 Profit / (Loss) for the year (11 ± 12)		-0.05	-
14 Earnings per share (of Rs. Lakhs 10/- each):			
(a) Basic			
(i) Continuing operations		-0.00	-
(ii) Total operations		-0.00	-
(b) Diluted			
(i) Continuing operations		-0.00	-
(ii) Total operations		-0.00	-
See accompanying notes forming part of the financial statements	6		
In terms of our report attached. For KALRA RAI AND ASSOCIATES Chartered Accountants (FRN: 008859N)		For and on the behalf of the Board of Directors of the Board of Directors	
Sd/- LAJPAT RAI KALRA Partner MEMBERSHIP NO. 087438 UDIN: 24087438BJZXBX9025 Place : Chandigarh Date : 14-05-2024		Sd/- RAHUL BATRA DIRECTOR DIN: 02229234	Sd/- VARUN BATRA DIRECTOR DIN: 02148383

BETA RESEARCH PRIVATE LIMITED		
SCO-184 1ST FLOOR SECTOR-5 PANCHKULA Panchkula HR 134114 IN		
CIN NUMBER U24303HR2022PTC104598		
CASHFLOW STATEMENT FOR THE PERIOD ENDED ON 31ST MARCH 2024		
Particulars	As at 31 March' 2024	As at 31 March' 2023
	Amount in Rs. Lakhs	Amount in Rs. Lakhs
A CASHFLOW FROM OPERATING ACTIVITIES		
Net Profit before tax and extraordinary items (as per Statement of Profit & Loss)	-0.05	-
Adjustments for non Cash/Non trade items:		
Depreciation & Amortization Expenses	-	-
Finance Cost	-	-
Interest received	-	-
Other inflows/(outflows) of cash	-	-
Operating profits before Working Capital Changes	-0.05	-
Adjusted For:		
(Increase)/Decrease in trade receivables	-	-
Increase/(Decrease) in trade payables	0.05	-
(Increase)/Decrease in inventories	-	-
Increase/(Decrease) in other current liabilities	-	-
(Increase)/Decrease in short term loans and advances	-	-
(Increase)/Decrease in other current assets	-	-
Working Capital Changes	0.05	-
Net cashflow from Operating Activities (A)	-	-
B CASHFLOW FROM INVESTING ACTIVITIES		
Purchase of fixed assets	-	-
Interest received	-	-
Cash used for Long Term Loans/Advances	-	-
Net cash used in Investing Activities (B)	-	-
C CASHFLOW FROM FINANCING ACTIVITIES		
Finance Cost	-	-
Increase/(Decrease) in short term borrowings	-	-
Increase in/(Repayment) of Long term Borrowings	-	-
Increase in/(Repayment) of Other Long term Liabilities	-	-
Increase/ (Decrease) in share capital	-	1.00
Other Inflows/ (Outflows) of cash	-	-
Net cash used in Financing Activities (C)	-	1.00
D Net Increase/(Decrease) in cash & cash equivalents (A+B+C)	-	1.00
E Cash & Cash equivalents at beginning of period	1.00	-
F Cash & Cash equivalents at end of period	1.00	1.00
G Net Increase/(Decrease) in cash & cash equivalents (F-E)	-	1.00
In terms of our report attached.		
For KALRA RAI AND ASSOCIATES		For and on the behalf of the Board of Directors of the Board of Directors
Chartered Accountants		
(FRN: 008859N)		
<i>Sd/-</i>	<i>Sd/-</i>	<i>Sd/-</i>
LAJPAT RAI KALRA	RAHUL BATRA	VARUN BATRA
Partner	DIRECTOR	DIRECTOR
MEMBERSHIP NO. 087438	DIN: 02229234	DIN: 02148383
UDIN: 24087438BJXBX9025		
Place : Chandigarh		
Date : 14-05-2024		

BETA RESEARCH PRIVATE LIMITED
SCO-184 1ST FLOOR SECTOR-5 PANCHKULA Panchkula HR 134114 IN
CIN NUMBER U24303HR2022PTC104598
Note 1 Share capital

Amount In Lakhs

Particulars	As at 31 March' 2024		As at 31 March' 2023	
	Number of shares	Amount in Rs. Lakhs	Number of shares	Amount in Rs. Lakhs
(a) Authorised - Equity shares of Rs. 1 each	500,000.00 -	5.00 -	500,000.00 -	5.00 -
(b) Issued - Equity shares of Rs. 1 each	100,000.00	1.00	100,000.00	1.00
	100,000.00	1.00	100,000.00	1.00
(c) Subscribed and fully paid up - Equity shares of Rs. 1 each	100,000.00	1.00	100,000.00	1.00
	100,000.00	1.00	100,000.00	1.00
(d) Subscribed but not fully paid up	-	-	-	-
	-	-	-	-
Total	100,000.00	1.00	100,000.00	1.00

Note 1(a) Reconciliation of number of shares outstanding is set out below:

Particulars	Equity Shares March' 2024		Equity Shares March' 2023	
	Number	Amount in (Rs. Lakhs)	Number	Amount in (Rs. Lakhs)
Shares outstanding at the beginning of the year	100,000.00	1.00	-	-
Shares Issued during the year	-	-	100,000.00	1.00
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	100,000.00	1.00	100,000.00	1.00

Note 1(b) Shares held by promoters at the end of the year 31 March' 2024

Name of Shareholder	As at 31 March' 2024		
	No. of Shares held	% of Holding	% Changes
Beta Drugs Limited	99,999.00	99.999%	-
Mr. Varun Batra	1.00	0.0010%	-

Note 1(b) Shares held by promoters at the end of the year 31 March' 2023

Name of Shareholder	As at 31 March' 2023		
	No. of Shares held	% of Holding	% Changes
Beta Drugs Limited	99,999.00	99.999%	100.0000%
Mr. Varun Batra	1.00	0.0010%	100.0000%

Note 1(c) Details of shares held by each shareholder holding more than 5% shares:

Class of shares / Name of shareholder	As at 31 March' 2024		As at 31 March' 2023	
	Number of shares held	% holding in that class of shares	Number of shares held	% holding in that class of shares
Equity shares with voting rights				
Mr. Varun Batra	1	0.001	1	0.001
Beta Drugs Limited	99,999	99.999	99,999	99.999
Total	100,000	100.00	100,000	100.00

BETA RESEARCH PRIVATE LIMITED**Notes forming part of the financial statements****Note 2 Reserves and surplus**

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
(a) Capital reserve		
Opening balance	-	-
Closing balance	-	-
(b) Securities premium account		
Opening balance	-	-
Closing balance	-	-
(c) Surplus / (Deficit) in Statement of Profit and Loss		
Opening balance	-	-
	-	-
Add: Profit / (Loss) for the year	-0.05	-
Closing balance	-0.05	-
Total	-0.05	-

BETA RESEARCH PRIVATE LIMITED
SCO-184 1ST FLOOR SECTOR-5 PANCHKULA Panchkula HR 134114 IN

Note 3 Other current liabilities

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
(a) Other payables	-	-
(b) Cheque issued yet not presented for Payment	-	-
(c) Other Advances	0.05	-
Total	0.05	-

Note 4 Cash and cash equivalents

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
CASH ON HAND		
(a) Cash on hand	-	-
Total	-	-
(b) Balances with banks		
(i) In current accounts HDFC Bank Ltd.	1.00	1.00
(c) Others (specify nature)		
Total	1.00	1.00
Total	1.00	1.00

BETA RESEARCH PRIVATE LIMITED
SCO-184 1ST FLOOR SECTOR-5 PANCHKULA Panchkula HR 134114 IN

Note 5 Other Expenses

Particulars	As at 31 March' 2024 Amount in Rs. Lakhs	As at 31 March' 2023 Amount in Rs. Lakhs
Legal & Professional Expenses	0.05	-
Total	0.05	-

NOTES TO ACCOUNTS OF STANDALONE FINANCIALS OF M/S BETA RESEARCH PVT. LTD.**NOTE '4': SIGNIFICANT ACCOUNTING POLICIES****(Forming part of Accounts)****FOR THE YEAR ENDED 31ST MARCH, 2024****4.1. Basis of Accounting**

The financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India under the historical convention on accrual basis. These financial statements have been prepared to comply, in all material aspects, with the accounting standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and the presentation requirements as prescribed by the Schedule III of the Companies Act, 2013 to the extent applicable.

4.2. Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires that management makes estimates and assumptions that affect the reported amounts of income and expenses of the year, the reported balance of assets and liabilities and the disclosure relating to contingent liabilities as at the date of the financial statements. These estimates are based upon management's best knowledge of current events and actions. The difference between the actual results and estimates are recognised in the period in which the results are known / materialized.

4.3. Property, Plant and Equipment and Intangible assets

Since the company has not started its operations, there are no Property, Plant and Equipment and Intangible assets as on 31.03.2024.

4.4. Valuation of Inventories

Since the company has not started its operations, there is no Inventory as on 31.03.2024

4.5. Revenue Recognition

Since the company has not started its operations, there is no revenue during the F.Y 2023-24.

4.6. Employee Benefits

Since the company has not started its operations, no employee benefit cost has been incurred till 31.03.2024.

4.7. Foreign Currency Transactions

Since the company has not started its operations, this point is not applicable.

4.8. Borrowing Costs

Since the company has not started its operations and has not taken any loan, there is no borrowing cost.

4.9. Investments

There are no investments in the company as on date.

4.10. Operating Lease

The company has not taken any asset on lease as on date.

4.11. Taxes on Income

Since the company has not started its operations there are no taxes as on date.

4.12. Earnings Per Share (EPS)

As explained, the company has not started its operations, there is just a legal & professional expense of Rs. 5,000/- during the year, hence EPS is Nil.

4.13. Cash Flow Statement:

- The Cash Flow Statement is prepared by the indirect method set out in Ind AS 7 on Cash Flow Statements and presents the cash flows by operating, investing and financing activities of the Company.



- Cash and cash equivalents presented in the Cash Flow Statement consists of balance in current accounts and cash balances.

4.14. Contingencies and Provisions

A provision is recognized when the Company has a present obligation as a result of past events. It is probable that an outflow of resources embodying economic benefit will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on the best estimate of the expenditure required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimate.

A contingent liability is disclosed, unless the possibility of an outflow of resources embodying the economic benefit is remote.

- 4.15 Internal Control Policy and BCP Management:** The Company has a comprehensive system of Internal Controls to safeguard its assets against loss from unauthorized use and to ensure reliability of financial reporting. The management assesses the operating effectiveness of these controls on regular basis. All the required security checks i.e., physical security of the company premises and its database are properly installed, daily backup is being done for all the accounting and related data. The company maintains a system of internal controls designed for effectiveness and efficiency of operations, compliance and regulations.

The system of internal controls monitors and ensures process for:

- Effectiveness and efficiency of operations;
- Reliability of financial reporting;
- Compliance with applicable laws and regulations.



NOTE 5: OTHER NOTES TO ACCOUNTS
(Forming part of Accounts)
FOR THE YEAR ENDED 31ST MARCH, 2024

5.1. Issued, Subscribed & Paid-up Capital:

Issued, Subscribed and paid-up capital of the company is Rs. 1,00,000.00 (divided into 1,00,000 shares of Rs, 1 each)

5.2. Reserves & Surplus:

The company has negative reserves of Rs. 5,000/- as on 31.03.2024.

5.3. Long-term Borrowings

Since the company has not started its operations, there are no long-term borrowings as on 31.03.2024.

5.4. Earnings Per Share (AS-20)

	<u>Year ended</u> <u>31st March, 2024</u>	<u>Year ended</u> <u>31st March, 2023</u>
Numerator		
Net Profit/(Loss) attributable to Equity shareholders	-5,000.00	0.00
Denominator		
Number of Equity shares	No.'s 1,00,000	No.'s 1,00,000
Nominal		
Value per Equity share	1	1
Earnings per Equity share		
- Basic and diluted	0.00	0.00

5.5. Segment Reporting

Since the Company has not started its operations, therefore segment reporting as required under Ind AS - 108 is not applicable.

5.6. Related Party Disclosures (Ind AS-24)

There are no related party transactions.

5.7. Ratios

Since the company has not started its operations, this point is not applicable.

5.8. Particulars relating to corporate social responsibility

Since the company has not started its operations, Corporate social responsibility as per Section 135 of the Companies Act 2013 is not applicable.

5.9. Property, Plant and Equipment and Intangible assets:

During the financial Year 2023-24 there are no additions to Property, Plant and Equipment and Intangible assets. Property, Plant and Equipment and Intangible assets as on 31.03.2024 is Rs. Nil.

5.10. Deferred Tax Assets & Liabilities

Since the company has not started its operations, no deferred tax asset or liability is created.

5.11. Other additional information

<u>Particulars</u>	<u>31st March, 2024</u>	<u>31st March, 2023</u>
	<u>AMOUNT</u>	<u>AMOUNT</u>
“A” Revenue from operations (under broad heads)		
Sales		
-Sales With in India	-	-
-Export Sales	-	-
Total	-	-
“B” Purchases		
-Chemicals, excipients & Packing Material	-	-

5.12. Expenditure In Foreign Currency (On Accrual Basis): - Following Expenses were incurred by the company during the year 2023-24.

There is no expenditure in foreign currency during F.Y 2023-24

5.13. Micro, Small & Medium Enterprises

Based on the information presently available, total outstanding as on 31.03.2024 is Rs. Nil to micro or small enterprises under the Micro, Small and Medium Enterprises Development Act, 2006.

5.14. Other statutory information

- i. No proceedings have been initiated during the year or are pending against the Company as at March 31, 2024 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.
- ii. The Company does not have any trading in Crypto Currency or Virtual Currency.
- iii. The Company does not have any transactions or balances with a Companies struck off under section 248 of the Companies Act, 2013 or Section 560 of the Companies Act 1956.
- iv. The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessment under the Income Tax Act, 1961.
- v. Company has not advanced or loaned or invested funds to any other person(s) or entity(is), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- vi. The Company has not received any fund from any person(s) or entity(is), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.



- vii. No charge is pending to be registered beyond statutory period with ROC.
- viii. The company has not used the borrowings from banks and financial institutions for any other purpose other than for the specific purpose for which it was taken.

In terms of our attached report of even date.

For KALRA RAI AND ASSOCIATES

CHARTERED ACCOUNTANTS

F R No. – 008859N

Sd/-

LAJPAT RAI KALRA

PARTNER

M No. -087438

Dated: 14/05/2024

Place: Chandigarh

UDIN: 24087438BJZXB9025

For and on behalf of the Board of Directors

sd/-

**Rahul Batra
(Director)**

DIN:02229234

sd/-

**Varun Batra
(Director)**

DIN:02148383



BETA DRUGS LIMITED

CIN: L24230HP2005PLC028969

Registered office: Village Nandpur, Baddi, Distt. SOLAN-174101, Himachal Pardesh.

Tel No. 01795-236196, Email: cs@betadrugslimited.com, Website:www.betadrugslimited.com

ATTENDANCE SLIP

(Please fill attendance slip and hand it over at the entrance of the meeting hall)

Joint Shareholders may obtain additional slip on request

DP ID No. : _____

Client ID No. : _____

Ledger Folio No. : _____

NAME AND ADDRESS OF THE SHAREHOLDER: _____

No. of shares held _____

I hereby record my presence at the **19th ANNUAL GENERAL MEETING** of the Company held on **Monday, the 30th day of September, 2024 at 10.30 a.m.** at Registered Office of the company situated at **Village Nandpur, Lodhimajra Road, Baddi, Distt Solan, H.P. 174101.**

• I certify that I am member/proxy of the company.

Signature of the shareholder or proxy

Note: You are requested to sign and handover this slip at the entrance of the meeting venue.



19TH ANNUAL REPORT

BETA DRUGS LIMITED

BETA DRUGS LIMITED

CIN: L24230HP2005PLC028969

Registered office: Village Nandpur, Baddi, Distt. SOLAN-174101, Himachal Pardesh. Tel No. 01795-236196, Website: www.betadrugslimited.com

Form No. MGT-11

Proxy form

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]

Name of the Member(s): _____

Registered address: _____

E-mail Id: _____

Folio No/ Client Id-DP ID: _____

I/ We being the member (s) of shares of the above named company, hereby appoint

1. Name: _____

Address: _____

E-mail Id: _____ Signature: _____, or failing him;

2. Name: _____

Address: _____

E-mail Id: _____ Signature: _____, or failing him;

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at **19th ANNUAL GENERAL MEETING** of the Company held on **Monday, the 30th day of September, 2024** at **10.30 a.m.** at **Village Nandpur, Lodhimajra Road, Baddi, Distt Solan, H.P. 174101** and at any adjournment thereof in respect of such resolutions as are indicated below:

Sr No.	Resolutions	Optional	
		For (✓)	Against (X)
ORDINARY BUSINESS			
1.	Adoption of Financial Statements (I) Audited Standalone Financial Statements of the Company for the financial year ended on March 31, 2024 and the Reports of the Board of Directors and Auditors thereon; and (II) Audited Consolidated Financial Statements of the Company for the financial year ended on March 31, 2024, together with the Report of the Auditors thereon		
2.	To appoint a Director in place of Mr. Varun Batra (DIN: 02148383), who retires by rotation and being eligible, offers himself for re-appointment.		
3.	To appoint a Director in place of Mrs. Seema Chopra (DIN: 08510586), who retires by rotation and being eligible, offers herself for re-appointment.		
4.	To appoint Statutory Auditors from the conclusion of this Annual General Meeting until the conclusion of the Twenty first Annual General Meeting and to fix their remuneration.		
SPECIAL BUSINESS			
5.	To ratify the remuneration payable to the Cost Auditor appointed by the Board of Directors of the Company for the financial year 2024-25 pursuant to Section 148 and all other applicable provisions of Companies Act, 2013.		
6.	To revise the remuneration payable to Mr. Rahul Batra (DIN No. 02229234), Managing Director of the company.		
7.	To revise the remuneration payable to Mr. Varun Batra (DIN No. 02148383), Joint Managing Director of the company.		
8.	Re-appointment of Mr. Balwant Singh (DIN: 01089968) as Whole-time Director of the Company w.e.f. 5th August, 2024 till 4th August, 2029.		
9.	Re-appointment of Mrs. Seema Chopra (DIN: 08510586) as Whole-time Director of the Company w.e.f. 1st August, 2024 till 31st July, 2029.		
10.	To revise the remuneration payable to Mr. Ashutosh Shukla (DIN No. 09461568), Whole time Director of the company.		
11.	To alter the incidental object of the Memorandum of Association of the company.		

Signed this _____ day of _____ 2024

Signature of Shareholder: _____

Signature of Proxy holder(s): _____

Affix
Revenue
Stamp not less
than Rs 1/-

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting. A proxy need not be a member of the company.



19TH ANNUAL REPORT

BETA DRUGS LIMITED

BETA DRUGS LIMITED

CIN: L24230HP2005PLC028969

Registered office: Village Nandpur, Baddi, Distt. SOLAN-174101, Himachal Pardesh, Tel No. 01795-236196, Website: www.betadrugslimited.com

BALLOT FORM FOR 19TH ANNUAL GENERAL MEETING HELD AT REGISTERED OFFICE ON MONDAY, 30.09.2024 AT 10:30 A.M.

Name of the member(s):	
Registered Address:	
Folio No	
No. of Shares	
*DP ID	
* Client ID	

* Applicable to holders holding shares in demat/electronic form

I/We hereby exercise my/our vote in respect to the Ordinary/Special Resolution to be passed through Postal Ballot for the Business stated in the Postal Ballot Notice by sending my/our assent (FOR) or dissent (AGAINST) to the said resolution by placing the right mark (✓) at the appropriate box below:

Item No.	Item	Nature of Resolution	Assent (FOR) (✓)	Dissent (AGAINST) (X)
1.	Adoption of Financial Statements (I) Audited Standalone Financial Statements of the Company for the financial year ended on March 31, 2024 and the Reports of the Board of Directors and Auditors thereon; and (II) Audited Consolidated Financial Statements of the Company for the financial year ended on March 31, 2024, together with the Report of the Auditors thereon	Ordinary		
2.	To appoint a Director in place of Mr. Varun Batra (DIN: 02148383), who retires by rotation and being eligible, offers himself for re-appointment.	Ordinary		
3.	To appoint a Director in place of Mrs. Seema Chopra (DIN: 08510586), who retires by rotation and being eligible, offers herself for re-appointment.	Ordinary		
4.	To appoint Statutory Auditors from the conclusion of this Annual General Meeting until the conclusion of the Twenty first Annual General Meeting and to fix their remuneration.	Ordinary		
5.	To ratify the remuneration payable to the Cost Auditor appointed by the Board of Directors of the Company for the financial year 2024-25 pursuant to Section 148 and all other applicable provisions of Companies Act, 2013.	Ordinary		
6.	To revise the remuneration payable to Mr. Rahul Batra (DIN No. 02229234), Managing Director of the company.	Special		
7.	To revise the remuneration payable to Mr. Varun Batra (DIN No. 02148383), Joint Managing Director of the company.	Special		
8.	Re-appointment of Mr. Balwant Singh (DIN: 01089968) as Whole-time Director of the Company w.e.f. 5th August, 2024 till 4th August, 2029.	Special		
9.	Re-appointment of Mrs. Seema Chopra (DIN: 08510586) as Whole-time Director of the Company w.e.f. 1st August, 2024 till 31st July, 2029.	Special		
10.	To revise the remuneration payable to Mr. Ashutosh Shukla (DIN No. 09461568), Whole time Director of the company.	Special		
11.	To alter the incidental object of the Memorandum of Association of the company.	Special		

Place: Baddi


Date:

Signature of Member



BETA DRUGS LIMITED

AGM VENUE MAP



BETA DRUGS LIMITED

Registered Office:
Village Nandpur, Lodhimajra Road
Baddi, Distt Solan, H.P. 174101



We team of **BETA DRUGS LTD.**,
wants to thank you from bottom of our hearts for
supporting us in achieving this newer heights.

*Thank
you*



BDL ONCOLOGY
(Beta Drugs Limited)

Beta Drugs Limited

Village Nandpur, Lodhimajra Road, Baddi, Distt Solan, H.P. 174101

Tel No. 01795-236196,

Email: cs@betadrugslimited.com,
Website: www.betadrugslimited.com